

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
13 June 2002 (13.06.2002)

PCT

(10) International Publication Number
WO 02/46408 A2(51) International Patent Classification⁷: C12N 15/12,
5/10, C07K 14/47, 16/18, C12Q 1/68, G01N 33/577,
33/68, A61K 38/12, 39/395US 60/243,593 (CIP)
Filed on 26 October 2000 (26.10.2000)
US 60/243,502 (CIP)
Filed on 26 October 2000 (26.10.2000)

(21) International Application Number: PCT/US01/46057

(22) International Filing Date: 24 October 2001 (24.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/242,882	24 October 2000 (24.10.2000)	US
60/242,765	24 October 2000 (24.10.2000)	US
60/242,768	24 October 2000 (24.10.2000)	US
60/242,789	24 October 2000 (24.10.2000)	US
60/242,767	24 October 2000 (24.10.2000)	US
60/243,502	26 October 2000 (26.10.2000)	US
60/243,622	26 October 2000 (26.10.2000)	US
60/243,593	26 October 2000 (26.10.2000)	US
60/243,591	26 October 2000 (26.10.2000)	US
60/243,950	27 October 2000 (27.10.2000)	US
60/273,047	2 March 2001 (02.03.2001)	US
60/300,206	22 June 2001 (22.06.2001)	US
60/316,509	31 August 2001 (31.08.2001)	US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US	60/242,882 (CIP)
Filed on	24 October 2000 (24.10.2000)
US	60/242,765 (CIP)
Filed on	24 October 2000 (24.10.2000)
US	60/300,206 (CIP)
Filed on	22 June 2001 (22.06.2001)
US	60/242,789 (CIP)
Filed on	24 October 2000 (24.10.2000)
US	60/242,768 (CIP)
Filed on	24 October 2000 (24.10.2000)
US	60/242,767 (CIP)
Filed on	24 October 2000 (24.10.2000)
US	60/243,622 (CIP)
Filed on	26 October 2000 (26.10.2000)
US	60/273,047 (CIP)
Filed on	2 March 2001 (02.03.2001)
US	60/243,591 (CIP)
Filed on	26 October 2000 (26.10.2000)
US	60/243,950 (CIP)
Filed on	27 October 2000 (27.10.2000)
US	60/316,509 (CIP)
Filed on	31 August 2001 (31.08.2001)

(71) Applicant (for all designated States except US): CURA-
GEN CORPORATION [US/US]; 555 Long Wharf Drive,
11th floor, New Haven, CT 06511 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LI, Li [CN/US];
56 Jerimoth Drive, Branford, CT 06405 (US). FURTAK,
Katarzyna [PL/US]; 31 Park Place, Ansonia, CT 06401
(US). PERNA, Amanda [US/US]; 555 Long Wharf Drive,
11th Floor, New Haven, CT 06511 (US). PATTURA-
JAN, Meera [IN/US]; 45 Harrison Avenue, Apartment
1C, Branford, CT 06405 (US). SHIMKETS, Richard,
A. [US/US]; 191 Leete Street, West Haven, CT 06516
(US). GUO, Xiaojia [CN/US]; 713 Robert Frost Drive,
Branford, CT 06405 (US). CASMAN, Stacie, J. [US/US];
17 Peck Street, North Haven, CT 06473 (US). BURGESS,
Catherine, E. [US/US]; 90 Carriage Hill Drive, Wethers-
field, CT 06109 (US). MALYANKAR, Uriel, M. [IN/US];
35 Averill Place, Branford, CT 06405 (US). TCHERNEV,
Velizar, T. [BG/US]; 45 Jefferson Road, #3-12, Branford,
CT 06405 (US). VERNET, Corine, A., M. [FR/US]; 1739
Foxon Road, North Branford, CT 06471 (US). SPYTEK,
Kimberly, A. [US/US]; 28 Court Street, #1, New Haven,
CT 06511 (US). AGEE, Michele [US/US]; 107 Knoll-
wood Road, Wallingford, CT 06492 (US). RASTELLI,
Luca [IT/US]; 52 Pepperbush Lane, Guilford, CT 06437
(US). SHENOY, Suresh, G. [IN/US]; 15 Millwood
Drive, Branford, CT 06405 (US). GROSSE, William, M.
[US/US]; 15 Rice Terrace Road, Apartment C, Branford,
CT 06405 (US). ALSOBROOK, John, P., II [US/US]; 60
Lake Drive, Madison, CT 06443 (US). LEPLY, Denise,
M. [US/US]; 51 Church Street, Branford, CT 06405 (US).
GERLACH, Valerie [US/US]; 18 Rock Pasture Road,
Branford, CT 06405 (US). EDINGER, Shlomit [US/US];
555 Long Wharf Drive, 11th Floor, New Haven, CT 06511
(US). MACDOUGALL, John, R. [CA/US]; 117 Russell
Street, Hamden, CT 06517 (US). PEYMAN, John, A.
[US/US]; 336 West Rock Avenue, New Haven, CT 06515
(US). GUNTHER, Erik [US/US]; 555 Long Wharf
Drive, 11th Floor, New Haven, CT 06511 (US). STONE,
David, J. [US/US]; 223 Whitehorn Drive, Guilford, CT
06437 (US). ELLERMAN, Karen [US/US]; 87 Montoya
Drive, Branford, CT 06405 (US). GANGOLLI, Esha, A.
[IN/US]; 383 Walden Green, Branford, CT 06405 (US).

[Continued on next page]

(54) Title: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS OF USING THE SAME

(57) Abstract: Disclosed are novel polypeptides and nucleic acids encoding same. Also disclosed are vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same.

WO 02/46408 A2



(74) **Agent:** ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glöovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS OF USING THE SAME

5

FIELD OF THE INVENTION

The invention relates to polynucleotides and the polypeptides encoded by such polynucleotides, as well as vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using the same.

10

BACKGROUND OF THE INVENTION

The invention generally relates to nucleic acids and polypeptides encoded therefrom. More specifically, the invention relates to nucleic acids encoding cytoplasmic, nuclear, membrane bound, and secreted polypeptides, as well as vectors, host cells, antibodies, and recombinant methods for producing these nucleic acids and polypeptides.

15

SUMMARY OF THE INVENTION

The invention is based in part upon the discovery of nucleic acid sequences encoding novel polypeptides. The novel nucleic acids and polypeptides are referred to herein as NOVX, or NOV1, NOV2, NOV3, NOV4, NOV5, NOV6, NOV7, NOV8, NOV9, and NOV10 nucleic acids and polypeptides. These nucleic acids and polypeptides, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as "NOVX" nucleic acid or polypeptide sequences.

20

25

In one aspect, the invention provides an isolated NOVX nucleic acid molecule encoding a NOVX polypeptide that includes a nucleic acid sequence that has identity to the nucleic acids disclosed in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30. In some embodiments, the NOVX nucleic acid molecule will hybridize under stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule that includes a protein-coding sequence of a NOVX nucleic acid sequence. The invention also includes an

isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof. For example, the nucleic acid can encode a polypeptide at least 80% identical to a polypeptide comprising the amino acid sequences of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31. The nucleic acid can be, for example, a genomic DNA fragment or a cDNA molecule that includes the nucleic acid sequence of any of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30.

Also included in the invention is an oligonucleotide, *e.g.*, an oligonucleotide which includes at least 6 contiguous nucleotides of a NOVX nucleic acid (*e.g.*, SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30) or a complement of said oligonucleotide.

Also included in the invention are substantially purified NOVX polypeptides (SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31). In certain embodiments, the NOVX polypeptides include an amino acid sequence that is substantially identical to the amino acid sequence of a human NOVX polypeptide.

The invention also features antibodies that immunoselectively bind to NOVX polypeptides, or fragments, homologs, analogs or derivatives thereof.

In another aspect, the invention includes pharmaceutical compositions that include therapeutically- or prophylactically-effective amounts of a therapeutic and a pharmaceutically-acceptable carrier. The therapeutic can be, *e.g.*, a NOVX nucleic acid, a NOVX polypeptide, or an antibody specific for a NOVX polypeptide. In a further aspect, the invention includes, in one or more containers, a therapeutically- or prophylactically-effective amount of this pharmaceutical composition.

In a further aspect, the invention includes a method of producing a polypeptide by culturing a cell that includes a NOVX nucleic acid, under conditions allowing for expression of the NOVX polypeptide encoded by the DNA. If desired, the NOVX polypeptide can then be recovered.

In another aspect, the invention includes a method of detecting the presence of a NOVX polypeptide in a sample. In the method, a sample is contacted with a compound that selectively binds to the polypeptide under conditions allowing for formation of a complex between the polypeptide and the compound. The complex is detected, if present, thereby identifying the NOVX polypeptide within the sample.

The invention also includes methods to identify specific cell or tissue types based on their expression of a NOVX.

Also included in the invention is a method of detecting the presence of a NOVX nucleic acid molecule in a sample by contacting the sample with a NOVX nucleic acid probe

or primer, and detecting whether the nucleic acid probe or primer bound to a NOVX nucleic acid molecule in the sample.

In a further aspect, the invention provides a method for modulating the activity of a NOVX polypeptide by contacting a cell sample that includes the NOVX polypeptide with a compound that binds to the NOVX polypeptide in an amount sufficient to modulate the activity of said polypeptide. The compound can be, *e.g.*, a small molecule, such as a nucleic acid, peptide, polypeptide, peptidomimetic, carbohydrate, lipid or other organic (carbon containing) or inorganic molecule, as further described herein.

Also within the scope of the invention is the use of a therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, *e.g.*, Cancer, Leukodystrophies, Breast cancer, Ovarian cancer, Prostate cancer, Uterine cancer, Hodgkin disease, Adenocarcinoma, Adrenoleukodystrophy, Cystitis, incontinence, Von Hippel-Lindau (VHL) syndrome, hypercalcaemia, Endometriosis, Hirschsprung's disease, Crohn's Disease, Appendicitis, Cirrhosis, Liver failure, Wolfram Syndrome, Smith-Lemli-Opitz syndrome, Retinitis pigmentosa, Leigh syndrome; Congenital Adrenal Hyperplasia, Xerostomia; tooth decay and other dental problems; Inflammatory bowel disease, Diverticular disease, fertility, Infertility, cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, Hemophilia, Hypercoagulation, Idiopathic thrombocytopenic purpura, obesity, Diabetes Insipidus and Mellitus with Optic Atrophy and Deafness, Pancreatitis, Metabolic Dysregulation, transplantation recovery, Autoimmune disease, Systemic lupus erythematosus, asthma, arthritis, psoriasis, Emphysema, Scleroderma, allergy, ARDS, Immunodeficiencies, Graft versus host, Alzheimer's disease, Stroke, Parkinson's disease, Huntington's disease, Cerebral palsy, Epilepsy, Multiple sclerosis, Ataxia-telangiectasia, Behavioral disorders, Addiction, Anxiety, Pain, Neurodegeneration, Muscular dystrophy, Lesch-Nyhan syndrome, Myasthenia gravis, schizophrenia, and other dopamine-dysfunctional states, levodopa-induced dyskinesias, alcoholism, epileptic seizures and other neurological disorders, mental depression, Cerebellar ataxia, pure; Episodic ataxia, type 2; Hemiplegic migraine, Spinocerebellar ataxia-6, Tuberous sclerosis, Renal artery stenosis, Interstitial nephritis, Glomerulonephritis, Polycystic kidney disease, Renal tubular acidosis, IgA nephropathy, and/or other pathologies and disorders of the like.

The therapeutic can be, *e.g.*, a NOVX nucleic acid, a NOVX polypeptide, or a NOVX-specific antibody, or biologically-active derivatives or fragments thereof.

For example, the compositions of the present invention will have efficacy for treatment of patients suffering from the diseases and disorders disclosed above and/or other pathologies and disorders of the like. The polypeptides can be used as immunogens to produce antibodies specific for the invention, and as vaccines. They can also be used to screen for potential
5 agonist and antagonist compounds. For example, a cDNA encoding NOVX may be useful in gene therapy, and NOVX may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from the diseases and disorders disclosed above and/or other pathologies and disorders of the like.

10 The invention further includes a method for screening for a modulator of disorders or syndromes including, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like. The method includes contacting a test compound with a NOVX polypeptide and determining if the test compound binds to said NOVX polypeptide. Binding of the test compound to the NOVX polypeptide indicates the test compound is a modulator of
15 activity, or of latency or predisposition to the aforementioned disorders or syndromes.

Also within the scope of the invention is a method for screening for a modulator of activity, or of latency or predisposition to disorders or syndromes including, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like by administering a test compound to a test animal at increased risk for the aforementioned
20 disorders or syndromes. The test animal expresses a recombinant polypeptide encoded by a NOVX nucleic acid. Expression or activity of NOVX polypeptide is then measured in the test animal, as is expression or activity of the protein in a control animal which recombinantly-expresses NOVX polypeptide and is not at increased risk for the disorder or syndrome. Next, the expression of NOVX polypeptide in both the test animal and the control animal is
25 compared. A change in the activity of NOVX polypeptide in the test animal relative to the control animal indicates the test compound is a modulator of latency of the disorder or syndrome.

In yet another aspect, the invention includes a method for determining the presence of or predisposition to a disease associated with altered levels of a NOVX polypeptide, a NOVX
30 nucleic acid, or both, in a subject (*e.g.*, a human subject). The method includes measuring the amount of the NOVX polypeptide in a test sample from the subject and comparing the amount of the polypeptide in the test sample to the amount of the NOVX polypeptide present in a control sample. An alteration in the level of the NOVX polypeptide in the test sample as compared to the control sample indicates the presence of or predisposition to a disease in the

subject. Preferably, the predisposition includes, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like. Also, the expression levels of the new polypeptides of the invention can be used in a method to screen for various cancers as well as to determine the stage of cancers.

5 In a further aspect, the invention includes a method of treating or preventing a pathological condition associated with a disorder in a mammal by administering to the subject a NOVX polypeptide, a NOVX nucleic acid, or a NOVX-specific antibody to a subject (*e.g.*, a human subject), in an amount sufficient to alleviate or prevent the pathological condition. In preferred embodiments, the disorder, includes, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like.

10 In yet another aspect, the invention can be used in a method to identity the cellular receptors and downstream effectors of the invention by any one of a number of techniques commonly employed in the art. These include but are not limited to the two-hybrid system, affinity purification, co-precipitation with antibodies or other specific-interacting molecules.

15 NOVX nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOVX substances for use in therapeutic or diagnostic methods. These NOVX antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. The disclosed NOVX proteins have multiple hydrophilic regions, each of which can be used as an immunogen. These NOVX proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.

20 The NOVX nucleic acids and proteins identified here may be useful in potential therapeutic applications implicated in (but not limited to) various pathologies and disorders as indicated below. The potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration in vivo and in vitro of all tissues and cell types composing (but not limited to) those defined here.

30 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references

mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following
5 detailed description and claims.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel nucleotides and polypeptides encoded thereby. Included in the invention are the novel nucleic acid sequences and their encoded polypeptides.
10 The sequences are collectively referred to herein as "NOVX nucleic acids" or "NOVX polynucleotides" and the corresponding encoded polypeptides are referred to as "NOVX polypeptides" or "NOVX proteins." Unless indicated otherwise, "NOVX" is meant to refer to any of the novel sequences disclosed herein. Table A provides a summary of the NOVX nucleic acids and their encoded polypeptides.

15 **TABLE A. Sequences and Corresponding SEQ ID Numbers**

NOVX No.	Internal Acc. No.	Homology	Nucleic Acid SEQ ID NO.	Polypeptide SEQ ID NO.
1a	nh0318116_20000809_da1	TRAF5	1	2
1b	nh0318116_20000809_da2	TRAF5	3	4
2a	246b18_20000718	KIAA 1246	5	6
2b	CG55265-02	Fibronectin/LLR/Ig	7	8
2c	CG55265-03	Fibronectin/LLR/Ig	9	10
3	ba342c24_20000805_da1	Dematin	11	12
4a	14578444_0_47	Matrilin-2	13	14
4b	CG51018-03	Matrilin-2	15	16
5	SC85803748_A	GABA-receptor	17	18
6a	ba465b22_20000727	Giant larvae homolog	19	20
6b	CG55891-02	Giant larvae homolog	21	22
7	dj1182a14_da1	Macrophage stimulating protein precursor	23	24
8a	138531995	Nucleotide-sugar transporter	25	26
8b	CG111627-01	Nucleotide-sugar transporter	27	26
9	AC018755_da1	OB binding protein-2	28	29

10	30675745_0_499_da1	Trypsin-like protein	30	31
----	--------------------	----------------------	----	----

NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.

The present invention is based in part on nucleic acids encoding proteins that are new members of the following protein families: TRAF5, KIAA 1246-like Leucine rich repeat and fibronectin containing membrane protein, dematin, matrilin-2, GABA-receptor, giant larvae homolog, macrophage stimulating protein precursor, nucleotide-sugar transporter, OB binding protein-2 and trypsin-like protein. More particularly, the invention relates to nucleic acids encoding novel polypeptides, as well as vectors, host cells, antibodies, and recombinant methods for producing these nucleic acids and polypeptides.

NOV1 is homologous to a TRAF5 family of proteins. Thus, the NOV1 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, Stroke, Tuberous sclerosis, Hypercalcaemia, Parkinson's disease, Huntington's disease, Cerebral palsy, Epilepsy, Lesch-Nyhan syndrome, Multiple sclerosis, Ataxia-telangiectasia, Leukodystrophies, Behavioral disorders, Addiction, Anxiety, Pain, Neuroprotection, Diabetes, Autoimmune disease, Immunodeficiencies, Renal artery stenosis, Interstitial nephritis, Glomerulonephritis, Polycystic kidney disease, Systemic lupus erythematosus, Renal tubular acidosis, IgA nephropathy, Systemic lupus erythematosus, Asthma, Emphysema, Scleroderma, Allergy, ARDS, Hemophilia, Hypercoagulation, Idiopathic thrombocytopenic purpura, Transplantation, Graft versus host disease (GVHD), Lymphoedema, Pancreatitis, Obesity, Hyperparathyroidism, Hypoparathyroidism, Endocrine dysfunctions, Growth and reproductive disorders, Fertility, Inflammatory bowel disease, Diverticular disease, Ulcers, Tonsillitis, Endometriosis, and/or other pathologies/disorders.

Tumor necrosis factor (TNF) receptor-associated factors (TRAFs) are signal transducers for members of the TNF receptor superfamily. TRAF proteins are composed of an N-terminal cysteine/histidine-rich region containing zinc RING and/or zinc finger motifs, a coiled coil (leucine zipper) motif, and a homologous region in the C terminus that defines the TRAF family, the TRAF domain. The TRAF domain is involved in self-association and

receptor binding. Members of tumor necrosis factor receptor (TNFR) family signal largely through interactions with death domain proteins and TRAF proteins. Tumor necrosis factor (TNF) receptor-associated factors (TRAFs) are signal transducers for members of the TNF receptor superfamily. The previously identified murine TRAF5 (mTRAF5) has been shown to
5 specifically interact with the lymphotoxin-beta receptor (LT-beta R) and activate the transcription factor NF-kappa B.

NOV2 is homologous to the KIAA 1246/fibronectin/leucine repeat family of proteins. Thus NOV2 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example:
10 Lymphatic Diseases, Skin and Connective Tissue Diseases, Diabetes and Kidney Disease, Cancers, tumors, and Brain Disorders, disorders that can be addressed by controlling and directing cell migration, Alzheimer's disease, Stroke, Tuberous sclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, Cerebral palsy, Epilepsy, Lesch-Nyhan syndrome, Multiple sclerosis, Ataxia-telangiectasia, Leukodystrophies, Behavioral disorders, Addiction,
15 Anxiety, Pain, Neuroprotection, Inflammatory bowel disease, Diverticular disease, Crohn's Disease and/or other pathologies/disorders.

The KIAA 1246-like proteins include the leucine-rich repeat and fibronectin containing membrane protein-like proteins.

The leucine rich-like proteins generally comprise leucine-rich repeats (LRRs),
20 relatively short motifs (22-28 residues in length) found in a variety of cytoplasmic, membrane and extracellular proteins. Although these proteins are associated with widely different functions, a common property involves protein-protein interaction. Although little is known about the 3-D structure of LRRs, it is believed that they can form amphipathic structures with hydrophilic surfaces capable of acting with membranes. *In vitro* studies of a synthetic LRR
25 from *Drosophila* Toll protein have indicated that the peptides form gels by adopting beta-sheet structures that form extended filaments. These results are consistent with the idea that LRRs mediate protein-protein interactions and cellular adhesion. Other functions of LRR-containing proteins include, for example, binding to enzymes and vascular repair. The 3-D structure of ribonuclease inhibitor, a protein containing 15 LRRs, has been determined,
30 revealing LRRs to be a new class of alpha/beta fold. LRRs form elongated non globular structures and are often flanked by cysteine-rich domains.

Fibronectins are multi-domain glycoproteins found in a soluble form in plasma, and in an insoluble form in loose connective tissue and basement membranes. They contain multiple copies of 3 repeat regions (types I, II and III), which bind to a variety of substances including

heparin, collagen, DNA, actin, fibrin and fibronectin receptors on cell surfaces. The wide variety of these substances means that fibronectins are involved in a number of important functions: e.g., wound healing; cell adhesion; blood coagulation; cell differentiation and migration; maintenance of the cellular cytoskeleton; and tumour metastasis. The role of fibronectin in cell differentiation is demonstrated by the marked reduction in the expression of its gene when neoplastic transformation occurs. Cell attachment has been found to be mediated by the binding of the tetrapeptide RGDS to integrins on the cell surface, although related sequences can also display cell adhesion activity. The fibronectin type III repeat region is an approximately 100 amino acid domain, different tandem repeats of which contain binding sites for DNA, heparin and the cell surface. The superfamily of sequences believed to contain FnIII repeats represents 45 different families, the majority of which are involved in cell surface binding in some manner, or are receptor protein tyrosine kinases, or cytokine receptors.

Based on the presence of LRR, fibronectin type III and immunoglobulin domains, it is likely that this novel protein mediates interactions between the cell and its surrounding environment.

NOV3 is homologous to a dematin protein. Thus, the NOV3 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in a variety of therapeutic and diagnostic applications.

Dematin is identified as a human erythroid cytoskeletal, actin-bundling protein. Dematin bundles actin filaments in a phosphorylation-dependent manner and is widely and abundantly expressed. In solution, it exists as a trimer of two 48kDa subunits and one 52kDa subunit. The 48kDa subunit contains a villin-like headpiece domain. Villin is an actin-binding protein of the brush border cytoskeleton. The headpiece domain is essential for villin's actin bundling and actin modulating activity in the microvillar cytoskeleton. Unlike villin, the actin bundling activity of dematin is regulated by cAMP protein kinase-mediated phosphorylation. In comparison to the 48kDa subunit, the 52kDa subunit contains an additional 22 amino acid sequence in the C-terminal headpiece domain. This insertion contains a novel 11 amino acid motif that is shared with human erythrocyte protein 4.2 (palladin). The 11 amino acid stretch forms a nucleotide binding P-loop that directly and specifically binds ATP. Each monomer of dematin contains two F-actin binding sites, one in the headpiece and one in the N-terminal domain. Thus, dematin is an erythroid actin bundling protein whose function may be facilitated via its interaction with ATP.

NOV4 is homologous to a matrilin-2 family of proteins. Thus, NOV4 nucleic acids,

polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: diseases of the heart, blood vessels, lungs, or other smooth muscle tissue as well as diseases of the extracellular matrix tissue, and/or other pathologies/disorders.

5 The matrilin family at present has four members that all share a structure made up of von Willebrand factor A domains, epidermal growth factor-like domains and a coiled coil alpha-helical module. The first member of the family, matrilin-1 (previously called cartilage matrix protein or CMP), is expressed mainly in cartilage. Matrilin-3 has a similar tissue distribution, while matrilin-2 and -4 occur in a wide variety of extracellular matrices. Matrilin-10 1 is associated with cartilage proteoglycans as well as being a component of both collagen-dependent and collagen-independent fibrils and on the basis of the related structures other matrilins may play similar roles. The matrilin genes are strictly and differently regulated and their expression may serve as markers for cellular differentiation.

NOV5 is homologous to the GABA-receptor protein family. Thus NOV5 nucleic
15 acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: cancer, trauma, regeneration (in vitro and in vivo), viral/bacterial/parasitic infection, multiple sclerosis, leukodystrophies, pain, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, cerebral palsy,
20 epilepsy, Lesch-Nyhan syndrome, Ataxia-telangiectasia, behavioral disorders, addiction, anxiety, retinal and visual disorders, and/or other pathologies/disorders.

Neurotransmitter-gated ion channels, such as gamma-aminobutyric acid (GABA), are transmembrane receptor-ion channel complexes that open transiently upon binding of specific ligands, allowing rapid transmission of signals at chemical synapses. Of the five families
25 known, four have been shown to form a sequence-related super-family. These are the gamma-aminobutyric acid (GABA), nicotinic acetylcholine, glycine and the serotonin receptors. The ionotropic glutamate receptors have a distinct primary structure. However, all these receptors are made up of varying subunits surrounding a central pore. Each of these subunits contains a large extracellular N-terminal ligand-binding region; 3 hydrophobic transmembrane domains;
30 a large intracellular region; and a fourth hydrophobic domain. GABA receptors are regulated by anions. They play an important role in regulating neurotransmission. GABA receptors are heterodimers and it serves as an inhibitory neurotransmitter to block the transmission of an impulse from one cell to another in the central nervous system. Medically, GABA has been used to treat both epilepsy and hypertension where it is thought to induce tranquility in

individuals who have a high activity of manic behavior and acute agitation. the expression of different subunits might play a role in neurotransmission in different organs. For example, these subunits show distinct patterns of expression in the brain and their expression is thought to be differentially regulated depending on the environment. GABA is the product of a biochemical decarboxylation reaction of glutamic acid by the vitamin pyridoxal.

NOV6 is homologous to the giant larvae homolog family of proteins. Thus NOV6 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: cancer, disorders of the eyes, ovaries, digestive tract, brain, and/or other pathologies/disorders.

Lethal (2) giant larvae was the first of more than 27 recessive oncogenes identified in *Drosophila*, which provides an excellent model to study neoplastic mechanisms due to the fact that homologs of human oncogenes and tumor suppressors have been isolated and most of the complexes and associated pathways are conserved. The *Drosophila* tumor suppressor genes scribble, discs large and lethal giant larvae appear to act in a common pathway. Mutations in any of these genes lead to loss of apical-basal cell polarity and overproliferation of epithelia, revealing a close connection between cytoarchitecture and growth control. Further, loss of cell polarity and tissue architecture are characteristics of malignant cancers derived from epithelial tissues.

NOV7 is homologous to members of the macrophage stimulating protein precursor family of proteins. Thus, the NOV7 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: Aicardi-Goutieres syndrome 1; Brugada syndrome; Deafness, autosomal recessive 6; Heart block, nonprogressive; Heart block, progressive, 2; Ichthyosiforme erythroderma, congenital, nonbullous; Long QT syndrome-3; Night blindness; congenital stationary; Pituitary ACTH-secreting adenoma; Small-cell cancer of lung; Ventricular fibrillation, idiopathic; entricular tachycardia, idiopathic; HIV infection, susceptibility/resistance to; Von Hippel-Lindau (VHL) syndrome; Cirrhosis; Transplantation, and/or other pathologies/disorders.

Macrophage-stimulating protein (MSP) is an 80-kD serum protein with homology to hepatocyte growth factor (HGF). Its receptor, RON tyrosine kinase, is a new member of the HGF receptor family. The MSP-RON signaling pathway has been implicated in the functional regulation of mononuclear phagocytes. However, the function of this pathway in other types of cells has not been elucidated. In contrast to the HGF receptor, which was expressed at the basolateral surface, RON was localized at the apical surface of ciliated epithelia in the airways

and oviduct. In addition, MSP was found in the bronchoalveolar space at biologically significant concentrations. MSP bound to RON on normal human bronchial epithelial cells with a high affinity ($K_d = 0.5$ nM) and induced autophosphorylation of RON. Activation of RON by MSP led to a significant increase in ciliary beat frequency of human nasal cilia. These findings indicate that the ciliated epithelium of the mucociliary transport apparatus is a novel target of MSP. As ciliary motility is critical for mucociliary transport, such findings suggest that the MSP-RON signaling pathway is a novel regulatory system of mucociliary function and might be involved in the host defense and fertilization.

NOV8 is homologous to the nucleotide-sugar transporter family of proteins. Thus, NOV8 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; cancer (preferably ovarian and pancreatic tumors). Furthermore, they could have efficacy for treatment of patients suffering from metabolic diseases, (preferably diabetes), and/or other pathologies/disorders.

Nucleotide sugar transporters are mainly located in the Golgi membranes and carry nucleotide sugars, that are produced outside the Golgi apparatus, into the organelle, where they serve as substrates for the elongation of carbohydrate chains by glycosyltransferases. They are thus indispensable for cellular glycoconjugate synthesis. Moreover, they may have regulatory roles in producing the structural variety of cellular glycoconjugates.

NOV9 is homologous to a OB binding protein-2 protein. Thus, the NOV9 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: 3-methylglutaconicaciduria, type III; Charcot-Marie-Tooth disease, type 4F; Colorectal cancer; Cone-rod retinal dystrophy-2; DNA ligase I deficiency; Glutaricaciduria, type IIB; Heart block, progressive familial, type I; Hydatidiform mole; Hyperferritinemia-cataract syndrome; Leber congenital amaurosis due to defect in CRX; Liposarcoma; Myotonic dystrophy; Retinitis pigmentosa, late-onset dominant; Spinocerebellar ataxia-13; T-cell acute lymphoblastic leukemia; Trichothiodystrophy; Xeroderma pigmentosum, group D; Diabetes mellitus, noninsulin-dependent; Polio, susceptibility to; Hemophilia; Hypercoagulation; Idiopathic thrombocytopenic purpura; Immunodeficiencies; Graft versus host; Von Hippel-Lindau (VHL) syndrome; Cirrhosis; Fertility; Systemic lupus erythematosus, Autoimmune disease, Asthma, Emphysema, Scleroderma, allergy, ARDS, and/or other pathologies/disorders.

A novel leptin-binding protein of the immunoglobulin superfamily (OB-BP1) and a cross-hybridizing clone (OB-BP2) are identical to Siglec-5. Siglec-5 (sialic acid-binding Ig-like lectin-5), is a novel transmembrane member of the immunoglobulin superfamily, highly related to the myeloid antigen, CD33. The sialic acid-binding immunoglobulin-like lectins (SIGLECs), such as CD33, are a subgroup of the immunoglobulin (Ig) superfamily that mediate protein-carbohydrate interactions. Thus, OB-BP1, OB-BP2/Siglec-5, and CD33/Siglec-3 constitute a unique related subgroup with a high level of overall amino acid identity and may mediate cell-cell recognition events by interacting with sialylated glycoprotein ligands expressed on specific cell populations. Further, OB-BP1 may have a role in leptin physiology, as a molecular sink to regulate leptin serum levels.

NOV10 is homologous to members of the trypsin-like family of proteins. Thus, the NOV10 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: digestion, blood clotting, immune reactions, fertilization of the ovum, various cancers (prostate and/or breast), infectious disease, cystic fibrosis, and/or other pathologies/disorders.

Trypsin is a proteolytic enzyme, or proteinase that acts to degrade protein. Trypsin is one of the three principal digestive proteinases, the other two being pepsin and chymotrypsin. In the digestive process, trypsin acts with the other proteinases to break down dietary protein molecules to their component peptides and amino acids. Trypsin continues the process of digestion (begun in the stomach) in the small intestine where a slightly alkaline environment (about pH 8) promotes its maximal enzymatic activity. Trypsin, produced in an inactive form by the pancreas (pancreatic protease), is remarkably similar in chemical composition and in structure to the other chief pancreatic proteinase, chymotrypsin. Both enzymes also appear to have similar mechanisms of action; residues of histidine and serine are found in the active sites of both. The chief difference between the two molecules seems to be in their specificity. Trypsin is the most discriminating of all the proteolytic enzymes in terms of the restricted number of chemical bonds that it will attack. For this reason, trypsin is widely employed as a reagent for the orderly and unambiguous cleavage of the amino acid sequence of proteins. Trypsin is a pancreatic serine protease with substrate specificity based upon positively charged lysine and arginine side chains. Serine proteases are one of a group of endoproteases from both animal and bacterial sources that share a common reaction mechanism based on formation of an acyl enzyme intermediate on a specific active serine residue. Serine proteases are all irreversibly inactivated by a series of organophosphorus esters, such as diisopropylfluorophosphate (DFP) and by naturally occurring inhibitors (serpins). This group

includes enzymes active in digestion, blood clotting, immune reactions, and fertilization of the ovum. Proteolytic enzymes that exploit serine in their catalytic activity are ubiquitous, being found in viruses, bacteria and eukaryotes. They include a wide range of peptidase activity, including exopeptidase, endopeptidase, oligopeptidase and omega-peptidase activity.

5 The NOVX nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOVX activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, e.g., neurogenesis, cell differentiation, cell proliferation, hematopoiesis, wound healing and angiogenesis.

10 Additional utilities for the NOVX nucleic acids and polypeptides according to the invention are disclosed herein.

NOV1

NOV1 includes two novel TNF Receptor Associated Factor 5-like (TRAF5-like) proteins. The disclosed sequences have been named NOV1a and NOV1b.

15 NOV1a

A disclosed NOV1a nucleic acid of 3675 nucleotides (also referred to as wugc_draft_h_nh0318116_20000809_da1) (SEQ ID NO:1) encoding a novel TRAF5-like protein is shown in Table 1A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 55-57 and ending with a TAG codon at nucleotides 1408-1410.

20 Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 1A. The start and stop codons are in bold letters.

Table 1A. NOV1a nucleotide sequence (SEQ ID NO:1).

```
GCAGCAGCCGCGCCTGCGACCGGCCTCGCGGAGCCGCGCGCCGAGCCCCACAATGGCTTATTTCAGAAGAG
CATAAAGGTATGCCCTGTGGTTTCATCCGCCAGAATTCCGGCAACTCCATTTCTTGGACTTTGAGCCAGT
ATAGAGTACCAAGTTTGTGGAGCGTTTGAAGAGCGCTACAAATGTGCCTTCTGCCACTCGGTGCTTCAACAAC
CCCCACCAGACAGGATGTGGGCACCGCTTCTGCCAGCACTGCATCCTGTCCCTGAGAGAATTAAACACAGTG
CCAATCTGCCCTGTAGATAAAGAGGTCAATCAATCTCAGGAGGTTTTTAAAGACAATTGTGCAAAAGAGAA
GTCTCAACTTATATGTATATGTCAGCAATGCTCCTGGATGTAATGCCAAGGTTATTCTGGGCCGGTACCAG
GATAAACGGGAGGAACCTGCAGCAACATGAGCATTAGCCTTACGGGAGCACATGCGTTTGGTTTTAGAAAAG
AATGTCCAATTAGAAGAACAGATTTCTGACTTACACAAGAGCCTAGAACAGAAAGAAAGTAAATCCAGCAG
CTAGCAGAACTATAAAGAACTTGAAAAGGAGTTCAAGCAGTTTGACAGTTGTTTTGGCAAAAATGGAAGC
TTCTTCCCAACATCCAGGTTTTTGCCAGTCACATTGACAAGTCAGCTTGGCTAGAAGCTCAAGTGCATCAA
TTATTACAAATGGTTAACCAGCAACAAAATAAATTTGACCTGAGACCTTTGATGGAAGCAGTTGATACAGTG
AAACAGAAAATTACCTGCTAGAAAACAATGATCAAAAGATTAGCCGTTTTAGAAGAGGAACTAACAAACAT
GATACCCACATTAATATTCATAAAGCAGCTGAGTAAAAATGAAGAGCGATTTAACTGCTGGAGGGTACT
TGCTATAATGGAAGCTCATTGGAAGGTGACAGATTACAAGATGAAGAAGAGAGAGGCGGTGGATGGGCAC
ACAGTGTCCATCTTCAGCCAGTCCTTCTACACCAGCCGCTGTGGCTACCGCTCTGTGCTAGAGCATACCTG
AATGGGGATGGGTGAGGAGGGGTGACACCTGTCCCTATACTTGTGGTTCATGCGAGGAGAGTTTGACTCA
CTGTTGCAGTGGCCATTACAGGAGAGGGTGACCTGATGCTTCTGGACCAAGAGTGGCAAAAAGAACATTATG
GAGACCTTCAACCTGACCCCAATAGCAGCAGCTTTAAAGACCTGATGGGAGATGAACATTGCATCTGGC
TGTCCCGCTTTGTGGCTCATTCTGTTTTGGAGAATGCCAAGAAGCGCTACATTAAAGATGACACTCTGTTT
TTGAAAGTGGCCGTGGACTTAACAGCTGGAGGATCTTAGTCACTGTTATGGGGTGATAAGAGGACTTCT
TGGGGCCAGAACTGTGGAGGAGAGCATTGATTATCATATTGACCTGGATTAGACTCAAAGCACATTTG
TATTTGCCTTTTTCCTTAACGTTTGAAGTCAGTTTAAACTTCTGAAGTGCTGTCTTTTACATTTTACTCT
GTCCAGTTTGAAACTTAAACTCTTAGAATATTCTTATTATTATTTTATATTTTCTTGAAGATGG
```

```

TAAGTTTCTTGAAGTTTTTGGGGCGTTTCTCTTTTACTGGTGCTTAGCGCAGTGTCTCGGGCACTCTAAATA
TTGAGTGTTATGGAGGACACAGAGGTAGCAGAAATCCCAGTTGAAAATGTTTGTATTTTTATGTTTGGCCT
ATTGATTTCTAGACCTGGCCTTAAGTCTGCAAAAGCCATCTTTATAAGGTAGGCTGTTCCAGTTAAGAAGTGG
GTGATGTAGTTACAAAGATAATATGCTCAGTTTGGACCTTTTTTTCAGTTAAATGCTAAATATATGAAAATT
ACTATACCTCTAAGTATTTTCATGAAATTCACCAGCAGTTTGCAGCACAGTTTTCAGGCTGCATAGAA
CTGGTGAATGGGGTAAGCATTTCATTCTCTCTGCTGAAGTAAAGCAGAAAGTACTGCATAGTATATAGAT
ATAGCCAGCTAGCTAAAGTTCAGATTTTGTAGGTTCAACCCCTATGAAAAAACTATTTCTAGGTCAAAA
ATGGTAAAAAATTAGCAGTTTCATAAGATTCAACCAATAAATATATATATACACACACATACATATACA
CCTATATATGTGTATACAAACAGTTCGAATGTATTTTGGTGACAGTAATAATCAATGTGAGGATGGATA
GAATTTAGTATATGATAGAGAAAATGTCATAAATGGATAAAAGGAATTTACAACCTTGAGGAGAAAACCTTTA
CAATTTCTATGGGTGTCAGAAGTACTCTCAGCGAAAACCTGATGGCTAAAACAGTATCTACTATTCTCTGAT
AACTTTTTTTTTTGAGACAGAGTTTCATTGTCAACCCAGGCTGGAGTACAGTGGCATGATCTCAGCTCACTGCA
AACTCTGCCTCCCGAATTCAAGTGATTCTCTGCCTCAGCTCCTGAGTAGCTGGGATTACAGGCGCCCGTCTC
ACCACCCAGGTAATTTTTGTATTTTTAGTAGAGACGGAGTTTTGCCATGTTGGCCAAGCTGATCTCAAAAC
TCTGTACCTCAAGTGATCTGCCCGCCTCGGCCTCCCAAAGTGCTGAGATTACAGGCATGACCCACCGGCTCA
AGCCTCTGACAACCTATTGAATTTGTAAGCTGCTATGCAAAATGGGCATTTATATAAACTTGTGATGTTTCTTG
TCAGAAATCTGAGTACTCTGTGAGAAGCAGAAATGATCAATTCTTATGCATCTATCTGTATGGGTCTGAAG
GTGTATATACAACTGAGATGAGTCCTTATGACTCTTGATAAGCCTGAGTTTAACAACAACAAAATAGCCA
TTTGTCTCTGAGCCCTTCTGCGTTGTTATGCCACTTCCCTACTGCTCATATGCACGCTGGCTCCCTGGGCAC
GCAAGGATGAGTATGGGCCATGGGCCCTGTAGAGCTGCTTACCTGGTGATGACCATGCACCTTACAATTTT
TGAAACAGTTAACCTATAGAAGCATGCTTTATATGAGTGTCTTCTGGGAAGAGGAACCTTCTTAATCTCTTC
TTCACAAACAGGATATATACTGAAGAACTAGAGTGTCACTGCTGGTGAAGTGTGGCACGGTTGCTCAACACATC
ACCTCGGACAAATTCAGGAAGCATTTCTTTAGCCCAAGTCCAGACCCAGGTGCTCTGTATGTTTGTTTTT
AATATTCATCATATCCAAGTTCACTCTGCTCTCTGAGCAGTGGAGATCATATTGCTGTAACCTCTTTTAA
GTAGTTGATGTGGAAAACATTTTAAAGTGAATTTGTCAAATGCTGGTTTTGTGTTTTATCCAACCTTTTGTG
CATATATATAAGTATGTGATGGCATGGTTTGTCTAGGAGTTCAGAGTTCCTTCATCATCGAAATAGTGATT
AAGTGATCCAGAACAAAGGAATACTAGAGTAAAAAGCACCTCTTTTTTCAGAAAAAATAAAAAAAAAAAAAA
AAA

```

The TRAF5 disclosed in this invention maps to chromosome 1.

The sequence of the invention was derived by laboratory cloning of cDNA fragments covering the full length and/or part of the DNA sequence of the invention, and/or by in silico prediction of the full length and/or part of the DNA sequence of the invention from public human sequence databases. The laboratory cloning was performed by the following methods- SeqCalling™ or Exon Linking. These methods are described in detail in Example 2.

RACE: Techniques based on the polymerase chain reaction such as rapid amplification of cDNA ends (RACE), were used to isolate or complete the predicted sequence of the cDNA of the invention. Usually multiple clones were sequenced from one or more human samples to derive the sequences for fragments. The following human samples from different donors were used adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain - whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea and uterus for the RACE reaction. The sequences derived from these procedures were included in the SeqCalling Assembly process described in the preceding paragraph.

In a search of sequence databases, it was found, for example, that the nucleic acid sequence of the disclosed NOV1a has 3675 of 3993 bases (92 %) identical to a 3993 bp TNF Receptor Associated Factor 5 mRNA from Homo sapiens (GENBANK-ID: AB000509|acc:AB000509). Public nucleotide databases include all GenBank databases and the GeneSeq patent database.

In all BLAST alignments herein, the "E-value" or "Expect" value is a numeric indication of the probability that the aligned sequences could have achieved their similarity to the BLAST query sequence by chance alone, within the database that was searched. The Expect value (E) is a parameter that describes the number of hits one can "expect" to see just by chance when searching a database of a particular size. It decreases exponentially with the Score (S) that is assigned to a match between two sequences. Essentially, the E value describes the random background noise that exists for matches between sequences.

The Expect value is used as a convenient way to create a significance threshold for reporting results. The default value used for blasting is typically set to 0.0001. In BLAST 2.0, the Expect value is also used instead of the P value (probability) to report the significance of matches. For example, an E value of one assigned to a hit can be interpreted as meaning that in a database of the current size one might expect to see one match with a similar score simply by chance. An E value of zero means that one would not expect to see any matches with a similar score simply by chance. See, e.g., <http://www.ncbi.nlm.nih.gov/Education/BLASTinfo/>. Occasionally, a string of X's or N's will result from a BLAST search. This is a result of automatic filtering of the query for low-complexity sequence that is performed to prevent artifactual hits. The filter substitutes any low-complexity sequence that it finds with the letter "N" in nucleotide sequence (e.g., "NNNNNNNNN") or the letter "X" in protein sequences (e.g., "XXX"). Low-complexity regions can result in high scores that reflect compositional bias rather than significant position-by-position alignment. Wootton and Federhen, Methods Enzymol 266:554-571, 1996.

The encoded protein of NOV1a having 451 amino acid residues (SEQ ID NO:2) is presented using the one-letter code in Table 1B. The full amino acid sequence of the protein of the invention was found to have 451 of 557 amino acid residues (81 %) identical to, and 451 of 557 amino acid residues (81 %) similar to, the 557 amino acid residue TNF Receptor Associated Factor 5 protein from Homo sapiens (Human) (SPTREMBL-ACC:O00463 TRAF5).

Table 1B. Encoded NOV1a protein sequence (SEQ ID NO:2).

MAYSEEHKGMPCGFIRQNSGNSISLDFEPSIEYQFVERLEERYKCAFCHSVLHNPHTGCGHRFCQHCILSL
 RELNTPVICPVDKEVIKSQEVFKDNCCKREVLNLYVYCSNAPGCNAKVLGRYQDKRRNLQQHEHSALREHM
 RLVLKENVQLEEQISDLHKSLEQKESKIQQLAETIKKLEKEFKQFAQLFGKNGSFLPNIOVFASHIDKSAWL
 EAQVHQLLMVNQQNKFDLRPLMEAVDTVKQKITLLENNDQRLAVLEETNKHDTHINIHKAQLSKNEERF
 KLEEGTCYNGKLIWKVTDYKMKKREAVDGHVTSIFSQSFYTSRCGYRLCARAYLNGDGSGRGSHLSLYFVVM
 RGEFDSLLQWPFQRQVTLMLLDQSGKKNIMETPKPDNSSFKRPDGMNIASGCPRFVAHSVLENAKNAYI
 KDDTLFLKVAVDLTDLEDL

NOV1b

In an alternative embodiment, a NOV1 variant is NOV1b of 3480 nucleotides (also referred to as wugc_draft_h_nh0318116_20000809_da2) (SEQ ID NO:3) is shown in Table 1C. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 55-57 and ending with a TAG codon at nucleotides 1213-1215. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 1C. The start and stop codons are in bold letters.

Table 1C. NOV1b nucleotide sequence (SEQ ID NO:3).

GCAGCAGCCGCGCCTGCAGACCGGCCTCGCGAGCCGCGCGCCGAGCCCCACAATGGCTTATTCAGAAGAG
 CATAAAGGTATGCCCTGTGGTTTCATCCGCCAGAATTCCGGCACTCCATTTCTTGGACTTTGAGCCCACT
 ATAGAGTACCAGTTTGTGGAGCGGTTGGAAGAGCGCTACAAATGTGCCTTCTGCCACTCGGTGCTTCAAC
 CCCCACCAGACAGGATGTGGGACCGCTTCTGCCAGCACTGCATCCTGTCCCTGAGAGAATTAAACACAGTG
 CCAATCTGCCCTGTAGATAAAGAGGTATCAAAATCTCAGGAGATTCTGACTTACACAAGAGCCTAGAACAG
 AAAGAAAGTAAAAATCCAGCAGCTAGCAGAACTATAAAGAACTTGAAAAGGAGTTCAAGCAGTTTGACAG
 TTGTTTGGCAAAAATGGAAGCTTCTCCCAACATCCAGGTTTTTGCCAGTCACATTGACAAGTCAGCTTGG
 CTAGAAGCTCAAGTGCATCAATTATTACAAATGGTTAAACCAGCAACAAAATAAAATTTGACCTGAGACCTTTG
 ATGGAAGCAGTTGATACAGTGAACAGAAAATTACCTGCTAGAAAACAATGATCAAAGATTAGCCGTTTAA
 GAAGAGGAACTAACAAACATGATACCCACATTAATTCATAAAGCACAGCTGAGTAAAAATGAAGAGCGA
 TTTAACTGCTGGAGGGTACTTGTCTATAATGGAAGCTCATTGGAAGGTGACAGATTACAAGATGAAGAA
 AGAGAGCGGTGGATGGGCACACAGTGTCCATCTTCAGCCAGTCTTCTACACCGCGCTGTGGCTACCGG
 CTCTGTCTAGAGCATACCTGAATGGGGATGGGTACGGGAGGGGGTACACCTGTCCCTATACCTTTGTGGTC
 ATGCGAGGAGAGTTTGACTCACTGTTCAGTGGCCATTGAGGAGAGGGTGACCCTGATGCTTCTGGACCAG
 AGTGGCAAAAAGAACATTATGGAGACCTTCAAACTGACCCCAATAGCAGCAGCTTTAAAAGACCTGATGGG
 GAGATGAACATTGGCATCTGGCTGTCCCGCTTTGTGGCTCATTCTGTTTTGAGAAATGCCAAGAACCGCTAC
 ATTAAGATGACACTCTGTCTTGAAGTGGCCGTGGACTTAACTGACCTGGAGGATCTCTAGTCACTGTTA
 TGGGGTGATAAGAGGACTTCTTGGGGCCAGAACTGTGGAGGAGAGCACATTGATTATCATATTGACCTGGA
 TTTAGACTCAAAGCACATTGTATTGCTTTTCTTAACTTTGAAGTCAGTTTAAAACCTTCTGAAGTGC
 TGTCTTTTACATTTTACTCTGTCCAGTTTGAACCTTAAACTCTTAGAATATCTCTATTATTATTATAT
 TTTATATTTCTTGAAAGATGGTAAGTTTCTTGAAGTTTGTGGGCGTTTCTCTTTACTGGTGCTTAGCGCA
 GTGTCTCGGGCACTCTAAATATTGAGTGTTATGGAGGACACAGAGGTAGCAGAAATCCAGTTGAAAATGTTT
 TGATATTTTATTGTTTGGCCTATTGATTCTAGACCTGGCCTTAACTCTGCAAAAGCCATCTTTATAAGGTAG
 GCTGTTCCAGTTAAGAAGTGGGTGATGTAGTTACAAAGATAATATGCTCAGTTTGGACCTTTTTTTCAGTTA
 AATGCTAAATATATGAAAATTACTATACCTCTAAGTATTTTCATGAAATTCACCAGCAGTTTGCAAGCACAG
 TTTTGCAAGGCTGCATAAGAACTGGTGAATGGGTAAGCATTTCATTCTTCTGCTGAAGTAAAGCAGAAA
 GTACTGCATAGTATATGAGATATAGCCAGCTAGCTAAAGTTTCAAGTTTGTAGGTTCAACCTATGAAAAA
 AACTATTTTTCATAGGTCAAAAATGGTAAAAAATTAGCAGTTTTCATAAGATTCAACCAATAAATATATATAT
 ACACACACATACATATACACCTATATATGTGTGTATACAAACAGTTTCAAGTATTTTGGTGACAGTAAT
 AAATCAATGTGAGGATGGATAGAATTTAGTATATGATAGAGAAAATGTCATAAATGGATAAAAGGAATTTAC
 AACTTGAGGAGAAAACCTTTACAATTTCTATGGGTGTGAGAAGTACTCTCAGCGAAAACCTGATGGCTAAAA
 CAGTATCTACTATTCTCTGATACTTTTTTTTTGAGACAGAGTTTCATTGTCAACCAGGCTGGAGTACAGTG
 GCATGATCTCAGCTCACTGCAAACTCTGCCTCCCGAATTCAAGTGATTCTCTGCCTCAGCCTCTGAGTAG
 CTGGGATTACAGCGCGCCGTCACCAACCCAGGTAATTTTGTATTTTTAGTAGAGACGGAGTTTGTCCATG
 TTGGCCAAGCTGATCTCAAACTCTGACCTCAAGTGATCTGCCGCGCTCGGCCTCCCAAGTGTGAGATTA
 CAGGCATGACCCACCGCTCAAGCCTCTGACAACTATTGAATTTGTAAGCTGCTATGCAAAATGGGCATTTAT
 ATAACTTGTGATGTTTCTGTGAGAACTCTGAGTACTCTGTGAAGAACAGAAATGATCATATTTATGCA
 TCTATCTGATGGGTCTGAAGGTGATATACAACTGAGATGAGTCCTTATGACTCTTGATAAGCTGAGTT
 TAACAACAACAAAATGCCAAGTTGTCTGAGCCCTTCTGCGTTGTTATGCCACTTCCCTACTGCTCATATG

```

CACGCTGGCTCCCCTGGGCACGCAAGGATGAGTATGGGCCATGGGCCCTGTAGAGCTGCTTACCTGGTGAT
GACCATGCACCTTACAATTTCTGAACAGTTAACCCCTATAGAAGCATGCTTTATATGAGTGTCTTCTGGGAAG
AGGAACCTTCTTAATCTCTTCTGTGGGATTTCAAAATGCTAAAGACTCACACTGCAGCAATCATCCCAGAT
GATTAAATTCAAAGAAATAGGTTCAACAGGAATATACTGAAGAACTAGAGTGTCACTGCTGGTGAAGTGT
GGCAGGTTGCTCAACACATCACCTCGGACAAATTCAGGAAGCATTCTTTAGCCCAAGTCCAGACCCAG
GTGCTCTGTATGTTTGTCTTTAATATTCATCATATCCAAGTTCACCTCTGTCTTCTGAGCAGTGGGAAGATCA
TATGCTGTAACTTCTTTAAGTAGTTGATGTGGAAAAATTAAAGTGAATTGTCAAATGCTGGTCTTT
GTGTTTTATCCAACITTTGTGCATATATATAAGTATGTCATGGCATGGTTTGCTTAGGAGTTCAGAGTTCC
TTTCATCATCGAAATAGTGATTAAGTATCCAGAACAGGAATACTAGAGTAAAAGCACCTCTTTTCAGA
AAAAAAAAAAAAAAAAAAAAA

```

In a search of sequence databases, it was found, for example, that the nucleic acid sequence of NOV1b has 3480 of 3993 bases (87 %) identical to a 3993 bp TNF Receptor Associated Factor 5 mRNA from Homo sapiens (GENBANK-ID: AB000509|acc:AB000509).

5 The encoded protein of NOV1b (SEQ ID NO:4) having 386 amino acid residues is presented using the one-letter code in Table 1D.

Table 1D. Encoded NOV1b protein sequence (SEQ ID NO:4).

```

MAYSEEHKGMPCGFIRQNSGNSISLDFEPSIEYQFVERLEERYKCAFCHSVLHNPHTGCGHRFCQHCILSL
RELNTVPICPVDKEVIKSQEISDLHKSLEQKESKIQQLAETIKKLEKEPKQFAQLFGKNGSFLPNIQVFASH
IDKSAWLEAQVHQLLQMVNQONKFDLRPLMEAVDTVQKILTLENNDQRLAVLEEETNKHDTINIHKAQL
SKNEERFKLLEGTCTYNGKLIWKVTDYKMKREAVDGHVTSIFSQSFYTSRCGYRLCARAYLNGDGSGRGSHL
SLYFVVMRGEFDSLLQWPFQRVTLMLLDQSGKKNIMETFKPDPNSSFKRPDGMNIIASGCPRFVAHSVLE
NAKNAYIKDDTLFLKVAVDLTDLEDL

```

10 The full amino acid sequence of the protein of NOV1b was found to have 386 of 557 amino acid residues (69 %) identical to, and 386 of 557 amino acid residues (69 %) similar to, the 557 amino acid residue TNF Receptor Associated Factor 5 protein from Homo sapiens (Human) (SPTREMBL-ACC:O00463 TRAF5).

15 The TRAF5-like protein, NOV1, disclosed in this invention is expressed in at least the following tissues: Aorta, Ascending Colon, Brain, Chorionic villus, Colon, Dermis, Epidermis, Foreskin, Kidney, Lung Lymphoid tissue, Pancreas, Parathyroid Gland, Peripheral Blood, Pituitary, Placenta, Prostate, Small Intestine, Spleen, Stomach, Tonsils, Uterus, Whole organism.

20 The SignalP, Psort and/or Hydropathy results predict that NOV1a and NOV1b have no known signal peptide and are likely to be localized to the cytoplasm with a certainty of 0.4500. In alternative embodiments, NOV1 polypeptide is located to the microbody (peroxisome) with a certainty of 0.3000, the mitochondrial matrix space with a certainty of 0.1000, or the lysosome (lumen) with a certainty of 0.1000.

Homologies to any of the above NOV1 proteins will be shared by the other NOV1 protein insofar as they are homologous to each other. Any reference to NOV1 is assumed to refer to both of the NOV1 proteins in general, unless otherwise noted.

Additional SNP variants of NOV1 are disclosed in Example 3 and TaqMan data can be found in Example 1. The amino acid sequence of NOV1 has high homology to other proteins as shown in Table 1E.

Table 1E. BLASTX results for NOV1			
Sequences producing High-scoring Segment Pairs:			Smallest Sum
		High Score	Prob P (N)
patp:AAW27609 Murine TRAF5 - Mus sp, 558 aa	1386	1.9e-205	
patp:AAW29257 Murine TRAF5, a TNF receptor associated factor family protein - Murine sp, 558 aa	1381	6.5e-205	
patp:AAW27610 Human TRAF5 - Homo sapiens, 557 aa	1689	1.0e-173	
patp:AAW29258 Human TRAF5, a TNF receptor associated factor family protein - Homo sapiens, 557 aa	1689	1.0e-173	
patp:AAY98168 Human TRAF5 protein - Homo sapiens, 557 aa	1689	1.0e-173	

5

NOV1 also has homology to the proteins shown in the BLASTP data in Table 1F.

Table 1F. BLASTP results for NOV1					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
ptnr:SPTREMBL- ACC:P70191	TRAF5 - <i>Mus musculus</i> (Mouse)	558	262/325 (80%)	296/325 (91%)	2.8e-205
ptnr:SPTREMBL- ACC:Q61480	TRAF5 - <i>Mus musculus</i> (Mouse)	558	261/325 (80%)	295/325 (90%)	9.5e-205
ptnr:SPTREMBL- ACC:O00463	TRAF5 (TNF RECEPTOR ASSOCIATED FACTOR 5) - <i>Homo sapiens</i> (Human)	557	336/392 (85%)	348/392 (88%)	1.5e-173
ptnr:pir-id:S68467	CD40 receptor-associated protein CAP-1 - human	543	148/335 (44%)	228/335 (68%)	1.5e-94
ptnr:SWISSNEW- ACC:Q13114	TNF receptor associated factor 3 (CD40 receptor associated factor 1) (CRAF1) (CD40 binding protein) (CD40BP) (LMP1 associated protein) (LAP1) (CAP-1) - <i>Homo sapiens</i> (Human)	568	163/401 (40%)	252/401 (62%)	1.0e-71

The homology between the sequences in Table 1F as well as between the NOV1 variants is shown graphically in the ClustalW analysis shown in Table 1G. In the ClustalW alignment of the NOV1 proteins, as well as all other ClustalW analyses herein, the black outlined amino acid residues indicate regions of conserved sequence (*i.e.*, regions that may be required to preserve structural or functional properties), whereas non-highlighted amino acid residues are less conserved and can potentially be altered to a much broader extent without altering protein structure or function.

Table 1G. ClustalW Analysis of NOV1

10	1) NOV1a (SEQ ID NO:2)
	2) NOV1b (SEQ ID NO:4)
	3) ptmr:SP TREMBL-ACC:P70191 (SEQ ID NO:32)
	4) ptmr:SP TREMBL-ACC:Q61480 (SEQ ID NO:33)
	5) ptmr:SP TREMBL-ACC:O00463 (SEQ ID NO:34)
15	6) ptmr:pir-id:S68467 (SEQ ID NO:35)
	7) ptmr:SWISSNEW-ACC:Q13114 (SEQ ID NO:36)
	10 20 30 40 50
20	NOV1a MAYSEEHKGMPCGFIR-----QNSGNSISLDFEFSIEYQFVERLEE
	NOV1b MAYSEEHKGMPCGFIR-----QNSGNSISLDFEFSIEYQFVERLEE
	P70191 MAHSEEQAAPVCAFIR-----QNSGNSISLDFEEDTEYQFVEQLEE
	Q61480 MAHSEEQAAPVCAFIR-----QNSGNSISLDFEEDTEYQFVEQLEE
	O00463 MAYSEEHKGMPCGFIR-----QNSGNSISLDFEFSIEYQFVERLEE
25	S68467 -MESSKKMDSE GALQTNPPLKLHTDRSACTPWFVPEOGGYKEKFKVTIVED
	Q13114 -MESSKKMDSE GALQTNPPLKLHTDRSACTPWFVPEOGGYKEKFKVTIVED
	60 70 80 90 100
30	NOV1a RYKCAFCHSVLHNPHTGCGHRFCQHCTLSLRELNTVPICPVDKEVIKSO
	NOV1b RYKCAFCHSVLHNPHTGCGHRFCQHCTLSLRELNTVPICPVDKEVIKSO
	P70191 RYKCAFCHSVLHNPHTGCGHRFCQOCTLSLRELNSVPICPVDKEVIKPO
	Q61480 RYKCAFCHSVLHNPHTGCGHRFCQOCTLSLRELNSVPICPVDKEVIKPO
	O00463 RYKCAFCHSVLHNPHTGCGHRFCQHCTLSLRELNTVPICPVDKEVIKSO
35	S68467 RYKCEKCHLVLCSPKQTECGHRFCESMAALLSS-SSPKCTACQESIVKD
	Q13114 RYKCEKCHLVLCSPKQTECGHRFCESMAALLSS-SSPKCTACQESIVKD
	110 120 130 140 150
40	NOV1a EVFKDNCKKREVLNLYVYCSNAP-GCNAKVILGRYQD-----
	NOV1b EVFKDNCKKREVLNLYVYCSNAP-GCNAKVILGRYQD-----
	P70191 EVFKDNCKKREVLNLYVYCKNAP-GCNARIILGRFQDHLQ-HCSFQAVPC
	Q61480 EVFKDNCKKREVLNLYVYCKNAP-GCNARIILGRFQDHLQ-HCSFQAVPC
	O00463 EVFKDNCKKREVLNLYVYCSNAP-GCNAKVILGRYQDHLQ-QCLFQPVQC
45	S68467 EVFKDNCKKREILALQIYCRNESRGCAEQTLGHLLVHLKNDCHFEELPC
	Q13114 EVFKDNCKKREILALQIYCRNESRGCAEQTLGHLLVHLKNDCHFEELPC
	160 170 180 190 200
50	NOV1a -----
	NOV1b -----
	P70191 PNESCREAMLKRDVKEHLSAYCRFREEKCLYCKRDIVVTNLQDHEENSCP
	Q61480 PNESCREAMLKRDVKEHLSAYCRFREEKCLYCKRDIVVTNLQDHEENSCP
	O00463 SNEKREAPVLRKDLKEHLSASCQFRKEKCLYCKRDIVVTNLQDHEENSCP
55	S68467 VRPDCKEKVLKDLRDLHVEKACKYREATCSHCKSQVPMIALQKHEDTDCP

Q13114 VRPDCMKSKVLRKDLRDVEKAKCKYREATCSHCKSOVPMIALQKHEEDTDCP
210 220 230 240 250
5 NOV1aKRRNF
NOV1b
P70191 AYPVSCPNRC-VQTIIPRARVNEHLTVCPAEQDCPFKHYGCTVKGKRGNI
Q61480 AYPVSCPNRC-VQTIIPRARVNEHLTVCPAEQDCPFKHYGCTVKGKRGNI
O00463 EYPVFCPNRC-AKTIILKTEVDEHLAVCPAEQDCPFKHYGCAVTDKRRNL
10 S68467 CVVVSCPHKCSVQITLLRSE-----GTNQOI
Q13114 CVVVSCPHKCSVQITLLRSELSAHLSECVNAPSTCSFKRYGCVFQGTNQOI
260 270 280 290 300
15 NOV1a QQEHSALREBMRVLVLEKNVQLEEQISDLHKSLEQESKIQQLAETIKKL
NOV1bEISDLHKSLEQESKIQQLAETIKKL
P70191 LEHERAALQDENLIVLEKNVQLEQISDLHKSLEQESKIQQLAETIKKL
Q61480 LEHERAALQDENLIVLEKNVQLEQISDLHKSLEQESKIQQLAETIKKL
O00463 QQEHSALREBMRVLVLEKNVQLEEQISDLHKSLEQESKIQQLAETIKKL
20 S68467 KAHEASSAVQEVNLLKEWSNSLEKKVSLLONESVEKNKSIQSLHNOICSF
Q13114 KAHEASSAVQEVNLLKEWSNSLEKKVSLLONESVEKNKSIQSLHNOICSF
310 320 330 340 350
25 NOV1a EKEFKQFAQLFGKNGSFLPNIQ-VFASHIDKSAWLEAQVHQLLOMVNQOQ
NOV1b EKEFKQFAQLFGKNGSFLPNIQ-VFASHIDKSAWLEAQVHQLLOMVNQOQ
P70191 EKELKQFTQMFGRNGTFLSNVO-ALTSHTDKSAWLEAQVRQLLOTVNQOP
Q61480 EKELKQFTQMFGRNGTFLSNVO-ALTSHTDKSAWLEAQVRQLLOTVNQOP
O00463 EKEFKQFAQLFGKNGSFLPNIQ-VFASHIDKSAWLEAQVHQLLOMVNQOQ
30 S68467 ETETIERQKEMLRNNEISKILHLQVIDSOAEKLEKDKETIRSPFRONWEAD
Q13114 ETETIERQKEMLRNNEISKILHLQVIDSOAEKLEKDKETIRPPFRONWEAD
360 370 380 390 400
35 NOV1a NKFDLRLPLMEAVDTVKOKITLLENNDQ-----RLAVLEBETNKHDTHI
NOV1b NKFDLRLPLMEAVDTVKOKITLLENNDQ-----RLAVLEBETNKHDTHI
P70191 SRLDLRLSLVDAVDSVKORITOLEASDQ-----RLVLEGETSKHDAHI
Q61480 SRLDLRLSLVDAVDSVKORITOLEASDQ-----RLVLEGETSKHDAHI
O00463 NKFDLRLPLMEAVDTVKOKITLLENNDQ-----RLAVLEBETNKHDTHI
40 S68467 S-----MKSSVESLQNRVTELESVDKSAGQVARNTGLLESQLSRHDOMT
Q13114 S-----MKSSVESLQNRVTELESVDKSAGQVARNTGLLESQLSRHDOMT
410 420 430 440 450
45 NOV1a NIIHKAQLSKNEERFKLEGTCTYNGKLIWKVTDYKMKKREAVDGHVTSIFS
NOV1b NIIHKAQLSKNEERFKLEGTCTYNGKLIWKVTDYKMKKREAVDGHVTSIFS
P70191 NIIHKAQLSKNEERFKLEGTCTYNGKLIWKVTDYKMKKREAVDGHVTSIFS
Q61480 NIIHKAQLSKNEERFKLEGTCTYNGKLIWKVTDYKMKKREAVDGHVTSIFS
O00463 NIIHKAQLSKNEERFKLEGTCTYNGKLIWKVTDYKMKKREAVDGHVTSIFS
50 S68467 SVHDIRADMDLRFQVLETSYNGVLIWKVTDYKMKKREAVDGHVTSIFS
Q13114 SVHDIRADMDLRFQVLETSYNGVLIWKVTDYKMKKREAVDGHVTSIFS
460 470 480 490 500
55 NOV1a QSFYTSRCGYRLCARAYLNGDGSGRGSHLSLYFVVMRGEFDSLLQWPFRO
NOV1b QSFYTSRCGYRLCARAYLNGDGSGRGSHLSLYFVVMRGEFDSLLQWPFRO
P70191 QPFYTSRCGYRLCARAYLNGDGSGRGSHLSLYFVVMRGEFDSLLQWPFRO
Q61480 QPFYTSRCGYRLCARAYLNGDGSGRGSHLSLYFVVMRGEFDSLLQWPFRO
O00463 QSFYTSRCGYRLCARAYLNGDGSGRGSHLSLYFVVMRGEFDSLLQWPFRO
60 S68467 QPFYTGFGYKMCARVYLNQDGMGKGTHLSLYFVVMRGEYDALLPWPFRO
Q13114 QPFYTGFGYKMCARVYLNQDGMGKGTHLSLYFVVMRGEYDALLPWPFRO
510 520 530 540 550

	NOV1a	RVTLMMLLDQSGKKN-IMETFKPDPN	SSSFKRPD	GEMN	IASGCP	RFVAHSV
	NOV1b	RVTLMMLLDQSGKKN-IMETFKPDPN	SSSFKRPD	GEMN	IASGCP	RFVAHSV
	P70191	RVTLMMLLDQSGKKNHIVETFKADPN	SSSFKRPD	GEMN	IASGCP	RFVSHST
5	Q61480	RVTLMMLLDQSGKKNHIVETFKADPN	SSSFKRPD	GEMN	IASGCP	RFVSHST
	O00463	RVTLMMLLDQSGKKN-IMETFKPDPN	SSSFKRPD	GEMN	IASGCP	RFVAHSV
	S68467	KVTLMMLMDQGSSRRHLGDAFKPDPN	SSSFKKPT	GEMN	IASGCP	VFVAQIV
	Q13114	KVTLMMLMDQGSSRRHLGDAFKPDPN	SSSFKKPT	GEMN	IASGCP	VFVAQIV
10		560	570			
	NOV1a	LENARKNAYIKDDTFLKVAVDLTDLEDL				
	NOV1b	LENARKNAYIKDDTFLKVAVDLTDLEDL				
	P70191	LENSKNTYIKDDTFLKVAVDLTDLEDL				
15	Q61480	LENSKNTYIKDDTFLKVAVDLTDLEDL				
	O00463	LENARKNAYIKDDTFLKVAVDLTDLEDL				
	S68467	LENG--TYIKDDTIFIKVIVDTS	SDL	PDP		
	Q13114	LENG--TYIKDDTIFIKVIVDTS	SDL	PDP		
20						

The presence of identifiable domains in NOV1, as well as all other NOVX proteins, was determined by searches using software algorithms such as PROSITE, DOMAIN, Blocks, Pfam, ProDomain, and Prints, and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro>). DOMAIN results for NOV1 as disclosed in Table 1H, were collected from the Conserved Domain Database (CDD) with Reverse Position Specific BLAST analyses. This BLAST analysis software samples domains found in the Smart and Pfam collections. For Table 1H and all successive DOMAIN sequence alignments, fully conserved single residues are indicated by black shading or by the sign (!) and "strong" semi-conserved residues are indicated by grey shading or by the sign (+). The "strong" group of conserved amino acid residues may be any one of the following groups of amino acids: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW.

Table 1H lists the domain description from DOMAIN analysis results against NOV1. This indicates that the NOV1 sequence has properties similar to those of other proteins known to contain this domain.

Table 1H. Domain Analysis of NOV1

IPR003007; MATH domain Score = 138.8, Expect = 9.6e-38

Secreted forms of the alpha subunit of recombinant mouse meprin A include an NH2-terminal prosequence, a catalytic domain, and three COOH-terminal domains designated as MAM (meprin, A-5 protein, receptor protein-tyrosine phosphatase mu), MATH (meprin and TRAF homology), and AM (after MATH). The MAM domain may be necessary for correct folding and transport through the secretory pathway, the MATH domain may be required for folding of an activable zymogen, and the AM domain may be important for activity against proteins and efficient secretion of the protein [PUB00006426].

MATH		TIKNFSKIKBEAKEGREGEYYTSPVEERFNIPWRLNVLRIRYRNGGG	
		++++ + + ++ ++++++ ++++ ++ + + +	
NOV1	303	KVTDYKMKKREAVDGHTVSIFSQSFYTSRCGYRLC---ARAYLNGDG	346
MATH		EGRSGKFLGLYLHCLKEEKDSPTIENLKWSIETFTLKLVSNDNGKSIRRM	
		+ + + ++++ + + + +++ + ++++ +	
NOV1	347	SGR-GSHLSLYFVVMRGEFDS----LLQWPFRQRTLMLLDQSGKK----	387
MATH		SSTTLTKTKTKDAKNNSHVFEKPTGEGWGKSGFKKFISWDDLEDDYNGYLV	
		++++ + ++ + + + + ++++ ++++ + ++ ++ + ++	
NOV1	388	-NIMETFKPD---PNSSSFKRPDGEMNIASGCPRFVAHSVLENAKNAYIK	433
MATH		DDSIIEAEVKI (SEQ ID NO:37)	
		+++ + +	
NOV1	434	DDTLFLKVAVDL 445 (SEQ ID NO:38)	

The NOV1 nucleic acids encoding the TRAF5-like proteins of the invention, or fragments thereof, are useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These materials are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below.

The disclosed NOV1a protein has multiple hydrophilic regions, each of which can be used as an immunogen. In one embodiment, a contemplated NOV1a epitope is from about amino acids 10 to 65. In another embodiment, a contemplated NOV1a epitope is from about amino acids 92 to 110. In other specific embodiments, contemplated NOV1a epitopes are from about amino acids 120 to 195, 218 to 245, 250 to 325, 330 to 350, 375 to 430 and 440 to 455.

The disclosed NOV1b protein has multiple hydrophilic regions, each of which can be used as an immunogen. In one embodiment, a contemplated NOV1b epitope is from about amino acids 10 to 70. In another embodiment, a contemplated NOV1b epitope is from about amino acids 82 to 135. In other specific embodiment, contemplated NOV1b epitopes are from about amino acids 146 to 177, 180 to 265, 270 to 287, 302 to 348, and 354 to 368.

NOV2

NOV2 includes three novel KIAA 1246-like proteins. The disclosed sequences have been named NOV2a, NOV2b and NOV2c.

10 NOV2a

The disclosed NOV2a nucleic acid of 3386 nucleotides (designated CuraGen Acc. No. JGIGC_ORDERED_CIT-HSPC_246B18_20000718_DA1 and also referred to as CG55265-01) (SEQ ID NO:5) encoding a novel human KIAA1246 -like protein is shown in Table 2A.

Table 2A. NOV2a nucleotide sequence (SEQ ID NO:5).

```

CATGGCTCCAGGACCCTTCTCCTCGGCCCTCCTCTCGCCGCCGCCCGCTGCCCTGCCCTT
TCTGCTGCTGCTCTGGGCGGGGGCATCTCGTGGCCAGCCCTGCCCCGGCCGCTGCATCTG
CCAGAACGTGGCGCCCACTGACAATGCTGTGCGCCAAGACCGGCTTGCTCTTTGTGCC
GCCCCGCATCGACCGGCGCGTGGTGGAGCTGCGGCTCACCGACAACCTTCATCGCCGCCGT
GCGCCGCCGAGACTTCGCCAACATGACCAGCCTGGTGCACCTCACTCTCTCCCGGAACAC
CATCGGCCAGGTGGCAGCTGGCGCCTTCGCCGACCTGCGTGCCCTCCGGGCCCTGCACCT
GGACAGCAACCGCCTGGCGGAGGTGCGCGGCGACCAAGCTCCGCGGCCTGGGCAACCTCCG
CCACCTGATCCTTGGAACAACAGATCCGCCGGGTGGAGTGGCGGCCCTTTGACGCCCTT
CCTGTCCACCGTGGAGGACCTGGATCTGTCTACAACAACCTGGAGGCCCTGCCGTGGGA
GGCGGTGGGCCAGATGGTGAACCTAAACACCTCACGCTGGACCACAACCTCATCGACCA
CATCGCGGAGGGGACCTTCGTGCAGCTTACAAGCTGGTCCGTCTGGACATGACCTCCAA
CCGCCTGCATAAACTCCCGCCGACGGGCTCTTCTGAGGTGCGAGGGCACCGGGCCCAA
GCCGCCCAACCCGCTGACCGTCAGCTTCGGCGGCAACCCCTGCACTGCAACTGCGAGCT
GCTCTGGCTGCGGCGGCTGACCCGCGAGGACGACTTAGAGACCTGCGCCACGCCCCGAACA
CCTCACCGACCGCTACTTCTGGTCCATCCCCGAGGAGGAGTTCCTGTGTGAGCCCCCGCT
GATCACACGGCAGGCGGGGGGCGGGCCCTGCTGGTGGGAAGGCCAGGCGGTGAGCCTGCG
CTGCCGAGCGGTGGGTGACCCGAGCCGGTGGTGCCTGGGTGGCACCTGATGGGCGGCT
GCTGGGGAACCTCAGCCGACCCGGGTCCGGGGGGACGGGACGCTGGATGTGACCATCAC
CACCTTGAGGGACAGTGGCACCTTCACTTGTATCGCCTCCAATGCTGCTGGGGAAGCGAG
GGCGCCCGTGGAGGTGTGCGTGGTACCTCTGCCTCTGATGGCACCCCGCCGGCTGCCCC
GCCGCTCTCACCGAGCCCGGCTCCTCTGACATCGCCACGCCGGGCAGACCAGGTGCCAA
CGATTCTGCGGCTGAGCGTCGGCTCGTGGCAGCCGAGCTCACCTCGAACTCCGTGCTCAT
CCGCTGGCCAGCCAGAGGCTGTGCCCGGAATACGATGTACCAGGTTCAGTACAACAG
TTCCGTTGATGACTCCCTCGTCTACAGGATGATCCCGTCCACCAGTCAGACCTTCCTGGT
GAATGACCTGGCGGCGGGCCGTGCCTACGACTTGTGCGTGTGGCGGTCTACGACGACGG
GGCCACAGCGCTGCCGCAACGCGAGTGGTGGGCTGTGTACAGTTCAACCACCGCTGGGGA
TCCGGCGCCCTGCCGCCGCTGAGGGCCATTCTTGGGCGGCACCATGATCATCGCCAT
CGGGGGCGTCATCGTCGCTCGGTCTCGTCTTCATCGTTCTGCTCATGATCCGCTATAA
GGTGTATGGCGACGGGACAGCCGCGCGTCAAGGGCTCCAGGTCGCTCCCGCGGGTCAG
CCACGTGTGCTCGCAGACCAACGGCGCAGGCACAGGCGGGCACAGGCCCCGGCCCTGCC
GGCCCAGGACCACTACGAGGCGCTGCGCGAGGTGGAGTCCAGGCTGCCCCCGCGCTCGC
CGTCGAGGCCAAGGCCATGGAGGCCGAGACGGCATCCGCGGAGCCGAGGTGGTCCCTGG
ACGTTCTCTGGGCGGCTCGGCCACCTCGCTGTGCTGCTGCCATCCGAGGAAACTTCCGG

```

```

GGAGGAGTCTCGGGCCGCGGTGGGCCCTCGAAGGAGCCGATCCGGCGCCCTGGAGCCACC
AACCTCGGCGCCCCCTACTCTAGCTCTAGTTCTTGGGGGAGCCGCGGCCCGGCCGAGGCC
GCAGCAGCGCTATTCTGTTGACGGGGACTACGGGGCACTATTCCAGAGCCACAGTTACCC
GCGCCCGCGCCCGCGGACAAAGCGCCACCGGTCCACGCCGACCTGGACGGGGCTGGAGG
GGGCGCGGCCGGGAGGATGGAGACCTGGGGCTGGGGCTCCGCCAGGGCGTGCCTGGCTTT
CACCAGCACCGAGTGGATGCTGGAGAGTACCGTGTGAGCGGCGGGCGGGCGCCGGGACGC
CTGGGTGCCGACACAAACGCCAGCCGACGACGCTGGGGCGGGACTGGGAGAAAGC
GCAGCGCCAAGACATTGGACACAGAGTGGAGACGCGCCCTTGTCCCCGGGAGGGGGCGGGG
CAGCCTCGGGCTGCGGCTCGAGGCCACGCCCCCGTGGCCAGGGCGGGGTTCCGGGACCGG
CTGCCGGCCTCCCTCCCCTATGGAATCCTCGACCCCCCTCCTACCCCTCCCTCGCGCG
CTCGCGGACCTCGCTGGAGCCGTTGCCCTACACAGCGAAGCGCGGGGAGGGGCGAGGCC
CCTGACACTGCAGCACTGAGACACGAGCCCCCTCCCCAGCCCGTACCCGGGGCGGGG
CGAGGGGCCCATTCTTGTATCTGGCTGGAATAGATCCTATTCTGTCCGCGGGCGGCTC
CAAAGCCTCCACCCCAACCCACGCACATTCTGGTCCGGTCCGGTCTGGCTTGGGGTCC
CCCTTTCTCTGTTTCCCTCGTTTGTCTCTATCCGCCCCCTTGTCTCTCTCTGTAGTGC
CTGTCTTTCCCTATTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT
TCCCTGGTTTTGTCTAGTCTCCCTGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT
GGCAGGTCCCACCTGGAAGGACCACTCTCCCAATAAATCCCCACACGAACAAATCCA
AAACCAAATCCCCCTCCCTACCGGAGCCGGGACCCCTCCGCCGAGCAGAATTAACTTTT
TTCTGTGTCTGAGGCCCTGCTGACCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT
TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT
GATTGCAGCATAAGGACTCTAAGTGAAGTGAAGGAGATGGGAAGATGACTAACTGGGG
CCGGAGGAGACTGGCAGACAGGCTTTATCCTCTGAGAGACTTAGAGGTGGGAATAATC
ACAAAAATAAAATGATCATAATAGCT

```

A NOV2a polypeptide (SEQ ID NO:6) encoded by SEQ ID NO:5 has 771 amino acid residues and is presented using the one-letter code in Table 2B.

Table 2B. Encoded NOV2a protein sequence (SEQ ID NO:6).

```

MAPGPFSSALLSPPPAALPFLLLWAGASRGQPCPGRCICQNVAPTLTMLCAKTGLLFVP
PAIDRRVVELRLTDNFIAAVRRRDFANMTSLVHLTLNRNTIGQVAAGAFADLRALRALHL
DSNRLAEVRGDLRLGLGNLRLHILGNQIRRVESAADFALSTVEDLDLSYNNLEALPWE
AVGQMVNLNTLTLDHNLIDHIAEGTFVQLHKLVRDMLTNRHLKLPDGLFLRSQGTGPK
PPTPLTVSFGGNPLHCNCELLWLRLTREDDLETCAPEHLTDYFWSIPEEEFLCEPPL
ITRQAGGRALVVEGQAVSLRCRAVGDPPEPVVHWVAPDGRLLGNSSRTRVRGDTLDVTIT
TLRDSGTFCTCIASNAAGEATAPVEVCVPLPLMAPPPAAPPPLTEPGSSDIATPGRPGAN
DSAAERLVAEELTNSVLRWPAQRVPVGIRMYQVQYNSVDDSLVYRMIPSTSTFLV
NDLAAGRAYDLCLAVYDDGATALPATRVVGCVPFTTAGDPAPCRPLRAHFLGGTMI IAI
GGVIVASVLVFI VLLMIRYKVGDDSRRVKGSRLPRVSHVCSQTNGAGTGAAQAPALP
AQDHYEALREVESQAAPAVEAKAMEAETASAEPEVVLGRSLGGSATSLCLLPSEETSG
EESRAAVGPRRSRSGALEPPTAPPTLALVPGGAAARPRPQQRYSFDDYDALFQSHSYP
RRARRTKHRSTPHLDGAGGGAAGEDGDLGLGSARACLAFTSTEWMLSTV

```

5

NOV2b

The DNA sequence and protein sequence for a novel Leucine rich repeat and fibronectin containing membrane protein-like gene were obtained by exon linking and extended by RACE and are reported here as NOV2b (also referred to as CuraGen Acc. No. CG55265-02). The NOV2b nucleic acid of 2451 nucleotides (SEQ ID NO:7) is shown in Fig. 2c. An open reading frame was identified beginning at nucleotides 52-54 and ending at nucleotides 2377-2379. The start (ATG) and stop (TGA) codons of the open reading frame are

highlighted in bold type. Putative untranslated regions (underlined), if any, are found upstream from the initiation codon and downstream from the termination codon.

Table 2C. NOV2b nucleotide sequence (SEQ ID NO:7).

TCCTTCCCCGGCAGGTCTCACCTCCCACCCCTCCTGCCTTCCCACTGCACCATGGCTCCAGGACC
CTTCTCCTCGGCCCTCCTCTCGCCGCCGCCGCTGCCCTGCCCTTTCTGCTGCTGCTCTGGGCGG
GGGCATCTCGTGGCCAGCCCTGCCCGGCCGCTGCATCTGCCAGAACGTGGCGCCACACTGACA
ATGCTGTGCGCCAAGACCGGCTTGCTCTTTGTGCCGCCGCCATCGACCGGCGGTGGTGGAGCT
GCGGCTCACCGACAATTCATCGCCGCCGCTGCGCCGCCGAGACTTCGCCAACATGACCAGCCTGG
TGCACCTCACTCTCTCCCGGAACACCATCGGCCAGGTGGCAGCTGGCGCCTTCGCCGACCTGCGT
GCCCTCCGGGCCCTGCACCTGGACAGCAACCGCTGGCGGAGGTGCGCGGCGACCAGCTCCGCGG
CCTGGGCAACCTCCGCCACCTGATCCTTGGAACAACAGATCCGCCGGGTGGAGTCGGCGCCCT
TTGACGCCTTCTGTCCACCGTGGAGGACCTGGATCTGTCTACAACAACCTGGAGGCCCTGCCG
TGGGAGGCGGTGGGCCAGATGGTGAACCTAAACACCCCTCACGCTGGACCACAACCTCATCGACCA
CATCGCGGAGGGGACCTTCGTGCAGCTTACAAGCTGGTCCGTCTGGACATGACCTCCAACCGCC
TGCATAAACTCCCGCCCGACGGGCTCTTCTGAGGTGCGAGGGCACCGGGCCCAAGCCGCCACC
CCGCTGACCGTCAGCTTCGGCGGCAACCCCTGCACTGCAACTGCGAGCTGCTCTGGCTGCGGCG
GCTGACCCGAGGACGACTTAGAGACCTGCGCCACGCCCCGAACACCTCACCGACCGCTACTTCT
GGTCCATCCCCGAGGAGGATTCCTGTGTGAGCCCCCGCTGATCACACGAGGCGGGGGCCGG
CCCTGGTGGTGAAGGCCAGGCGGTGAGCCTGCGCTGCCGAGCGGTGGGTGACCCGAGCCGGTG
GTGCACTGGGTGGACCTGATGGGCGGCTGCTGGGGAATCCAGCCGACCCGGGTCCGGGGGGA
CGGGACGCTGGATGTGACCATCACCACTTGAAGGACAGTGGCACCTTCACTTGTATCGCCTCCA
ATGCTGCTGGGGAAGCGACGCGCGCCGCTGGAGGTGTGCGTGGTACCTCTGCCTCTGATGGCACCC
CCGCGGCTGCCCGCCGCTCTCACCGAGCCCGGCTCCTCTGACATCGCCACGCGGGCAGACC
AGGTGCCAACGATTCTGCGGCTGAGCGTCGGCTCGTGGCAGCCGAGCTCACCTCGAATCCGTGC
TCATCCGCTGGCCAGCCAGAGGCTGTGCCGGAATACGCATGTACCAGGTTCACTACAACAT
TCCGTTGATGACTCCCTCGTCTACAGGTGGGTGTACAGGATGATCCCGTCCACCAGTCAGACCTT
CCTGGTGAATGACCTGGCGGCGGGCCGTGCCTACGACTTGTGCGTGTGGCGGTCTACGACGAC
GGGGCCACAGCGCTGCCGGCAACGCGAGTGGTGGGCTGTGTACAGTTACCACCGCTGGGGATCC
GGCGCCTGCCCGCCGCTGAGGGCCATTCTTGGGCGGCACCATGATCATCGCCATCGGGGGCG
TCATCGTCCGCTCGGTCTCTTCATCGTTCTGCTCATGATCCGCTATAAGGTGTATGGCGAG
GGGGACAGCCCGCGTCAAGGGCTCCAGGTGCGTCCCGCGGGTCAGCCACGTGTGCTCGCAGAC
CAACGGCGCAGGCACAGGCGCGGCACAGGCCCGGCCCTGCCGGCCAGGACCACTACGAGGCGC
TGCGCGAGGTGGAGTCCCAGGCTGCCCGCCGCTCGCCGTGAGGCCAAGGCCATGGAGGCCGAG
ACGGCATCCGCGGAGCCGAGGTGGTCTTGGACGTTCTCTGGGCGGCTCGGCCACCTCGCTGTG
CCTGCTGCCATCCGAGGAACTTCCGGGGAGGAGTCTCGGGCCGCGGTGGGCCCTCGAAGGAGCC
GATCCGCGCCCTGGAGCCACCAACCTCGGCGCCCCCTACTTAGCTCTAGTTCTTGGGGGAGCC
GCGGCCCGGCGAGGCCGAGCAGCGCTATTCTGACGCGGGACTACGGGGCACTATTCCAGAG
CCACAGTTACCCGCGCCGCGCCCGGCGGACAAAGCGCCACCGGTCCACGCCGCACCTGGACGGG
CTGGAGGGGGCGCGCCGGGGAGGATGGAGACCTGGGGCTGGGCTCCGCCAGGGCGTGCCTGGCT
TTACCAGCACCGAGTGGATGCTGGAGATACCGTGTGAGCGGCGGGCGGGCGCCGGGACGCCTG
GGTGCCGACAGCAACCGCCAGCCGCACGGACGCTGGGGCGGGAC

The sequence of NOV2b was derived by laboratory cloning of cDNA fragments, by *in silico* prediction of the sequence. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, were cloned. *In silico* prediction was based on sequences available in Curagen's proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof. The DNA sequence and protein sequence for a k1246-like gene were obtained by exon linking and are reported here as NOV2. These primers and methods used to amplify NOV2 cDNA are described in the Examples.

The NOV2b encoded protein having 775 amino acid residues is presented using the

Table 2D. NOV2b polypeptide (SEQ ID NO:8).

MAPGPFSSALLSPPPAALPFLLLWAGASRGQPCPGRCICQNVAPTLTMLCAKTGLLFVP
PAIDRRVVELRLTDNFIAAVRRRDFANMTSLVHLTSLRNTIGQVAAGAFADLRALRALHL
DSNRLAEVRGDQLRGLGNLRHLILGNNQIRRVESAAFDALSTVEDLDLSYNNLEALPWE
AVGQMVNLNTLTLDHNLIDHIAEGTFVQLHKLVRDLMTSNRLHKLPPDGLFLRSQGTGPK
PPTPLTVSFGGNPLHCNCELLWLRRLTREDDLETCAPEHLTDYFWSIPEEEFLCEPPL
ITRQAGGRALVVEGQAVSLRCRAVGDPVHVWVAPDGRLLGNSSTRVVRGDGTLDTIT
TLRDSGTFTCIASNAAGEATAPVEVCVPLPLMAPPPAAPPPLTEPGSSDIATPGRPGAN
DSAAERRLVAAELTNSVLRWPAQRVPVPGIRMYQVQYNSSVDDSLVYRWVYRMIPSTSQ
TFLVNDLAAGRAYDLCVLAVYDDGATALPATRVVGCVQFTTAGDPAPCRPLRAHFLGGTM
IIAIGGVIVASVLVFI VLLMIRYKVYGDGDSRRVKGSRLPRVSHVCSQTNGAGTGAAQA
PALPAQDHYEALREVESQAAPAVAVEAKAMEAETASAEPEVVLGRSLGGSATSLCLLPSE
ETSGEESRAAVGPRRSRSGALEPPTSAPPTLALVPGGAAARPRPQQRYSFDDYDYGALFQS
HSYPRRARRTKRHRSTPHLDGAGGGAAGEDGDLGLSARACLAFTSTEWMLLESTV

In a search of sequence databases, it was found, for example, that the nucleic acid sequence of NOV2 has 1742 of 2177 bases (80%) identical to a gb:GENBANK-
ID:AB040917|acc:AB040917.1 mRNA from Homo sapiens (Homo sapiens mRNA for
KIAA1484 protein, partial cds). The full amino acid sequence of the protein of NOV2 was
found to have 460 of 468 amino acid residues (98%) identical to, and 462 of 468 amino acid
residues (98%) similar to, the 492 amino acid residue ptnr:TREMBLNEW-ACC:AAH04018
protein from Mus musculus (Mouse) (UNKNOWN (PROTEIN FOR MGC:7599)).

The PSORT, SignalP and hydropathy profile for NOV2b predict that this sequence has
a signal peptide and is likely to be localized at the plasma membrane with a certainty of
0.7000. In alternative embodiments, NOV2b is located to the endoplasmic reticulum
(membrane) with a certainty of 0.2000 or the mitochondrial inner membrane with a certainty
of 0.1000. The signal peptide is predicted by SignalP to be cleaved between amino acid 31
and 32: SRG-QP.

NOV2c

The NOV2c nucleic acid of 3568 nucleotides (also referred to as CG55265-03) (SEQ
ID NO:9) is shown in Fig. 2E. An open reading frame was identified beginning at nucleotides
100-102 and ending at nucleotides 2497-2499. The start and stop codons of the open reading
frame are highlighted in bold type. Putative untranslated regions (underlined), if any, are
found upstream from the initiation codon and downstream from the termination codon.

Table 2E. NOV2c nucleotide sequence (SEQ ID NO:9)

28

The NOV2c encoded protein having 799 amino acid residues (SEQ ID NO:10) is presented using the one-letter code in Table 2F.

Table 2F. NOV2c polypeptide (SEQ ID NO:10)

```

MAAKSHAWVTGSFPGRSHLPPLLPSHCTMAPGPFSSALLSPPPAALPFLLLLWAGASRGQ
PCPGRCICQNVAPTLTMLCAKTGLLFVPPAIDRRVVELRLTDNFIAAVRRRDFANMTSLV
HLTLSRNTIGQVAAGAFADLRALRALHLDNRLAEVRGDQLRGLGNLRHLILGNNQIRRV
ESAAFDAPLSTVEDLDLSYNNLEALPWEAVGQMVNLNTLTLDHNLIDHIAEGTFVQLHKL
VRLDMTSNRLHKLPPDGLFLRSQGTGPKPPTPLTVSFGGNPLHCNCELLWLRLTREDDL
ETCATPEHLTDTRYFWSIPEEEFLCEPPLITRQAGGRALVVEGQAVSLRCRAVGDEPVPVH
WVAPDGRLLGNSSRTRVRGDTLDVTITTLRDSGTFTCIASNAAGEATAPVEVCVPLPL
MAPPPAAPPLTEPGSSDIATPGRPGANDSAAERRLVAAELTSNSVLIRWPAQRPVPGIR
MYQVQYNSSVDDSLVYRIMPSTSQTFLVNDLAAGRAYDLCVLAVYDDGATALPATRVVGC
VQFTTAGDPAPCRPLRAHFLGGTMIIAIGGVIASVLVFI VLLMIRYKVYGDGDSRRVKG
SRSLPRVSHVCSQTNGAGTGAAQAPALPAQDHYEALREVESQAAPAVAVEAKAMEAETAS
AEPEVVLGRSLGGSATSLCLLPSEETSGEESRAAVGPRRSRSGALEPPTSAPPTLALVPG
GAAARPRPQQRYSFDDYGALFQSHSYPRRARRTKRHRSTPHLDGAGGGAAGEDGDLGLG
SARACLAFTSTEWMLSTV

```

In a search of sequence databases, it was found, for example, that the nucleic acid sequence of NOV2c has 1353 of 1641 bases (82%) identical to a gb:GENBANK-ID:BC004018|acc:BC004018.1 mRNA from *Mus musculus* (*Mus musculus*, clone MGC:7599, mRNA, complete cds). The full amino acid sequence of the protein of NOV2c was found to have 700 of 700 amino acid residues (100%) identical to, and 700 of 700 amino acid residues (100%) similar to, the 700 amino acid residue ptnr:SPTREMBL-ACC:Q9P244 protein from *Homo sapiens* (Human) (KIAA1484 PROTEIN).

The PSORT, SignalP and hydropathy profile for NOV2c predict that this sequence has a signal peptide and is likely to be localized at the endoplasmic reticulum (membrane) with a certainty of 0.8500. In alternative embodiments, NOV2c is located to the plasma membrane with a certainty of 0.4400, the microbody (peroxisome) with a certainty of 0.3000, or the mitochondrial inner membrane with a certainty of 0.1000. The signal peptide is predicted by SignalP to be cleaved at amino acid 59-60: SRG-QP

Homologies to any of the above NOV2 proteins will be shared by the other NOV2 proteins insofar as they are homologous to each other. Any reference to NOV2 is assumed to refer to all three of the NOV2 proteins in general, unless otherwise noted.

The amino acid sequence of NOV2 has high homology to other proteins as shown in Table 2G.

Table 2G. BLASTX results for NOV2

Sequences producing High-scoring Segment Pairs:	Smallest Sum	
	High Score	Prob P(N)
patp:AAB09968 Human brain-specific transmembrane glycoprotein - <i>Homo sapiens</i> , 789 aa.	1637	1.3e-173

patp:AAB12448 Human hh00149 protein-Homo sapiens, 785 aa	1637	1.3e-173
patp:AAB84469 Amino acid sequence of an interferon omega-1 like protein - Homo sapiens, 628 aa	1668	1.7e-171
patp:AAB70072 Human secreted protein #11 - Homo sapiens, 468 aa	981	4.3e-102
patp:AAB42689 Human ORFX ORF2453 polypeptide sequence Homo sapiens, 144 aa	408	3.7e-37

NOV2 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 2H.

Table 2H. BLASTP results for NOV2					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
ptnr:SPTREMBL- ACC:Q9P244	KIAA1484 PROTEIN - <i>Homo sapiens</i> (Human)	700(fragment)	700/700 (100%)	700/700 (100%)	0.0
ptnr:SPTREMBL- ACC:Q99KT6	UNKNOWN (PROTEIN FOR MGC:7599) - <i>Mus musculus</i> (Mouse)	492	460/468 (98%)	462/468 (98%)	7.7e-250
ptnr:SPTREMBL- ACC:Q9ULH4	KIAA1246 PROTEIN - <i>Homo sapiens</i> (Human)	832(fragment)	334/606 (55%)	432/606 (71%)	1.9e-173
ptnr:SPTREMBL- ACC:Q9BE71	HYPOTHETICAL 84.7 KDA PROTEIN - <i>Macaca fascicularis</i> (Crab eating macaque) (Cynomolgus monkey)	789	334/606 (55%)	431/606 (71%)	1.9e-173
ptnr:SPTREMBL- ACC:Q9CYK3	573042005RIK PROTEIN - <i>Mus musculus</i> (Mouse)	788	341/617 (55%)	432/617 (70%)	8.1e-173

5

The homology of the sequences shown in Table 2H as well as between the NOV2 variants is shown graphically in the ClustalW analysis shown in Table 2I.

Table 2I. ClustalW Analysis of NOV2

- | | | | |
|----|----|--------------------------|----------------|
| 10 | 1) | NOV2a | (SEQ ID NO:6) |
| | 2) | NOV2b | (SEQ ID NO:8) |
| | 3) | NOV2c | (SEQ ID NO:10) |
| | 4) | ptnr:SPTREMBL-ACC:Q9P244 | (SEQ ID NO:39) |
| | 5) | ptnr:SPTREMBL-ACC:Q99KT6 | (SEQ ID NO:40) |
| | 6) | ptnr:SPTREMBL-ACC:Q9ULH4 | (SEQ ID NO:41) |
| 15 | 7) | ptnr:SPTREMBL-ACC:Q9BE71 | (SEQ ID NO:42) |
| | 8) | ptnr:SPTREMBL-ACC:Q9CYK3 | (SEQ ID NO:43) |

		10	20	30	40	50
	NOV2a
	NOV2b
5	NOV2c
	Q9P244
	Q99KT6
	Q9ULH4	LESVSGGEGCVAEPGSPGAPRSRPRCHPAGGRCCLAQALSDQTMETLLGG				
	Q9BE71
~10	Q9CYK3
		60	70	80	90	100
	NOV2a
15	NOV2b
	NOV2c
	Q9P244
	Q99KT6
	Q9ULH4	LLAFGMAFAVVDACPKYCVCONLSESLGTLCPSKGLLFVPPDIDRRRVEL				
20	Q9BE71
	Q9CYK3
		110	120	130	140	150
25	NOV2a
	NOV2b
	NOV2c
	Q9P244
	Q99KT6
30	Q9ULH4	RLTDNFIAAVRRRDFANMTSLVHLTSLRNTIGQVAAGAFADLRALRALHL				
	Q9BE71
	Q9CYK3
		160	170	180	190	200
35	NOV2a
	NOV2b
	NOV2c
	Q9P244
40	Q99KT6
	Q9ULH4	DSNRLAEVRGDQLRGLGNLRHLILGNNQIRRVESAAFDALSTVEDLDLS				
	Q9BE71
	Q9CYK3
		210	220	230	240	250
45	NOV2a
	NOV2b
	NOV2c
50	Q9P244
	Q99KT6
	Q9ULH4	YNNLEALPWEAVGQMVNLTTLTDHNLIDHIAEGTFVQLHKLVRDMTSN				
	Q9BE71
	Q9CYK3
55		260	270	280	290	300
	NOV2a
	NOV2b
60	NOV2c
	Q9P244
	Q99KT6
	Q9ULH4	RLHKLPPDGLFLRSQG---TGPKPPTPLTVSFGGNPLHCNCELLWLRRLT				

Q9BE71 R L Q K L P P D P I F A R S Q A S L L T A T P F A P P L S F S F G G N P L H C N C E L L W L R R I E
Q9CYK3 R L Q K L P P D P I F A R S Q A S L L T A T P F A P P L S F S F G G N P L H C N C E L L W L R R I E

310 320 330 340 350

5 NOV2a R E D D L E T C A T P E H L T D R Y F W S I P E E E F L C E P P L I T R Q A G G R A L V V E G Q A V
NOV2b R E D D L E T C A T P E H L T D R Y F W S I P E E E F L C E P P L I T R Q A G G R A L V V E G Q A V
NOV2c R E D D L E T C A T P E H L T D R Y F W S I P E E E F L C E P P L I T R Q A G G R A L V V E G Q A V
Q9P244 R E D D L E T C A T P E H L T D R Y F W S I P E E E F L C E P P L I T R Q A G G R A L V V E G Q A V
10 Q99KT6 R E D D L E T C A T P E H L T D R Y F W S I P E E E F L C E P P L I T R Q A G G R A L V V E G Q A V
Q9ULH4 R D D D L E T C G S P G G L K G R Y F W H V R E E E F V C E P P L I T Q H T - H K L L V L E G Q A A
Q9BE71 R D D D L E T C G S P G G L K G R Y F W H V R E E E F V C E P P L I T Q H T - H K L L V L E G Q A A
Q9CYK3 R D D D L E T C G S P G S L K G R Y F W H I R E E E F V C E P P L I T Q H T - H K L L V L E G Q A A

360 370 380 390 400

15 NOV2a S L R C R A V G D P E P V V H W A P D G R L L G N S S R T R V R G D G T L D V T I T T L R D S G T
NOV2b S L R C R A V G D P E P V V H W A P D G R L L G N S S R T R V R G D G T L D V T I T T L R D S G T
NOV2c S L R C R A V G D P E P V V H W A P D G R L L G N S S R T R V R G D G T L D V T I T T L R D S G T
20 Q9P244 S L R C R A V G D P E P V V H W A P D G R L L G N S S R T R V R G D G T L D V T I T T L R D S G T
Q99KT6 S L R C R A V G D P E P V V H W A P D G R L L G N S S R T R V R G D G T L D V T I T T L R D S G T
Q9ULH4 T L K C K A I G D P S P L I H W A P D D R L V G N S S R T A V Y D N G T L D I F I T T S Q D S G A
Q9BE71 T L K C K A I G D P S P L I H W A P D D R L V G N S S R T A V Y D N G T L D I F I T T S Q D S G A
Q9CYK3 T L K C K A I G D P S P L I H W A P D D R L V G N S S R T A V Y D N G T L D I F I T T S Q D S G P

410 420 430 440 450

30 NOV2a F T C I A S N A A G E A T A P V E V C V V P L P L M A P P P - - A A P P P - - L T E P G S S D I A T
NOV2b F T C I A S N A A G E A T A P V E V C V V P L P L M A P P P - - A A P P P - - L T E P G S S D I A T
NOV2c F T C I A S N A A G E A T A P V E V C V V P L P L M A P P P - - A A P P P - - L T E P G S S D I A T
Q9P244 F T C I A S N A A G E A T A P V E V C V V P L P L M A P P P - - A A P P P - - L T E P G S S D I A T
Q99KT6 F T C I A S N A A G E A T A P V E V C V V P L P L M A P P P - - A A P P P - - L T E P G S S D I A T
Q9ULH4 F T C I A A N A A G E A T A M V E V S I V O L P H L S N S T S R T A P P K S R L S D I T G S S K T S
Q9BE71 F T C I A A N A A G E A T A T V E V S I V O L P H L S N S T S R T A P P K S R L S D I T G S S K T S
35 Q9CYK3 F T C I A A N A A G E A T A T V E V S I V O L P H L S N S T S R M A P P K S R L S D I T G S S K T S

460 470 480 490 500

40 NOV2a P G R P G A N - - - - - D S A A E R R L V A A E L T S N S V L I R W P A Q R P V P G I R M Y Q V Q Y
NOV2b P G R P G A N - - - - - D S A A E R R L V A A E L T S N S V L I R W P A Q R P V P G I R M Y Q V Q Y
NOV2c P G R P G A N - - - - - D S A A E R R L V A A E L T S N S V L I R W P A Q R P V P G I R M Y Q V Q Y
Q9P244 P G R P G A N - - - - - D S A A E R R L V A A E L T S N S V L I R W P A Q R P V P G I R M Y Q V Q Y
Q99KT6 P G R P G A N - - - - - D S A T E R R L V A A E L T S S S V L I R W P A Q R P V P G I R M Y Q V Q Y
Q9ULH4 R G G G S G G G E P P K S P P E R A V L V S E V T T S A L V K W S V S K S A P R V K M Y Q L Q Y
45 Q9BE71 R G G G S G G G E P P K S P P E R A V L V S E V T T S A L A K W S V S K S T E R V K M Y Q L Q Y
Q9CYK3 R G G G S G G A G E P P K S T P E R A V I V S D V T T S A L V K W S V S K S A P R V K M Y Q L Q Y

510 520 530 540 550

50 NOV2a N S S V D D S L V Y - - - - - R M I P S T S Q T F L V N D L A A G R A Y D L C V L A V Y D D G A T A L
NOV2b N S S V D D S L V Y R W V Y R M I P S T S Q T F L V N D L A A G R A Y D L C V L A V Y D D G A T A L
NOV2c N S S V D D S L V Y - - - - - R M I P S T S Q T F L V N D L A A G R A Y D L C V L A V Y D D G A T A L
Q9P244 N S S V D D S L V Y - - - - - R M I P S T S Q T F L V N D L A A G R A Y D L C V L A V Y D D G A T A L
Q99KT6 N S S A D D S L V Y - - - - -
55 Q9ULH4 N C S D D E V L I Y - - - - - R M I P A S N K A F V V N N L V S G T G Y D L C V L A M W D D I A T T L
Q9BE71 N C S D D E V L I Y - - - - - R M I P A S N K A F V V N N L V S G T G Y D L C V L A M W D D I A T T L
Q9CYK3 N C S D D E V L I Y - - - - - R M I P A S N K A F V V N N L V S G T G Y D L C V L A M W D D I A T T L

560 570 580 590 600

60 NOV2a P A T R V V G C V Q F T T A G D P A P C R P L R A H F L G G T M I I A I G G V I V A S V L V F I V L
NOV2b P A T R V V G C V Q F T T A G D P A P C R P L R A H F L G G T M I I A I G G V I V A S V L V F I V L
NOV2c P A T R V V G C V Q F T T A G D P A P C R P L R A H F L G G T M I I A I G G V I V A S V L V F I V L

Q9P244 PATRVVGCVOFTTAGDPAPCRPLRAHFLGGTMILVIGGVIVASVLVFIVL
Q99KT6
Q9ULH4 TATNIVGCAOFFTKADYPQCQSMHSQILGGTMILVIGGIIVATLLVFIVL
Q9BE71 TATNIVGCAOFFTKADYPQCQSMHSQILGGTMILVIGGIIVATLLVFIVL
5 Q9CYK3 TATNIVGCAOFFTKADYPQCQSMHSQIKGGTMILVIGGIIVATLLVFIVL

610 620 630 640 650

10 NOV2a LMIRYKVVCDGDSRRVKGSRSLPRVSHVCSQTNGAGT---GAAQAPALPA
NOV2b LMIRYKVVCDGDSRRVKGSRSLPRVSHVCSQTNGAGT---GAAQAPALPA
NOV2c LMIRYKVVCDGDSRRVKGSRSLPRVSHVCSQTNGAGT---GAAQAPALPA
Q9P244 LMIRYKVVCDGDSRRVKGSRSLPRVSHVCSQTNGAGT---GAAQAPALPA
Q99KT6 ---SSS---CPCT---
Q9ULH4 LMMVRYKVCNHEAPSMAAA---VSNVYSQTNGAQPSPPSAPAGAPPO
15 Q9BE71 LMMVRYKVCNHEAPSMAAA---VSNVYSQTNGAQPSPPSAPAGAPPO
Q9CYK3 LMMVRYKVCNHDTPGKMAAAT---VSNVYSQTNGSQPPPLEGIPVQQLPO

660 670 680 690 700

20 NOV2a QDHYEALREVESQAAPAVAVEAKAMEAETASAEPEVVLGRG---
NOV2b QDHYEALREVESQAAPAVAVEAKAMEAETASAEPEVVLGRG---
NOV2c QDHYEALREVESQAAPAVAVEAKAMEAETASAEPEVVLGRG---
Q9P244 QDHYEALREVESQAAPAVAVEAKAMEAETASAEPEVVLGRG---
Q99KT6 ---HYVDQDGLAIRVPLASA---
25 Q9ULH4 GPPKVVVRNELLDFTASLARADSSSSSSSLGSGEAAGLGRAPWRIPPSAP
Q9BE71 GPPKVVVRNELLDFTASLARADSSSSSSSLGSGEAAGLGRAPWRLPPSAP
Q9CYK3 APPKVVVRNELMDFSTSLARACDSSSSSSSLGSGEAAGLGRGPWRLPPAP

710 720 730 740 750

30 NOV2a ---LGGSATSLCLLPSEETSGEESRAAVG---PRRSRSGALEP
NOV2b ---LGGSATSLCLLPSEETSGEESRAAVG---PRRSRSGALEP
NOV2c ---LGGSATSLCLLPSEETSGEESRAAVG---PRRSRSGALEP
Q9P244 ---LGGSATSLCLLPSEETSGEESRAAVG---PRRSRSGALEP
35 Q99KT6 ---
Q9ULH4 RPKPSLDRIMCAFASLDLKSQRKEELLDSRTPACRGAGTSARGHHSRDRE
Q9BE71 RPKPSLDRIMCAFASLDLKSQRKEELLDSRTPACRGAGTSARGHHSRDRE
Q9CYK3 RPKPSLDRIMCAFASLDLKSQRKEELLDSRTPACRGAGTSSRGHHSRDRE

760 770 780 790 800

40 NOV2a PTSAPPTLALVPGGAAARPRPOQRYSFDDG-DYGALFQSHSYPI--RRARR
NOV2b PTSAPPTLALVPGGAAARPRPOQRYSFDDG-DYGALFQSHSYPI--RRARR
NOV2c PTSAPPTLALVPGGAAARPRPOQRYSFDDG-DYGALFQSHSYPI--RRARR
45 Q9P244 PTSAPPTLALVPGGAAARPRPOQRYSFDDG-DYGALFQSHSYPI--RRARR
Q99KT6 ---
Q9ULH4 LLGPBAARARSLLPLPLEGKAKRSHSFDMDGFAAAAAGGVVPGGYSPPRK
Q9BE71 LLGPBAARARSLLPLPLEGKAKRSHSFDMDGFAAAAAGGVVPGGYSPPRR
Q9CYK3 LLGPBATTRARSLLPLPLEGKAKRSHSFDMDGFAAAAA--AVPGGYSPPRR

810 820 830 840

50 NOV2a TKRHRSTPHLDGACGGAAGEDGDLGLGSARACLAFTSTEWMLSTV
NOV2b TKRHRSTPHLDGACGGAAGEDGDLGLGSARACLAFTSTEWMLSTV
55 NOV2c TKRHRSTPHLDGACGGAAGEDGDLGLGSARACLAFTSTEWMLSTV
Q9P244 TKRHRSTPHLDGACGGAAGEDGDLGLGSARACLAFTSTEWMLSTV
Q99KT6 ---
Q9ULH4 VSNIWTKRSLSVNCGMLLPFEESDLVGARG---TFGSSEWVMESTV
Q9BE71 VSNIWTKRSLSVNCGMLLPFEESDLVGARG---TFGSSEWVMESTV
60 Q9CYK3 VSNIWTKRSLSVNCGMLLPFEESDLVGARG---TFGSSEWVMESTV

The presence of identifiable domains in the protein disclosed herein was determined by searches versus domain databases such as Pfam, PROSITE, ProDom, Blocks or Prints and then identified by the Interpro domain accession number. Significant domains are summarized in Table 2J.

Table 2J. Domain Analysis of NOV2

		Score	Expect
IPR001611; LRR	Leucine Rich Repeat	91.3	1.9e-23
IPR000483; LRRCT	Leucine rich repeat C-terminal domain	29.4	8.5e-05
IPR003600; ig	Immunoglobulin domain	34.4	4.1e-09
IPR003961; fn3	Fibronectin type III domain	34.5	2.4e-06

Leucine-rich repeats (LRRs) are relatively short motifs (22-28 residues in length) found in a variety of cytoplasmic, membrane and extracellular proteins. Although these proteins are associated with widely different functions, a common property involves protein-protein interaction. Little is known about the 3D structure of LRRs, although it is believed that they can form amphipathic structures with hydrophobic surfaces capable of interacting with membranes. In vitro studies of a synthetic LRR from *Drosophila* Toll protein have indicated that the peptides form gels by adopting beta-sheet structures that form extended filaments. These results are consistent with the idea that LRRs mediate protein-protein interactions and cellular adhesion. Other functions of LRR-containing proteins include, for example, binding to enzymes and vascular repair. The 3-D structure of ribonuclease inhibitor, a protein containing 15 LRRs, has been determined, revealing LRRs to be a new class of alpha/beta fold. LRRs form elongated non-globular structures and are often flanked by cysteine rich domains.

LRR: domain 1 of 7, from 66 to 89: score 5.1, E = 1.3e+02

NLEELDLSNNNLGSLPPESFGNLP (SEQ ID NO:44)

+ || | + | + + | + ++

NOV2 66 RVVELRLTDNFIA-AVRRRDFANMT 89 (SEQ ID NO:45)

LRR: domain 2 of 7, from 90 to 113: score 15.7, E = 1.1

NLEELDLSNNNLGSLPPESFGNLP (SEQ ID NO:46)

+ | + | || + | + ++ +++ | ++ | +

NOV2 90 SLVHLTLRNTIG-QVAAGAFADLR 113 (SEQ ID NO:47)

LRR: domain 3 of 7, from 114 to 137: score 9.3, E = 45

NLEELDLSNNNLSGSLPPESFGNLP (SEQ ID NO:48)

|+|+|++|+| ++ + +++|

NOV2 114 ALRALHLDNSRLA-EVRGDQLRGLG 137 (SEQ ID NO:49)

--5 LRR: domain 4 of 7, from 138 to 161: score 15.5, E = 1.3

NLEELDLSNNNLSGSLPPESFGNLP (SEQ ID NO:50)

||++| | ||+++ +++ +|

NOV2 138 NLRHLILGNNQIR-RVESAAFDAFL 161 (SEQ ID NO:51)

10 LRR: domain 5 of 7, from 163 to 186: score 17.8, E = 0.25

NLEELDLSNNNLSGSLPPESFGNLP (SEQ ID NO:52)

| ||||+|||+ || |+|++

NOV2 163 TVEDLDLSYNNLE-ALPWEAVGQMV 186 (SEQ ID NO:53)

15 LRR: domain 6 of 7, from 187 to 210: score 16.0, E = 0.9

NLEELDLSNNNLSGSLPPESFGNLP (SEQ ID NO:54)

|| +| |++| + ++ +++| +|+

NOV2 187 NLNTLTLDHNLID-HIAEGTFVQLH 210 (SEQ ID NO:55)

20 LRR: domain 7 of 7, from 211 to 233: score 11.5, E = 20

NLEELDLSNNNLSGSLPPESFGNLP (SEQ ID NO:56)

+| +||+ +|+| +|||+ |+

NOV2 211 KLVRLDMTSNRLH-KLPPD-GLFLR 233 (SEQ ID NO:57)

25 Leucine Rich Repeats are short sequence motifs present in a number of proteins with diverse functions and cellular locations. Leucine Rich Repeats are often flanked by cysteine rich domains. This domain is often found at the C-terminus of tandem leucine rich repeats.

CD molecules are leucocyte antigens on cell surfaces. CD antigens nomenclature is updated at http://www.ncbi.nlm.nih.gov/prov/cd/index_molecule.htm

30 Some platelet glycoproteins belong to this group. The CD42a-d-complex serves as receptor for von Willebrand factor (vWf) and thrombin. The actual binding site for vWf and thrombin lies on CD42b (GPIb alpha). The complex mediates adhesion of platelets to subendothelial matrices (exposed upon damage to the endothelium) at high shear rates and amplifies the platelet response to thrombin during platelet activation where thrombin is

35 involved. CD42a is the platelet glycoprotein IX (GPIX), CD42b is the platelet glycoprotein Ib alpha chain (GPIba) also called GPIbalpha or glycocalicin, CD42c is the platelet glycoprotein Ib beta chain (GPIb beta or GPIb-beta) and CD42d is the platelet glycoprotein V (GPV). These proteins contain the leucine-rich repeat and the two cysteine-rich flanking regions.

LRRCT: domain 1 of 1, from 252 to 297: score 29.4, E = 8.5e-0

NPFNCDCELRWLLRWLRRETNPRRLEDQEDLRCASPESLRGQPLLELL

||++|+||+||+|| || || +|| ||+| ++ ++++

5 NOV2 252 NPLHCNCELLWLRRLTRE---DDLE-----TCATPEHLTDYFWSIP 290

PSDFSCP (SEQ ID NO:58)

++| |+

NOV2 291 EEFLCE 297 (SEQ ID NO:59)

10

The basic structure of immunoglobulin (Ig) molecules is a tetramer of two light chains and two heavy chains linked by disulfide bonds. There are two types of light chains: kappa and lambda, each composed of a constant domain (CL) and a variable domain (VL). There are five types of heavy chains: alpha, delta, epsilon, gamma and mu, all consisting of a variable domain (VH) and three (in alpha, delta and gamma) or four (in epsilon and mu) constant domains (CH1 to CH4). Members of the immunoglobulin superfamily are found in hundreds of proteins of different functions. Examples include antibodies, the giant muscle kinase titin and receptor tyrosine kinases. Immunoglobulin-like domains may be involved in protein-protein and protein-ligand interactions. This entry includes IG domains that cannot be classified into one of IGv1, IGc1, IGc2 and IG.

20

ig: domain 1 of 1, from 314 to 372: score 34.4, E = 4.1e-09

GESVTLTCSVSGFGPP.P.VTWLRNGK.....LSLTI.

|+ |+|++ |+| |+| +++++ ++++++ +++ +| ++

25 NOV2 314 GQAVSLRCRAV--GDPEPVVHWVAPDGRLLGNSSRTRVRGDGTLDDVT 358

SVTPEDSGGTYTCVV (SEQ ID NO:60)

+| || ||+|| +

NOV2 359 ITTLRDS-GTFTCIA 372 (SEQ ID NO:61)

30

Fibronectins are multi-domain glycoproteins found in a soluble form in plasma, and in an insoluble form in loose connective tissue and basement membranes. They contain multiple copies of 3 repeat regions (types I, II and III), which bind to a variety of substances including heparin, collagen, DNA, actin, fibrin and fibronectin receptors on cell surfaces. The wide variety of these substances means that fibronectins are involved in a number of important functions: e.g., wound healing; cell adhesion; blood coagulation; cell differentiation and migration; maintenance of the cellular cytoskeleton; and tumour metastasis. The role of fibronectin in cell differentiation is demonstrated by the marked reduction in the expression of

35

its gene when neoplastic transformation occurs. Cell attachment has been found to be mediated by the binding of the tetrapeptide RGDS to integrins on the cell surface, although related sequences can also display cell adhesion activity.

Plasma fibronectin occurs as a dimer of 2 different subunits, linked together by 2 disulphide bonds near the C-terminus. The difference in the 2 chains occurs in the type III repeat region and is caused by alternative splicing of the mRNA from one gene. The observation that, in a given protein, an individual repeat of one of the 3 types (e.g., the first FnIII repeat) shows much less similarity to its subsequent tandem repeats within that protein than to its equivalent repeat between fibronectins from other species, has suggested that the repeating structure of fibronectin arose at an early stage of evolution. It also seems to suggest that the structure is subject to high selective pressure.

The fibronectin type III repeat region is an approximately 100 amino acid domain, different tandem repeats of which contain binding sites for DNA, heparin and the cell surface. The superfamily of sequences believed to contain FnIII repeats represents 45 different families, the majority of which are involved in cell surface binding in some manner, or are receptor protein tyrosine kinases, or cytokine receptors.

```

fn3: domain 1 of 1, from 422 to 502: score 34.5, E = 2.4e-06
      PSAPTNLTVTDVTSTSLTLSWSPPTGNGPITGYEVTYRQPKNGGEWN
20      | ++|++ ++| |+| ++| + ++ | |+|  ++ + + +
      NOV2   422   SAAERRLVAAELTNSVLIWPAQRPVPGIRMYQVQY-NSSVDDSLV 467

      ELTVPGTTTSYTLTGLKPGTEYEVVRVQAVNGGGGPES (SEQ ID NO:62)
      +++|+|+ ++ +++| +|+ | ++| || ++ ++
25      NOV2   468 YRMIPSTSQTFLVNDLAAGRAYDLCVLAVYDD--GAT   502 (SEQ ID NO:63)

```

The NOV2 nucleic acids encoding the KIAA 1246-like proteins of the invention, or fragments thereof, are useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These materials are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below.

The disclosed NOV2b protein has multiple hydrophilic regions, each of which can be used as an immunogen. In one embodiment, a contemplated NOV2b epitope is from about amino acids 42 to 50. In another embodiment, a contemplated NOV2b epitope is from about

amino acids 70 to 90. In other specific embodiments, contemplated NOV2b epitopes are from about amino acids 110 to 160, 172 to 180, 210 to 250, 255 to 300, 325 to 360, 400 to 427, 450 to 480, 522 to 530, 560 to 590, 598 to 622, 668 to 685, and 695 to 750.

The disclosed NOV2c protein has multiple hydrophilic regions, each of which can be used as an immunogen. In one embodiment, a contemplated NOV2c epitope is from about amino acids 8 to 26. In another embodiment, a contemplated NOV2c epitope is from about amino acids 67 to 74. In other specific embodiment, contemplated NOV2c epitopes are from about amino acids 100 to 120, 150 to 185, 198 to 205, 242 to 275, 280 to 330, 355 to 385, 425 to 454, 470 to 498, 550 to 558, 580 to 650, 680 to 710, and 727 to 780.

NOV3

A disclosed NOV3 nucleic acid of 2660 nucleotides (also referred to as SGGC_DRAFT_BA342E24_20000805_DA1) encoding a novel human DEMATIN-like protein is shown in Table 3A. An open reading frame was identified beginning with a ATG initiation codon at nucleotides 451-453 and ending with a CTG codon at nucleotides 1599-1661. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 3A. The start and stop codons are in bold letters.

Table 3A. NOV3 Nucleotide Sequence (SEQ ID NO:11)

<u>CACGAGAAGACAGGAGGAAGAAAGGGAGAGAGGGCCAGGCAGTTCGCACTGTGAACAGAACAGGAGAAGGCC</u>
<u>AAGCGGGGCAAGTTCCCTGCCCCACCGACGCCAGCCTGCTTGGATGACTTGCCCTCGTTTCATAATTCACTT</u>
<u>ACTGTCTGCACCGCCGCGCTCAGCCTGGCTGGACCTGCTGCCTGTGTGGCCCGAGCCAGAGGCCCCCA</u>
<u>CACTCCAGCTGCTCTTCTACAGATGCCATCAACGAGCAGGACTCTGGGTGGCTCCACTGTCTAAGCCTGG</u>
<u>AGAGTCACCGCCGAGGATGAGGACGCGCCAGCCCGGGGAACGCGCCAGCTGCTTTCGCGGCCCAAGCG</u>
<u>CGCAGTGCCCGAGCAGCCGCGCGAGCCTGACAGCTGTCTCTCCCTTCGCGCACAGGGCTCTGCGAGTGA</u>
<u>CCCGCGGGCGAGCTCCGTGCTGCAATGGAACGGCTGCAGAAGCAACCACTTACCTCCCCGGGAGCGTGAG</u>
<u>CCCCCTCCCGAGATTCCAGTGTGCCTGGCTCTCCCTCCAGCATCGTGGCCAAGATGGACAATCAGGTGCTGG</u>
<u>GCTACAAGGACCTGGCTGCCATCCCCAAGGACAAGGCCATCCTGGACATCGAGCGGCCCGACCTCATGATC</u>
<u>TACGAGCCTCACTTCACTTATCCCTCCTGGAACAGTGGAGCTGCCTCGCAGCCGCGAGCGCTCGCTGTC</u>
<u>ACCCAAATCCACATCCCCCCCCACCATCCCCAGAGGTGTGGGCGGACAGCCGGTCGCTGGAATCATCTCTC</u>
<u>AGGCCTCGGCCCCAGAACCACTGGAACCCCCCGACCACTGCCCCATTTCCACCACCTGAGACCTCC</u>
<u>CGCCAGATTTCAACATCTACAAGAAGCCTCCCATCTATAAGCAGAGAGAGTCCGTGGGAGGCAGCCCTCA</u>
<u>GACCAAGCACCTCATCGAGGATCTCATCATCGAGTCATCAAGTTTCTGCGAGCCAGCCCCAGACCCCA</u>
<u>ACCAGCCAGCCAAATCGAAACCGACTACTGGCCATGCCCCCGTCTCTGGCTGTGTGGAGACAGAATGG</u>
<u>AGGAAGCGGAAGGCGTCTCGGAGGGGAGCAGAGGAAGAGGAGGAGGAGGAAGATGACGACTCTGGAGAGGA</u>
<u>GATGAAGGCTCTCAGGGAGCGTCAGAGAGAGGAAGTCACTAAGGTTACTTCCAACCTGGGAAAGATGATCT</u>
<u>TGAAAGAAGAGATGGAAAAGTCAATTGCCGATCCGAAGGAAAACCGCTCTCTGCCTGACCGGACACCCCTC</u>
<u>CATACCTCCTTGCAACGAGGAACGTCTAAATCTTCTCTCTCCCCGCTATGGCAGGACCACCTGAGCCG</u>
<u>GCTACAGTCCACAGAGTTCAGCCCATCAGGGAGTGAGACTGGAAGCCAGGCCTGCAGATCTATCCCTATG</u>
<u>AAATGCTAGTGGTGACCAACAAGGGGCGAACCAAGCTGCCACCGGGGTGGATCGGATGCGGCTTGAGAGG</u>
<u>CATCTGTCTGCCGAGGACTTCTCAAGGGTATTGGCCATGTCCCCTGAAGAGTTTGGAAGCTGGCTCTGTG</u>
<u>GAAGCGGAATGAGCTCAAGAAGAAGGCCTCTCTTCTGATGGCCCCACCTGCTCCGGGACGGCCCCCTT</u>
<u>ACCCTGCTGCTTTCAGGGTTTTTCCCCGGCGGTGGGAGGGGAGGAGGTGGGGTGGAAATAGGGTGGGC</u>
<u>TCCTTTCTCAGGTAGAGTGGGGGGCCAAACCTCTGCAGTCCCCGGCAGTGAGCTATGGACTTTCTTCCC</u>
<u>CCTCACGAGGCTGGGGGCTCTCTGCTCTCGTCCCTGGCCCTCCCTGTACAGGGCAAGCCAGTCTGGGCTC</u>
<u>TGGCACACAGAGTTTATGTTTGGCGCCCTCTCCCTGCCCTCACCCAGAGGTGAGAGGAATGAGGGGCAT</u>
<u>TGGTGGTTAGGCCGGTTGGCTGTCTTGAACAGCTGGAGGGAAGATGCAGGGGTGGGAAGCGGCCAGGCAGA</u>
<u>AAGAGCTCCAGGCTCTTGTGTGCGCCACCCAGCCCTCCCATACTCACTCCTGACAGCTTTCTGCACTGCA</u>
<u>GCTTCTCTCTCTGACTCTAGTGGGAACAGGCCCCAGCTCAGCTCCGCGAGGGAGGTACCCCTCCAC</u>

TTCAGCTTGCCCTGACCTCCGCTCGCAAACCCGAGCTTCCAAGCCTTTTGCTCCAGCCCTGCGGCTTCCC
 CAGAAGCCTGGGCTTAGGGTGGAGATGCCGCTACCCGATCCTGGCCCTCCACCTGCCTCCAGGCCACGAA
 ATGGGAATTCCAGCACTAAGCCAGGCACCGGGCAGAAGCTGGGCCTTCCGCTCCCTTGGATGGGGTCAAG
 AGGCCAGGCCTGGCATTCTTGGAGTGTCTGGCTACCGCTCTCACACTACACCCACGACCCCTCAC
 ACCTATGCTCTCTCAAGAAATGTAATTTATTGGGGCCCCCAGCTGCTTCTCTCACCTGCCCTGCCCTA
 CCTTACACCCCGAGCTTGACTTCTTTCCAGTCCACGTGGATATAATGATATCTATATTTTGGCCAGGTCT
 GGTATTGCTCCTGCCAGACCTGACATCCCTTTCCACTGTGTGTGTGACCATGCTGGGGAGGGGACT
 CTGCTTGGGAATTAAAGGTTGCTTTGGGTCCCT

The disclosed NOV3 nucleic acid sequence has 1504 of 1516 bases (99%) identical to human dematin (GENBANK-ID: L19713) (E = 0).

A disclosed NOV3 protein (SEQ ID NO:12) encoded by SEQ ID NO:11 has 383
 5 amino acid residues, and is presented using the one-letter code in Table 3B. Signal P, Psort
 and/or Hydropathy results predict that NOV3 contains a signal peptide, and is likely to be
 localized to the microbody (peroxisome) with a certainty of 0.3000. In other embodiments, it
 is likely to be localized to nucleus with a certainty of 0.3000 and to the mitochondrial matrix
 space with a certainty of 0.1000.

10

Table 3B. Encoded NOV3 protein sequence (SEQ ID NO:12).

MERLQKQPLTSPGSVSPSRDSSVPGSPSSIVAKMDNQVLGYKDLAAIPKDKAILDIERPDLMIYEPHFTYS
 LLEHVELPRSRERSLSPKSTSPPPSPPEVWADSRSPGIIISQASAPRTTGTPTRLPHFHPETSRPDSNIYK
 KPPIYKORES VGGSPQTKHLIEDLII ESSKFPAQPPDPNQPAKIETDYWCPPSLAVVETEWKRKASRR
 GAEHEEEEEEDDDSGEEMKALRERQREELSKVTSNLGKMLKEEMKSLPIRRKTRSLPDRTPFHTSLHOGT
 SKSSSLPAYGRTTSLRLQSTEFSPSGSETGSPGLQIYPYEMLVVTNKGRTKLPPGVDRMLERHLSAEDFS
 RVFAMSPPEEFGKLALWKRNELKKKASLF

The amino acid sequence of NOV3 had high homology to other proteins as shown in Table 3C .

Table 3C . BLASTX results from PatP database for NOV3

patp:AAG03676 Human secreted protein
 Score= 305 (107.4 bits), Expect = 4.0e-25, P = 4.0e-25
 IDENTITIES = 59/61 (96%), POSITIVES = 59/61 (96%), FRAME = +1

15

In addition, the NOV3 amino acid sequence has 382 of 405 amino acid residues (94%)
 identical to, and 382 of 405 amino acid residues (94%) similar to, the human erythrocyte
 membrane protein band 4.9 (dematin) (GENBANK ID: AAH06318) (E = 1.0e⁻¹⁶⁸). The global
 sequence homology is 62.396% amino acid homology and 54.576% amino acid identity.

20

NOV3 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 3D.

Table 3D. BLAST results for NOV3					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 13623437 gb AA H06318.1 AAH06318	erythrocyte membrane protein band 4.9 (dematin) [Homo sapiens]	405	382/405 (94%) ,	382/405 (94%)	1e-168
gi 14751945 ref X P_048027.1	erythrocyte membrane protein band 4.9 (dematin) [Homo sapiens]	383	380/383 (99%) ,	380/383 (99%)	1e-168
gi 585044 sp Q084 95	DEMA_HUMAN DEMATTN(ERY -THROCYTE MEMBRANE PROTEIN BAND 4.9)	383	378/383 (98%) ,	379/383 (98%)	1e-168
gi 4503581 ref NP _001969.1	Erythrocyte membrane protein band 49 (dematin) [Homo sapiens]	405	380/405 (93%) ,	380/405 (93%)	1e-167
gi 14751939 ref X P_048026.1	erythrocyte membrane protein band 4.9 (dematin) [Homo sapiens]	405	380/405 (93%) ,	380/405 (93%)	1e-166

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 3E.

Table 3E. ClustalW Analysis of NOV3

- 1) Novel NOV3 (SEQ ID NO:12)
 2) gi|13623437|gb|AAH06318.1|AAH06318 (BC006318) erythrocyte membrane protein band 4.9 (dematin) [Homo sapiens] (SEQ ID NO:64)
 3.) gi|14751945|ref|XP_048027.1| erythrocyte membrane protein band 4.9 (dematin) [Homo sapiens] (SEQ ID NO:65)
 4.) gi|585044|sp|Q08495|DEMA_HUMAN DEMATIN (ERYTHROCYTE MEMBRANE PROTEIN BAND 4.9)[Homo sapiens] (SEQ ID NO:66)
 5.) gi|4503581|ref|NP_001969.1| erythrocyte membrane protein band 4.9 (dematin) [Homo sapiens] (SEQ ID NO:67)
 6.) gi|14751939|ref|XP_048026.1| erythrocyte membrane protein band 4.9 (dematin) [Homo sapiens] (SEQ ID NO:68)

NOV3	10	20	30	40	50
gi 1362343	MERLQKQPLTSPGVS	SPSRDSSVPGSPSSIVAKMD	NOVLGYKDAAIPKD	
gi 1475194	MERLQKQPLTSPGVS	SPSRDSSVPGSPSSIVAKMD	NOVLGYKDAAIPKD	
gi 585044	MERLQKQPLTSPGVS	SPSRDSSVPGSPSSIVAKMD	NOVLGYKDAAIPKD	
gi 4503581	MERLQKQPLTSPGVS	SPSRDSSVPGSPSSIVAKMD	NOVLGYKDAAIPKD	
gi 1475193	MERLQKQPLTSPGVS	SPSRDSSVPGSPSSIVAKMD	NOVLGYKDAAIPKD	
NOV3	60	70	80	90	100
gi 1362343	KAILDIERPDLMIYEPHFTYS	LLHVELPRSRERSLSPKSTSPPPSPEVW		
gi 1475194	KAILDIERPDLMIYEPHFTYS	LLHVELPRSRERSLSPKSTSPPPSPEVW		
gi 585044	KAILDIERPDLMIYEPHFTYS	LLHVELPRSRERSLSPKSTSPPPSPEVW		
gi 4503581	KAILDIERPDLMIYEPHFTYS	LLHVELPRSRERSLSPKSTSPPPSPEVW		
gi 1475193	KAILDIERPDLMIYEPHFTYS	LLHVELPRSRERSLSPKSTSPPPSPEVW		
NOV3	110	120	130	140	150
gi 1362343	ADSRSPGIISQASAPRTTGT	TPRTSLPHFHHPETSRPDSNIYKKPPIYKQR		
gi 1475194	ADSRSPGIISQASAPRTTGT	TPRTSLPHFHHPETSRPDSNIYKKPPIYKQR		
gi 585044	ADSRSPGIISQASAPRTTGT	TPRTSLPHFHHPETSRPDSNIYKKPPIYKQR		
gi 4503581	ADSRSPGIISQASAPRTTGT	TPRTSLPHFHHPETSRPDSNIYKKPPIYKQR		
gi 1475193	ADSRSPGIISQASAPRTTGT	TPRTSLPHFHHPETSRPDSNIYKKPPIYKQR		
NOV3	160	170	180	190	200
gi 1362343	ESVGGSPQTKHLIEDLII	ESSKFPAAQPPDPNQPAKIEDYWPCCPSLAV		
gi 1475194	ESVGGSPQTKHLIEDLII	ESSKFPAAQPPDPNQPAKIEDYWPCCPSLAV		
gi 585044	ESVGGSPQTKHLIEDLII	ESSKFPAAQPPDPNQPAKIEDYWPCCPSLAV		
gi 4503581	ESVGGSPQTKHLIEDLII	ESSKFPAAQPPDPNQPAKIEDYWPCCPSLAV		
gi 1475193	ESVGGSPQTKHLIEDLII	ESSKFPAAQPPDPNQPAKIEDYWPCCPSLAV		
NOV3	210	220	230	240	250
gi 1362343	VETEWKRKRKASRRGA	EEEEEEEDDDSGEEMKALRERQREELSKVTSNLGK		
gi 1475194	VETEWKRKRKASRRGA	EEEEEEEDDDSGEEMKALRERQREELSKVTSNLGK		
gi 585044	VETEWKRKRKASRRGA	EEEEEEEDDDSGEEMKALRERQREELSKVTSNLGK		
gi 4503581	VETEWKRKRKASRRGA	EEEEEEEDDDSGEEMKALRERQREELSKVTSNLGK		
gi 1475193	VETEWKRKRKASRRGA	EEEEEEEDDDSGEEMKALRERQREELSKVTSNLGK		
NOV3	260	270	280	290	300
gi 1362343	MILKEEMEKSLPIRRKTR	SLPDRTPFHTSLHOGTSKSSSLPAYGRTTLSR		
gi 1475194	MILKEEMEKSLPIRRKTR	SLPDRTPFHTSLHOGTSKSSSLPAYGRTTLSR		
gi 585044	MILKEEMEKSLPIRRKTR	SLPDRTPFHTSLHOGTSKSSSLPAYGRTTLSR		
gi 4503581	MILKEEMEKSLPIRRKTR	SLPDRTPFHTSLHOGTSKSSSLPAYGRTTLSR		
gi 1475193	MILKEEMEKSLPIRRKTR	SLPDRTPFHTSLHOGTSKSSSLPAYGRTTLSR		
NOV3	310	320	330	340	350
gi 1362343	LQSTEFSPSGSETGSPGLQ	NGEGQGRMDRGNSLPCVLEQKI	LYPYEMLVV	
gi 1475194	LQSTEFSPSGSETGSPGLQ	NGEGQGRMDRGNSLPCVLEQKI	LYPYEMLVV	
gi 585044	LQSTEFSPSGSETGSPGLQ	NGEGQGRMDRGNSLPCVLEQKI	LYPYEMLVV	
gi 4503581	LQSTEFSPSGSETGSPGLQ	NGEGQGRMDRGNSLPCVLEQKI	LYPYEMLVV	
gi 1475193	LQSTEFSPSGSETGSPGLQ	NGEGQGRMDRGNSLPCVLEQKI	LYPYEMLVV	

```

gi|1475194| LQSTEFSPSGSETGSPDFC-----TYPYEMLVV
gi|585044| LQSTEFSPSGSETGSPGLC-----TYPYEMLVV
gi|4503581| LQSTEFSPSGSETGSPCLCNGEGQGRMDRGNSLPCVLEQKIYPYEMLVV
gi|1475193| LQSTEFSPSGSETGSPAPCNGEGQGRMDRGNSLPCVLEQKIYPYEMLVV
               360       370       380       390       400
.....|.....|.....|.....|.....|.....|
NOV3          TNKGRTKLPPGVDRMRLERHLSAEDFSRVFAMSPPEFGKLALWKRNELKK
gi|1362343| TNKGRTKLPPGVDRMRLERHLSAEDFSRVFAMSPPEFGKLALWKRNELKK
gi|1475194| TNKGRTKLPPGVDRMRLERHLSAEDFSRVFAMSPPEFGKLALWKRNELKK
gi|585044| TNKGRTKLPPGVDRMRLERHLSAEDFSRVFAMSPPEFGKLALWKRNELKK
gi|4503581| TNKGRTKLPPGVDRMRLERHLSAEDFSRVFAMSPPEFGKLALWKRNELKK
gi|1475193| TNKGRTKLPPGVDRMRLERHLSAEDFSRVFAMSPPEFGKLALWKRNELKK
               410
.....|.....|
NOV3          KASLF
gi|1362343| KASLF
gi|1475194| KASLF
gi|585044| KASLF
gi|4503581| KASLF
gi|1475193| KASLF

```

Tables 3F-3G list the domain description from DOMAIN analysis results against NOV3. This indicates that the NOV3 sequence likely has properties similar to those of other proteins known to contain these domains.

5

Table 3F Domain Analysis of NOV3

gnl|Smart|smart00153, VHP, Villin headpiece domain (SEQ ID NO:69)
 Length = 36 residues, 100.0% aligned
 Score = 58.5 bits (140), Expect = 7e-10

```

NOV3:          348  HLSAEDFSRVFAMSPPEFGKLALWKRNELKKKASLF  383  (SEQ ID NO:70)
               +|| ||| || |+ ||| || |||+||| ||
smart00153:    1   YLSDEDFEEVFGMTKEEFYKLPWKQNLKKKGLGF  36

```

Table 3F Domain Analysis of NOV3

gnl|Pfam|pfam02209, VHP, Villin headpiece domain (SEQ ID NO:71)
 Length = 36 residues, 100.0% aligned
 Score = 57.4 bits (137), Expect = 1e-09

```

NOV3:          348  HLSAEDFSRVFAMSPPEFGKLALWKRNELKKKASLF  383  (SEQ ID NO:72)
               +|| ||| || |+ ||| || |||+||| ||
pfam02209:    1   YLSDEDFEEVFGMTKEEFYKLPWKQNLKKKGLGF  36

```

10

As shown in the domain analyses above, a disclosed NOV3 polypeptide is a member of the erythroid actin-bundling protein family. One of the conserved regions found in this protein

family is a villin-like headpiece domain. This headpiece domain is essential for actin bundling and actin modulating activity.

NOV3 is expressed in at least the following tissues: Brain, anaplastic oligodendroglioma, and Colon. In addition, the NOV3 sequence is predicted to be expressed in the Liver because of the expression pattern of a closely related *Papio* insulin-like growth factor binding protein-3 complex acid-labile subunit homolog (GENBANK-ID: S83462).

The expression pattern, and protein similarity information for the invention suggest that the novel human DEMATIN protein described in this invention may be useful in potential therapeutic applications implicated in various diseases and disorders. The homology to antigenic secreted and membrane proteins suggests that antibodies directed against the novel genes may be useful in treatment and prevention of certain diseases and disorders.

NOV4

NOV4 includes two novel matrilin-2-like proteins disclosed below. The disclosed sequences have been named NOV4a and NOV4b.

NOV4a

The disclosed NOV4a nucleic acid of 3447 nucleotides (also designated CuraGen Acc. No. 14578444_0_47) encoding a novel matrilin-2-like protein is shown in Table 4A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 64-66 and ending with a TGA codon at nucleotides 2932-2934. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 4A. The start and stop codons are in bold letters.

Table 4A. NOV4a nucleotide sequence (SEQ ID NO:13).

```
GGTAGCCGACGCGCCGGCCGCGCGTGACCTTGCCCTCTTGCTCGCCTTGAAATGGAAAAGATGCTCG
CAGGCTGCTTTCTGCTGATCCTCGACAGATCGTCTCTCCCTGCCGAGGCCAGGCAGCGGTACGTGG
GAGGTCCATCTCTAGGGCAGACACGCTCGGACCCACCCGACAGACGGCCCTTCTGGAGAGTTCTGTGAG
AACAAGCGGGCAGACCTGGTTTTCATCATTGACAGCTCTCGCAGTGTCAACACCCATGACTATGCAAAGG
TCAAGGAGTTTCATCGTGGACATCTTGCAATTCTTGACATTTGGTCTGATGTACCCGAGTGGGCCCTGCT
CCAATATGGCAGCACTGTCAAGAATGAGTTCTCCCTCAAGACCTTCAAGAGGAAGTCCGAGGTGGAGCGT
GCTGTCAAGAGGATGCGGCATCTGTCCACGGGACCATGACTGGGCTGGCCATCCAGTATGCCCTGAACA
TCGCATTCTCAGAAGCAGAGGGGGCCCGGCCCTGAGGGAGAATGTGCCACGGGTCAATATGATCGTGAC
AGATGGGAGACCTCAGGACTCCGTGGCCGAGGTGGCTGCTAAGGCACGGGACACGGGCATCCTAATCTTT
GCCATTGGTGTGGGCCAGGTAGACTTCAACACCTTGAAGTCCATTGGGAGTGAGCCCCATGAGGACCATG
TCTTCTTGTGGCCAATTTAGCCAGATTGAGACGCTGACCTCCGTCTTCCAGAAGAAGTTGTGCACGGC
CCACATGTGCAGCACCTGGAGCATAACTGTGCCCACTTCTGCATCAACATCCCTGGCTCATACGTCTGC
AGGTGCAACAAGGCTACATTCTCAACTCGGATCAGACGACTTGCAGAATCCAGGATCTGTGTGCCATGG
AGGACCACAACCTGTGAGCAGCTCTGTGTGAATGTGCCGGGCTCCTTCGTCTGCCAGTGCTACAGTGGCTA
CGCCCTGGCTGAGGATGGGAAGAGGTGTGTGGCTGTGGACTACTGTGCCTCAGAAAACACCGGATGTGAA
CATGAGTGTGTAAATGCTGATGGCTCCTACCTTTGCCAGTGCCATGAAGGATTTGCTCTTAACCCAGATG
AAAAAACGTGCACAAAGATAGACTACTGTGCCTCATCTAATCATGGATGTAGTACGAGTGTGTAAACAC
AGATGATTCTTCTGCTGCACTGCCTGAAAGGCTTTACCTGAATCCAGATAAGAAAACCTGCAGAAGG
ATCAACTACTGTGCACTGAACAAACCGGGCTGTGAGCATGAGTGCCTCAACATGGAGGAGAGTACTACT
CGCGCTGCCACCGTGGCTACACTCTGGACCCCAATGGCAAAACCTGCAGCCGAGTGGACCACTGTGCACA
```

```

GCAGGACCATGGCTGTGAGCAGCTGTGTCTGAACACGGAGGATTCCTTCGTCTGCCAGTGTCTCAGAAGGC
TTCCTCATCAACGAGGACCTCAAGACCTGCTCCCGGGTGGATTACTGCCTGCTGAGTGACCATGGTTGTG
AATACTCCTGTGTCAACATGGAACAGATCCTTTGCCTGTGCTGCTGAGGGACACGTGCTCCGACAGCGA
TGGGAAGACGTGTGCAAAATGGACTCTTGTGCTCTGGGGGACCAACGGTGTGTGAACATTCTGTGTGAAGC
AGTGAAGATTCTGTTGTGTGCCAGTGTCTTTGAAGGTTATATACTCCGTGAAGATGGAAAAACCTGCAGAA
GGAAAGATGTCTGCAAGCTATAGACCATGGCTGTGAACACATTTGTGTGAACAGTGAACGACTCATACAC
GTGCGAGTGTCTGGAGGGATTCCGGCTCACTGAGGATGGGAAACGCTGCCGAATTTCTCAGGGGAAGGAT
GTCGTGCAAAATCAACCCACCATGGCTGCGAACACATTTGTGTTAATAATGGGAATTCCTACATCTGCAAAAT
GCTCAGAGGGATTGTTCTAGCTGAGGACGGGAAGACGGTGAAGAAATGCACTGAAGGCCCAATTGACCT
GGTCTTTGTGATCGATGGATCCAAGAGTCTTGGAGAAGAGAAATTTGAGGTCTGGAAGCAGTTTGTCACT
GGAATTATAGATTCTTGACAATTTCCCCCAAAGCCGCTCGAGTGGGGCTGCTCCAGTATTCACACAGG
TCCACACAGAGTTCACTCTGAGAACTTCAACTCAGCCAAAGACATGAAAAAGCCGTGGCCCAATGAA
ATACATGGGAAAGGGCTCTATGACTGGGCTGGCCCTGAAACACATGTTTGAGAGAAGTTTACCCCAAGGA
GAAGGGGCCAGGCCCTTTTCCACAAGGGTGCCAGAGCAGCCATTGTGTTACCGACGGACGGGCTCAGG
ATGACGTCTCCGAGTGGGCCAGTAAAGCCAAAGCCCAATGGTATCACTATGTATGCTGTTGGGGTAGGAAA
AGCCATTGAGGAGGAACTACAAGAGATTGCCTCTGAGCCACAAACAAGCATCTCTTCTATGCCGAAGAC
TTCAGCACAAATGGATGAGATAAGTGAAGAACTCAAGAAAGGCATCTGTGAAGCTCTAGAAGACTCCGATG
GAAGACAGGACTCTCCAGCAGGGGAAC TGCCAAAAACGGTCCAAACAGCCAACAGAAATCTGAGCCAGTCAC
CATAAATCTCCAGACCTACTTTCTGTTCTAATTTTGCAGTGCAACACAGATATCTGTTTGAAGAAGAC
AATCTTTTACGGTCTACACAAAAGCTTTCCATTCAACAAAACCTTCAGGAAGCCCTTTGGAAGAAAAAC
ACGATCAATGCAATGTGAAACCTTATAATGTTCCAGAACCTTGCAACAGAAAGTAAAGAAATTAAC
ACAGCGCTTAGAAGAAATGACACAGAGAATGGAAGCCCTGGAAAAATCGCTGAGATACAGATGAAGATTA
GAAATCGCGACACATTTGTAGTCATTGTATCACGGATTACAATGAACGCAGTGCAAGCCCCAAAGCTCA
GGCTATTGTTAAATCAATATGTTGTGAAGTAAACCAATCAGTACTGAGAAACCTGGTTTGCCACAGAAC
AAAGACAAGAAGTATACATAACTTGTATAAATTTATCTAGGAAAAAAATCCTTCAGAAATCTAAGATGA
ATTTACCAAGGTGAGAAATGAATAAGCTATGCAAGGTATTTTGTAAATATACTGTGGACACAACTGTCTCTG
CCTCATCTGCTTAGTGTGCAATCTCATTGACTATACGATAAAGTTTGACAGTCTTACTTCTGTAGA
ACACTGGCCATAGGAAATGCTGTTTCTTGTACTGGAATTTACCTTGATATATGTATATGGATGTATGCA
TAAATCATAGGACATATGTACTTGTGGAACAAGTTGGATTTTATACAATATTAATAATCACCACCTC
AGAGAAAACTAAAAAA

```

The NOV4a encoded protein having 977 amino acid residues (SEQ ID NO:13) is presented using the one-letter code in Table 4B.

Table 4B. Encoded NOV4a protein sequence (SEQ ID NO:14).

```

GSRRAGRRVTLPLLLALKMEKMLAGCFLLILGQIVLLPAEARQSRGRSISRGHARTHPTALLESSCENK
RADLVFIIDSSRSVNTHDYAKVKEFIVDILQFLDIGPDVTRVGLLQYGSTVKNEFSLKTFKRKSEVERAVKR
MRHLSTGTMGLAIQYALNIAFSEABGARPLRENVPRVIMIVTDGRPDQSVAEVAAKARDTGILIFAIGVGQ
VDENTLTKSIGSEPHEDHVLVANFQSIETLTSVFQKLCATAMCSTLEHNCALFCINIPGSYVCRCKQGYIL
NSDQTTTCRIQDLAMEDHNCEQLCVNVPGSFVCQCYSGYALAEDEGKRCVAVDYCASENHGCEHECVNADGSY
LCQCEGFALNPDEKCTCKIDYCASSNHGCQYECVNTDDSYSCHLKGFTLNPDKKTCRINICALNKPGE
HECVNMEESYYCRCHRGYTLDPNGKPCSRVDHCAQQDHGCEQLCLNTEDSFVCQCEGFLINEDLKTCSRVD
YCLLSDHGCEYSVNMDSFACQCEGHVLRSDGKTKAKLDSALGDHGCEHSCVSSSEDSFVCQCFEGYILR
EDGKTCRRKDVCAIDHGCEHICVNSDDSYTCECLEGFRLTEDGKRCRISSGKDVCKSTHHGCEHICVNNGN
SYLCKCSEGFVLAEDGRRCKKCTEGPIDLVFVIDGSKSLGEENFEVVKQFVTGIIDSLTISPKAARVGLLQY
STQVHTEFTLRNFNSAKDMKKAVAHMKYMGKSGMTGLALKHMFERSFTQEGARPPSTRVPRAAIVFTDGRA
QDDVSEWASKAKANGITMYAVGVGAIEEELQEIASEPTNKLHLYAEDFSTMDIEISELKKGI CEALSDG
RQDSPAGELPKTVQPTSEPVITINIQDLLSCSNFAVQHRVLFEDNLLRSTQQLSHSTKPSGSPLEEKHDQ
CKCENLIMFQNLANEVRKLTQRLEEMTQRMEALENRLRYR

```

5

10

In a search of sequence databases, it was found, for example, that the NOV4a nucleic acid sequence has 1571 of 1862 bases (84%) identical to a *Mus musculus* matrilin-2 precursor mRNA (GENBANK-ID: MMU69262). The full amino acid sequence of the NOV4a protein of the invention was found to have 829 of 959 amino acid residues (86%) identical to, and 887 of 959 residues (92%) positive with, the 956 amino acid residue MATRILIN-2 PRECURSOR protein from *Mus musculus* (ptnr: SWISSPROT-ACC:O08746).

The NOV4a matrilin-2-like protein disclosed in this invention is expressed in at least the following tissues: dense and loose connective tissue structures; subepithelial connective tissue of the skin and digestive tract; specialized cartilages; and blood vessel walls; fibroblasts of the dermis, tendon, ligaments, perichondrium and periosteum; connective tissue elements of the heart; smooth muscle cells; and epithelia and loose connective tissue cells of the alimentary canal and respiratory tract.

NOV4b

The NOV4b nucleic acid of 2756 nucleotides (also designated CuraGen Acc. No. CG51015-03) encoding a novel MATRILIN-2-like protein is shown in Table 4C. An open reading frame was identified beginning at nucleotides 30-32 and ending at nucleotides 2718-2720. This open reading from begins with an ATG initiation codon and ends with a TGA stop codon. The start and stop codons of the open reading frame are highlighted in bold type. Putative untranslated regions (underlined) are found upstream from the initiation codon and downstream from the termination codon.

Table 4C. NOV4b nucleotide sequence (SEQ ID NO:15).

TGACCTTGCCCTCTTGCTCGCCTTGAAAATGGAAAAGATGCTCGCAGGCTGCTTTCTGCTGATC
CTCGGACAGATCGTCTCTCTCTGCGGAGGCCAGGGAGCGGTACGTTGGGAGGTCCATCTCTAG
GGGACAGACACGCTCGGACCCACCCGACAGCGGCCCTTCTGGAGAGTTCTGTGAGAACATGCGGG
CAGACCTGGTTTTTCATCATTGACAGCTCTCGAGTGTCAACACCCATGACTATGCAAAGGTCAAG
GAGTTTCATCGTGGACATCTTGCAATTCTTGGACATTGGTCCTGATGTCACCCGAGTGGGCTGCT
CCAATATGGCAGCACTGTCAAGAATGAGTTCTCCCTCAAGACCTTCAAGAGGAAGTCCGAGGTGG
AGCGTGCTGTCAAGAGGATGCGGCATCTGTCCACGGGCACCATGACCGGGCTGGCCATCCAGTAT
GCCCTGAACATCGCATTCTCAGAAGCAGAGGGGGCCCGGCCCTGAGGGAGAATGTGCCACGGGT
CATAATGATCGTGACAGATGGGAGACCTCAGGACTCCGTGGCCGAGGTGGCTGCTAAGGCACGGG
ACACGGGCATCCTAATCTTTGCCATTGGTGTGGGCCAGGTAGACTTCAACACCTTGAAGTCCATT
GGGAGTGAGCCCCATGAGGACCATGTCTTCTTGTGGCCAATTTAGCCAGATTGAGACGCTGAC
CTCCGTGTTCCAGAAGAAGTTGTGCACGGGCCACATGTGCAGCACCTTGGAGCATAACTGTGCCC
ACTTCTGCATCAACATCCCTGGCTCATACTGTGCAGGTGCAAACAAGGCTACATTCTCAACTCG
GATCAGACGACTTGCAGAAATCCAGGATCTGTGTGCCATGGAGGACCACAAGTGTGAGCAGCTCTG
TGTGAATGTGCCGGGCTCCTTCGTCTGCCAGTGCTACAGTGGCTACGCCCTGGCTGAGGATGGGA
AGAGGTGTGTGGCTGTGGACTACTGTGCCTCATCTAATCACGGATGTGAGCAGAGTGTGTTAAC
ACAGATGATTCCTATTCTGCCACTGCCTGAAAGGCTTTACCCTGAATCCAGATAAGAAAACCTG
CAGAAGGATCAACTACTGTGCACTGAACAAAACCGGCTGTGAGCATGAGTGCCTCAACATGGAGG
AGAGCTACTACTGCCGCTGCCACCGTGGCTACACTCTGGACCCCAATGGCAAACCTGCAGCCGA
GTGGACCACTGTGCACAGCAGGACCATGGCTGTGAGCAGCTGTGTCTGAACACGGAGGATTCCTT
CGTCTGCCAGTGCTCAGAAGGCTTCCTCATCAACGAGGACCTCAAGACCTGCTCCCGGTGGATT
ACTGCCTGCTGAGTGACCATGGTTGTGAATACTCCTGTGTCAACATGGACAGATCCTTTGCCGTG
CAGTGTCTTGAGGGACACGTGCTCCGCAGCGATGGGAAGACGTGTGCAAAATTGGACTCTTGTGC
TCTGGGGGACCACGGTTGTGAACATTCTGTGTGAAGCAGTGAAGATTCGTTTGTGTGCCAGTGCT
TTGAAGTTATATACCTCCGTGAAGATGGAAAACCTGCAGAAGGAAAGATGTCTGCCAAGCTATA
GACCATGGCTGTGAACACATTGTGTGAACAGTGATGACTCATAACGTCGAGTGCTTGGAGGG
ATTCCGGCTCGCTGAGGATGGGAAACGCTGCCGAAGGAAGGATGTCTGCAAATCAACCCACCATG
GCTGCGAACACATTTGTGTTAATAATGGGAATTCCTACATCTGCAAATGCTCAGAGGGATTTGTT
CTAGCTGAGGACGGAAGACGCTGCAAGAAATGCACTGAAGGCCCAATTGACCTGGTCTTTGTGAT
CGATGGATCCAAGAGTCTTGAGAAGAGAATTTTGAGGTCGTGAAGCAGTTTGTCACTGGAATTA
TAGATTCTTGACAATTTCCCCCAAAGCCGCTCGAGTGGGGCTGCTCCAGTATTCCACACAGGTC

CACACAGAGTTCACTCTGAGAACTTCAACTCAGCCAAAGACATGAAAAAGCCGTGGCCACAT
 GAAATACATGGGAAAGGGCTCTATGACTGGGCTGGCCCTGAAACACATGTTTGAGAGAAGTTTTA
 CCCAAGGAGAAGGGGCCAGGCCCTTTCCACAAGGGTGCCAGAGCAGCCATTGTGTTACCGAC
 GGACGGGCTCAGGATGACGTCTCCGAGTGGGCCAGTAAAGCCAAGGCCAATGGTATCACTATGTA
 TGCTGTTGGGGTAGGAAAAGCCATTGAGGAGGAAGTACAAGAGATTGCCTCTGAGCCACAAACA
 AGCATCTCTTCTATGCCGAAGACTTCAGCACAATGGATGAGATAAGTAAAAACTCAAGAAAGGC
 ATCTGTGAAGCTCTAGAAGACTCCGATGGAAGACAGGACTCTCCAGCAGGGGAACTGCCAAAAAC
 GGTCCAACAGCCAACAGTGCAACACAGATATCTGTTTGAAGAAGACAATCTTTACGGTCTACAC
 AAAAGCTTTCCATTCAACAAAACCTTCAGGAAGCCCTTTGGAAGAAAAACACGATCAATGCAAA
 TGTGAAAACCTTATAATGTTCCAGAACCTTGCAACGAAGAAGTAAGAAAATTAACACAGCGCTT
 AGAAGAAATGACACAGAGAATGGAAGCCCTGAAAATCGCCTGAGATACAGATGAAGATTAGAAA
 TCGCGACACATTTGTAAAGGGCGAAT

The NOV4 disclosed in this invention maps to chromosome 8. This assignment was made using mapping information associated with genomic clones, public genes and ESTs sharing sequence identity with the disclosed sequence and CuraGen Corporation's Electronic Northern bioinformatic tool.

The NOV4b encoded protein having 896 amino acid residues (SEQ ID NO:16) is presented using the one-letter code in Table 4D.

Table 4D. Encoded NOV4b protein sequence (SEQ ID NO:16).

MEKMLAGCFLLILGQIVLLPAEARERSRGRSISRGRHARTHPTALLESSCENMRADLVFIIDS
 RSVNTHDYAKVKEFIVDILQFLDIGPDVTRVGLLQYGSTVKNEFSLKTFKRKSEVERAVKMR
 HLSTGTMGLAIQYALNIAFSEAEGARPLRENVPRVIMIVTDGRPQDSVAEVAAKARDTGILIF
 AIGVGQVDFNTLKSIGSEPHEDHVFLVANFSQIETLTSVFQKKLCTAHMCSTLEHNCAHFCINI
 PGSYVCRCKQGYIILNSDQTTCRIQDLCAMEDHNCEQLCVNVPGSFVCQCYSGYALAEDGKRCVA
 VDYCASSNHGCQHECVNTDDSYSCHCLKGFTLNPDKKTCRRINICALNKPGEHECVNMEESYY
 CRCHRGYTLDPNGKTCRSVDHCAQQDHGCEQLCLNTEDSFVCQCEGFLINEDLKTCSRVDYCL
 LSDHGCEYSCVNMDRSFACQCPGHHVLRSDGKTCALDSCALGDHGCEHSCVSSDSFVCQCFE
 GYILREDGKTCRRKDVCAIDHGCEHICVNSDDSYTCECLEGFRLAEDGKRCRRKDVCKSTHHG
 CEHICVNNGNSYICKCSEGFVLAEDGRRCCKCTEGPIDLVFVIDGSKSLGEENFEVVKQFVTGI
 IDSLTISPKAARVGLLQYSTQVHTEFTLRNFNSAKDMKKAHAHMKYMGKGSMTGLALKHMFERS
 FTQGEGARPLSTRVPRAAIVFTDGRAQDDVSEWASKAKANGITMYAVGVGKAIEEELQEIASSEP
 TNKHLFYAEDFSTMDEISEKLKKGICEALEDSDGRQDSPAGELPKTVQQPTVQHRYLFEEDNLL
 RSTQKLSSHSTKPSGSPLEEKHDQCKCENLIMFQNLANEEVRKLQRLLEMTQRMELNRLRYR

In a search of sequence databases, it was found, for example, that the NOV4b nucleic acid sequence of this invention has 1897 of 1996 bases (95%) identical to a gb:GENBANK-ID:BC010444|acc:BC010444.1 mRNA from Homo sapiens (Homo sapiens, matrilin 2, clone MGC:17281 IMAGE:4215380, mRNA, complete cds) (Fig. 3A). The full amino acid sequence of the NOV4b protein of the invention was found to have 613 of 656 amino acid residues (93%) identical to, and 626 of 656 amino acid residues (95%) similar to, the 937 amino acid residue ptrn:TREMBLNEW-ACC:AAH10444 protein from Homo sapiens (Human) (MATRILIN 2).

The NOV4b MATRILIN-2-like gene disclosed in this invention is expressed in at least the following tissues: Mammalian Tissue, Adipose, Heart, Aorta, Vein, Adrenal

Gland/Suprarenal gland, Pancreas, Parathyroid Gland, Thyroid, Pineal Gland, Parotid Salivary glands, Stomach, Liver, Small Intestine, Appendix, Colon, Ascending Colon, Lymph node, Cartilage, Smooth Muscle, Brain, Cerebellum, Pituitary Gland, Amygdala, Cerebral Medulla/Cerebral white matter, Basal Ganglia/Cerebral nuclei, Substantia Nigra, Hippocampus, Spinal Chord, Cervix, Mammary gland/Breast, Ovary, Placenta, Uterus, Vulva, Prostate, Testis, Lung, Urinary Bladder, Kidney, Retina, Skin. Expression information was derived from the tissue sources of the sequences that were included in the derivation of the sequence of NOV4b (CuraGen Acc. No. CG51015-03). The NOV4b sequence is predicted to be expressed in the following tissues because of the expression pattern of (GENBANK-ID: gb:GENBANK-ID:BC010444|acc:BC010444.1) a closely related Homo sapiens, matrilin 2, clone MGC:17281 IMAGE:4215380, mRNA, complete cds homolog in species Homo sapiens:brain.

The PSORT, SignalP and hydropathy profile for NOV4 predict that this sequence has a signal peptide and is likely to be localized to the endoplasmic reticulum (membrane) with a certainty of 0.8200. In alternative embodiments, NOV4 is located to the plasma membrane with a certainty of 0.2710, the endoplasmic reticulum (lumen) with a certainty of 0.1000, or extracellularly with a certainty of 0.1000. The signal peptide of NOV4a is predicted by SignalP to be cleaved at amino acid position 41 and 42: AEA-RQ. The signal peptide of NOV4b is predicted by SignalP to be cleaved at amino acid 23 and 24: AEA-RE.

Homologies to any of the above NOV4 proteins will be shared by the other NOV4 protein insofar as they are homologous to each other as shown above. Any reference to NOV4 is assumed to refer to both of the NOV4 proteins in general, unless otherwise noted.

Additional SNP variants of NOV4 are disclosed in Example 3. The amino acid sequence of NOV1 has high homology to other proteins as shown in Table 4E.

Table 4E. BLASTX results for NOV4

Sequences producing High-scoring Segment Pairs:	High Score	Smallest Sum Prob P(N)
patp:AAB20159 Human protein SECP5 - Homo sapiens, 959 aa	5165	0.0
patp:AAE03877 Human gene 3 encoded secreted protein fragment- Homo sapiens, 983 aa	4647	0.0
patp:AAE03843 Human gene 3 encoded secreted protein HOGDP46- Homo sapiens, 934 aa	4595	0.0
patp:AAE03820 Human gene 3 encoded secreted protein HOGDP46- Homo sapiens, 794 aa	4208	0.0
patp:AAB20158 Human protein SECP4 - Homo sapiens, 776 aa	4133	0.0

NOV4 also has homology to the proteins shown in the BLASTP data in Table 4F.

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
ptnr:REMTREMBL- ACC:CAC32426	Sequence 9 from Patent WO0105971 <i>Homo sapiens</i> (Human)	959	956/959 (99%)	958/959 (99%)	0.0
ptnr:SWISSNEW- ACC:O00339	Matrilin-2 precursor - <i>Homo</i> <i>sapiens</i> (Human)	956	949/959 (98%)	952/959 (99%)	0.0
ptnr:TREMBLNEW- ACC:AAH10444	MATRILIN 2 - <i>Homo</i> <i>sapiens</i> (Human)	937	854/863 (98%)	856/863 (99%)	0.0
ptnr:SPTREMBL- ACC:Q99K64	MATRILIN 2 - <i>Mus</i> <i>musculus</i> (Mouse)	956	832/959 (86%)	888/959 (92%)	0.0
ptnr:SWISSPROT- ACC:O08746	MATRILIN-2 PRECURSOR - <i>Mus</i> <i>musculus</i> (Mouse)	956	829/959 (86%)	887/959 (92%)	0.0

5

```

1) NOV4a (SEQ ID NO:14)
2) NOV4b (SEQ ID NO:16)
3) ptnr:REMTREMBL-ACC:CAC32426 (SEQ ID NO:73)
4) ptnr:SWISSNEW-ACC:O00339 (SEQ ID NO:74)
5) ptnr:TREMBLNEW-ACC:AAH10444 (SEQ ID NO:75)
6) ptnr:SPTREMBL-ACC:Q99K64 (SEQ ID NO:76)
7) ptnr:SWISSPROT-ACC:O08746 (SEQ ID NO:77)

```

10

15

20

25

30

35

40

ILQFLDIGPDVTRVGLLQYGSTVKNFESLKTFRKSEVERAVKMRHLST

		160	170	180	190	200
5	NOV4a	GTMTGLAIQYALNIAFSEAEGARPLRENVPRVIMIVTDGRPDQSVAEVAA				
	NOV4b	GTMTGLAIQYALNIAFSEAEGARPLRENVPRVIMIVTDGRPDQSVAEVAA				
	CAC32426	GTMTGLAIQYALNIAFSEAEGARPLRENVPRVIMIVTDGRPDQSVAEVAA				
	O00339	GTMTGLAIQYALNIAFSEAEGARPLRENVPRVIMIVTDGRPDQSVAEVAA				
	AAH10444	GTMTGLAIQYALNIAFSEAEGARPLRENVPRVIMIVTDGRPDQSVAEVAA				
-10	Q99K64	GTMTGLAIQYALNIAFSEAEGARPLRENVPRVIMIVTDGRPDQSVAEVAA				
	O08746	GTMTGLAIQYALNIAFSEAEGARPLRENVPRVIMIVTDGRPDQSVAEVAA				
		210	220	230	240	250
15	NOV4a	KARDTGILIFAIGVGQVDENTLKSIGSEPHEDHVLVANFSQIETLTSVF				
	NOV4b	KARDTGILIFAIGVGQVDENTLKSIGSEPHEDHVLVANFSQIETLTSVF				
	CAC32426	KARDTGILIFAIGVGQVDENTLKSIGSEPHEDHVLVANFSQIETLTSVF				
	O00339	KARDTGILIFAIGVGQVDENTLKSIGSEPHEDHVLVANFSQIETLTSVF				
	AAH10444	KARDTGILIFAIGVGQVDENTLKSIGSEPHEDHVLVANFSQIETLTSVF				
20	Q99K64	KARNTGILIFAIGVGQVDLNTLKAIGSEPHEDHVLVANFSQIESLTSVF				
	O08746	KARNTGILIFAIGVGQVDLNTLKAIGSEPHEDHVLVANFSQIESLTSVF				
		260	270	280	290	300
25	NOV4a	QKKLCTAHMCSTLEHNC AHFCINIPGSYVCRCKQGYILNSDQTTCRIQDL				
	NOV4b	QKKLCTAHMCSTLEHNC AHFCINIPGSYVCRCKQGYILNSDQTTCRIQDL				
	CAC32426	QKKLCTAHMCSTLEHNC AHFCINIPGSYVCRCKQGYILNSDQTTCRIQDL				
	O00339	QKKLCTAHMCSTLEHNC AHFCINIPGSYVCRCKQGYILNSDQTTCRIQDL				
	AAH10444	QKKLCTAHMCSTLEHNC AHFCINIPGSYVCRCKQGYILNSDQTTCRIQDL				
30	Q99K64	QKKLCTAHMCSTLEHNC AHFCINIPGSYVCRCKQGYILNSDQTTCRIQDL				
	O08746	QKKLCTAHMCSTLEHNC AHFCINIPGSYVCRCKQGYILNSDQTTCRIQDL				
		310	320	330	340	350
35	NOV4a	CAMEDHNCBQLCVNVPGSFVQCQYSGYALAE DGKRCVAVDYCASENHGCE				
	NOV4b	CAMEDHNCBQLCVNVPGSFVQCQYSGYALAE DGKRCVAVDYCASENHGCE				
	CAC32426	CAMEDHNCBQLCVNVPGSFVQCQYSGYALAE DGKRCVAVDYCASENHGCE				
	O00339	CAMEDHNCBQLCVNVPGSFVQCQYSGYALAE DGKRCVAVDYCASENHGCE				
	AAH10444	CAMEDHNCBQLCVNVPGSFVQCQYSGYALAE DGKRCVAVDYCASENHGCE				
40	Q99K64	CATEDHGCEQLCVNMLGSFVQCQYSGYALAE DGKRCVAVDYCASENHGCE				
	O08746	CATEDHGCEQLCVNMLGSFVQCQYSGYALAE DGKRCVAVDYCASENHGCE				
		360	370	380	390	400
45	NOV4a	HECVNADGSYLCCHEGFALNPDEKTC TKIDY CASSNHGCOHECVNTDDS				
	NOV4b	HECVNADGSYLCCHEGFALNPDEKTC TKIDY CASSNHGCOHECVNTDDS				
	CAC32426	HECVNADGSYLCCHEGFALNPDEKTC TKIDY CASSNHGCOHECVNTDDS				
	O00339	HECVNADGSYLCCHEGFALNPDEKTC TKIDY CASSNHGCOHECVNTDDS				
	AAH10444	HECVNADGSYLCCHEGFALNPDEKTC TKIDY CASSNHGCOHECVNTDDS				
50	Q99K64	HECVNAESSYLCCHEGFALNSDKKTC SKIDY CASSNHGCOHECVNAQTS				
	O08746	HECVNAESSYLCCHEGFALNSDKKTC SKIDY CASSNHGCOHECVNAQTS				
		410	420	430	440	450
55	NOV4a	YSCHCLKGFTLNPDKKTCRRIN YCALNKP GCEHECVNMEE SYCRCHRGY				
	NOV4b	YSCHCLKGFTLNPDKKTCRRIN YCALNKP GCEHECVNMEE SYCRCHRGY				
	CAC32426	YSCHCLKGFTLNPDKKTCRRIN YCALNKP GCEHECVNMEE SYCRCHRGY				
	O00339	YSCHCLKGFTLNPDKKTCRRIN YCALNKP GCEHECVNMEE SYCRCHRGY				
	AAH10444	YSCHCLKGFTLNPDKKTCRRIN YCALNKP GCEHECVNMEE SYCRCHRGY				
60	Q99K64	ALCRCLKGFM LNPD RKTCRRIN YCALNKP GCEHECVNTEEGHYCRCHRGY				
	O08746	ALCRCLKGFM LNPD RKTCRRIN YCALNKP GCEHECVNTEEGHYCRCHRGY				
		460	470	480	490	500

50

5	CAC32426	KGSMTGLALKHMFERSFTQEGGARPPSTRVPRAAIVFTDGRAQDDVSEWA
	O00339	KGSMTGLALKHMFERSFTQEGGARPPSTRVPRAAIVFTDGRAQDDVSEWA
	AAH10444	KGSMTGLALKHMFERSFTQEGGARPLSTRVPRAAIVFTDGRAQDDVSEWA
	Q99K64	KGSMTGLALKHMFERSFTQEGGARPPSTQVPRVAIVFTDGRAQDDVSEWA
	O08746	KGSMTGLALKHMFERSFTQEGGARPPSTQVPRVAIVFTDGRAQDDVSEWA
10	NOV4a	SKAKANGITMYAVGVGKAIEEELQEIASEPTNKHLFYAEDFSTMDEISEK
	NOV4b	SKAKANGITMYAVGVGKAIEEELQEIASEPTNKHLFYAEDFSTMDEISEK
	CAC32426	SKAKANGITMYAVGVGKAIEEELQEIASEPTNKHLFYAEDFSTMDEISEK
	O00339	SKAKANGITMYAVGVGKAIEEELQEIASEPTNKHLFYAEDFSTMDEISEK
	AAH10444	SKAKANGITMYAVGVGKAIEEELQEIASEPTNKHLFYAEDFSTMDEISEK
	Q99K64	SKAKANGITMYAVGVGKAIEEELQEIASEPTDKHLFYAEDFSTMGEISEK
	O08746	SKAKANGITMYAVGVGKAIEEELQEIASEPTDKHLFYAEDFSTMGEISEK
20	NOV4a	LKKGICEALEDSGGRQDSPAGELPKTVQQPTSEPVTTINTQDLLSCSNFA
	NOV4b	LKKGICEALEDSGGRQDSPAGELPKTVQQPT-----
	CAC32426	LKKGICEALEDSGGRQDSPAGELPKTVQQPTSEPVTTINTQDLLSCSNFA
	O00339	LKKGICEALEDSGGRQDSPAGELPKTVQQPTSEPVTTINTQDLLSCSNFA
	AAH10444	LKKGICEALEDSGGRQDSPAGELPKTVQQPT-----
	Q99K64	LKEGICEALEDSGGRQDSAAWDLQQAHQPTPEPVTTIKIKDLLSCSNFA
	O08746	LKEGICEALEDSGGRQDSAAWDLQQAHQPTPEPVTTIKIKDLLSCSNFA
30	NOV4a	VQHRYLFEEDNLLRSTQKLSHSTKPSGSPLEEKHDQCKCENLIMFONLAN
	NOV4b	VQHRYLFEEDNLLRSTQKLSHSTKPSGSPLEEKHDQCKCENLIMFONLAN
	CAC32426	VQHRYLFEEDNLLRSTQKLSHSTKPSGSPLEEKHDQCKCENLIMFONLAN
	O00339	VQHRYLFEEDNLLRSTQKLSHSTKPSGSPLEEKHDQCKCENLIMFONLAN
	AAH10444	VQHRYLFEEDNLLRSTQKLSHSTKPSGSPLEEKHDQCKCENLIMFONLAN
	Q99K64	VQHRFLFEEDNLSRSTQKLFHSTKSSGNPLEESQDQCKCENLILFONVAN
	O08746	VQHRFLFEEDNLSRSTQKLFHSTKSSGNPLEESQDQCKCENLILFONVAN
40	NOV4a	EEVRKLTQRLEEMTQRMEEALENRLRYR
	NOV4b	EEVRKLTQRLEEMTQRMEEALENRLRYR
	CAC32426	EEVRKLTQRLEEMTQRMEEALENRLRYR
	O00339	EEVRKLTQRLEEMTQRMEEALENRLRYR
	AAH10444	EEVRKLTQRLEEMTQRMEEALENRLRYR
	Q99K64	EEVRKLTQRLEEMTQRMEEALENRLKYR
	O08746	EEVRKLTQRLEEMTQRMEEALENRLKYR

Table 4H lists the domain description from pfam analysis results for NOV4. This indicates that the NOV4 sequence has properties similar to those of other proteins known to contain this domain.

Table 4H. Domain Analysis of NOV4

		Score	Expect
IPR002035; vwa	von Willebrand factor type A domain	429.1	4.1e-125
IPR000561; EGF	EGF-like domain	274.8	1.1e-78

The von Willebrand factor is a large multimeric glycoprotein found in blood plasma. Mutant forms are involved in the aetiology of bleeding disorders. In von Willebrand factor, the type A domain (vWF) is the prototype for a protein superfamily. The vWF domain is found in various plasma proteins: complement factors B, C2, CR3 and CR4; the integrins (I-domains); collagen types VI, VII, XII and XIV; and other extracellular proteins. Proteins that incorporate vWF domains participate in numerous biological events (e.g., cell adhesion, migration, homing, pattern formation, and signal transduction), involving interaction with a large array of ligands. Secondary structure prediction from 75 aligned vWF sequences has revealed a largely alternating sequence of alpha-helices and beta-strands. Fold recognition algorithms were used to score sequence compatibility with a library of known structures: the vWF domain fold was predicted to be a doubly-wound, open, twisted beta-sheet flanked by alpha-helices. 3D structures have been determined for the I-domains of integrins CD11b (with bound magnesium) and CD11a (with bound manganese). The domain adopts a classic alpha/beta Rossmann fold and contains an unusual metal ion coordination site at its surface. It has been suggested that this site represents a general metal ion-dependent adhesion site (MIDAS) for binding protein ligands. The residues constituting the MIDAS motif in the CD11b and CD11a I-domains are completely conserved, but the manner in which the metal ion is coordinated differs slightly.

Alignments of top-scoring domains:

vwa: domain 1 of 2, from 75 to 250: score 211.3, E = 1.4e-59

```

vwa          DIVFLLDGSGSIGSQNFERVKDFVERVVERLDVGPRDKKEEDAVRVG
25          | + | | + + | + | +   ++ ++ | | + | + + + +   + | | + | |
NOV4      75  DLVFIIDSSRSVNTHDYAKVKEFIVDILQFLDIGP-DV-----TRVG 115

vwa          LVQYSDNVRTEIKFKLNDYQNKDEVLQALQKIRYEDYGGGGTNTGAALQ
30          | + | | + + | + |   | + | + + + + + | + | | + | + + + + | + |
NOV4     116  LLQYGSTVKNE--FSLKTFKRKSEVERAVKMR---HLSTGMTGLAIQ 159

vwa          YVVRNLFTEASGSRIEPVAEEGAPKVLVVLTDGRSQDDPSPTIDIRDVLN
35          | +   +   + | + | |   | + | +   + | + + | + | + | + | + | +   +   + | + +
NOV4     160  YALNIAFSEAEGARP---LRENVPRVIMIVTDGRPQDS-----VAEVAA 200

vwa          ELKKEAGVEVFAIGVGNADNNNLEELREIASKPD.DHVFKVSDFEALDTL
40          + + + +   + | +   + | | | | | + + |   +   + | + + | + | + | | |   | + | + + + + | |
NOV4     201  KARD-TGILIFAIGVGQVD---FNTLKSIGSEPHeDHVFLVANFSQIETL 246

vwa          QELL (SEQ ID NO:78)

```

+

25

30

40

EGF: domain 2 of 10, from 301 to 336: score 40.4, E = 4.2e-08

EGF CAPNN.PCSNGGTCVNTPGGSSDNFGGYTCECPPGDYYSYTGKRC (SEQ ID NO:84)

||++++| + |||+| ++ | + | | + + |||

NOV4 301 CAMEDHNCEQ--LCVNVPG-----SFVCQCYSG-YALAEDGKRC 336 (SEQ ID NO:85)

EGF: domain 3 of 10, from 342 to 377: score 37.4, E = 3.3e-07

EGF CAPNN.PCSNGGTCVNTPGGSSDNFGGYTCECPPGDYYSYTGKRC (SEQ ID NO:86)

||++|++| + +||| | + | +|++| ++| + + | + |

NOV4 342 CASENHGCEH--ECVNADG-----SYLCQCHEG-FALNPDEKTC 377 (SEQ ID NO:87)

EGF: domain 4 of 10, from 383 to 418: score 30.8, E = 3.3e-05

EGF CAPNN.PCSNGGTCVNTPGGSSDNFGGYTCECPPGDYYSYTGKRC (SEQ ID NO:88)

||+ |++| + +||| + +|+|+| | + | + + | + |

NOV4 383 CASSNHGQY--ECVNTDD-----SYSCHCLKG-FTLNPKKTC 418 (SEQ ID NO:89)

EGF: domain 5 of 10, from 424 to 459: score 33.0, E = 6.7e-06

EGF CAPNN.PCSNGGTCVNTPGGSSDNFGGYTCECPPGDYYSYTGKRC (SEQ ID NO:90)

||+| ++| + +||| ++ +|+|+| | | + + || |

NOV4 424 CALNKPGEH--ECVNME--SYYCRCHRG-YTLDPNGKPC 459 (SEQ ID NO:91)

EGF: domain 6 of 10, from 465 to 500: score 30.0, E = 5.5e-05

EGF CAPNN.PCSNGGTCVNTPGGSSDNFGGYTCECPPGDYYSYTGKRC (SEQ ID NO:92)

||++++| + | +|++ ++ | + | + | + + + | + |

NOV4 465 CAQQDHGCEQ--LCLNTED-----SFVCQCEG-FLINEDLKTC 500 (SEQ ID NO:93)

EGF: domain 7 of 10, from 506 to 541: score 32.1, E = 1.2e-05

EGF CAPNN.PCSNGGTCVNTPGGSSDNFGGYTCECPPGDYYSYTGKRC (SEQ ID NO:94)

| + +++| ||| + ++ | +| +| ++| +| +|

NOV4 506 CLLSDHGCEY--SCVNMDR-----SFACQCEG-HVLRSDGKTC 541 (SEQ ID NO:95)

EGF: domain 8 of 10, from 547 to 582: score 32.6, E = 8.9e-06

EGF CAPNN.PCSNGGTCVNTPGGSSDNFGGYTCECPPGDYYSYTGKRC (SEQ ID NO:96)

||++++| + ||++++ ++ | + | + | | +| +|

NOV4 547 CALGDHGCEH--SCVSSD-----SFVCQCFEG-YILREDGKTC 582 (SEQ ID NO:97)

EGF: domain 9 of 10, from 588 to 623: score 38.6, E = 1.4e-07

EGF

CAPNN.PCSNGGTCVNTPGGSSDNFGGYTCECPPGDYLSYTGKRC

(SEQ ID NO:98)

|+ +++| + +|||+ + +||| +| ++| +|||

NOV4 588

CQAIDHGCEH--ICVNSDD-----SYTCECLEG-FRLTEDGKRC

623 (SEQ ID NO:99)

EGF: domain 10 of 10, from 632 to 667: score 38.4, E = 1.7e-07

EGF

CAPNN.PCSNGGTCVNTPGGSSDNFGGYTCECPPGDYLSYTGKRC

(SEQ ID NO:100)

| ++ ++| + +||| ++ +| |+| +| ++|+ +|+||

NOV4 632

CKSTHHGCEH--ICVNNGN-----SYICKCSEG-FVLAEDGRRC

667 (SEQ ID

NO:101)

The NOV4 nucleic acids encoding the Matrilin-2 proteins of the invention, or fragments thereof, are useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These materials are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below.

The disclosed NOV4a protein has multiple hydrophilic regions, each of which can be used as an immunogen. In one embodiment, a contemplated NOV4a epitope is from about amino acids 40 to 95. In another embodiment, a contemplated NOV4a epitope is from about amino acids 112 to 150. In other specific embodiments, contemplated NOV4a epitopes are from about amino acids 170 to 200, 220 to 235, 255 to 260, 280 to 320, 330 to 480, 500 to 695, 720 to 800, 824 to 890, and 905 to 960.

The disclosed NOV4b protein has multiple hydrophilic regions, each of which can be used as an immunogen. In one embodiment, a contemplated NOV4b epitope is from about amino acids 25 to 53. In another embodiment, a contemplated NOV4b epitope is from about amino acids 58 to 77. In other specific embodiment, contemplated NOV4b epitopes are from about amino acids 104 to 135, 156 to 180, 201 to 218, 235 to 240, 260 to 295, 308 to 420, 427 to 502, 510 to 585, 590 to 610, 620 to 625, 652 to 742, and 758 to 890.

NOV5

A disclosed NOV5 nucleic acid (SEQ ID NO:17) of 1779 nucleotides (also referred to as SC85803748_A) encoding a GABA receptor-like protein is shown in Table 5A. An open

reading frame was identified beginning with an ATG initiation codon at nucleotides 71-73 and ending with a TGA codon at nucleotides 1445-1447. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 5A, and the start and stop codons are in bold letters.

5

Table 5A. NOV5 Nucleotide Sequence (SEQ ID NO:17)	
<u>AAGAAGAACTGTGATCACAGTATTGGTTGCGTTACCTGCATCCTTTCTGTTTTTTTGGTTTGGGAAGAGATGGTC</u>	
<u>CTGGCTTTCCAGTTAGTCTCCTTCACCTACATCTGGATCATATTGGTTTGTGCTGCTTCTAACATCAAGATGACAC</u>	
<u>ACCAGCGGTGCTCCTCTTCAATGAAACAAACCGTAAGATGCTCAATGAAGAAAGATGACAGTACCAAAGCGCGGCC</u>	
<u>TCAGAAATATGAGCAACTTCTCCATATAGAGGACAACGATTTTCGCAATGAGACCTGGATTGGAGGTTCTCCAGTG</u>	
<u>CCAGTAGGTATAGATGTCCATGTTGAAAGCATTGACAGCATTTTCAGAGACTAACATGGACTTTACAATGACTTTTT</u>	
<u>ATCTCAGGCATTACTGGAAAGACGAGAGGCTCTCCTTTCTAGCACAGCAACAAAGCATGACATTGATCATAG</u>	
<u>AAAGAGTATCCCCCGCCCTGAACACTTGCGGTATTGCTTATTCATCAGAAGGCTGTATCTGTTATAGTCCAGAGG</u>	
<u>TCTTTCTTCTACCCCTCATCCATACTTCCCTCATCTCCAGACATCCATGCACCTGGTACATCTAAAAGCAGTTTGT</u>	
<u>CTGATAGCCTTGTATGTATATCTGAAAAAACTTGCCAGGACACAGTAAAAACACACCTCTTGCAATGGCCTACAA</u>	
<u>TGAGGATGACCTAATGCTATACTGGAAACACGGAAACAAGTCCCTTAAATACTGAAGAACATATGTCCTTTCTCAG</u>	
<u>TTCTTCATTGAAGACTTCAGTGCACTAGTGGATTAGCTTTCTATAGCAGCACAGGTACAGCATTTTACATGGGTG</u>	
<u>ATTCATCAGCATTTATGGACATCTACTGTTTTTAAATAGACATTACATTTCTTCATCATAAATTTTGAAATTAC</u>	
<u>TCAAATATTGATGATTGGAATCACCACAGTGCTGACCATGTCCACAATCATCACTGCTGTGAGCGCCTCCATGCCC</u>	
<u>CAGGTGTCCTACCTCAAGGCTGTGGATGTGTACCTGTGGGTGAGTCCCTCTTTGTGTTCTGTCAGTCATTGAGT</u>	
<u>ATGCAGCTGTGAACTACCTCACCACAGTGGGAAGAGCGGAAACAATTCAAGAAGACAGGAAAGGTACAGATTTCTAG</u>	
<u>GATGTACAATATTGATGCAGTTCAAGCTATGGCCTTTGATGGTTGTTACCATGACAGCGAGATTGACATGGACCAG</u>	
<u>ACTTCCCTCTCTCTAAACTCAGAAGACTTCATGAGAAGAAAATCGATATGCAGCCCCAGCACCGATTTCATCTCGGA</u>	
<u>TAAAGAGAAGAAAATCCCTAGGAGGACATGTGGTAGAATCATTCTGGAAAAACAACCATGTCATTGACACCTATTC</u>	
<u>TAGGATTTTATTCCCCATTGTGTATATCCCATTTGTGTATATCTTTATTTAATTTGTTTTACTGGGGTGTATATGTA</u>	
<u>TGAAGGGGAATTTCAAATGTATACAACTTTAAAGCCAGATGATGTTAAAAACAAACTCTTGAATATGAGTTGGA</u>	
<u>ATTGAAGACTTCAGTGCACTAGTGGATTAGCTTTCTATAGCAGCACAGGTACAGCATTTTACATGGGTGATTCAAT</u>	
<u>CAGCATTTATTGGACATCTACTGTTTACTTTTGGTCTTTGATGATGGTGATGTACAGATGGGTGGAATCACCAC</u>	
<u>AGTGTCTGACCATGTCCACAATCATCACTGCTGTGAGCGCCTCCATGCCCCAGGTGTCCTACCTCAAGGCTGTGGAT</u>	
<u>GTGTACCTGTGGGTGAGCTCCCTCTTTGTGTTCTGTGTCAGTCATTGAGTAT</u>	

Genomic clone AC026100 on chromosome 3 was identified by TBLASTN using a proprietary sequence file for members of GABA receptor and/or Ion channel family, run against the genomic daily files made available by GenBank or obtained from Human Genome Project Sequencing centers. These genomic clones were analyzed by Genscan and Grail and other programs to identify regions that were putative exons i.e. putative coding sequences. These clones were also analyzed by BLASTN, TBLASTN, TFASTN, TFASTA, BLASTX and/or other programs to identify genomic regions with DNA similarity or translating to proteins with similarity to the original protein or protein family of interest.

A disclosed NOV5 polypeptide (SEQ ID NO:18) encoded by SEQ ID NO:17 is 458 amino acid residues and is presented using the one-letter code in Table 5B. Signal P, Psort and/or Hydropathy results predict that NOV5 is likely to be localized in the endoplasmic reticulum (membrane) with a certainty of 0.6850. In alternative embodiments, NOV5 is localized in the plasma membrane with a certainty of 0.6400, Golgi body with a certainty of 0.4600, and endoplasmic reticulum (lumen) with a certainty of 0.1000. NOV5 has a signal

peptide and is likely cleaved between amino acid residues 20 and 21, *i.e.*, at the dash in the sequence VCA-AS.

Table 5B. Encoded NOV5 protein sequence (SEQ ID NO:18)

```
MVLAFQLVSFTYIWIILVCAASNIMTHQRCSSSMKQTVRCSMKKDDSTKARPQKYEQLLHIEDNDFAMRPG
FGGSPVPVGIDVHVESIDSISETNMDFTMTFYLRHYWKDERLSFPSTANKSMTFDHRKSI PRPEHLRYSLFI
RRLYLILYQCRSFFSPSSILPSSPDIHAPGTSKSSLSDSLVCISEKNLPGHSKNTPLAMAYNEDDLMLYWKHG
NKSLNTEEHMSLSQFFIEDFSASSGLAFYSSTGTAFYMGDSSAFIGHLLFLNRHLHFFIINFEITQILMIGI
TTVLTMTSTIITAVSASMPQVSYLKAVDVYLWVSSLFVFLSVIEYAAVNYLTVEERKQPKTKGVQISRMYN
IDAVQAMAFDGCYHDSEIDMDQTSLSLNSDFMRKRSICSPSTDSSRIKRRKSLGGHVGRILLENHVIDTY
SRILFPPIVYIPLCISLFLNLFYWGYYV
```

NOV5 is expressed in at least the following tissues: kidney, retina. In addition, the NOV5 is predicted to be expressed in retinal tissues because of the expression pattern of a closely related Rat mRNA for GABA receptor rho-3 subunit, complete cds homolog in species *Rattus norvegicus* (GENBANK-ID: D50671). Additional data for NOV5 variants and NOV5 expression is provided in the Examples.

In a search of sequence databases, it was found, for example, that the nucleic acid sequence of this invention has 563 of 765 bases (73%) identical to a gb:GENBANK-ID: RATGABA| acc:D50671 mRNA from *Rattus norvegicus* (Rat mRNA for GABA receptor rho-3 subunit, complete cds). The full amino acid sequence of the protein of the invention was found to have 299 of 464 amino acid residues (64%) identical to, and 347 of 464 amino acid residues (74%) similar to, the 464 amino acid residue ptr:SWISSPROT-ACC:P50573 Gamma-Aminobutyric-Acid Receptor Rho-3 Subunit Precursor ("GABA(A)") Receptor protein from *Rattus norvegicus* (Rat).

In a search of the public sequence data bases, it was shown that NOV5 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 5C.

Table 5C. BLASTP results for NOV5

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
SWISSPROT P50573	GAMMA-AMINOBUTYRIC-ACID RECEPTOR RHO-3 SUBUNIT PRECURSOR (GABA(A) RECEPTOR) - <i>Rattus norvegicus</i>	464	299/464 (64%)	347/464 (74%)	6.1e- 138
SPTREMBL Q9YGQ2	GAMMA-AMINOBUTYRIC-ACID RECEPTOR RHO-3 SUBUNIT PRECURSOR - <i>Morone americana</i> (White perch)	470	216/466 (46%)	302/466 (64%)	6.4e- 88
SWISSNEW P24046	Gamma-aminobutyric-acid receptor rho-1 subunit precursor (GABA(A) receptor) - <i>Homo sapiens</i>	473	198/424 (46%)	266/424 (62%)	1.8e- 81

SWISSPROT P50572	GAMMA-AMINOBUTYRIC-ACID RECEPTOR RHO-1 SUBUNIT PRECURSOR (GABA(A) RECEPTOR) - Rattus norvegicus	474	196/416 (47%)	262/416 (62%)	1.5e- 79
SWISSPROT P56475	GAMMA-AMINOBUTYRIC-ACID RECEPTOR RHO-1 SUBUNIT PRECURSOR (GABA(A) RECEPTOR) - Mus musculus	474	196/416 (47%)	262/416 (62%)	4.0e- 79

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 5D.

Table 5D ClustalW Sequence Alignment

- 1) NOV5 (SEQ ID NO:18)
- 2) P50573 (SEQ ID NO:102)
- 3) Q9YGQ2 (SEQ ID NO:103)
- 4) P24046 (SEQ ID NO:104)
- 5) P50572 (SEQ ID NO:105)
- 6) P56475 (SEQ ID NO:106)

	10	20	30	40	50											
NOV5	MVLA	FQLVS	-----	FT	YTWI	ILVCAASNIKMTI	ORCSS	-----	SMK	36						
P50573	MVLA	FWLAR	-----	FT	YTWI	TLMLDASAVKEPH	QOCLS	-----	SPKQT	38						
Q9YGQ2	MRV	VLLALR	---	L	---	MCLAWLW	VTQLNS	STNKRRH	KELYIGENTKQK	45						
P24046	MRFG	IFLLW	GWVLATES	RMHWP	GREVHE	MSKKG	-RPQR	ORREV	HEDAHK	49						
P50572	MKFG	IFLLW	GWVLAAEST	VHWP	GREVHE	PSKKG	SRPQR	ORRG	AHDDAHK	50						
P56475	MKFG	IFLLW	GWVLAAEST	AHW	PGREVHE	PSRKGS	SRPQR	ORRG	AHDDAHK	50						
	60	70	80	90	100											
NOV5	QTVR	CSMKK	DDSTK	ARPK	MEQLL	HIEDN	DFAMR	PGFGG	SPVPV	GIDVHV	86					
P50573	RIRE	TRMRK	DDLTK	VWPLK	REQLL	HIEDH	DFSTR	PGFGG	SPVPV	GIDVQV	88					
Q9YGQ2	GRVD	LKLLK	KVDST	KSM	LKSE	QLLR	IEDH	DFAMR	PGFGG	SAIPV	GIDVQV	95				
P24046	QVSP	ILRRS	PDITK	SPLTK	SEQLL	RIDDH	DFSMR	PGFGG	PAIPV	GVDVQV	99					
P50572	QGSP	ILRRS	PDITK	SPLTK	SEQLL	RIDDH	DFSMR	PGFGG	PAIPV	GVDVQV	100					
P56475	QGSP	ILRRS	PDITK	SPLTK	SEQLL	RIDDH	DFSMR	PGFGG	PAIPV	GVDVQV	100					
	110	120	130	140	150											
NOV5	ESID	SISEV	NMDFT	MTFY	LRHYW	KDERL	SFPST	ANKSMT	FDHR	KSI	PRPE	136				
P50573	ESID	SISEV	NMDFT	MTFY	LRHYW	KDERL	SFPST	INKSMT	FDHR	-----	-----	131				
Q9YGQ2	ESID	SISEV	NMDFT	MTLY	LRHYW	QDDR	PAFPSS	NKSRT	FDAR	-----	-----	138				
P24046	ESLD	SISEV	NMDFT	MTLY	LRHYW	KDERL	SFPST	NNLSMT	FDGR	-----	-----	142				
P50572	ESLD	SISEV	NMDFT	MTLY	LRHYW	KDERL	SFPST	NNLSMT	FDGR	-----	-----	143				
P56475	ESLD	SISEV	NMDFT	MTLY	LRHYW	KDERL	SFPSS	NNLSMT	FDGR	-----	-----	143				
	160	170	180	190	200											
NOV5	HLRY	SLFIR	RLYL	LYC	ORSF	FPSS	ILPSS	PDHAP	GTSK	SSLS	DSLVC	186				
P50573	-LIQ	KIWV	PDIF	FFVH	SKRSF	IHD	TTVEN	IMLR	VHPD	GNVLF	SLRIT	VSA	180			
Q9YGQ2	-LVK	KIWV	PDIF	FFVH	SKRSF	IHD	TTMEN	IMLR	VYPD	GNILY	SVRIT	VTA	186			
P24046	-LVK	KIWV	PDIF	FFVH	SKRSF	IHD	TTD	NVML	RVQPD	GKVL	YSLRV	TVTAM	191			
P50572	-LVK	KIWV	PDIF	FFVH	SKRSF	IHD	TTD	NVML	RVQPD	GKVL	YSLRV	TVTAM	192			
P56475	-LVK	KIWV	PDIF	FFVH	SKRSF	IHD	TTD	NVML	RVQPD	GKVL	YSLRV	TVTAM	192			
	210	220	230	240	250											
NOV5	SEK	---	NL	PGH	SKNT	PLA	---	M	---	AYN	EDDL	MLYWK	HGNK	SLNTE	EBHMSL	228


```

P50573  CQMDFSRFPLDTQNCSELES--YAYNEEDMLYWKHGKSLNTEEHISL 228
Q9YGQ2  CQMDFSRFPLDTQNCSELESYAYAYNENDLCSTGRIGTIPURTDE-IVL 235
P24046  CNMDFSRFPLDTQTCSELES--YAYTEDDLMLYWKKGNDLSLKTDERISL 239
P50572  CNMDFSRFPLDTQTCSELES--YAYTEDDLMLYWKKGNDLSLKTDERISL 240
P56475  CNMDFSRFPLDTQTCSELES--YAYTEDDLMLYWKKGNDLSLKTDERISL 240

      260      270      280      290      300
NOV5     SQFFIEDFSASSGLAFYSSTG-----T---AFYMGDSSAFIGHLL 265
P50573   SQFFIEEFSASSGLAFYSSTGWMYRLFINEVLRRIHFFFLQTYFAMLM 278
Q9YGQ2   SQFFVEDFQPSGLAFYSSTGWMYRLFINEVLRRIHFFFLQTYFAMLM 285
P24046   SQFLIQEFHTTTKLAFYSSSTGWMYRLFINEVLRRIHFFFLQTYFAMLM 289
P50572   SQFLIQEFHTTTKLAFYSSSTGWMYRLFINEVLRRIHFFFLQTYFAMLM 290
P56475   SQFLIQEFHTTTKLAFYSSSTGWMYRLFINEVLRRIHFFFLQTYFAMLM 290

      310      320      330      340      350
NOV5     FLNRHLHFEIINFETQILMIGITTVLTMSTIITAVSASMPQVSYLEKAVD 315
P50573   VMLSWVSFWIDRRAPARVSLGITTTLTMSTIITGVASMPQVSYLEKAVD 328
Q9YGQ2   VMLSWVSFWIDRRAPARVSLGITTTLTMSTIITGVASMPQVSYLEKAVD 335
P24046   VMLSWVSFWIDRRAPARVPLGITTTLTMSTIITGVNASMPRVSYIKAVD 339
P50572   VMLSWVSFWIDRRAPARVPLGITTTLTMSTIITGVNASMPRVSYIKAVD 340
P56475   VMLSWVSFWIDRRAPARVPLGITTTLTMSTIITGVNASMPRVSYIKAVD 340

      360      370      380      390      400
NOV5     IYLVWVSLFVFLSVIEYAAVNYLTTVEERKQFKKTGKVQTSRMYNIDAVQ 365
P50573   IYLVWVSLFVFLSVIEYAAVNYLTTVEEWKQLNRR--GKISGMYNIDAVQ 376
Q9YGQ2   IYLVWVSLFVFLSVIEYAAVNYLTTVEEEMKQLRS--AKIPNYN--ASQ 379
P24046   IYLVWVSLFVFLSVIEYAAVNYLTTVEERKEKQLR--EKIPCTSGLPQPR 387
P50572   IYLVWVSLFVFLSVIEYAAVNYLTTVEERKEKQLR--EKISCTCGLPQPR 388
P56475   IYLVWVSLFVFLSVIEYAAVNYLTTVEERKEKQLR--EKISCTCGLPQPR 388

      410      420      430      440      450
NOV5     AMAFDGCGYHDSIEDMDQTSLSLNSDFMRKKSICSPSTDSRIK----- 409
P50573   AMAFDGCGYHDSIEDMDQTSLSLNSDFMRKKSICSPSTDSRIK----- 420
Q9YGQ2   AMAFDGCGYHDSIEDMDQTSLSLNSDFMRKKSICSPSTDSRIK----- 427
P24046   TAMLDGNYSDGEVNDLDNYMPENGEKPDMMVOLTLASERSSP----- 430
P50572   GVMLDSSYSYDGEVNDLGGYMPENGEKPDMMVOLTLASERSSP----- 431
P56475   GVMLDSSYSYDGEVNDLGGYMPENGEKPDMMVOLTLASERSSP----- 431

      460      470      480      490
NOV5     RRKSLGCHVGRIILENNHVIDTYSRIIFPIVYIPLCISLFNLFYWGVIYV 458
P50573   RRKSLGCHVGRIILENNHVIDTYSRIIFPIVYIPLCISLFNLFYWGVIYV 464
Q9YGQ2   RKHPLRQNL-SFIMNSYIMIDSYSRVIFPLAYL-----LFNLIYWSMVA 470
P24046   QRKSQRSSY-VSMRIDTHAIDKYSRIIFPAAYI-----LFNLIYWSIFS 473
P50572   QRKSQRGSY-VSMRINTHAIDKYSRIIFPAAYI-----LFNLIYWSIFS 474
P56475   QRKSQRGSY-VSMRINTHAIDKYSRIIFPAAYI-----LFNLIYWSIFS 474

```

In a search of the proprietary PatP sequence data base, it was shown that NOV5 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 5E.

Table 5E. PatP BLASTP results for NOV5

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
AAR31188	GABA-A receptor beta-2 subunit - Homo sapiens	474	119/382 (31%)	199/382 (52%)	8.6e-37

AAR59866	GABA receptor beta2 subunit - Homo sapiens	474	119/382 (31%)	199/382 (52%)	8.6e-37
AAR93118	GABA-A receptor epsilon subunit - Homo sapiens	440	115/394 (29%)	201/394 (51%)	1.1e-32
AAW26464	GABA-A receptor epsilon subunit - Homo sapiens	440	115/394 (29%)	201/394 (51%)	1.1e-32
AAB00174	Breast cancer protein BCR3 - Homo sapiens	440	115/394 (29%)	201/394 (51%)	1.1e-32

In addition, the NOV5 protein is predicted to contain the following protein domains (as defined by Interpro) at the indicated nucleotide positions: domain name IPR001175 at amino acid positions 53 to 129, domain name IPR001175 at amino acid positions 287 to 346, etc.

This indicates that the sequence of the invention has properties similar to those of other proteins known to contain this/these domain(s) and similar to the properties of these domains. Table 5F list the domain description from DOMAIN analysis results against NOV5. This homology indicates that the NOV5 sequence has properties similar to those of other proteins known to contain this domain.

Table 5F. Domain Analysis of NOV5							
Scores for sequence family classification (score includes all domains):							
Model	InterPro					Score	E-value
-----	-----					-----	-----
Neur_chan_LBD	Neurotransmitter-gated ion-channel lig					70.6	1.7e-18
Neur_chan_memb	Neurotransmitter-gated ion-channel tra					23.4	2e-10
Parsed for domains:							
Model	Domain	seq-f	seq-t	hmm-f	hmm-t	score	E-value
-----	-----					-----	-----
Neur_chan_LBD	1/2	66	132 ..	17	102 ..	63.4	1.7e-16
Neur_chan_LBD: domain 1 of 2, from 66 to 132							
Neur_chan_LBD	2/2	203	249 ..	175	238 ..	7.2	0.69
Neur_chan_LBD: domain 2 of 2, from 203 to 249							
Neur_chan_memb	1/1	274	454 ..	1	291 []	23.4	2e-10
Neur_chan_memb: domain 1 of 1, from 274 to 454							
ClustalW alignment of NOV5 with Neur_chan_LBD							
Neur_chan_LBD	*->dkrvRPvnggdvPpvtVsvgltlqqiisVdEknqdltnvwlrggqW						
	+ + + + + + ++++++ + + + + + ++ + + +						
C441_NOV5	66	DFAMRPGFGGS-P-VPVGIDVHVESIDSISSETNMDFTMTFYLRLH-YW 109					
Neur_chan_LBD	tDpRLaWnpsdplddegyggikslrlpsddnhdmlldkI (SEQ ID NO:107)						
	+ + + +++ + +++++ ++						
C441_NOV5	110	KDERLSFPSTA-----NKSMTFDHR-----KSI 132 (SEQ ID NO:108)					

Neurotransmitter-gated ion-channels {PDOC00209, PS00236; Neurotr_Ion_Channel} provide the molecular basis for rapid signal transmission at chemical synapses. They are post-synaptic oligomeric transmembrane complexes that transiently form a ionic channel

upon the binding of a specific neurotransmitter. The neurotransmitter-gated ion-channel domain consensus pattern is as follows:

C-x-[LIVMFQ]-x-[LIVMF]-x(2)-[FY]-P-x-D-x(3)-C (SEQ ID NO:109),

wherein the two C's are linked by a disulfide bond.

5 The above defined information for NOV5 suggests that this NOV5 protein may function as a member of a GABA receptor protein family. GABA receptor activity in mammalian cells correlate with known diseases and disorders (See, e.g., OMIM 600232, 137192, 137142 and 600233). Therefore, the NOV5 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV5 compositions of the present invention will have efficacy for treatment of patients suffering from: cancer, trauma, regeneration (*in vitro* and *in vivo*), viral/bacterial/parasitic infection, multiple sclerosis, leukodystrophies, pain, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, Angelman syndrome (AS; 105830), Prader-Willi syndrome (PWS; 176270), bipolar affective disorder, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, Ataxia-telangiectasia, behavioral disorders, addiction, anxiety, retinal and visual disorders. The NOV5 nucleic acid encoding fatty acid-binding protein, and the fatty acid-binding protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

20 NOV5 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOV5 substances for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. The disclosed NOV5 protein has multiple hydrophilic regions, each of which can be used as an immunogen. In one embodiment, a contemplated NOV5 epitope is from about amino acids 1 to 10. In another embodiment, a NOV5 epitope is from about amino acids 20 to 80. In additional embodiments, NOV5 epitopes are from about amino acids 85 to 150, from about amino acids 155 to 240, from about amino acids 325 to 430, and from about amino acids 445 to 458. These novel proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.

NOV6

Yet another NOVX protein of the invention, referred to herein as NOV6, is a giant larvae-like protein.

Although some members of the giant larvae-like protein family may be localized in the nucleus, the protein predicted here is similar to the *Drosophila* giant larvae protein, which has membrane and cytoskeletal localization and may be released extracellularly. Therefore it is likely that this novel giant larvae-like protein is available at the same sub-cellular localization and hence accessible to a diagnostic probe and for the various therapeutic applications described herein.

The giant larvae homolog-like gene disclosed in this invention maps to chromosome 17. This assignment was made using mapping information associated with genomic clones, public genes and ESTs sharing sequence identity with the disclosed sequence and CuraGen Corporation's Electronic Northern bioinformatic tool.

Two alternative NOV6 nucleic acids and encoded polypeptides are provided, namely NOV6a and NOV6b.

NOV6a

In one embodiment, a disclosed NOV6 variant is NOV6a (alternatively referred to herein as sggc_draft_ba465b22_20000727), which encodes a novel giant larvae-like protein and includes the 3147 nucleotide sequence (SEQ ID NO:19) shown in Table 6A. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 131-133 and ending with a TGA codon at nucleotides 2843-2845. Putative untranslated regions upstream from the start codon are underlined in Table 6A, and the start codon is in bold letters.

Table 6A. NOV6a Nucleotide Sequence (SEQ ID NO:19).

CGCCCAGCAGCCCGTGGGCAGGGCGGGCGGAGCGAGCGGGGCCGGCGGGCGCCGAGGGACGCCGAGGCTCGG
GCGGGGGCTGGCCCGGGGTTCCAGGTCTCCAGTGGGGGCTGCAGACTAAGCAAAATGAGGCGGTTCCTGAGGCCAG
 GGATGACCTGTGCGGGAGAGGCTCAAGCGGGACCTGTTCAGTTTAAACAAGACGGTGGAGCATGGCTTCCCCGCA
 CCAGCCCAGCGCCTCGGCTACAGCCGTCCTGCACATCCTGGCCATCGGCACCCGTTCTGGAGCCATCAAGCTC
 TACGGAGCCCCAGGCGTGGAGTTTATGGGGCTGCACCAGGAGAACAACGCTGTGACGCAGATCCACCTCCTGCCCCG
 GCCAGTGCCAGCTGGTCACCCTGCTGGATGACAACAGCCTGCACCTTTGGAGCCTGAAGGTCAAGGGCGGGGCATC
 GGAGCTGCAGGAGGATGAGAGCTTCACTGCGTGGACCCCCAGGGGCTGCCCCAGTGCCACACAGATCACCGTG
 GTCCTGCCACATTCCTCCTGCGAGCTGCTCTACTGGGCAACGAGAGTGGCAACGTGTTTGTGGTGACGTGCCAG
 CTTTTCGTGCCTGGAGGACCGGACCATCAGCTCGGACGCGGTGCTGCAGCGGTTGCCAGAGAGGCCCGCCACCG
 GCGTGTGTTTCAGATGGTGGAGGCACTGCAGGAGCACCTCGAGACCCCAACCAGATCCTGATCGGCTACAGCCGA
 GGCCTCGTTGTTCATCTGGGACCTACAGGGCAGCGCGTCTCTACCACTTCTCAGCAGCCAGCAACTGGAGAAACA
 TCTGGTGGCAGCGGGACGGCCGCTGCTCGTCACTGTGACGGCAGCTACTGCCAGTGGCCCGTGTCCAG
 CGAAGCCCAGCAACAGAGCCCCCTCCGAGCCTCGTGCTTACGGTCCCTTTCCTTGCAAAGCGATTACAGAAATC
 CTCTGGCTGACCACTAGGCAGGGGTTGCCCTTACCATCTTCAGGGTGGCATGCCACGGGCCAGCTACGGGGACC
 GCCACTGCATCTCAGTGATCCACGATGGCCAGCAGACGGCCTTCGACTTCACTCCCGTGTTCATCGGCACGGTGGC
 GTTCTGGGATGCCTCGGTGTCTGCTGCGGCTGCTCTACAACTCAGCACTGTGCGCGTGTTCCTCACCGACAG
 GACCCCAACGGAACCTCAGTGCCAGGGCGAGGACGAGTGGCCCCCACTCCGCAAGGTGGGCTCCTTTGACCCCT
 ACAGTGATGACCCCCGGCTGGGCATCCAGAAGATCTTCTCTGCAAGTACAGCGGCTACCTGGCTGTGGCAGGCAC
 GGCAGGGCAGGTGCTGTAAGTGAATGACGAGGAGCGGAGCAGGCTGTGGAGCAGGTGGAGGCCGACCTG
 CTGCAGGACCAAGAGGGCTACCGCTGGAAGGGGACGAGCGCCTGGCAGCCCGCTCAGGGCCCGTGCGCTTGGAGC

```

CTGGCTTTAGCCCTTCGTGTTGGTGCAGTGTAGCCCCCGGCTGTGGTCACCTCCTTGGCCCTGCACTCTGAGTG
GCGGCTCGTGGCTTCGGCACCAGCCATGGCTTTGGCTCTTTGACCACCAGCAGCGGCGGAGGTCTTTGTTAAG
TGCACACTGCACCCCACTGACCACTGGCTTTGGAGGGCCACTCTCCGCGTCAAGTCCCTCAAGAAGTCTTGC
GTCAGTCAATCCGCGGATGCGTCGGAGCCGGGTGTCCAGCCGGAAGCGGCACCCGGCTGGCCCCCAGGAGAGGC
ACAGGAGGGGAGTGCCAAGGCTGAGCGGCCAGGCCTCCAGAAATGGAGCTGGCGCTGTGCAGCGCAAGATCGAG
GCTCGCTCGGCAGAGGACTCCTTCAAGGCTTCGTCCGGACCTGTACTTTGCTGACACCTACCTGAAGGACAGCT
CCCGGCACTGCCCCCTCGTGTGGGCTGGCACCACCAATGGGGGACCATCTATGCCCTTCTCCCTGCGTGTGCCTCCCG
CGAGCGGAGAAATGGATGAGCCTGTGCGGGCAGAGCAGGCCAAGGAGATCCAGCTGATGCACCGGGCGCCGGTGGTG
GGCATCTGGTGTCTGACGGACACAGCGTACCCCTTCCGAGCCCTCGAAGTGGCCCATGATCTGTGCAAGAGCC
GTGACATGCAGGGAAGCCACCAGCTGCTCGTGTATCAGAGGAGCAGTTCAAGGTGTTACGCTGCCCAAGGTGAG
TGCCAAGCTGAAGTTGAAGCTGACGGCCCTGGAGGGCTCAAGAGTGGCGCGGCTCAGCGTGGCCCACTTCGGCAGT
CGTCGAGCCGAGGACTACGGGAGCACCACCTGGCAGTCCCTTACCAACCTGGGCGACATCCAGGTGGTCTCGTGC
CCCTGCTCAAGCCCCAGGTGCGCTACAGCTGCATCCGCGGGAGGACGTCAGTGGCATCGCCTCTGCGTCTTCAC
CAAATATGGCCAAGGCTTCTACCTGATCTCACCTCGAGTTTGAGCGCTTCTCTCTCCACCAAGTGGCTGGTG
GAGCCCGGTGTCTGGTGGATTGAGCAGAAACCAAGAACCCGCCCTGGTAACGGTGCGGGCCCAAGAAGGCC
CGAGCCGAGCCAGGAATCAGGACTCAGAGTGATGGCGAGGAGAAGCAGCCCGCTGGTGTGAGCGCGCTCT
GCTCAGTGATGAGAGAGCGGCAACTGGCGTTACATCGAGCCGCGTGGGGTGCAGCCTCAGCAATGGCGGAGCAG
AGTGAGTGGCTGAGCGTCCAGGCTGCGCGATGAGCACACTACTACTGATGGCCTTTCGGGGGTCCCTGCCCAA
CCGGAGAGGCCCGGTGCACAGGGCCCCCGAGGGGCTGGGGGCATCCCGGCTTCCACAATGCAGTGTCTGGGCCT
CGGGAGAGGAGAGACCCAGTCCCTGGGCTGCCCTTCCGGGCTCGTGTCTGGGTCTTTGGTCAATGTGTGC
ACAGTTTTTATTGCTCCCATCCCTTTTGTAGTGGGCTGGGTTTTAAGTTATAAATGTTAACTGCCTCTGGGTGAA
AAAGTTTTTAATAAACACCTATTACCTCTTG

```

The sequence of NOV6a was derived by laboratory cloning of cDNA fragments, by *in silico* prediction of the sequence. The cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, were cloned. *In silico* prediction was based on sequences available in CuraGen's proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof.

The cDNA coding for the NOV6a sequence was cloned by the polymerase chain reaction (PCR). Primers were designed based on *in silico* predictions of the full length or some portion (one or more exons) of the cDNA/protein sequence of the invention, or by translated homology of the predicted exons to closely related human sequences or to sequences from other species. The DNA sequence and protein sequence for a novel larvae-like gene were obtained by exon linking and are reported here as NOV6a. These primers and methods used to amplify NOV6a cDNA are described in the Examples.

The NOV6a polypeptide (SEQ ID NO:20) encoded by SEQ ID NO:19 is 904 amino acid residues in length and is presented using the one-letter amino acid code in Table 6B. The SignalP, Psort and/or Hydropathy results predict that NOV6a has no known signal peptide and is likely to be localized in the nucleus with a certainty of 0.9600. In alternative embodiments, a NOV6a polypeptide is located to the microbody (peroxisome) with a certainty of 0.5072, the mitochondrial matrix space with a certainty of 0.3600, or the lysosome (lumen) with a certainty of 0.1695.

Table 6B. Encoded NOV6a protein sequence (SEQ ID NO:20).

MRRFLRPGHDPVRERLKRDLFQFNKTVEHGFPHQPSALGYSPSLHLILAIGTRSGAIKLYGAPGVEFMGLHQ
 ENNAVQTQIHLPLPGQCQLVTLDDNSLHLWSLKVKGASELQEDSFITLRGPPGAAPSATQITVVLPHSSCE
 LLYLGTEGNSVNVVQLPAFRALEDRTISSDAVLQRLPEEARHRRVFEMVEALQEHPRDPNQILIGYSRGLV
 VIWDLQGSRLVYHFLSSQLENIWWQRDGRLLVSCSDSGSYCQWPVSSEAQQPEPLRSLVYPGPFCKAIT
 RILWLTTTQGLPFTIFQGGMPRASYGDRHCISVIHDGQQTAFDFTSRVIGTVRFWDASGVCLRLLYKLSTV
 RVFLTDTDPNENFSAQGEDEWPPLRKVGSDPYSDDPRLGIQKIFLCKYSGYLAVAGTAGQVLVLELND
 AEQAVEQVEADLLQDEGYRWKGERLAARS GPVRFEPGFQPFVLVQCOPPAVVTSLALHSEWRLVAFGTS
 HGFGLFDHQRRQVFVKCTLHPSDQLALEGPLSRVSKLSLRQSFRMRRSRVSSSRKRHPAGPPGEAQEG
 SAKAERPGLQNMELAPVQRKIEARS AEDSFTGFVRTLYFADTYLKDSSRHCPSLWAGTNGGTIYAFSLRVP
 PAERRMDEPVRAEQAKEIQLMHRAPVVGILVLDGHSVPLPEPLEVAHDLKSPDMQGS HQLLVVSEEQFKV
 FTLPKVS AKLKLKLTAL EGSRRVRSVAHFGSRAEDYGEHHLAVLTNLGDIQVVS LPLLPKQVRYSCIRR
 EDVSGIASCVFTKYQGQFYLI SPSEFERFSLSTKWLVEPRCLVDSAETKNRHPGNGAGPKKAPSRARNSGT
 QSDGEEKQPLVMERALLSDERAATGVHIEPPWGAASAMAEQSEWLSVQAAR

NOV6b

In an alternative embodiment, a NOV6 variant is NOV6b (alternatively referred to herein as CG55891-02), which includes the 3492 nucleotide sequence (SEQ ID NO:21) shown in Table 6C. An open reading frame for the mature protein was identified beginning at nucleotides 131-133 and ending at nucleotides 3188-3190. The start and stop codons of the open reading frame are highlighted in bold type. Putative untranslated regions are underlined, and found upstream from the initiation codon and downstream from the termination codon.

Table 6C. NOV6b Nucleotide Sequence (SEQ ID NO:21).

CGCCAGCAGCCCGTGGGCGGCGCGGCGGAGCGAGCGGGGCGGCGGCGGCGGCGGAGGGACGCCGAGGCC
 TCGGCGCGGGGCTGGCCCGGGTCCAGGCTCTCAGTGGGGCTGCAGACTAAGCAAATGAGCGGTTCTT
 GAGGCCAGGGCATGACCTGTGCGGGAGAGGCTCAAGCGGGACCTGTTCCAGTTTAAACAAGACGGTGGAGCA
 TGGCTTCCCGCACAGCCAGCGCCTGCGCTACAGCCGCTCCTGCACATCCTGGCCATCGGCACCCGTTT
 TGGAGCCATCAAGCTCTACGAGCCCGAGGCGTGGAGTTTATGGGGCTGCACAGGAGAACAAACGCTGTGAC
 GCAGATCCACCTCCTGCCCGGCGAGTCCAGCTGGTCAACCTGCTGGATGACAAAGCCTGCACCTTTGGAG
 CCTGAAGGTCAAGGGCGGGGCATCGGAGCTGCAGGAGGATGAGAGCTTCACTGCGTGGACCCCGAGGGG
 TGCCCCAGTGCCACACAGATCACCGTGCTGCTGCCACATTCTCCTGCGAGCTGCTCTACCTGGGACCGGA
 GAGTGGCAACGTTGTTTGGTGCAGCTGCCAGCTTTTCTGCGCTGGAGGACCGGACCATCAGCTCGGACGC
 GGTGCTGCAGCGGTTGCCAGAGGAGGCGCCACCGCGTGTGTTTCAGATGGTGGAGGCACTGCAGGAGCA
 CCTCGAGAGCCCCAACAGATCCTGATCGGCTACAGCCGAGGCTCGTTGTCTCTGGGACCTACAGGGCAG
 CCGCGTGTCTACCACTTCTCAGCAGCCAGCAACTGGAGAACATCTGGTGGCAGCGGGACCGCGCTGTCT
 CGTCAGCTGTCACTCTGACGGCAGCTACTGCCAGTGGCCGTTCCAGCGAAGCCAGCAACAGAGCCCT
 CCGCAGCCTCGTGCTTACGGTCCCTTTCTTGCAAAGCGATTACAGAAATCTCTGGCTGACCACTAGGCA
 GGGTTTGGCCTTACCACCTTCCAGGGTGGCATGCCAGGGCAGCTACGGGGACCGCCACTGCATCTCAGT
 GATCCACGATGGCCAGCAGCGGCTTCGACTTACCTCCCGTGTCTCGGCTTCACTGTCTCACAGAGGC
 AGACCTTGACCCACCTTTGACGACCCCTATGCCCTGGTGGTGTCTGGCTGAGGAGGAGCTGGTGGTGATTGA
 CCTGCAGACAGCAGGCTGGCCACCGGTCCAGCTGCCCTACCTGGCTTCTCTGCACTGTTCCGCCATCACCTG
 CTCTCACACGCTCTCAACATCCCGCTGAAGCTGTGGGAGCGGATCATTGCCGCCGGCAGCCCGCAGAACGC
 ACACTTCTCCACCATGGAGTGGCCAATTGATGGTGGCACCAGCCTGACCCAGCCCCACCCAGAGGGACCT
 GCTGCTCACAGGGCAGGAGACGGCAGGTCGGTCTTGGGATGCTCGGGTGTCTGCTGCGGCTGCTCTA
 CAACTCAGCAGCTGTGCGGTGTTCTTACCGACACGGACCCCAACGAGAACTTCAGTGCCAGGGCGAGGA
 CGAGTGGCCCCACTCCGCAAGGTGGGCTCCTTTGACCCCTACAGTGATGACCCCGGCTGGGCATCCAGAA
 GATCTTCTCTGCAAGTACAGCGGCTACCTGGCTGTGGCAGGCACGGCAGGGCAGGTGCTGGTACTGGAAT
 GAATGACGAGGACAGCGGAGCAGGCTGTGGAGCAGGTGGAGGCCGACCTGCTGCAGGACCAAGAGGGCTACCG
 CTGGAAGGGGACAGCGCCTGGCAGGCCCTCAGGGCCCGTGCCTTTGAGCTTGGCTTTCAGCCCTTCGT
 GTTGGTGCAGTGTACGCCCCGGCTGTGGTCACTCTTGGCCCTGCACTCTGAGTGGCGGCTCGTGGCCTT
 CGGCACAGCCATGGCTTTGGCCTCTTTGACCAACAGCAGCGGCGGAGGCTTTGTTAAGTGCACTGCA
 CCCCAGTGACCAAGTGGCTTGGAGGGCCACTCTCCCGCTCAAGTCCCTCAAGAAGTCTTGGCTCAGTC
 ATTCCGCGGATGCGTGGAGCGGGGTGTCAGCCGGAAGCGGACCCCGCTGGCCCCCAGGAGGAGGAG
 GCCTGAGGCAAGGAGGGAGTGCAGAGGCTGAGCGGCCAGGCTCCAGAACATGGAGCTGGCGCTGTGCA
 GCGCAAGATCGAGGCTCGCTCGGAGAGGACTCTTACAGGCTTCTCGGACCCCTGACTTTGCTGACAC
 CTACCTGAAGACAGCTCCCGCACTGCCCTCGCTGTGGGCTGGCAACCAATGGGGGCAACATCTATGCCTT
 CTCCCTGCGTGTGCTCCCGCGGAGCGGAGAAATGGATGAGCTGTGCGGGCAGAGCAGCCAGGAGATCA
 GCTGATGACCGGGCGCGGTGGTGGGCATCTGTGCTGCAGGACACAGCGTACCCCTTCCGAGCCCTT

CGAAGTGGCCCATGATCTGTGGAAGAGCCCTGACATGCAGGGAAGCCACCAGCTGCTCGTCTATCAGAGGA
 GCAGTTCAAGGTGTTTACGCTGCCCAAGGTGAGTGCCAAGCTGAAGTTGAAGCTGACGGCCCTGGAGGGCTC
 AAGAGTGCGGCGGGTACGCTGGCCCACTTCGGCAGTCGTCGAGCCGAGGACTACGGGGAGCACCACCTGGC
 AGTCTTACCAACCTGGGCGACATCCAGGTGGTCTCGCTGCCCTGCTCAAGCCCCAGGTGCGCTACAGCTG
 CATCCGCGGGAGGACGTAGTGGCATCGCTCTCTGCTCTTACCAAAATATGGCCAAGGCTTCTACCTGAT
 CTCACCTCGGAGTTTGAGCGCTTCTCTCTTCCACCAAGTGGCTGGTGGAGCCCCGGTGTCTGGTGGATTC
 AGCAGAAACCAAGAACCACCGCCCTGGTAACGGTGGGGCCCCAAGAAGGCCCGAGCCGAGCCAGGAACTC
 AGGGACTCAGAGTGATGGCGAGGAGAAGCAGCCCGGCTGGTGATGGAGCGCGCTCTGCTCAGTGATGAGAG
 AGCGGCAACTGGCGTTTACATCGAGCCCGCTGGGGTGCAGCCTCAGCAATGGCGGAGCAGAGTGAGTGGCT
 GAGCGTCCAGGCTGCGCGATGAGCACACTACTACTGATGGCCTTTCGGGGGTCCCTGCCCAACCGGAGA
 GGCGGTGCAAGGGCCCCGCAAGGGCTGGGGGCATCCCGCTTCCACAATGCAGCTGCTCTGGGCCTCGG
 GAGAGGAGAGACCCAGTCCCTGGGCTGCCCTTCCCGGCGCTCGTCTGTCTGGGTCTTGGTCAATGTTG
 CACAGTTTTATTGCTCCCATCCCTTTTGTAGTGGGCTGGGTTTAAAGTTATAAATGTTAACTGCCTCTGG
 GTGAAAAAGTTTTTAATAACACCTATTACCTCTTG

The sequence of NOV6b was derived by laboratory cloning of cDNA fragments, by *in silico* prediction of the sequence. The cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, were cloned. *In silico* prediction was based on sequences available in CuraGen's proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof.

The cDNA coding for the NOV6b sequence was cloned by the polymerase chain reaction (PCR). PCR primers were designed based on *in silico* predictions of the full length or some portion (one or more exons) of the cDNA/protein sequence of the invention. The DNA sequence and protein sequence for a novel larvae-like gene were obtained by exon linking, or SeqCalling™ Technology and are reported here as NOV6b. These primers and methods used to amplify NOV6b cDNA are described in the Examples.

The NOV6b polypeptide (SEQ ID NO:22) encoded by SEQ ID NO:21 is 1019 amino acid residues in length and is presented using the one-letter amino acid code in Table 6D. The SignalP, Psort and/or Hydropathy results predict that NOV6b has no known signal peptide and is likely to be localized in the nucleus with a certainty of 0.9600. In alternative embodiments, a NOV6a polypeptide is located to the microbody (peroxisome) with a certainty of 0.5028, the mitochondrial matrix space with a certainty of 0.3600, or the lysosome (lumen) with a certainty of 0.1782.

Table 6D. Encoded NOV6b protein sequence (SEQ ID NO:22).

MRRFLRPGHDPVRERLKRDLFQFNKTVEHGFPHQPSALGYSPSLHILAIGTRSGAIKLYGAPGVEFMGLHQ
 ENNAVTTQIHLLPGQCQLVTLDDNSLHLWSLKVKGASELQEDSFTRLRGPPGAAPSATQITVVLPHSSCE
 LLYLGTESGNVVFVQLPAFRALEDRTISSDAVLQRLPEEARHRRVFEMVEALQEHPRDPNQILIGYSRGLV
 VIWDLQGSRLVYHFLSSQQLENIWWQRDGRLLVSCSDGSYCQWPVSSEAQQPEPLRSLVPYGFPPCKAIT
 RILWLTTTRQGLPFTIFQGMPRASYGDRHCISVIHDGQQTAFDFTSRVIGFTVLTEADPAATFDDPYALVV
 LAEEELVVIDLQTAGWPPVQLPYLASLHCSAITCSHHVSNIPKLWERI AAGSRQNAHFSTMEWPIDGGT
 SLTPAPPQRDLTLTGHDGTVRFWDASGVCLRLLYKLSLTVRVFLTDTPNENFSAQGEDEWPPLRKVGSGD
 PYSDDPRLGIQKIFLCKYSGYLAVAGTAGQVLVLELNDEAAEQAVEQVEADLLQDQEGYRWKGHERLAARS
 GPVRFEPGFQPFVLVQCQPPAVVTSALHSEWRLVAFGTSHGFGFLDHQQRQVVFVKCTLHPSDQLALEGP
 LSRVKSLLKSLRQSFRRMRSRVSSRRKHPAGPPGEVRPEAQEGSAKAERPGLQNMELAPVQRKIEARSAE
 DSFTGFVRTLYFADTYLKDSSRHCPSLWAGTNGGTIYAFSLRVPPAERRMDEPVRAEQAKEIQLMHRAPVV
 GILVLDGHSVPLPEPLEVAHDLSKSPDMQGSQHLVVSEEQFKVFTLPKVSARKLKLTALEGSRRVRRSV

AHFGSRR AEDYGEHHLAVLTNLGDIQVVS LPLLKPQVRYSCIRREDVSGIASCVF TKYGQGFYLISPSEFE
 RFSLSTKWLVEPRCLVDSAETKNHRPGNGAGPKKAPSRARNSGTQSDGEEKQPG LVMERALLSDERAATGV
 HIEPPWGAASAMAEQSEWLSVQAAR

NOV6 Clones

Unless specifically addressed as NOV6a or NOV6b, any reference to NOV6 is assumed to encompass all variants. Residue differences between any NOVX variant sequences herein are written to show the residue in the "a" variant, the residue position with respect to the "a" variant, and the residue in the "b" variant.

The amino acid sequence of NOV6 has high homology to other proteins as shown in Table 6E.

Table 6E. BLASTX results from Patp database for NOV6

		High Score	Smallest Sum Prob P(N)
Sequences producing High-scoring Segment Pairs:			
patp:AAG75075	Human colon cancer antigen protein	1207	1.2e-122
patp:AAB53381	Human colon cancer antigen protein sequence	154	9.9e-10
patp:AAB68519	Human GTP-binding associated protein	75	0.026
patp:AAG01592	Human secreted protein	84	0.11
patp:AAU00325	Fertilisation-independent endosperm protein	92	0.64

In a search of sequence databases, it was found, for example, that the NOV6a nucleic acid sequence has 3147 of 3480 bases (90%) identical to a giant larvae homolog mRNA from Homo sapiens (GENBANK-ID: HSHGLHOMO|acc:X87342). Further, the full amino acid sequence of the disclosed NOV6a protein of the invention has 904 of 1015 amino acid residues (89%) identical to, and 904 of 1015 amino acid residues (89%) similar to GIANT LARVAE HOMOLOGUE protein from Homo sapiens (ACC:Q14521). NOV6a is a novel variant of the 1015 amino acid residue GIANT LARVAE HOMOLOGUE protein from Homo sapiens (ACC:Q14521). The disclosed NOV6a protein lacks 111 amino acids compared to the GIANT LARVAE HOMOLOGUE protein.

In a similar search of sequence databases, it was found, for example, that the NOV6b nucleic acid sequence has 2464 of 2723 bases (90%) identical to a gb:GENBANK-ID:HSHGLHOMO|acc:X87342.1 mRNA from Homo sapiens (H.sapiens mRNA for human giant larvae homolog). Further, the full amino acid sequence of the protein of the invention was found to have 1015 of 1019 amino acid residues (99%) identical to, and 1015 of 1019 amino acid residues (99%) similar to, the 1015 amino acid residue ptrn:SPTREMBL-ACC:Q14521 protein from Homo sapiens (Human) (GIANT LARVAE HOMOLOGUE). The

amino acid sequence of the disclosed NOV6b protein of the invention has an insertion of 4 internal amino acids compared to ptnr:SP TREMBL-ACC:Q14521 protein from Homo sapiens (Human) (GIANT LARVAE HOMOLOGUE).

Additional BLASTP results are shown in Table 6F.

Table 6F. NOV6 BLASTP results					
Gene Index / Identifier	Protein / Organism	Length (aa)	Identity (%)	Positives (%)	Expect
Q14521	GIANT LARVAE HOMOLOGUE - Homo sapiens (Human)	1015	571/571 (100%)	571/571 (100%)	0.0
AAK52346	LETHAL GIANT LARVAE-LIKE PROTEIN 2 - Mus musculus (Mouse)	1027	491/545 (90%)	508/545 (93%)	0.0
Q61856	ORF - Mus musculus (Mouse)	1034	320/538 (59%)	403/538 (74%)	4.2e-257
Q15334	TUMOUR SUPPRESSOR PROTEIN, HUGL - Homo sapiens (Human)	1057	310/510 (60%)	384/510 (75%)	6.9e-246
O00188	LLGL - Homo sapiens (Human)	1032	309/541 (57%)	390/541 (72%)	1.2e-241

A multiple sequence alignment is given in Table 6G, with the NOV6 protein of the invention being shown in line 1 and 2, in a ClustalW analysis comparing NOV6 with related protein sequences of Table 4F.

Table 6G. ClustalW Analysis of NOV6

1. SEQ ID NO:20, NOV6a
2. SEQ ID NO:22, NOV6b
3. SEQ ID NO:110, Q14521, GIANT LARVAE HOMOLOGUE - Homo sapiens (Human)
4. SEQ ID NO:111, AAK52346, LETHAL GIANT LARVAE-LIKE PROTEIN 2 - (Mouse)
5. SEQ ID NO:112, Q61856, ORF - Mus musculus (Mouse)
6. SEQ ID NO:113, Q15334, TUMOUR SUPPRESSOR PROTEIN, HUGL - (Human)
7. SEQ ID NO:114, O00188, LLGL - Homo sapiens (Human)

	10	20	30	40	50
NOV6a
NOV6b
Q14521
AAK52346
Q61856
Q15334
O00188
	60	70	80	90	100
NOV6a	IGTRSGAIKLYGAPGVEFMGLHQENNAVTQIHLLPGQCQLVTLLDDNSLH				
NOV6b	IGTRSGAIKLYGAPGVEFMGLHQENNAVTQIHLLPGQCQLVTLLDDNSLH				
Q14521	IGTRSGAIKLYGAPGVEFMGLHQENNAVTQIHLLPGQCQLVTLLDDNSLH				
AAK52346	IGTRSGAVKLYGAPGVEFMGLHKENNAVTQIHLLPGQCQLVTLLDDNSLH				
Q61856	IGTRSGAVKIYGAPGVEFTGLHRDAATVTOMHFLPGQGRLLVTLLDDSSLH				
Q15334	IGTRSGAVKIYGAPGVEFTGLHRDAATVTOMHFLPGQGRLLVTLLDDSSLH				

000188 **IGTRSCAVKIYGAPGVETGLERDAATVTQMHPITGGRLLSILDDSSLH**

110 120 130 140 150

5 NOV6a LWSLKVKGGCASELQEDSFITLRGPP-----GAAPSAITQITVVI PHSSCEL
NOV6b LWSLKVKGGCASELQEDSFITLRGPP-----GAAPSAITQITVVI PHSSCEL
Q14521 LWSLKVKGGCASELQEDSFITLRGPP-----GAAPSAITQITVVI PHSSCEL
AAK52346 LWSLKVKGGVSELQEEESFITLRGPP-----GAAPSAITQITVVI PHSSCEL
Q61856 LWEIIHHNGCAHLEEGLSFHPPSRG SFDNASFPASLTRVTVVLLVAG-NT
10 Q15334 LWEIVHHNGCAHLEEGLSFHPPSRG SFDNASFPASLTRVTVVLLVAGDI
000188 LWEIVHHNGCAHLEEGLSFHPPSRG SFDNASFPASLTRVTVVLLVAGDI

160 170 180 190 200

15 NOV6a LYLGTESGN-VFVVQLPAFRALEDRTISSDAVLQRLPEEARHRRVFEMVE
NOV6b LYLGTESGN-VFVVQLPAFRALEDRTISSDAVLQRLPEEARHRRVFEMVE
Q14521 LYLGTESGN-VFVVQLPAFRALEDRTISSDAVLQRLPEEARHRRVFEMVE
AAK52346 LYLGTESGN-VLVVQLPGFRTLHDRTICSDVQLQWLPPEARHRRVFEMVE
Q61856 AALGTESGS-IFFLDVATLALLEGQTLSPDVVLRSPDDYRCGKALGPVE
20 Q15334 AALGTESGS-IFFLDVATLALLEGQTLSPDVVLRSPDDYRCGKALGPVE
000188 AGLGTESGS-IFFLDVATLALLEGQTLSPDVVLRSPDDYRCGKALGPVE

210 220 230 240 250

25 NOV6a ALQEHPRDPNQILIGYSRGLVVIWDLQGSRLVLYHFLSSQOLENIWWORDG
NOV6b ALQEHPRDPNQILIGYSRGLVVIWDLQGSRLVLYHFLSSQOLENIWWORDG
Q14521 ALQEHPRDPNQILIGYSRGLVVIWDLQGSRLVLYHFLSSQOLENIWWORDG
AAK52346 ALQEHPRDPNQILIGYSRGLVVIWDLQGSRLVLYHFLSSQOLENASWORDG
Q61856 SLQGHLDQPSKILIGYSRGLVVIWDLQGSRLVLYHFLSSQOLESLCWGRDG
30 Q15334 SLQGHLDQPSKILIGYSRGLVVIWDLQGSRLVLYHFLSSQOLESLCWGRDS
000188 SLQGHLDQPSKILIGYSRGLVVIWDLQGSRLVLYHFLSSQOLESLCWGRDS

260 270 280 290 300

35 NOV6a RLLVVSCHSDGSYCQWPVSSEAQ-QPEELRSLVPYGPFFCKAITRILWLTT
NOV6b RLLVVSCHSDGSYCQWPVSSEAQ-QPEELRSLVPYGPFFCKAITRILWLTT
Q14521 RLLVVSCHSDGSYCQWPVSSEAQ-QPEELRSLVPYGPFFCKAITRILWLTT
AAK52346 CLIVTCHSDGSYCQWPVSSEDQ-NPEELRSSIPYGPFFCKAITRILWLTT
Q61856 SSIISHSDDGSYAVWSVDAGSFPTLQETVATTTPYGPFFCKAINKILWRNC
40 Q15334 STVVSCHSDGSYAVWSVDAGSFPTLQETVATTTPYGPFFCKAINKILWRNC
000188 STVVSCHSDGSYAVWSVDAGSFPTLQETVATTTPYGPFFCKAINKILWRNC

310 320 330 340 350

45 NOV6a RQGLPFTIFQSGMPRASYGDRHCISVIHDGQQTAFDFTSRVIGFTVLTEA
NOV6b RQGLPFTIFQSGMPRASYGDRHCISVIHDGQQTAFDFTSRVIGFTVLTEA
Q14521 RQGLPFTIFQSGMPRASYGDRHCISVIHDGQQTAFDFTSRVIGFTVLTEA
AAK52346 RQGLPFTIFQSGMPRASYGDRHCISVHNGQQTAFDFTSRVIDFTVLSEA
Q61856 ESCDHFIIIFS GMPRASYGDRHCISVLAETLVTLDFHRIIDFTVHST
50 Q15334 ESCDHFIIIFS GMPRASYGDRHCISVLAETLVTLDFHRIIDFTVHST
000188 ESCDHFIIIFS GMPRASYGDRHCISVLAETLVTLDFHRIIDFTVHST

360 370 380 390 400

55 NOV6a DEPAATFDDPYALVVLAEELVVIDLQTAGWPPVQPYLASLHCSAITCSH
NOV6b DEPAATFDDPYALVVLAEELVVIDLQTAGWPPVQPYLASLHCSAITCSH
Q14521 DEPAATFDDPYALVVLAEELVVIDLQTAGWPPVQPYLASLHCSAITCSH
AAK52346 DEPAATFDDPYALVVLAEELVVIDLQTAGWPPVQPYLASLHCSAITCSH
Q61856 QEEDECDNPQALAVLLEELVVIDLQTAGWPPVQPYLASLHCSAITCSA
60 Q15334 QEEDECDNPQALAVLLEELVVIDLQTAGWPPVQPYLASLHCSAITCSA
000188 QEEDECDNPQALAVLLEELVVIDLQTAGWPPVQPYLASLHCSAITCSA

410 420 430 440 450

69

	Q14521	PGLQNMELAPVQRKIEARSAEDSFTGTFVRLTYFADTYLKDSSRHCPSLWA
	AAK52346	TGLQNMELAPVQRKIEARSAEDSFTGTFVRLTYFADTYLKDSSRHCPSLWA
	Q61856	TCPHDLEMTVPQRRIEPRSAEDSLSGVVRCLYFADTFLRDCAHFGPTMWA
	Q15334	ACPHDLEMTVPQRRIEPRSAEDSLSGVVRCLYFADTFLRDCAHFGPTMWA
5	000188	ACPHDLEMTVPQRRIEPRSAEDSLSGVVRCLYFADTFLRDGPPTGPTMWA
		760 770 780 790 800
	NOV6a	GTNGGTIYAFSLRVPPA---ERRMDEPVRAEQAKEIQLMHRAPVVGILV
10	NOV6b	GTNGGTIYAFSLRVPPA---ERRMDEPVRAEQAKEIQLMHRAPVVGILV
	Q14521	GTNGGTIYAFSLRVPPA---ERRMDEPVRAEQAKEIQLMHRAPVVGILV
	AAK52346	GTNGSTVYAFSLRVPPA---EKKINKPVRAEQAKEIQLMHRAPVVGILV
	Q61856	GTNSGSVFAYALEVPAATAGGKKRPEQAVEAVLGKEVQLMHRAPVVATAV
	Q15334	GTNSGSVFAYALEVPAAVGGEKKRPEQAVEAVLGKELQLMHRAPVVATAV
15	000188	GTNSGSVFAYALEVPAAVGGEKKRPEQAVEAVLGKKEQLMHRAPVVATCR
		810 820 830 840 850
	NOV6a	LDCHSVPLPEPLEVAHDLSSKSPDMQGSQQLLVVSEEQFKVFTLPKVSACL
20	NOV6b	LDCHSVPLPEPLEVAHDLSSKSPDMQGSQQLLVVSEEQFKVFTLPKVSACL
	Q14521	LDCHSVPLPEPLEVAHDLSSKSPDMQGSQQLLVVSEEQFKVFTLPKVSACL
	AAK52346	LDCHNVPLPEPLEVAHDLSSKSPDMQGSQQLLVVSEEQFKVFTLPKVSACL
	Q61856	LDGRGRPLPEPEYASRDLAQAPDMQGGHAVLIASEEQFKVFTLPKVSACL
	Q15334	LDG-GRPLPEPEYASRDLAQAPHMQGGHAVLIASEEQFKVFTLPKVSACL
25	000188	VGRGRGRPLPEPEYASRDLAQAPDMQGGHAVLIASEEQFKVFTLPKVSACL
		860 870 880 890 900
	NOV6a	KKLTALLEGSRVRR-VSVAHFGSRRADYGEHHLAVLTNLGDIQVVSLEPL
30	NOV6b	KKLTALLEGSRVRR-VSVAHFGSRRADYGEHHLAVLTNLGDIQVVSLEPL
	Q14521	KKLTALLEGSRVRR-VSVAHFGSRRADYGEHHLAVLTNLGDIQVVSLEPL
	AAK52346	KKLTALLEGSRVRR-VGVAHFGSRRADYGEHHLAVLTNLGDIQVVSLEPL
	Q61856	KKLTALLEGSRVRR-VGVAHFGSRRADYGEHHLAVLTNLGDIQVVSLEPL
	Q15334	KKLTALLEGSRVRR-VGVAHFGSRRADYGEHHLAVLTNLGDIQVVSLEPL
35	000188	KKLTALLEGSRVRR-VGVAHFGSRRADYGEHHLAVLTNLGDIQVVSLEPL
		910 920 930 940 950
	NOV6a	LKPOVRYSCIRREDVSGIASCVFTRHGGFYLIISPSEFERFSLSTKWLVE
40	NOV6b	LKPOVRYSCIRREDVSGIASCVFTRHGGFYLIISPSEFERFSLSTKWLVE
	Q14521	LKPOVRYSCIRREDVSGIASCVFTRHGGFYLIISPSEFERFSLSTKWLVE
	AAK52346	LKPOVRYSCIRREDVSGIASCVFTRHGGFYLIISPSEFERFSLSTKWLVE
	Q61856	LKPOVRYSCIRREDVSGIASCVFTRHGGFYLIISPSEFERFSLSTKWLVE
	Q15334	LKPOVRYSCIRREDVSGIASCVFTRHGGFYLIISPSEFERFSLSTKWLVE
45	000188	LKPOVRYSCIRREDVSGIASCVFTRHGGFYLIISPSEFERFSLSTKWLVE
		960 970 980 990 1000
	NOV6a	BRCLVDSAETKNH-RP--GNGAGPKKAPS---RARNSGTQSDGEEKQPG
50	NOV6b	BRCLVDSAETKNH-RP--GNGAGPKKAPS---RARNSGTQSDGEEKQPG
	Q14521	BRCLVDSAETKNH-RP--GNGAGPKKAPS---RARNSGTQSDGEEKQPG
	AAK52346	BRCLVDSTKAKKHNRPSNNGTGPMTSSG---HVRNSKSDGEEKQPG
	Q61856	BRCLVDSTKAKKHNRPSNNGTGPMTSSG---HVRNSKSDGEEKQPG
	Q15334	BRCLVDSTKAKKHNRPSNNGTGPMTSSG---HVRNSKSDGEEKQPG
55	000188	BRCLVDSTKAKKHNRPSNNGTGPMTSSG---HVRNSKSDGEEKQPG
		1010 1020 1030 1040 1050
	NOV6a	LVMERALLSDRAATGVHIEPPWGAASAMAEQSE-----WLSV
60	NOV6b	LVMERALLSDRAATGVHIEPPWGAASAMAEQSE-----WLSV
	Q14521	LVMERALLSDRAATGVHIEPPWGAASAMAEQSE-----WLSV
	AAK52346	PVMEHALLNDAWVLKEIQSTLEGDRRSYGNWHPH-----RVAV
	Q61856	SKRADTMEPPRAALSPVSTDSASGDTMLDTTG-----DVTV

Q15334 SMGPDTPPEPPEAALSPMSIDSATSADTTLDTTGDVTVEDVKDFLGSSEES
000188 SMGPDTPPEPPEAALSPMSIDSATSADTTLTRQG-----TS

```

                                1060
5      ....|....|....|..
      NOV6a      QAAR-----
      NOV6b      QAAR-----
      Q14521      QAAR-----
      AAK52346    GCRLSNGEAE-----
-10    Q61856     EYVKDFLG-----
      Q15334      EKNLRLAEDEAHACCI
      000188      QWKM-----

```

15 DOMAIN results for NOV6 were collected from the Pfam database, and then identified by the Interpro domain accession number. The results are listed in Table 6H with the statistics and domain description. This indicates that the NOV6 polypeptides have properties similar to those of other proteins known to contain these domains.

Table 6H. Domain Analysis of NOV6

Table 6H. Domain Analysis of NOV6				
PSSMs producing significant alignments:			Score (bits)	E value
WD domain, G-protein beta repeat			3.5	3.3e+02
WD	1lrtl.ghsssvtslafdpdgllatgsaDgtvriwd		(SEQ ID NO:115)	
	++ ++ + + +++ ++++ + ++ + + + ++++			
NOV6a	NKTVEhGFPHQPSALGYSPSLHILAIGTRSGAIKLYG		(SEQ ID NO:116)	

20

The NOV6 disclosed in this invention is expressed in at least the following tissues: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources. In addition, NOV6 is predicted to be expressed in the following tissues because of the expression pattern of (GENBANK-ID: X05426) the lethal(2) giant larvae protein in species *Drosophila melanogaster*: eyes, ovaries, digestive tract, brain. Further tissue expression analysis is provided in the Examples.

The protein similarity information, expression pattern, and map location for the giant larvae-like protein and nucleic acid disclosed herein suggest that this protein may have important structural and/or physiological functions. Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications. For example,

the compositions of the present invention will have efficacy for treatment of patients suffering from cancer, disorders of the eyes, ovaries, digestive tract, and brain, as well as other diseases, disorders and conditions.

5 The novel nucleic acid encoding the *Drosophila* larvae-like protein of the invention, or fragments thereof, are useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These materials are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the

10 "Anti-NOVX Antibodies" section below. The disclosed NOV6 protein has multiple hydrophilic regions, each of which can be used as an immunogen. In one embodiment, a contemplated NOV6 epitope is from about amino acids 5 to 45. In another embodiment, a contemplated NOV6 epitope is from about amino acids 60 to 90. In other specific

15 embodiments, contemplated NOV6 epitopes are from about amino acids 100 to 125, 160 to 200, 220 to 260, 290 to 320, 350 to 400, 420 to 460, 490 to 510, 520 to 600, 610 to 630, 640 to 670, 675 to 710, 725 to 740, 740 to 760, 770 to 790, and 795 to 900.

NOV7

20 A disclosed NOV7 nucleic acid of 2011 nucleotides (also referred to dj1182a14_da1) encoding a novel Macrophage Stimulating Protein Precursor-like receptor protein is shown in Table 7A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 1-3 and ending with a TAG codon at nucleotides 1999-2001. A putative untranslated region is found downstream from the termination codon, and is underlined in Table 7A. The start and stop codons are in bold letters.

Table 7A. NOV7 Nucleotide Sequence (SEQ ID NO:23)

ATGGGGTGGCTCCCACTCCTGCTGCTTCTGACTCAATGCTTAGGGGTCCCTGGTCAGCGCTCGCCATTGAA
 TGACTTCCAAGTGCTCCGGGGCACAGAGCTACAGCACCTGCTACATGCGGTGGTGCCCGGGCCTTGGCAGG
 AGGATGTGGCAGATGCTGAAGAGTGTGCTGGTGGTGTGGGCCCTTAATGGACTGCCGGGCCTTCCACTAC
 AACGTGAGCAGCCATGGTTGCCAACTGCTGCCATGGACTCAACACTCGCCCCACAGAGGCTGCGGCGTTC
 TGGGCGCTGTGACCTCTCCAGAAGAAAGACTACGTACGGACCTGCATCATGAACAATGGGGTTGGGTACC
 GGGGCACCATGGCCACGACCGTGGGTGGCCTGCCCTGCCAGGCTTGGAGCCACAAGTTCCCAAATGATCAC
 AAGTACACGCCCCACTCTCCGAATGGCCTGGAAGAGAACTTCTGCCGTAACCTGATGGCGACCCCGGAGG
 TCCCTGGTGTCTACACAACAGACCCTGCTGTGCGCTTCCAGAGCTGCGGCATCAAATCCTGCCGGGAGGCCG
 CGTGTGTCTGGTGAATGGCGAGGAATACCGCGGCGCGGTAGACCGCACGGAGTCAGGGCGCGAGTGCCAG
 CGCTGGGATCTTCAGCACCCGACACGACCCCTTCGAGCCGGGCAAGTTCTTCGACCAAGGTCTGGACGA
 CAACTATTGCCGAATCCTGACGGCTCCGAGCGGCCATGGTGTCTACACTACGGATCCGAGATCGAGCGAG
 AGTTCTGTGACTCCCCCGCTGCGGTTCCGAGGCACAGCCCGCCAGAGGCCACAAGTGTGACGTGCTTTC
 CGCGGAAGGGTGAGGGCTACCGGGGCAAGCCAATACCACCACCGCGGGCTACCTTGCCAGCGTTGGGA
 CGCGCAAATCCCGCATCAGCACCGATTACGCCAGAAAATACGCGTGCAAGGACCTTCGGGAGAACTTCT
 GCCGGAACCCGACGGCTCAGAGGCGCCCTGGTGTCTCACAATGCCGCGCGGCATGCGCGCGGCTTTTGC
 TACCAGATCCGCGTGTGTACAGACGACGTGCGGCCCGAGACTGCTACCAACGGCGCAGGGGAGCAGTACCGC
 GGCACGGTCAGCAAGACCCGCAAGGGTGTCCAGTGCCAGCGCTGGTCCGCTGAGACGCGCACAAGCCGCA
 GTTCACGTTTACCTCCGAACCGCATGCACAACCTGGAGGAGAACTTCTGCCGGAACCCAGATGGGGATAGCC
 ATGGGCGCTGGTGTACACGATGGACCAAGGACCCATTTCGACTACTGTGCCCTGCGAGCTGCGCTGAT
 GACCAACCGCCATCAATCCTGGACCCCGCAGACCGTGCAGTTTGAGAAGTGTGGCAAGAGGTGGATCG
 GCTGGATCAGCGCGTTCGAAGCTGCGCGTGGTTGGGGGCCATCCGGGCAACTCACCTTGACAGTCAGCT
 TGCGGAATCGGTATGCTGCCTCTCACGGCTATGAGGTATGGTTGGGCAACCTGTTCCAGAACCACAGCA
 TGGAGAGCCAAGCCTACAGCGGTCCTCAGTAGCCAAGATGGTGTGTGGGCCCTCAGGCTCCAGCTTGTCC
 TGCTCAAGCTGGAGAGATCTGTGACCTGAACCAACGCTGTGGCCCTGATCTGCCTGCCCTGAAATGGTAT
 GTGGTGCCTCCAGGGACCAAGTGTGAGATTGCAGGCTGGGGTGAGACCAAGGTACGGGTAATGACACAGT
 CCTAAATGTGGCCTTGCTGAATGTCTCAACACAGAGTGAACATCAAGCACCGAGGACGTGGTGACT
 ACGGGGGCCCACTTGCTGCTTACCCCAACTGTGGGTCTGGAAGGAATTATAATCCCCAACCGAGTA
 TGCGCAAGGTCTGCTGCGCAGCTGTCTCACGCGTGTCTGTGTTTGTGGACTGGATTACAAGGTCTAT
 GAGACTGGGTTAGGCCAGCCTT

The disclosed NOV7 nucleic acid sequence, localized to the q21 region of chromosome 3, has 1508 of 1524 bases (98%) identical to a gb:GENBANK-

- 5 ID:HUMMST1A|acc:L11924 mRNA from Homo sapiens(Homo sapiens macrophage-stimulating protein (MST1) mRNA, complete cds (E = 0.0).

A disclosed NOV7 polypeptide (SEQ ID NO:24) encoded by SEQ ID NO:23 is 666 amino acid residues long and is presented using the one-letter amino acid code in Table 7B. Signal P, Psort and/or Hydropathy results predict that NOV7 contains a signal peptide and is
 10 likely to be localized in the lysosome (lumen) with a certainty of 0.5493. In other embodiments, NOV7 is also likely to be localized extracellularly with a certainty of 0.3700, to the microbody (peroxisome) with a certainty of 0.1588, and the endoplasmic reticulum (membrane) with a certainty of 0.1000. The most likely cleavage site for a NOV7 peptide is between amino acids 18 and 19, at: VPG-QR.

15

Table 7B. Encoded NOV7 protein sequence (SEQ ID NO:24).

MGWLPLLLLLTQCLGVPGQRSPLNDFQVLRGTQLQHLHAVVPGPWQEDVADAEACAGRCGPLMDCRAFHY
 NVSSHGQQLLPWTQHSFPHRLRRSGRCDLFQKKDYVRTCIMNNGVGYRGTMATTVGGLPCQAWSHKFPNDH
 KYTPTLRNGLEENFCRNPDPGDPGGPWCYTTDPVRFQSCGKSCREAAVCWNGEYRGAVDRTEGREGCQ
 RWDLQHPHQHPFEPGKFLDQGLDDNYCRNPDGSRPWCYTTPQIEREFCDLPRCGSEAQPRQEATTVSCF
 RGKGEYRGTTANTTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNPDGSEAPWCFTLRPGMRAAFC
 YQIRRCTDDVRPQTATTAQSSSTAARSARPARVSSASAGPLRRRTSRSSRLPNRMHNWRTSAGTQMGI
 MGPGATRWTOGPHSTTVPCDAALMTSRHQSWTPQTRCSLRVARGWIGWISGVPSCAWLGAIRATHPGQSA

CGIGMLPLTGIEVWLGTLFQNPQHGEPSLQRPVAKMVCGPSGSQLVLLKLESVTLNQRVALICLPPEWY
VPPPGTKCEIAGWGETKGTGNDTVLNVALLNVISNQCNIKHRGRGDYGGPLACFTHNCWVLEGIIPNRV
CARSCWPAVFTRVSVFVDWIHKVMRLG

The NOV7 amino acid sequence has 368 of 368 amino acid residues (100%) identical to, and 368 of 368 amino acid residues (100%) similar to, the 711 amino acid residue ptnr:SPTREMBL-ACC:Q14870 protein from *Homo sapiens* (Human) Macrophage-Stimulating Protein Precursor (E = $9.9e^{-310}$).

NOV7 is expressed in at least HepG2 (liver cell line). SNP data for NOV7 can be found below in Example 3.

NOV7 also has homology to the amino acid sequence shown in the BLASTP data listed in Table 7C.

Table 7C. BLAST results for NOV7					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 11544434 emb CAC17639.1 (AL137798)	dJ1182A14.3 (similar to MST1 (macrophage stimulating 1 (hepatocyte growth factor- like))) [Homo sapiens]	648	454/717 (63%)	474/717 (65%)	0.0
gi 10337615 ref NP_066278.1 	macrophage stimulating 1 (hepatocyte growth factor- like) [Homo sapiens]	711	360/367 (98%)	360/367 (98%)	0.0
gi 15294659 ref XP_054070.1 	macrophage stimulating 1 (hepatocyte growth factor- like) [Homo sapiens]	711	360/367 (98%)	360/367 (98%)	0.0
gi 123114 sp P26927 HGFL HUMAN	HEPATOCYTE GROWTH FACTOR-LIKE PROTEIN PRECURSOR (MACROPHAGE STIMULATORY PROTEIN) (MSP) (MACROPHAGE STIMULATING PROTEIN)	711	359/367 (97%)	359/367 (97%)	0.0
gi 1141775 gb AAC63092.1 (U28054)	hepatocyte growth factor-like protein homolog [Homo sapiens]	567	313/332 (94%)	321/332 (96%)	0.0

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 7D.

Table 7D. Information for the ClustalW proteins

- 1) NOV7 (SEQ ID NO:24)
- 2) gi|11544434|emb|CAC17639.1| (AL137798) dJ1182A14.3 (similar to MST1 (macrophage stimulating 1 (hepatocyte growth factor-like))) [Homo sapiens] (SEQ ID NO:117)
- 3) gi|10337615|ref|NP_066278.1| macrophage stimulating 1 (hepatocyte growth factor-like) [Homo sapiens] (SEQ ID NO:118)
- 4) gi|15294659|ref|XP_054070.1| macrophage stimulating 1 (hepatocyte growth factor-like) [Homo sapiens] (SEQ ID NO:119)
- 5) gi|123114|sp|P26927|HGFL HUMAN Hepatocyte Growth Factor-Like Protein Precursor (Macrophage Stimulatory Protein) (Msp) (Macrophage Stimulating Protein) (SEQ ID NO:120)
- 6) gi|1141775|gb|AAC63092.1| (U28054) hepatocyte growth factor-like protein homolog [Homo sapiens] (SEQ ID NO:121)

5

10

15

20

25

30

35

40

45

50

55

60

NOV7

gi|11544434|emb
gi|10337615|ref
gi|15294659|ref
gi|123114|sp|P2
gi|1141775|gb|A

GVNAQTKNGATPLYLACQEGHLEVTVQLVQECGADPHARAHDMGTPHAAACMGHSFVIV

10 20 30 40 50 60

8 8 8 8 1

NOV7

gi|11544434|emb
gi|10337615|ref
gi|15294659|ref
gi|123114|sp|P2
gi|1141775|gb|A

LLTQCLGVPGQRSP
WLVSCTDVSLSBQDKGATATHFAASRGHSKVLWSLLHGGEISADLWGGTALYDAAENG

70 80 90 100 110 120

22 22 22 22 10

NOV7

gi|11544434|emb
gi|10337615|ref
gi|15294659|ref
gi|123114|sp|P2
gi|1141775|gb|A

ELECCQILVVNGAELEVRDRDGYAAADLNDFLNDFLNDFLNDF

130 140 150 160 170 180

48 180 48 48 48 23

NOV7

gi|11544434|emb
gi|10337615|ref
gi|15294659|ref
gi|123114|sp|P2
gi|1141775|gb|A

DVADAEBCAGRCGP
ELEAKQPDSCMSSPNTTVSVQPLNFDLSSPTSTSNYDSCSSSSSSIKGQHPPLGLSSTR

190 200 210 220 230 240

101 240 101 101 101 76

NOV7

gi|11544434|emb
gi|10337615|ref
gi|15294659|ref
gi|123114|sp|P2
gi|1141775|gb|A

QKIDYVRTCIMNNGVGY
AADIQSYMDDLNPGLPWCITIGKPIPPPPPPSPFPFPFPFPPTGQLPPPPSPSPKPPVVG

250 260 270 280 290 300

146 300 146 146 146 121

NOV7

gi|11544434|emb
gi|10337615|ref
gi|15294659|ref
gi|123114|sp|P2
gi|1141775|gb|A

TLRNGLEENFCRNP
PQAADIYMQTKNKLHVETELKKEPSSCDGHLRQRDSSRKPRAFSKQPFSTGDYYRQL

310 320 330 340 350 360

183 360 183 183 183 158

NOV7

gi|11544434|emb
gi|10337615|ref
gi|15294659|ref
gi|123114|sp|P2
gi|1141775|gb|A

KSCREAAACVWCNGEYRGAVDR
GRCPGETLVARFGMAHTEELBPGNHVPNGCAADPKASREOQLPPPPPELPEAASSPP

370 380 390 400 410 420

232 420 232 232

76

BEST AVAILABLE COPY

	gi	11544434	emb	PVSRGEAHSPTNERLRQLLRQRAVGKLLHHWRS	LRPHVPPSPGTAHGVYWPQHFLSPLDG	960				
	gi	10337615	ref	PVAKMVCGPSGSQVLVLLK	LERSVTLNQRVALICLPPEWYVPPG	599				
	gi	15294659	ref	PVAKMVCGPSGSQVLVLLK	LERSVTLNQRVALICLPPEWYVPPG	599				
	gi	123114	sp P2	PVAKMVCGPSGSQVLVLLK	LERSVTLNQRVALICLPPEWYVPPG	599				
5	gi	1141775	gb A	PVAKMVCGPSGSQVLVLLK	LERSVTLNQRVALICLPPE	567				
				970	980	990	1000	1010	1020	
	NOV7			-----	-----	-----	-----	-----	-----	
					TKCEIAGWG	ETKGTG			NDTVLNVALLNVIS	602
10	gi	11544434	emb	GAPPRYESLTLDLFMLGYFQLPEMQLSREDRKFRHLLCYEMPHRLD					SHPWERTIRFHRV	1020
	gi	10337615	ref		TKCEIAGWG	ETKGTG			NDTVLNVALLNVIS	628
	gi	15294659	ref		TKCEIAGWG	ETKGTG			NDTVLNVALLNVIS	628
	gi	123114	sp P2		TKCEIAGWG	ETKGTG			NDTVLNVALLNVIS	628
	gi	1141775	gb A		TKCEIAGWG	ETKGTG			NDTVLNVALLNVIS	567
				1030	1040	1050	1060	1070	1080	
	NOV7			-----	-----	-----	-----	-----	-----	
				NOECNIKHRGR				SDYGGPLACFTHNCVLEG		632
	gi	11544434	emb	LEEVEAGRRCWSDGFBDLRHRFPNGLEAGPAPEEQAKIK				KEQERTESAAPVQKCD		1080
20	gi	10337615	ref	NOECNIKHRGRVRESMCTEGLL			APVGACE	GDYGGPLACFTHNCVLEG		677
	gi	15294659	ref	NOECNIKHRGRVRESMCTEGLL			APVGACE	GDYGGPLACFTHNCVLEG		677
	gi	123114	sp P2	NOECNIKHRGRVRESMCTEGLL			APVGACE	GDYGGPLACFTHNCVLEG		677
	gi	1141775	gb A	NOECNIKHRGRVRESMCTEGLL			APVGACE	GDYGGPLACFTHNCVLEG		567
				1090	1100	1110	1120	1130		
	NOV7			-----	-----	-----	-----	-----		
					IIIPNRVCARS	WPVAVTRVSVFVDWIHKVMRLG				666
	gi	11544434	emb	PPKGQREALAPVPQPPFPFAPFPARRAS	PERLPQSOTLRVPKPPKTLWN					1130
	gi	10337615	ref		IIIPNRVCARS	WPVAVTRVSVFVDWIHKVMRLG				711
	gi	15294659	ref		IIIPNRVCARS	WPVAVTRVSVFVDWIHKVMRLG				711
	gi	123114	sp P2		IIIPNRVCARS	WPVAVTRVSVFVDWIHKVMRLG				711
30	gi	1141775	gb A		IIIPNRVCARS	WPVAVTRVSVFVDWIHKVMRLG				567

Tables 7E-K list the domain descriptions from DOMAIN analysis results against NOV7. This indicates that the NOV7 sequence has properties similar to those of other proteins known to contain these domains.

Table 7E. Domain Analysis of NOV7

gnl|Pfam|pfam00051, kringle, Kringle domain. Kringle domains have been found in plasminogen, hepatocyte growth factors, prothrombin, and apolipoprotein A. Structure is disulfide-rich, nearly all-beta. (SEQ ID NO:122)
 CD-Length = 79 residues, 100.0% aligned
 Score = 117 bits (292), Expect = 3e-27

Query: 191 CVCNCGEEYRGAVDRTESGRECORWDLQHPHQHPF-EPGKFLDQGLDDNYCRNPDGSRP 249
 | ||| ||| |||| |||| | ||+| | ++ +|| +||||||| |||
 Sbjct: 1 CYHNGENYRGTAATTESGAPCORWDSQTPHRHSKYTPERYPAKGLGENYCRNPDGDERP 60
 Query: 250 WCYTTPQIEREFCDLPRC 268
 |||||++ ||+|||
 Sbjct: 61 WCYTTPRVRWEYCDIPRC 79

Table 7F. Domain Analysis of NOV7

gnl|Pfam|pfam00051, kringle, Kringle domain. Kringle domains have been found in plasminogen, hepatocyte growth factors, prothrombin, and apolipoprotein A. Structure is disulfide-rich, nearly all-beta. (SEQ ID NO:123)
 CD-Length = 79 residues, 100.0% aligned
 Score = 112 bits (279), Expect = 9e-26

Query: 283 CFRGKGEGYRGTTANTTTAGVPCQWDAQIPHQHRF-TPEKYACKDLRENFCRNPDGSEAP 341
 |+ | | | | | | | | | | + | | | | | + | | | | | | | | | | + | | | | | | | |
 Sbjct: 1 CYHNGENYRGTAATTESGAPCQRWDSQTPHRHSKYTPERYPAKGLGENYCRNPDGDERP 60
 Query: 342 WCFTLRPGMRAAFQYQIRRC 361
 | | + | | + | + | | | |
 Sbjct: 61 WCYTTDPVRWEYC-DIPRC 79

Table 7G. Domain Analysis of NOV7

gnl|Pfam|pfam00051, kringle, Kringle domain. Kringle domains have been found in plasminogen, hepatocyte growth factors, prothrombin, and apolipoprotein A. Structure is disulfide-rich, nearly all-beta. (SEQ ID NO:124)
 CD-Length = 79 residues, 100.0% aligned
 Score = 104 bits (259), Expect = 2e-23

Query: 110 CIMNNGVGYRGTMATTVGGLPCQAWSHKFPNDH-KYTPT--LRNGLEENFCRNPDGDPGG 166
 | | | | | | | | + | | | | | + | + | | | | | | | | + | | | | | | | |
 Sbjct: 1 CYHNGENYRGTAATTESGAPCQRWDSQTPHRHSKYTPERYPAKGLGENYCRNPDGDE-R 59
 Query: 167 PWCYTTDPAVRFQSCGIKSC 186
 | | | | | | | | | | + | | | |
 Sbjct: 60 PWCYTTDPVRWEYCDIPRC 79

5

Table 7H. Domain Analysis of NOV7

gnl|Smart|smart00130, KR, Kringle domain; Named after a Danish pastry. Found in several serine proteases and in ROR-like receptors. Can occur in up to 38 copies (in apolipoprotein(a)). Plasminogen-like kringles possess affinity for free lysine and lysine- containing peptides. (SEQ ID NO:125)
 CD-Length = 83 residues, 97.6% aligned
 Score = 111 bits (279), Expect = 1e-25

Query: 191 CVWCNGEEYRGAVDRTESGRECQRWDLQHPHQHPFEPGKFLDQGLDDNYCRNPDG-SERP 249
 | | | | | | | | + | | + | | | | | | | | | | + | + | | + | | | | | | | |
 Sbjct: 3 CYAGNGESYRGTAATTKSGKPCQRWDSQTPHLHRFTPERFPGLGLEHNYCRNPDGDESGP 62
 Query: 250 WCYTTDPQIEREFCDLPRCGS 270
 | | | | | | | | + | + | + | + | | |
 Sbjct: 63 WCYTTDPNVRWEYCDIPQCES 83

Table 7I. Domain Analysis of NOV7

gnl|Smart|smart00130, KR, Kringle domain; Named after a Danish pastry. Found in several serine proteases and in ROR-like receptors. Can occur in up to 38 copies (in apolipoprotein(a)). Plasminogen-like kringles possess affinity for free lysine and lysine- containing peptides. (SEQ ID NO:126)
 CD-Length = 83 residues, 97.6% aligned
 Score = 106 bits (265), Expect = 4e-24

Query: 108 RTCIMNNGVGYRGTMATTVGGLPCQAWSHKFPNDHKYPTLRN--GLEENFCRNPDPGDPG 165
 | | | | | | | | | | + | | | | | | | | | | + | + | + | | | | | | | | | | | |
 Sbjct: 1 RDCYAGNGESYRGTAATTKSGKPCQRWDSQTPHLHRFTPERFPELGLHNYCRNPDPGDSE 60
 Query: 166 GPWCYTTPPAVRFAQSGIKSC 186
 | | | | | | | | | | | | | | + | + | | | | | | | | | | | | | | | | | | | | | |
 Sbjct: 61 GPWCYTTPNVRWEYCDIPQC 81

Table 7J. Domain Analysis of NOV7

gnl|Smart|smart00130, KR, Kringle domain; Named after a Danish pastry. Found in several serine proteases and in ROR-like receptors. Can occur in up to 38 copies (in apolipoprotein(a)). Plasminogen-like kringles possess affinity for free lysine and lysine- containing peptides. (SEQ ID NO:127)
 CD-Length = 83 residues, 97.6% aligned
 Score = 104 bits (260), Expect = 1e-23

Query: 283 CFRGKGEVGYRGTAATTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNPDPG-SEAP 341
 | + | | | | | | | | | + | | | | | | | | | | + | | | | | | | | | | | | | | | | |
 Sbjct: 3 CYAGNGESYRGTAATTKSGKPCQRWDSQTPHLHRFTPERFPELGLHNYCRNPDPGDSEGP 62
 Query: 342 WCFTLRPGMRAAFQYQIRRCTD 363
 | | + | | | + | | | + | | | | | | | | | | | | | | | | | | | | | | | |
 Sbjct: 63 WCYTTPNVRWEYCD-IPQCES 83

5

Table 7K. Domain Analysis of NOV7

gnl|Smart|smart00473, PAN_AP, divergent subfamily of APPLE domains; Apple-like domains present in Plasminogen, C. elegans hypothetical ORFs and the extracellular portion of plant receptor-like protein kinases. Predicted to possess protein- and/or carbohydrate-binding functions (SEQ ID NO:128)
 CD-Length = 79 residues, 94.9% aligned
 Score = 52.0 bits (123), Expect = 1e-07

Query: 25 DFQVLRGTQLQLLHAVVPGPWQEDVADAEACAGRC-GPLMDCRAFHYNVSSHGCQLLPW 83
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Sbjct: 5 CFVRLPNTKL-----PDFSPIVISVASLEBCAQKCLNSNCSCRSFTYNNDTKGCLLWSE 58
 Query: 84 TQHSPTHRLRRSGRCDLFQKK 104
 + + | | | | + + | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 Sbjct: 59 SSLGDARQLLPSSGGVDYYEKI 79

10 NOV7 also had homology to proteins in the PATP database as shown by the BLAST data in Table 7L below.

Table 7L. BLAST PATP results for NOV7

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
patp:AAR66602	Human L5/3 tumour suppressor protein	711	368/368 (100%)	368/368 (100%)	0.0
patp:AAB84520	Amino acid sequence of human macrophage stimulating protein (MSP)	710	368/368 (100%)	368/368 (100%)	0.0

Macrophage-stimulating protein (MSP) is an 80-kD serum protein with homology to hepatocyte growth factor (HGF) (Sakamoto O, et.al.; J ClinInvest 1997 Feb 15;99(4):701-9). Its receptor, RON tyrosine kinase, is anew member of the HGF receptor family. The MSP-
 5 RON signaling pathway hasbeen implicated in the functional regulation of mononuclear phagocytes. However, the function of this pathway in other types of cells has not been elucidated. Here we show that in contrast to the HGF receptor, which was expressed at the basolateral surface, RON was localized at the apical surface of ciliated epithelia in the airways and oviduct. In addition, MSP was found in the bronchoalveolar space at biologically
 10 significant concentrations. MSP bound to RON on normal human bronchial epithelial cells with a high affinity ($K_d = 0.5$ nM) and induced autophosphorylation of RON. Activation of RON by MSP led to a significant increase in ciliary beat frequency of human nasal cilia. These findings indicate that the ciliated epithelium of the mucociliary transport apparatus is a novel target of MSP.

15 The above defined information for NOV7 suggests that this NOV7 protein may function as a member of a Macrophage Stimulating Protein Precursor family. Therefore, the NOV7 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV7 compositions of the present invention will have efficacy
 20 for treatment of patients suffering from Aicardi-Goutieres syndrome 1; Brugada syndrome; Deafness, autosomal recessive 6; Heart block, nonprogressive; Heart block, progressive, 2; Ichthyosiforme erythroderma, congenital, nonbullous; Long QT syndrome-3; Night blindness; congenital stationary; Pituitary ACTH-secreting adenoma; Small-cell cancer of lung; Ventricular fibrillation, idiopathic; entricular tachycardia, idiopathic; HIV infection,
 25 susceptibility/resistance to; Von Hippel-Lindau (VHL) syndrome; Cirrhosis; Transplantation. The NOV7 nucleic acid encoding Macrophage Stimulating Protein Precursor receptor-like protein, and the Macrophage Stimulating Protein Precursor receptor-like protein of the

invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

NOV7 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOV7 substances for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. The disclosed NOV7 protein has multiple hydrophilic regions, each of which can be used as an immunogen. In one embodiment, a contemplated NOV7 epitope is from about amino acid 30 to 40. In another embodiment, a NOV7 epitope is from about amino acid 60 to 80. In additional embodiments, NOV7 epitopes are from about amino acid 85 to 140, from about amino acid 150 to 190, from about amino acid 205 to 350, from about amino acid 360 to 470, from about amino acid 480 to 620, from about amino acid 700 to 750, from about amino acid 500 to 530, from about amino acid 570 to 600, and from about amino acid 605 to 660. This novel protein can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.

NOV8

Yet another NOVX protein of the invention, referred to herein as NOV8, is a nucleotide-sugar transporter-like protein.

Nucleotide sugar transporters are mainly located in the Golgi membranes and carry nucleotide sugars, that are produced outside the Golgi apparatus, into the organelle, where they serve as substrates for the elongation of carbohydrate chains by glycosyltransferases. Thus, such transporters are indispensable for cellular glycoconjugate synthesis. Moreover, the disclosed NOV8 protein of the invention may have regulatory roles in producing the structural variety of cellular glycoconjugates.

The novel nucleotide-sugar transporter gene disclosed in this invention maps to chromosome 6. This information was assigned using OMIM and the electronic northern tool from Curatools to derive the the chromosomal mapping of the SeqCalling assemblies, Genomic clones, and/or EST sequences that were included in the invention.

Two alternative NOV8 nucleic acids and encoded polypeptides are provided, namely NOV8a and NOV8b.

NOV8a

In one embodiment, a NOV8 variant is NOV8a (alternatively referred to herein as 138531995), which encodes a novel nucleotide-sugar transporter-like protein and includes the 1463 nucleotide sequence (SEQ ID NO:25) shown in Table 8A. An open reading frame for the mature protein was identified beginning with an ATG initiation codon at nucleotides 165-167 and ending with a TGA codon at nucleotides 1461-1463. Putative untranslated regions upstream from the start codon is underlined in Table 8A, and the start and stop codons are in bold letters.

Table 8A. NOV8a Nucleotide Sequence (SEQ ID NO:25).

GCAGGGGCGGAGGGGCGCGGGAGGGAGGCGGGAAGAGCGCGGCACTTCCGCTGGCCGCTG
GCTCGCTGGCCGCTCCTGGAGGCGGCGGGAGCGCAGGGGCGCGCGGCCCGGGACTCGC
ATCCCCCGTTCCCCCTCCACCCACGCGGCTGGACCATGGACGCCAGATGGTGGGCAGTGG
 TGGTGTGGCTGCGTTCCCCTCCCTAGGGGCGGAGTGGGGAGACTCCCGAAGCCCTCCGGAGT
 CATGGACCCAGCTATGGTTCTTCCGATTTGTGGTGAATGCTGCTGGCTATGCCAGCTTTATGG
 TACCTGGCTACCTCATGGTGCAGTACTTCAGGCGGAAGAACTACCTGGAGACCGGTAGGGGCC
 TCTGCTTTCCCCTGGTGAAAGCTTGTGTGTTTGGCAATGAGCCCAAGGCCTCTGATGAGGTTTC
 CCCTGGCGCCCCGAACAGAGGCGGCAGAGACCACCCGATGTGGCAGGCCCTGAAGCTGCTCT
 TCTGTGCCACAGGGCTCCAGGTGTCTTATCTGACTTGGGGTGTGCTGCAGGAAAGAGTGATGA
 CCGCAGCTATGGGGCCACAGCCACATCACCGGGTGAGCGCTTTACGGAATCGCAGTTCCTGG
 TGCTAATGAACCGAGTGCTGGCACTGATTGTGGCTGGCCTCTCCTGTGTTCTCTGCAAGCAGC
 CCCGGCATGGGGCACCCATGTACCGGTACTCCTTTGCCAGCCTGTCCAATGTGCTTAGCAGCT
 GGTGCCAATACGAAGCTCTTAAGTTCGTGAGCTTCCCAACCCAGGTGCTGGCCAGGCCTTA
 AGGTGATCCCTGTGCTGATGGGAAAGCTTGTGTCTCGGCGCAGCTACGAACACTGGGAGT
 ACCTGACAGCCACCCCTCATCTCCATTGGGGTCAGCATGTTTCTGCTATCCAGCGGACCAGAGC
 CCCGACGTCCCCAGCCACCACACTCTCAGGCCTCATCTTACTGGCAGGTTATATTGCTTTTG
 ACAGCTTCACTCAAACCTGGCAGGATGCCCTGTTTGCTATAAGATGTCATCGGTGCAGATGA
 TGTTTGGGGTCAATTTCTTCTCCTGCCTCTTCACAGTGGGCTCACTGCTAGAACAGGGGGCCC
 TACTGGAGGGAACCGCTTCATGGGGCGACACAGTGAGTTTGCTGCCCATGCCCTGCTACTCT
 CCATCTGCTCCGCATGTGGCCAGCTCTTCATCTTTTACACCATTTGGGCAGTTTGGGGCTGCCG
 TCTTCACCATCATATGACCTCCGCCAGGCCTTTGCCATCCTTCTTCTGCTGCTCTCTATG
 GCCACACTGTCACTGTGGTGGGAGGGCTGGGGTGGCTGTGGTCTTTGCTGCCCTCCTGCTCA
 GAGTCTACGCGCGGGGCCGTCTAAAGCAACGGGGAAGAAGGCTGTGCCTGTTGAGTCTCCTG
 TGCAGAAGGTTTGA

The sequence of NOV8a was derived by laboratory cloning of cDNA fragments, by *in silico* prediction of the sequence. The cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, were cloned. *In silico* prediction was based on sequences available in CuraGen's proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof.

The DNA sequence and protein sequence for a novel nucleotide-sugar transporter-like gene were obtained by SeqCalling™ Technology and are reported here as NOV8a. These primers and methods used to amplify NOV8a cDNA are described in the Examples.

The NOV8a polypeptide (SEQ ID NO:26) encoded by SEQ ID NO:25 is 432 amino acid residues in length and is presented using the one-letter amino acid code in Table 8B. The SignalP, Psort and/or Hydropathy results predict that NOV8a has a signal peptide and is likely

to be localized in the plasma membrane with a certainty of 0.6400. In alternative embodiments, a NOV8a polypeptide is located to the Golgi body with a certainty of 0.4600, the endoplasmic reticulum (membrane) with a certainty of 0.3700, or the endoplasmic reticulum (lumen) with a certainty of 0.1000. The SignalP predicts a likely cleavage site for a NOV8a peptide is between amino acid positions 20 and 21, i.e. at the dash in the sequence GAG-GE.

Table 8B. Encoded NOV8a protein sequence (SEQ ID NO:26).

MDARWVAVVLAAPPSLGAGGETPEAPPESWTQLWFFRFVVNAAGYASFMVPGYLMVQYFRRKNYLETGR
GLCFPLVKACVFGNEPKASDEVPLAPRTEAAETTPMWQALKLLFCATGLQVSYLTWGLQERVMTRSYGA
TATSPGERFTDSQFLVLMNRVLALIVAGLSCVLCKQPRHGAPMYRYSFASLSNVLSSWCQYEALKFVSFP
TQVLAKASKVIPVMLMGKLVSRRSYEHWEYLATLISIGVSMFLLSSGPEPRSSPATTLISGLILLAGYIA
FDSFTSNWQDALFAYKMSSVQMMFGVNFSCLEFTVGSLLLEQGALLEGTRFRMGRHSEFAAHALLLSICSAC
GQLFIIFYTIGQFGAAVFTIIMTLRQAFAILLSCLLYGHTVTTVVGGGLGVAVVFAALLLRVYARGRLKQRGK
KAVPVESPVQKV

Additional SNP variants of NOV8a are disclosed in Example 3.

NOV8b

In an alternative embodiment, a NOV8 variant is NOV8b (alternatively referred to herein as CG111627-01), which includes the 1742 nucleotide sequence (SEQ ID NO:27) shown in Table 8C. An open reading frame for the mature protein was identified beginning at nucleotides 111-113 and ending at nucleotides 1407-1409. The start and stop codons of the open reading frame are highlighted in bold type. Putative untranslated regions (underlined), if any, are found upstream from the initiation codon and downstream from the termination codon.

Table 8C. NOV8b Nucleotide Sequence (SEQ ID NO:27).

CGGCCGCGTCGACGCTGGCCGCTCCTGGAGGCGGCGGCGGAGCGCAGGGGGCGCGCGGCCCG
GGGACTCGCATTCGCCGTTCCCCCTCCACCCACGCGGCCTGGACCATGGACGCCAGATGGT
GGGCAGTGGTGGTGGCTGGCTGCGTTCCCCCTCCCTAGGGGAGGTGGGAGACTCCCGAAGCCC
CTCCGGAGTCATGGACCCAGCTATGGTTCTTCCGATTGTGGTGAATGCTGCTGGCTATGCCA
GCTTTATGGTACCTGGCTACCTCCTGGTGCACTTTCAGGCGGAAGAACTACCTGGAGACCG
GTAGGGGCTCTGCTTTCCCTGGTGAAAGCTTGTGTGTTTGGCAATGAGCCCAAGGCCTCTG
ATGAGGTTCCCTGGCGCCCCGAACAGAGGCGGCAGAGACCACCCGATGTGGCAGGCCCTGA
AGCTGCTCTTCTGTGCCACAGGGCTCCAGGTGTCTTATCTGACTTGGGGTGTGCTGCAGGAAA
GAGTGATGACCCGAGCTATGGGGCCACAGCCACATCACCGGTGAGCGCTTTACGGACTCGC
AGTTCCTGGTGCTAATGAACCGAGTGCTGGCACTGATTGTGGCTGGCCTCTCCTGTGTCTCT
GCAAGCAGCCCCGCGCATGGGGCACCATGTACCGGTACTCCTTGGCAGCCTGTCCAATGTGC
TTAGCAGCTGGTGCCAATACGAAGCTCTTAAGTTCGTGAGCTTCCCCACCCAGGTGCTGGCCA
AGGCCTCTAAGGTGATCCCTGTGCTGATGGGAAAGCTTGTGTCTCGGCGCAGCTACGAAC
ACTGGGAGTACCTGACAGCCACACTCATCTCCATTGGGGTACAGCATGTTTCTGCTATCCAGCG
GACCAGAGCCCCGAGCTCCCGAGCCACCACACTCTCAGGCCTCATCTTACTGGCAGGTTATA
TTGCTTTTGACAGCTTCACCTCAAAGTGGCAGGATGCCCTGTTGCCTATAAGATGTATCGG
TGCAGATGATGTTTGGGGTCAATTTCTCTCCTGCCTCTTACAGTGGGCTCACTGCTAGAAC
AGGGGGCCCTACTGGAGGGAACCGCTTCATGGGGCGACACAGTGAGTTTGTGCTGCCCATGCCC

```

TGCTACTCTCCATCTGCTCCGCATGTGGCCAGCTCTTCATCTTTACACCATTTGGGCAGTTTG
GGGCTGCCGTCTTCACCATCATCATGACCCTCCGCCAGGCCCTTGCCATCCTTCTTTCTCTGCC
TTCTCTATGGCCACACTGTCACTGTGGTGGGAGGGCTGGGGTGGCTGTGGTCTTTGCTGCCC
TCCTGCTCAGAGTCTACGCGCGGGGCCGTCTAAAGCAACGGGGAAAGAAGGCTGTGCCTGTTG
AGTCTCCTGTGCAGAAGGTTTGAGGGTGGAAAGGGCCTGAGGGGTGAAGTGAAATAGGACCCT
CCCACCATCCCCTTCTGCTGTAACTCTGAGGGAGCTGGCTGAAAGGGCAAAATGCAGGTGTT
TTCTCAGTATCACAGACCAGCTCTGCAGCAGGGGATTGGGGAGCCAGGAGGCAGCCTTCCCT
TTTGCCTTAAGTCNACCCATCTTCCANGTAAGCAGTTTATTCTGAGCCCCGGGGGTAGACAGT
CCTCAGTGAGGGGTTTTGGGGAGTTTGGGGTCAAGAGAGCATAGGTAGGTTCCACAGTTACTC
TTCCCAACAAGTTCCTTAAGTCTTGCCCTAGCTGTGCTCTG

```

The sequence of NOV8b was derived by laboratory cloning of cDNA fragments, by *in silico* prediction of the sequence. The cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, were cloned. *In silico* prediction was based on sequences available in CuraGen's proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof.

The cDNA coding for the NOV8b sequence was cloned by the polymerase chain reaction (PCR). PCR primers were designed based on *in silico* predictions of the full length or some portion (one or more exons) of the cDNA/protein sequence of the invention. The DNA sequence and protein sequence for a novel nucleotide-sugar transporter-like gene were obtained by exon linking, or SeqCalling™ Technology and are reported here as NOV8b. These primers and methods used to amplify NOV8b cDNA are described in the Examples.

The NOV8b polypeptide (SEQ ID NO:26) encoded by SEQ ID NO:27 is identical to the NOV8a polypeptide (SEQ ID NO:26).

NOV8 Clones

Unless specifically addressed as NOV8a or NOV8b, any reference to NOV8 is assumed to encompass all variants. Residue differences between any NOVX variant sequences herein are written to show the residue in the "a" variant, the residue position with respect to the "a" variant, and the residue in the "b" variant.

The amino acid sequence of NOV8 has high homology to other proteins as shown in Table 8D.

Table 8D. BLASTX results from Patp database for NOV8		
Sequences producing High-scoring Segment Pairs:	High Score	Smallest Sum Prob P(N)

patp:AAB12162	Hydrophobic domain protein	2227	1.0e-230
patp:AAB34721	Human secreted protein	2227	1.0e-230
patp:AAE03771	Human gene 8 encoded secreted protein	2227	1.0e-230
patp:AAE03784	Human gene 8 encoded secreted protein	2227	1.0e-230
patp:AAE03789	Human gene 8 encoded secreted protein	2227	1.0e-230

In a search of sequence databases, it was found, for example, that the NOV8a nucleic acid sequence has 220 of 376 bases (58%) identical to a gb:GENBANK-ID:AB013805|acc:AB013805 mRNA from Homo sapiens (Homo sapiens mRNA for neural plakophilin-related arm-repeat protein (NPRAP)). The full amino acid sequence of the NOV8a protein of the invention was found to have 121 of 325 amino acid residues (37%) identical to, and 187 of 325 amino acid residues (57%) similar to, the 345 amino acid residue ptrn:TREMBLNEW-ACC:BAB09511 protein from Arabidopsis thaliana (Mouse-ear cress) (UDP-GALACTOSE TRANSPORTER RELATED PROTEIN-LIKE).

Similarly, in a search of sequence databases, it was found, for example, that the NOV8b nucleic acid sequence has 1716 of 1722 bases (99%) identical to a gb:GENBANK-ID:AX136243/acc:AX136243.1 mRNA from Homo sapiens (Sequence 165 from Patent EP1067182). The full amino acid sequence of the protein of the invention was found to have 197 of 397 amino acid residues (49%) identical to, and 269 of 397 amino acid residues (67%) similar to the 465 amino acid residue ptrn:SPTREMBL-AC:Q9VEI3 protein from Drosophila melanogaster (Fruit fly) (CG7623 PROTEIN).

Additional BLASTP results are shown in Table 8E.

Table 8E. NOV8 BLASTP results					
Gene Index / Identifier	Protein / Organism	Length (aa)	Identity (%)	Positives (%)	Expect
AAL07487	EMBRYONIC SEVEN-SPAN TRANSMEMBRANE PROTEIN-LIKE PROTEIN - Mus musculus (Mouse)	431	396/432 (91%)	408/432 (94%)	1.8e-211
Q9VEI3	CG7623 PROTEIN - Drosophila melanogaster (Fruit fly)	465	197/397 (49%)	269/397 (67%)	8.3e-95
AAK93522	SD04658P - Drosophila melanogaster (Fruit fly)	465	197/397 (49%)	269/397 (67%)	8.3e-95
O16377	M03F8.2 PROTEIN - Caenorhabditis elegans	417	153/365 (41%)	217/365 (59%)	6.3e-65
Q9D1L5	1110003M08RIK PROTEIN - Mus musculus (Mouse)	124	103/124 (83%)	112/124 (90%)	1.3e-55

A multiple sequence alignment is given in Table 8F, with the NOV8 protein of the invention being shown in line 1 and 2, in a ClustalW analysis comparing NOV8 with related protein sequences of Table 8E.

Table 8F. ClustalW Analysis of NOV8

5	1.	SEQ ID NO:26,	NOV8a
	2.	SEQ ID NO:26,	NOV8b
	3.	SEQ ID NO:129,	AAL07487, TRANSMEMBRANE PROTEIN-LIKE PROTEIN - (Mouse)
	4.	SEQ ID NO:130,	Q9VEI3, CG7623 PROTEIN - (Fruit fly)
	5.	SEQ ID NO:131,	AAK93522, SD04658P - (Fruit fly)
10	6.	SEQ ID NO:132,	O16377, M03F8.2 PROTEIN - Caenorhabditis elegans
	7.	SEQ ID NO:133,	Q9D1L5, 1110003M08RIK PROTEIN - Mus musculus (Mouse)

		10	20	30	40	50
15	NOV8a	MDAR-----WWAVVVLAAFP-----SLG-----AGGETPE				
	NOV8b	MDAR-----WWAVVVLAAFP-----SLG-----AGGETPE				
	AAL07487	MDAR-----WWAVVVLATLP-----SLG-----AGGESPE				
	Q9VEI3	MYAYNKMGRVPELVICSFIIVTLLVIHFFSDDLRLASLGGYYNQDVTLSQL				
	AAK93522	MYAYNKMGRVPELVICSFIIVSLLVIHFFSDDLRLASLGGYYNQDVTLSQL				
20	O16377	-----MDRSIMP-----IDSPA				
	Q9D1L5	MDAR-----WWAVVVLATLP-----SLG-----AGGESPE				
		60	70	80	90	100
25	NOV8a	APPESWTQLWFFRFVUNAAGYASFMVPGYLLMVQYFRRKNYLETG-RGLCF				
	NOV8b	APPESWTQLWFFRFVUNAAGYASFMVPGYLLVQYFRRKNYLETG-RGLCF				
	AAL07487	APPQSWTQLWLFRLNVAAGYASFMVPGYLLVQYLRKNYLETG-RGLCF				
	Q9VEI3	VESQNSDYAWFLKLLVNCFGYSCVFVPGFLIYKYVGRINYLERNKTFH				
	AAK93522	VESQNSDYAWFLKLLVNCFGYSCVFVPGFLIYKYVGRINYLERNKTFH				
30	O16377	RDKPPDELVWPLRLFLLLGYSTVATPAAILIYYVRRNRHAFETPYLSIR				
	Q9D1L5	APPQSWTQLWLFRLNVAAGYASFMVPGYLLVQYLRKNYLETG-RGLCF				
		110	120	130	140	150
35	NOV8a	PLVKACVFGNE--PKASDEVPLAPRTEAAETTP-----MWQALKLLFCAT				
	NOV8b	PLVKACVFGNE--PKASDEVPLAPRTEAAETTP-----MWQALKLLFCAT				
	AAL07487	PLVKACVFGNE--PKAPDEVLLAPRTETAESTP-----SQVVLKLVFCAS				
	Q9VEI3	KAINMCITGNSGYDQLDAGTSTADKDRPAASTAPKRTSSQEAVQLLWCFG				
	AAK93522	KAINMCITGNSGYDQLDAGTSTADKDRPAASTAPKRTSSQEAVQLLWCFG				
40	O16377	LLLRSAFVGNPEYQLIPTGEKQARKENDSIPQTR-AQCINVIILLFFFS				
	Q9D1L5	PLVKACVFGNE--PKAPDEVLLAPRTETAESTP-----SQVVLKLVFCAS				
		160	170	180	190	200
45	NOV8a	GLQVSYLTWGVLQERVMTRSYG-ATATSPGERFTDSQFLVLMNRVLALIV				
	NOV8b	GLQVSYLTWGVLQERVMTRSYG-ATATSPGERFTDSQFLVLMNRVLALIV				
	AAL07487	GLQVSYLTWGVLQERVMTGSYG-ATATSPGEHFTDSQFLVLMNRVLALVV				
	Q9VEI3	GLMISYLTWGVLQEKIMTONY--LNFTGESAKFKDSQFLVFSNRLLAFLV				
	AAK93522	GLMISYLTWGVLQEKIMTONY--LNFTGESAKFKDSQFLVFSNRLLAFLV				
50	O16377	GIQVTLVAMGVLQERIIIRGYRRSDQLEVEDKFEGETQFLIFCNRIVALVL				
	Q9D1L5	GLQVSYLTWGVLQERVMTRSYG-ATATSPGERFTDSQFLVLMNRVLALIV				
		210	220	230	240	250
55	NOV8a	AGLSCVLC--KQPRHGAPMYRYSFASLSNVLSSWCQYEALKFVSFPQTQVL				
	NOV8b	AGLSCVLC--KQPRHGAPMYRYSFASLSNVLSSWCQYEALKFVSFPQTQVL				
	AAL07487	AGLYCVLR--KQPRHGAPMYRYSFASLSNVLSSWCQYEALKFVSFPQTQVL				
	Q9VEI3	ALAYLQWQP-SPVRHRAPLYKYASYASFSNIMSAWFOYEALKFVNFPQTQVL				
	AAK93522	ALAYLQWQP-SPVRHRAPLYKYASYASFSNIMSAWFOYEALKFVNFPQTQVL				

016377	SLMILAKDWTQKPPHVPFLVYVHSYTSFNTISSWCOYEALKYVSFPCTI
Q9D1L5	-----
	260 270 280 290 300
5	NOV8a AKASKVIPVMLMGKLVSRRSYEHWEYLTAATLISIGVSMELLSSGPEPRSS
	NOV8b AKASKVIPVMLMGKLVSRRSYEHWEYLTAATLISIGVSMELLSSGPEPRSS
	AAL07487 AKASKVIPVMMGKLVSRRSYEHWEYLTAATLISIGVSMELLSSGPEPRSS
	Q9VEI3 AKSCKIIPVMLMGKIMSKAKYESYEVVTALLISLGMIFFMSCGSDSSKAS
10	AAK93522 AKSCKIIPVMLMGKIMSKAKYESYEVVTALLISLGMIFFMSCGSDSSKAS
	016377 CKASKVVVTMLMGRLVRGQRYSWFEYGCCTIAFGASLFLSSSSKGAGS
	Q9D1L5 -----
	310 320 330 340 350
15	NOV8a --PATTLSGLILLAGYIAFDSETSNWQDALFA--YKMSSVQMMFGVNFFS
	NOV8b --PATTLSGLILLAGYIAFDSETSNWQDALFA--YKMSSVQMMFGVNFFS
	AAL07487 --PATTLSGLVLLAGYIAFDSETSNWQDALFA--YKMSSVQMMFGVNLFSS
	Q9VEI3 --GVTTLTGIFLLSMYMFVDSFTANWQGSLEFS--YGMTPLQMMCGVNLFSS
20	AAK93522 --GVTTLTGIFLLSMYMFVDSFTANWQGSLEFS--YGMTPLQMMCGVNLFSS
	016377 TITYTISFSGLMAGYLLFDATLNLWQKALFDTKPKVSKYQMMFGVNFFS
	Q9D1L5 -----
	360 370 380 390 400
25	NOV8a CLFTVGSLLLEQCALLEGTRFMGRHSEFAAHALLLSICSACGQLFIYFTIG
	NOV8b CLFTVGSLLLEQCALLEGTRFMGRHSEFAAHALLLSICSACGQLFIYFTIG
	AAL07487 CLFTVGSLLLEQCALLEGARFMGRHSEFAAHALLLSICSACGQLFIYFTIG
	Q9VEI3 SIFTGASLSMQGGFMDSLAFATEHPKRVFDMVVLSCSAVGOLFIFYHTID
30	AAK93522 SIFTGASLSMQGGFMDSLAFATEHPKRVFDMVVLSCSAVGOLFIFYHTID
	016377 AILCAVSLIEQGLWSSIKFGAEHVDESRDVFLLSLSCAICQIFIFYSTIE
	Q9D1L5 -----
	410 420 430 440 450
35	NOV8a QFGAAVFTIIMTLRQAFAILLSCLLYGHTVTVVGGGLGVAVVFAALLLRVY
	NOV8b QFGAAVFTIIMTLRQAFAILLSCLLYGHTVTVVGGGLGVAVVFAALLLRVY
	AAL07487 QFGAAVFTIIMTLRQAFAILLSCLLYGHTVTVVGGGLGVAVVFAALLLRVY
	Q9VEI3 VFGPVVFTIIMTLRQAVAIMLSCFIYQHSISLLGIFGVLIQVVAIFLRVY
40	AAK93522 VFGPVVFTIIMTLRQAVAIMLSCFIYQHSISLLGIFGVLIQVVAIFLRVY
	016377 RFGPIVFAVIMTIRQIFIRNTLIRAEDHGVEMAPPPPEERLKFLSMI
	Q9D1L5 -----
	460 470
45	NOV8a ARGRLKQRGKKAVPVESPVQKV
	NOV8b ARGRLKQRGKKAVPVESPVQKV
	AAL07487 ARGRLKQRGKKAVPTPEPVQKV
	Q9VEI3 CTQRLRAIRKRAEANKPKMAV-
50	AAK93522 CTQRLRAIRKRAEANKPKMAV-
	016377 IAVIHI-----
	Q9D1L5 -----

55 Domain results for NOV8 were collected from BLAST sample domains found in the Smart and Pfam collections. The results are listed in Table 8G with the statistics and domain description. This indicates that the NOV8 polypeptides have properties similar to those of other proteins known to contain these domains.

Table 8G. Domain Analysis of NOV8				
PSSMs producing significant alignments:			Score (bits)	E value
DUF6,	Integral membrane protein		-141.5	8.4
DUF6	sSakNAfkckfkSiFswHNETvNIWtykkekflerlvklsHLlGfil			
NOV8a	226	MG---KLVSRRSYEHWE-----YLTATLI	246	
DUF6	FffllildflflvpilasvtshLyilqdrvvfgfftdlcvhdlagWpfy			
NOV8a	247	SIGVSMFLSSSGPEPRSSPATT-----LSGLIL-----LAG---Y	278	
DUF6	.fl.gafLCLllSsiyHtfschSlekvsefflkldYlGIsllIvaSfipi			
NOV8a	279	iAFdSF-----TSNWQDALFAYKMS-----	298	
DUF6	iYyaFychpfrrtlyisiilvLGliaiyvsldkFsspkfRkrRvplRag			
NOV8a	299	-----SVQMMFG-VNFFSCLFTVGSLLLEQGALLEGTRFMGRHSEFAAH	340	
DUF6	fFvllglsGviPlHaliifgghenlkvrilpwwllmallyivGavfyg			
NOV8a	341	ALLLSICSA-CGQLFIFYTIGQFGA--AVFTIIMTLRQAFAILLSCLLYG	387	
DUF6	tRIPERffrCPHaGKFDivGhSHQLFHVlVV..laafcHyravl (SEQ ID NO:134)			
NOV8a	388	-----H--T-----VTVVggLGVAVVFALL 406 (SEQ ID NO:26)		

5 The NOV8 disclosed in this invention is expressed in at least the following tissues:
 Adrenal gland, Aorta, Blood, Brain, Breast, CNS, Colon, Esophagus, Foreskin, Germ Cell,
 Lung, Lymph, Skeletal Muscle, Ovary, Pancreas, Parathyroid, Placenta, Pooled, Prostate,
 Salivary Glands (including parotid), Spleen, Stomach, Synovial membrane, Testis, Tonsil,
 Uterus, Whole embryo, brain, breast, breast_normal, cervix, colon, eye, kidney, leiomyos,
 10 lung, lung cell line, ovary, pancreas, placenta, skin, uterus. This information was derived by
 determining the tissue sources of the sequences that were included in the invention including
 but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE
 sources. This list of tissue sources is by no way limiting. Further tissue expression analysis is
 provided in the Examples.

15 The protein similarity information, expression pattern, and map location for the novel
 nucleotide-sugar transporter-like protein and nucleic acid disclosed herein suggest that this
 novel nucleotide-sugar transporter may have important structural and/or physiological
 functions characteristic of the nucleotide-sugar transporter family. Therefore, the NOV8
 nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic
 20 applications and as a research tool. For example, the compositions of the present invention
 will have efficacy for treatment of patients suffering from muscular dystrophy, Lesch-Nyhan
 syndrome, myasthenia gravis, Von Hippel-Lindau (VHL) syndrome, pancreatitis, xerostomia,

arthritis, tendinitis, fertility, and cancer (preferably ovarian and pancreatic tumors).

Furthermore, the NOV8 nucleic acids and polypeptides of the invention could have efficacy for treatment of patients suffering from metabolic diseases, preferably obesity and diabetes, as well as other diseases, disorders and conditions.

5 The novel nucleic acid encoding the nucleotide-sugar transporter-like protein of the invention, or fragments thereof, are useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These materials are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated
10 according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. The disclosed NOV8 protein has multiple hydrophilic regions, each of which can be used as an immunogen. In one embodiment, a contemplated NOV8 epitope is from about amino acids 10 to 40. In another embodiment, a contemplated NOV8 epitope is from about amino acids 55 to 75. In other
15 specific embodiments, contemplated NOV8 epitopes are from about amino acids 80 to 110, 125 to 155, 175 to 190, 220 to 240, 250 to 260, 275 to 290, 310 to 340, and 410 to 475.

NOV9

20 Still another NOVX protein of the invention, referred to herein as NOV9 (alternatively referred to as AC018755_da1), is an OB binding protein-2-like protein. OB binding proteins are located at the plasma membrane and associate with transmembrane subgroup members of the immunoglobulin superfamily, such as sialic acid-binding Ig-like lectin 5 (siglec-5). Such associations constitute a unique related subgroup with a high level of overall amino acid identity. These associations serve to mediate sialic acid-dependent binding to human
25 erythrocytes and soluble glycoconjugates, suggesting involvement in cell-cell interactions and recognition events.

 The OB Binding Protein-2 disclosed in this invention maps to chromosome 19q13.3. This information was assigned using publicly available reference material from OMIM and Pubmed.

30 The NOV9 nucleic acid (SEQ ID NO:28) of 1368 nucleotides encoding a novel OB binding protein-2-like protein is shown in Table 9A. An open reading frame for the mature protein was identified beginning with a ATG initiation codon at nucleotides 1-3 and ending with a TGA codon at nucleotides 1366-68. The start and stop codons are in bold letters.

Table 9A. NOV9 Nucleotide Sequence (SEQ ID NO:28).

```

ATGCTGCCCCCTGCTGCTGCTGCCCCCTGCTGTGGGGGGTTCCCTGCAGGAGAAGCCAGTGTAC
GAGCTGCAAGTGCAGAAGTCGGTGACGGTGACAGGAGGGCCCTGTGCGTCTTGTGCCCTGCTCC
TTCTCTTACCCCTGGAGATCCTGGTATTCCTCTCCCCCACTCTACGTCTACTGGTTCCGGGAC
GGGAGATCCCATACTACGCTGAGGTTGTGGCCACAAACAACCCAGACAGAAGAGTGAAGCCA
GAGACCCAGGGCCGATTCCGCTCCTTGGGGATGTCCAGAAGAAGAACTGCTCCCTGAGCATC
GGAGATGCCAGAATGGAGGACACGGGAAGCTATTTCTTCCGCGTGAGAGAGGAAGGGATGTA
AAATATAGCTACCAACAGAATAAGCTGAACTTGAGGTGACAGCCCTGATAGAGAAACCCGAC
ATCCACTTTCTGGAGCCTCTGGAGTCCGGCCGCCCCACAAGGCTGAGCTGCAGCCTTCCAGGA
TCCTGTGAAGCGGGACCACTCTCACATTCCTCTGGACGGGGAATGCCCTCAGCCCCCTGGAC
CCCAGACACCCGCTCCTCGGAGCTCACCTCACCCCCAGGCCCGAGGACCATGGCACCAAC
CTCACCTGTGATGAAACGCCAAGGAGCTCAGGTGACCACGGAGAGAACTGTCCAGCTCAAT
GTCTCCGATGTCCACAGACCATCACCATCTTCAGGAACGGCATAGCCCTAGAGATCCTGCAA
AACACTCATACCTTCCGGTCTCGAGGGCCAGGCTCTGCGGCTGCTCTGTGATGCTCCAGC
AACCCCCCTGCACACAGCTGGTTCCAGGGCTCCCTGCCCCGAACGCCACCCCCATCTCCAAT
ACCGGGATCTTGGAGCTTCGTGAGTAAGGTCTGCAGAAGAAGGAGGCTTCACTGCCGCGCT
CAGCACCCGCTGGGCTTCTGCAAAATTTTCTGAATCTCTCAGTTTACTGGAGATCGAACCTC
GGGACAGGAGTGGTTCTGACAGCCCTGGTGGTGTGTTGTCATGGCCCTGCTCTGTATCTGT
CTGTGCTCATCTTCTTTTAATAGTGAAGCCCGCAGGAAGCAAGCAGCTGGGAGAGCAGAG
AAAATGGATGATGAAGACCCATTATGGGTACCATCACCTCGGGTTCCAGGAAGAAGCCCTGG
CCAGACAGCCCCGGAGATCAAGCATCTCCTCTGGGGATGCCCTCCCTTGGGAAGAACAAAAG
GAGCTCCATTATGCCTCCCTTAGTTTTCTGAGATGAAGTCGAGGGAGCCTAAGGACCAAGGAG
GCCCCAAGCACCGAGTACTCGGAGATCAAGACAAGCAAGTGA

```

The sequence of NOV9 was derived by laboratory cloning of cDNA fragments covering the full length and/or part of the DNA sequence of the invention, and/or by *in silico* prediction of the full length and/or part of the DNA sequence of the invention from public human sequence databases.

The cDNA coding for the NOV9 sequence was cloned by the polymerase chain reaction (PCR). Primers were designed based on *in silico* predictions of the full length or some portion (one or more exons) of the cDNA/protein sequence of the invention, or by translated homology of the predicted exons to closely related human sequences or to sequences from other species. The DNA sequence and protein sequence for an OB binding protein-2-like gene were obtained by exon linking and are reported here as NOV9. These primers and methods used to amplify NOV9 cDNA are described in the Examples.

The NOV9 polypeptide (SEQ ID NO:29) encoded by SEQ ID NO:28 is 455 amino acid residues in length and is presented using the one-letter amino acid code in Table 9B. The SignalP, Psort and/or Hydropathy results predict that NOV9 has a signal peptide and is likely to be localized in the plasma membrane with a certainty of 0.4600. In alternative embodiments, a NOV9 polypeptide is located to the endoplasmic reticulum (membrane) with a certainty of 0.1000, the endoplasmic reticulum (lumen) with a certainty of 0.1000, or outside the cell with a certainty of 0.1000. The SignalP predicts a likely cleavage site for a NOV9 peptide is between amino acid positions 16 and 17, i.e. at the dash in the sequence SLQ-EK.

Table 9B. Encoded NOV9 protein sequence (SEQ ID NO:29).

```

MLPLLLLPLLLWGGSLQEKPVYELQVQKSVTVQEGLCVLVPCSFSPWRSWYSSPPLYVYWFRDGEIPYYA

```


EVVATNNPDRRVKPEETOGRFRLGQVQKNCSLSIGDARMEDTGSYFFRVERGRDVKYSYQQNKLNEVT
 ALIEKPDHIFLEPLESGRPTRLSCSLPGSCEAGPPLTFSTGNALSPLDPETTRSELTLTPRPEDHGTN
 LTCQMKRQGAQVTTERTVOLNVSDAPQTITIFRNGIALEILQNTSYLPVLEGQALRLLCDAPSNPPAHWS
 FQGSFALNATPISNTGILELRRVRSAAEGGFTCRAQHPLGFLQIFLNLSTVWRSNLGTGVVPAALGGAGV
 MALLCICLCLIFFLIVKARRKQAAGRPEKMDDEPIMGTITSGSRKCPWPDSPGDQASPPGDAPPLEEQK
 ELHYASLSFSEMKSRPEKQDEAPSTTEYSEIKTSK

SNP variants are disclosed in Example 3. The amino acid sequence of NOV has high homology to other proteins as shown in Table 9C.

Table 9C. BLASTX results from Patp database for NOV9

Sequences producing High-scoring Segment Pairs:		High Score	Smallest Sum Prob P(N)
patp:AAW55884	Human CD33-like protein - Homo sapiens	1735	1.4e-178
patp:AAM00948	Human bone marrow protein	1731	3.7e-178
patp:AAB29191	CD33 protein - Homo sapiens	1724	2.0e-177
patp:AAW25945	Ob binding protein - Synthetic	1632	1.1e-167
patp:AAU02894	Ob binding protein sequence #2 - Homo sapiens	1632	1.1e-167

5

In a search of sequence databases, it was found, for example, that the nucleic acid sequence of this invention has 992 of 997 bases (99%) identical to a gb:GENBANK-ID:HSU71383|acc:U71383 mRNA from Homo sapiens (Human OB binding protein-2 (OB-BP2) mRNA). The full amino acid sequence of the protein of the invention was found to have 330 of 332 amino acid residues (99%) identical to, and 330 of 332 amino acid residues (99%) similar to, the 551 amino acid residue ptrn:SPTREMBL-ACC:O15389 protein from Homo sapiens (Human) (OB BINDING PROTEIN-2).

10

Additional BLASTP results are shown in Table 9D.

Table 9D. NOV9 BLASTP results

Gene Index / Identifier	Protein / Organism	Length (aa)	Identity (%)	Positives (%)	Expect
O15389	OB BINDING PROTEIN-2 (SIGLEC5) - Homo sapiens (Human)	551	330/332 (99%)	330/332 (99%)	7.7e-179
AAD50978	SIALIC ACID BINDING IG-LIKE LECTIN-5 - Homo sapiens (Human)	551	329/332 (99%)	330/332 (99%)	2.0e-178
O43699	CD33L1 Protein - Homo sapiens (Human)	442	249/455 (54%)	314/455 (69%)	2.1e-114
O15388	OB BINDING PROTEIN-1 - Homo sapiens (Human)	440	242/455 (53%)	306/455 (67%)	2.6e-107
Q9BYI9	FOAP-9 - Homo sapiens (Human)	463	227/458 (49%)	296/458 (64%)	7.6e-101

15

A multiple sequence alignment is given in Table 9E in a ClustalW analysis comparing NOV9 with related protein sequences disclosed in Table 9D.

Table 9D. ClustalW Analysis of NOV9

1. SEQ ID NO:29, NOV9
2. SEQ ID NO:135, O15389, OB BINDING PROTEIN-2 (SIGLEC5) - (Human)
3. SEQ ID NO:136, AAD50978, SIALIC ACID BINDING IG-LIKE LECTIN-5 - (Human)
4. SEQ ID NO:137, O43699, CD33L1 Protein - Homo sapiens (Human)
5. SEQ ID NO:138, O15388, OB BINDING PROTEIN-1 - Homo sapiens (Human)
6. SEQ ID NO:139, Q9BYI9, FOAP-9 - Homo sapiens (Human)

		10	20	30	40	50
NOV9	MLPL	LLLPL	LWGG	SLOE	RPV	ELQVOKSVTVQEGLCVLVPCSFSPWRS
O15389	MLPL	LLLPL	LWGG	SLOE	RPV	ELQVOKSVTVQEGLCVLVPCSFSPWRS
AAD50978	MLPL	LLLPL	LWGG	SLOE	RPV	ELQVOKSVTVQEGLCVLVPCSFSPWRS
O43699	MLP	LLLPL	LWAGALAG	RRR	OLG	PSLTVQEGLCVLVPCRLPTTLP
O15388	MLP	LLLPL	LWAGALAG	RRR	OLG	PSLTVQEGLCVLVPCRLPTTLP
Q9BYI9	MLL	LLLPL	LWGRERAEG	QTSKLLT	MOSS	SVTVQEGLCVHVPCSFSPSHG
		60	70	80	90	100
NOV9	WYS	SPPL	YVYWF	RGEI	PYYAEV	VATN
O15389	WYS	SPPL	YVYWF	RGEI	PYYAEV	VATN
AAD50978	WYS	SPPL	YVYWF	RGEI	PYYAEV	VATN
O43699	SY	Y	G	YWF	LEG	ADVP
O15388	SY	Y	G	YWF	LEG	ADVP
Q9BYI9	WI	YP	G	PV	YHGYWF	REG
		110	120	130	140	150
NOV9	RKN	CSLS	IGD	ARMED	TG	SYFFR
O15389	RKN	CSLS	IGD	ARMED	TG	SYFFR
AAD50978	RKN	CSLS	IGD	ARMED	TG	SYFFR
O43699	RKN	CSLS	IR	DARR	DN	AYFFR
O15388	RKN	CSLS	IR	DARR	DN	AYFFR
Q9BYI9	T	ENC	IL	S	IR	DARR
		160	170	180	190	200
NOV9	IHF	LEP	LES	GR	P	RL
O15389	IHF	LEP	LES	GR	P	RL
AAD50978	IHF	LEP	LES	GR	P	RL
O43699	I	S	I	P	G	T
O15388	I	S	I	P	G	T
Q9BYI9	I	L	I	P	G	T
		210	220	230	240	250
NOV9	L	T	L	T	P	R
O15389	L	T	L	T	P	R
AAD50978	L	T	L	T	P	R
O43699	L	T	L	T	P	R
O15388	L	T	L	T	P	R

Q9BYI0 LTLIPQPDHGTSLTQVTFPGASVTINRTVHLNVSYPQNLITVTFSGD

260 270 280 290 300

5 NOV9 GIALSILQNTSYLPVLEGOALRLLCDAP---SNPPAH-SWFQGSFALNAT
015389 GIALSILQNTSYLPVLEGOALRLLCDAP---SNPPAHL-SWFQGSFALNAT
AAD50978 GIALSILQNTSYLPVLEGOALRLLCDAP---SNPPAHL-SWFQGSFALNAT
043699 SAAFKILQNTSSLPVLEGOALRLLCDAD---GNPPAHL-SWFQGSFALNAT
015388 SAAFKILQNTSSLPVLEGOALRLLCDAD---GNPPAHL-SWFQGSFALNAT

10 Q9BYI0 GTVSTVILNGSSLSPEGOSLRLLCAVDAVDSEPPARLSLSWRGLTLCPS

310 320 330 340 350

15 NOV9 PISNTGILELRRVRSABEGGFTCRAQHPLGFLQIILNLSV
015389 PISNTGILELRRVRSABEGGFTCRAQHPLGFLQIILNLSVSLPQLLGPS
AAD50978 PISNTGILELRRVRSABEGGFTCRAQHPLGFLQIILNLSVSLPQLLGPS
043699 PISNTGILELRRVRSABEGGFTCRAQHPLGFLQIILNLSVSLPQLLGPS
015388 PISNTGILELRRVRSABEGGFTCRAQHPLGFLQIILNLSVSLPQLLGPS
Q9BYI0 QPSNPGILELRRVRSABEGGFTCRAQHPLGFLQIILNLSVSLPQLLGPS

20 360 370 380 390 400

NOV9
015389 CSWEAEGHLCRCFSFRARPAPSLCWRLEEKPLEGNSSQGSFKVNSSSAGPW
25 AAD50978 CSWEAEGHLCRCFSFRARPAPSLCWRLEEKPLEGNSSQGSFKVNSSSPGPW
043699
015388
Q9BYI0

30 410 420 430 440 450

NOV9
015389 ANSSLILHGGSLDLKVSCKANNIYGSQSGSVLLQGKSNLGTGVVPAAL
35 AAD50978 ANSSLILHGGSLDLKVSCKANNIYGSQSGSVLLQGKSNLGTGVVPAAL
043699
015388
Q9BYI0

40 460 470 480 490 500

NOV9
015389 GGAGYMALCCHCCHIFFLVKARRKQAAAGRPKMDDEDPIMCHI
AAD50978 GGAGYMALCCHCCHIFFLVKARRKQAAAGRPKMDDEDPIMCHI
043699 GGAGYMALCCHCCHIFFLVKARRKQAAAGRPKMDDEDPIMCHI
45 015388 WCASITTLVFLCVCFIFR-VKTRRKQAAQPVNTDDVNPVM
Q9BYI0 GGAGATALLVFLCVCFIFR-VKTRRKQAAQPVNTDDVNPVM

510 520 530 540 550

50 NOV9 VSGSRKHPWPSPGDQSPPGAPPLKEEDELHYASLSFSFMSSEPKD
015389 VSGSRKHPWPSPGDQSPPGAPPLKEEDELHYASLSFSFMSSEPKD
AAD50978 VSGSRKHPWPSPGDQSPPGAPPLKEEDELHYASLSFSFMSSEPKD
043699 VSGSRGHQHQFQTGIVDHPAAGPSEDELHYAVLHFMHPPSEPK
015388 VSGSRGHQHQFQTGIVDHPAAGPSEDELHYAVLHFMHPPSEPK
55 Q9BYI0 SQGPLTEPWAEPSPPDQPPASARSSVG-EGELOVASLSFOMKPPWSESG

560

60 NOV9 QEAPSTTEYSEIKTSK
015389 QEAPSTTEYSEIKTSK
AAD50978 QEAPSTTEYSEIKTSK
043699 ---VTDTEYSEIKIHK
015388 ---VTDTEYSEIKIHK

Domain results for NOV9 were collected from BLAST sample domains found in the Smart and Pfam collections. The disclosed NOV9 polypeptide contains domain IPR003006 at amino acids 50 to 117, and at amino acid positions 262 to 315. This indicates that the NOV9 sequence of the invention has properties similar to those of other proteins known to contain this domain, as well as to the immunoglobulin domain itself. Table 9F lists the domain description.

Table 9F. Domain Analysis of NOV9				
PSSMs producing significant alignments:			Score (bits)	E value
Ig,	Immunoglobulin domain		13.3	0.014
Ig	svsgfgpp.p.vtWlrngk.....			
	+++ ++ +++++ + + ++++++ ++++++ +			
NOV9	50	WYS---SPpLyVYWFRDGEipyyaevvatnnpdrrvkpetqgrfrll		93
Iglslti.svtpeDsgGtYt (SEQ ID NO:140)			
	++ ++++ ++ ++++++ + + +			
NOV9	94	gdvqkknCSLSIgDARMEDT-GSYF 117 (SEQ ID NO:29)		

The OB Binding Protein-2 disclosed in this invention is expressed in at least the following tissues: bone marrow, liver, spleen, lung, and peripheral blood leukocytes. This information was derived by determining the tissue sources of the sequences that were included in the invention. SeqCalling sources, PublicEST sources and publicly available reference material from OMIM and Pubmed.

In addition, the sequence is predicted to be expressed in the following tissues because of the expression pattern of (GENBANK-ID: gb:GENBANK-ID:HSU71383|acc:U71383) a closely related Human OB binding protein-2 (OB-BP2) mRNA, complete cds homolog in species Homo sapiens :activated monocyte.

The protein similarity information, expression pattern, and map location for the OB Binding Protein-2-like protein and nucleic acid disclosed herein suggest that this OB Binding Protein-2 may have important structural and/or physiological functions characteristic of the sialic acid-binding immunoglobulin-like lectins (SIGLECs) family. Therefore, the NOV9 nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. For example, the compositions of the present invention

will have efficacy for treatment of patients suffering from: 3-methylglutaconicaciduria, type III; Charcot-Marie-Tooth disease, type 4F; Colorectal cancer; Cone-rod retinal dystrophy-2; DNA ligase I deficiency; Glutaricaciduria, type IIB; Heart block, progressive familial, type I; Hydatidiform mole; Hyperferritinemia-cataract syndrome; Leber congenital amaurosis due to defect in CRX; Liposarcoma; Myotonic dystrophy; Retinitis pigmentosa, late-onset dominant; Spinocerebellar ataxia-13; T-cell acute lymphoblastic leukemia; Trichothiodystrophy; Xeroderma pigmentosum, group D; Diabetes mellitus, noninsulin-dependent; Polio, susceptibility to; Hemophilia; Hypercoagulation; Idiopathic thrombocytopenic purpura; Immunodeficiencies; Graft versus host; Von Hippel-Lindau (VHL) syndrome; Cirrhosis; Fertility; Systemic lupus erythematosus, Autoimmune disease, Asthma, Emphysema, Scleroderma, allergy, ARDS and other diseases and disorders associated with the like.

The novel nucleic acid encoding the OB binding protein-2-like protein of the invention, or fragments thereof, are useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These materials are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. The disclosed NOV9 protein has multiple hydrophilic regions, each of which can be used as an immunogen. In one embodiment, a contemplated NOV9 epitope is from about amino acids 10 to 30. In another embodiment, a contemplated NOV9 epitope is from about amino acids 40 to 60. In other specific embodiments, contemplated NOV9 epitopes are from about amino acids 60 to 100, 100 to 120, 120 to 140, 145 to 170, 175 to 230, 260 to 290, 290 to 320, and 360 to 450.

NOV10

A disclosed NOV10 nucleic acid of 1811 nucleotides (also referred to as 30675745_0_499_da1) encoding a novel Trypsin-like protein is shown in Table 10A. An open reading frame was identified beginning with a ATG initiation codon at nucleotides 368-370 and ending with a TAG codon at nucleotides 1553-1555. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 10A. The start and stop codons are in bold letters.

Table 10A. NOV10 Nucleotide Sequence (SEQ ID NO:30)

ACAAATCCTTCTGTGAACTCTACTGTGTCAGGCCAGCCTGAGTTCATTTCTCCTTGAGCAGGAACAGTT
 CATGGACGAACCTGAGGACCACTCTGAGGACAAGAGGCATCCAGTGTGATGAGTGGAAACATGACGACATT
 TTATGGCTACAGAGTTAAGGCAAGGGTTGAATTCACGAGTCAAAAAGCAGCCCTTTTCAGAGACCCAAC
 TCTCTGGGGTGCTCAGGGGCTTGGGCTGGATTGAGAAGAAAACGACAAGAGTAAGCTGCCCTCTCTTCT
 CTGGCCATCTCAAAACCACAGTGCAGGGCCAACTGGTCTGCCTCTTTACCACACAGAACCAAGCACTAG
 GGATAAGACAGCTGCCCATGGTGTCCGCGGCGGGTCTCTCTGGGGATGGCAAGATGCCAGGGGTGCTCCT
 GGTGTGCTCGGCCTTCTCTATTCTTCCACCAGTTGTGGGCTCCAGAAAGCTTCCGTTTCTACGGTCTCT
 GACCCCAAGGAGGGCTTGGTCAGCAGCATGGAGTTCCCGTGGGTGGTGTGCTGCAGGACTCCCACTACAC
 CACACCTGGCTTTCGGCTGCATCCTGAGCGAGTTCTGGGTCTCAGCATCGCATCCGCCATTGAGAACAG
 GAAGGACATTGTGCTTATAGTGGGTATAAGTAACATGGATCCTAGCAAGATTGCTCACACAGAGTATCCA
 GTCATACCATCATCATCCATGAGGACTTTGATAACAACTCCATGAGCAACAACATAGCCCTCCTGAAGA
 CAGACACAGCGATGCATTTTGGCAACCTGGTCCAGTCCATCTGCTTCTCCTCGGCAGAAATGCTGCATACACC
 ACCAGTCTTGCAAGAACTGCTGGGTGTGAGGATGGAATCCACATCTGCAACAGGAAATCAATGACGATG
 AGTGTCTGAGGAAATCTTGTGAAAGATCTTGACATGTGTCCCTATACAACTCCAGAAGACAGAAT
 GCGGCAGCCACACGAAAGAGGAAACCAAGACTGCCTGCTTGGGGGACCCAGGAAGCCCAATGATGTGCCA
 GCTACAGCAGTTCGATCTGTGGGTTCTGAGAGGAATCCTGAACTTCGGTGGTGAGACGTGCCCTGGCCTG
 TTTCTGTACACCAAGGTGGAAGACTACAGCAAAATGGATCAGATCCAAGGCTGAGAGGGCCGGCCTCCCC
 TGTCTCTACTCCACCCTGGGAAAAGTTGATTTCTTCTCCACCATGGACCAATGCCGCCATGACACA
 GAAGACATATTTGATTCGAACTGGGCCATGTTGGATCACTTGCAGGGACAAAGAAAGGACCATCAGC
 CATTACGACTAGGAAACAGCTCTAGAGATAGTCTAGATGTTAGGGAGAAGGATGTAAAGGAATCAGGCA
 GGTCTCCTGAGGCGTCTGTACAACCCCTTATACTATGACTATTACGGTGGGGAGGTGGGGGAAGGTAGGAT
 TTTTGCAGGTACAGAACAGGTTGTATCAGCCCGAAGAAATCATCTTGGTTTCTTCTCGTCTTGTCTTTCTT
 TGCAGCAGTATCTAGTCCAGGAGTACCCCAACAACTGAAGAGTAAACTGAGAATGCTGAGTGCCAGGC
 ATTCAACCATGCTGTTTTGATGTCGTGTTTTGATAGTTGCACACTGGGGCTGCCACGGATAAGCCCATGGC
 ATACACTGGGCTGGCTCTCCCTCTCTATCCCTCTCCAGGTGTGGGAAGGTCACTTTCACTATGCTTGT
 GAACTAAATGCTGGCTAACAAGTGTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

The disclosed NOV10 nucleic acid sequence maps to chromosome 16 and has 1129 of
 1129 bases (100%) identical to a gb:GENBANK-ID:HSM802210|acc:AL137484 mRNA from
Homo sapiens (*Homo sapiens* mRNA; cDNA DKFZp434I2330 (from clone
 5 DKFZp434I2330); partial cds).

A disclosed NOV10 protein (SEQ ID NO:31) encoded by SEQ ID NO:30 has 395
 amino acid residues, and is presented using the one-letter code in Table 10B. Signal P, Psort
 and/or Hydropathy results predict that NOV10 contains a signal peptide, and is likely to be
 localized extracellularly with a certainty of 0.9190. The most likely cleavage site for a NOV10
 10 peptide is between amino acids 30 and 31, at: TSC-GV.

Table 10B. Encoded NOV10 protein sequence (SEQ ID NO:31).

MVSAA³LSGDGKMRGVLLVLLGLLYSSTSCGVQKASVFYGPDPKEGLVSSMEFPWVVS¹LQDSQYTHLAFG
 CILSEFWVLSIASAIQNRKD¹IVVIVGISNMDPSKIAHTY¹PVNTII¹IHEDFDNNSMSNNIAL¹LKTD¹TAMH
 FGNLVQ¹SICFLGRMLHT¹PPVLQNCWVSGWNPTSATGNHMTMSVLRKIFVKDLDMCPLYKLQKTECGSHTK
 EETK¹TACLDGDPGSPMMCQLQ¹QFDLWVLRGILNFGGETCPGLFLYTKVEDYSKWITSKAERAGPPLSLHH
 WEKLI¹SFHHGFPNAAMTQK¹TYSDSELGHVGSYLQ¹QRRIT¹HSRLGNSSRDSL¹DVREKDVKESGRSPEAS
 VQPLYDYDGGEVGEGRIFAGQNRLYQPEEII¹LVSFVLVFFCSSI

Additional SNP variants of NOV10 are disclosed in Example 3. The NOV10 amino
 acid sequence has 79 of 263 amino acid residues (30%) identical to, and 128 of 263 amino
 15 acid residues (48%) similar to, the 269 amino acid residue ptrn:SWISSPROT-ACC:Q29461
 protein from *Bos taurus* (Bovine) [ELASTASE 2 PRECURSOR (EC 3.4.21.71)].

NOV10 is expressed in at least the testis because of the expression pattern of a closely related homolog [(GENEBANK-ID: gb:GENEBANK-ID:HSM802210|acc:AL137484) (*Homo sapiens* mRNA; cDNA DKFZp434I2330 (from clone DKFZp434I2330)]. Additional sites of tissue expression for NOV10 are disclosed in Example 1.

NOV10 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 10C.

Table 10C. BLAST results for NOV10					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 11360059 pir T46470;gi 6808103 emb CAB70765.1 (AL137484)	hypothetical protein DKFZp434I2330 .1 - human (fragment) [<i>Homo sapiens</i>]	290	278/290 (95%)	278/290 (95%)	e-167
gi 14775106 ref X P_048011.1	hypothetical protein XP_048011 [<i>Homo sapiens</i>]	270	256/270 (94%)	257/270 (94%)	e-153
gi 12838178 dbj B AB24114.1 (AK005546)	putative [<i>Mus musculus</i>]	624	73/235 (31%)	108/235 (45%)	3e-17
gi 12839985 dbj BAB 24725.1 (AK006746)	putative [<i>Mus musculus</i>]	326	77/266 (28%)	128/266 (47%)	7e-17
gi 13811665 gb AA K40233.1 AF356627 _1 (AF356627)	coagulation factor XI [<i>Mus musculus</i>]	624	72/235 (30%)	107/235 (44%)	1e-16

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 10D.

Table 10D. ClustalW Analysis of NOV10

- 1) NOV10 (SEQ ID NO:31)
- 2) gi|11360059|pir|| T46470; gi|6808103|emb| CAB70765.1| (AL137484) hypothetical protein DKFZp434I2330.1- [*Homo sapiens*] (SEQ ID NO:141)
- 3) gi|14775106|ref| XP_048011.1| hypothetical protein XP_048011 [*Homo sapiens*] (SEQ ID NO:142)
- 4) gi|12838178|dbj| BAB24114.1 | (AK005546) putative [*Mus musculus*] (SEQ ID NO:143)
- 5) gi|12839985|dbj|BAB24725.1| (AK006746) coagulation factor XI [*Mus musculus*] (SEQ ID NO:144)
- 6) gi|13811665|gb|AAK40233.1|AF356627_1 (AF356627) coagulation factor XI [*Mus musculus*] (SEQ ID NO:145)

	10	20	30	40	50
NOV10	MVSAAGLSGDKMRGVLLVLLGLLYSSSTSCGVQKASVFYGPDPKEGLVSS			
gi 1136005	----- ----- ----- ----- ----- ----- ----- ----- ----- -----				
gi 1477510	----- ----- ----- ----- ----- ----- ----- ----- ----- -----				
gi 1283817	----- ----- ----- ----- ----- ----- ----- ----- ----- -----	-----MTSLHQVLYFIFFASVSSECVTKVFKDISFQGGDLSTVFTPS			
gi 1283998	----- ----- ----- ----- ----- ----- ----- ----- ----- -----				
gi 1381166	----- ----- ----- ----- ----- ----- ----- ----- ----- -----	-----MTSLHQVLYFIFFASVSSECVTKVFKDISFQGGDLSTVFTPS			

5
10
15
20
25
30
35
40
45
50
55
60
65
70

NOV10
gi|1136005
gi|1477510
gi|1283817
gi|1283998
gi|1381166

MEFPWVVS LQDSQYTHLAFGCILS-----EFWVLSIASAIONRKDIVVIV

ATYCR LVCTHHP RCLLFTFMAESSSDPTKWFACILKDSVTEILPMVNMT
-----MCRQPMKRWK
ATYCR LVCTHHP RCLLFTFMAESSSDPTKWFACILKDSVTEILPMVNMT

110 120 130 140 150

NOV10
gi|1136005
gi|1477510
gi|1283817
gi|1283998
gi|1381166

GISNMDPSKIAHTEYPVNTIIIHEDFNNSMSNNIALLKTD-----
-----AHTEYPVNTIIIHEDFNNSMSNNIALLKTD-----
-----MSNNIALLKTD-----
GAISGYSFKQCPQQLSTCSKDVYVNLDMKGMNYNSSVVKNAARECQERCTD
DRRTGLLLPLVLLLFGACSSLAWVCG--RRMSRSQQQLNNAS-----
GAISGYSFKQCPQQLSTCSKDEYVNLDMKGMNYNSSVVKNAARECQERCTD

160 170 180 190 200

NOV10
gi|1136005
gi|1477510
gi|1283817
gi|1283998
gi|1381166

DAHCFQFTYATGYFPSVDHRKMCLLKYTRTGTPTTITKLNGVVSGFSLKS

DAHCFQFTYATGYFPSVDHRKMCLLKYTRTGTPTTITKLNGVVSGFSLKS

210 220 230 240 250

NOV10
gi|1136005
gi|1477510
gi|1283817
gi|1283998
gi|1381166

-----TAMHFGNLVQSICFLGR-----
-----TAMHFGNLVQSICFLGR-----
-----TAMHFGNLVQSICFLGR-----
CGLSNLACIRDIFPNTVLADLNIDSVAPDAFVCRICTHPTCLFFTF
-----AIVEGK--PASAIVEG-----
CGLSNLACIRDIFPNTVLADLNIDSVAPDAFVCRICTHPTCLFFTF

260 270 280 290 300

NOV10
gi|1136005
gi|1477510
gi|1283817
gi|1283998
gi|1381166

-----MLHTPP-----VLQNCWVSC--WN
-----MLHTPP-----VLQNCWVSC--WN
-----MLHTPP-----VLQNCWVSC--WN
SQAWPKESQRHLCLLKTSESGLPSTRITKSHALSGFSLQHCRHSVPVFCH
-----KPAN-----ILEFPWHVC-----
SQAWPKESQRHLCLLKTSESGLPSTRITKIHALSGFSLQHCRHSVPVFCH

310 320 330 340 350

NOV10
gi|1136005
gi|1477510
gi|1283817
gi|1283998
gi|1381166

PTSATGNHMTMSVLRKIFVKOLDMCPYKLOKTECGSHTKEETKTAC---
PTSATGNHMTMSVLRKIFVKOLDMCPYKLOKTECGSHTKEETKTAC---
PTSATGNHMTMSVLRKIFVKOLDMCPYKLOKTECGSHTKEETKTAC---
PSFYNDTDFLGEEDDIVDVKGQETCQKCTCTNNARCOFFTYYP SHRLQNER
-----TMNHGSHLCGGSILN-----EWWVLSASHCFD---
PSFYNDTDFLGEEDDIVDVKGQETCQKCTCTNNARCOFFTYYP SHRLQNER

360 370 380 390 400

NOV10
gi|1136005
gi|1477510
gi|1283817
gi|1283998
gi|1381166

-----LGDPGSP-----MMCOLO-----QFDLWVLR
-----LGDPGSP-----MMCOLO-----QFDLWVLR
-----LGDPGSP-----MMCOLO-----QFDLWVLR
NRRGR CYLK LSSNGSPTRILHGRGGISGYSLRLCKMDNVCTTKINPRVVG
-----QLNN--SKLEITHGT
NRRGR CYLK LSSNGSPTRILHGRGGISGYSLRLCKMDNVCTTKINPRVVG

410 420 430 440 450

NOV10
gi|1136005
gi|1477510
gi|1283817
gi|1283998

GILNFGCETCPGLFLYTKVEDYS-----KWITSKAERAG--PPLSSLH
GILNFGCETCPGLFLYTKVEDYS-----KWITSKAERAG--PPLSSLH
GVLNFGCETCPGLFLYTKVEDYS-----KWITSKAERAG--PPLSSLH
GAASVHGEPWQVTLHISQGHLCGGSIIIGNQWILTAHCFSGIETPKKLR
EDLSTKGIKYQVKDKFLHPKFD-----DQLLDNDIALLLKSPILNS

	gi 1381166	CAASVHCENPWQVTHISQGHLCGGSIIIGNQHTLTAAHCFSGIETPKNR
		460 470 480 490 500
5	NOV10	HWEKLSFSHHGP-----NAAMTQKTYSDSELG
	gi 1136005	HWEKLSFSHHGP-----NAAMTQKTYSDSELG
	gi 1477510	HWEKLSFSHHGP-----NATMTQKTYSDSELG
	gi 1283817	VYGGIVNOSEINEGTAFFRVQEMIIHDOYTTABSCYDIALLKLESAMNYT
	gi 1283998	VNRIPCTSEISD-----IQAWRNCWVTGWC
10	gi 1381166	VYGGIVNOSEINEGTAFREQEMIIHDOYTTABSCYDIALLKLESAMNYT
		510 520 530 540 550
	NOV10	-----EVGSYLOQ-----RRITHSRLGNSSRD
15	gi 1136005	-----EVGSYLOQ-----RRITHSRLGNSSRD
	gi 1477510	-----EVGSYLOQ-----RRITHSRLGNSSRD
	gi 1283817	DFQRPICLPSKGRNAVETECWVTGWYTALRGEVQSLQAKVPLVSN
	gi 1283998	-----ITNTSEKGVQ-----PTILQAVKVDLYRW
20	gi 1381166	DFQRPICLPSKGRNAVETECWVTGWYTALRGEVQSLQAKVPLVSN
		560 570 580 590 600
	NOV10	SLDVREK-----DVKESSR--SPEASVQPLYDYDYG--GEV
	gi 1136005	SLDVREK-----DVKESSR--SPEASVQPLYDYDYG--GEV
25	gi 1477510	SLDVREK-----DVKESSR--SPEASVQPLYDYDYG--GEV
	gi 1283817	ECQTRYRRHKITNKMICAGYKECKDKTCKGDSGGPLSCKNNGV--WHLV
	gi 1283998	WCGYILS--LLTKNMLCAGTQDPCKDACQGDSSGALVCNKRNTAIWYQV
	gi 1381166	ECQTRYRRHKITNKMICAGYKECKDKTCKGDSGGPLSCKNNGV--WHLV
30		610 620 630 640 650
	NOV10	GEGRIFACONRLYQPEEIIILVSFVLVFFCSSI
	gi 1136005	GEGRIFACONRLYQPEEIIILVSFVLVFFCSSI
	gi 1477510	GEGRIFACONRLYQPEEIIILVSFVLVFFCSSI
35	gi 1283817	GITSWGECCGQKERPGVYTNVAKYVDWILEKTQTV
	gi 1283998	GIVSWGMCCKGNLPGVYTKVSHYVRWISKQTAKAGRPYMYEQNSACPLV
	gi 1381166	GITSWGECCGQKERPGVYTNVAKYVDWILEKTQTV
40		660
	NOV10	-----
	gi 1136005	-----
	gi 1477510	-----
	gi 1283817	-----
45	gi 1283998	LSCRAILFLYFVMFLLT
	gi 1381166	-----

Table 10E lists the domain description from DOMAIN analysis results against NOV10. This indicates that the NOV10 sequence has properties similar to those of other proteins known to contain this domain.

Table 10E Domain Analysis of NOV10

gnl|Pfam|pfam00089, trypsin, Trypsin (SEQ ID NO: 146)
Length = 217 residues, 95.4% aligned
Score = 90.5 bits (223), Expect = 1e-19

NOV10:	52	EFPWVVSLODSQYTHLAFGCILSEFVWLSIASAIQNRKDIVVIVGISNMDPSKIAHTEYP	111
		++ + + + ++ + ++ ++	
00089:	11	SFPWQVSLQVSS-GHFCGGSLSISENVLTAAHCVSGASSVRVVLGEHNLGTTEGTQKFD	69
NOV10:	112	VNTIIIHEDFDNNSMSNNIALLKTDAMHFGNLVQSICFLGRMLHTPPVLQNCWVSGWNP	171

```

      ~  ||+|  +++ +  +|+|||  + +  |+ |+ ||  ||  || |||
00089:  70  VKKIIVHFNINPD--TNDIALLLKLSPTVLGDTVRPIC-LPSASSDLFVGTTCSVSGWGR  126
5      NOV10:  172  TSATGNHMTMSVLKRFVKDLDMC----PLYKLQKTECGSHTKEETKTACLGDGPGSPMMC  227
      |  |  |  +  +  +  +  |  |  |  || || |  |++|
00089:  127  TKNLGTSDTLQEV-VVPIVSRETCSRAYSAGGTVIDTMI--GALGGKDACQDGGGPLVC  183
      NOV10:  228  QLQOFDLWVLRGILNFGGETCPG---LFLYTKVEDYSKWI  264  (SEQ ID NO:31)
      +  |  ||  |  |  +||+|  |  ||
10      00089:  184  SDGE-----LVGI-VSWGYCAVGNYPGVYTRVSRYLWDI  217  (SEQ ID NO:147)

```

Proteins with gnl|Pfam|pfam00089 Trypsin-like domains include all the proteins in families S1, S2A, S2B, S2C, and S5 in the classification of peptidases. Also included are proteins that are clearly members, but that lack peptidase activity, such as haptoglobin and protein Z (PRTZ*).

Trypsin-Like Proteases may act as metastatic agents in certain cancers, e.g., breast cancer. The ability of tumors to metastasize from their original location to the brain, bone and lymphatic tissue, is not well addressed by current therapies. Normal cells exist in contact with a complex protein network, called the extracellular matrix (ECM). The ECM is a barrier to cell movement and cancer cells must devise ways to break their attachments, degrade, and move through the ECM in order to metastasize. Proteases are enzymes that degrade other proteins and have long been thought to aid in freeing the tumor cells from their original location by chewing up the ECM. Recent studies have suggested that they may promote cell shape changes and motility through the activation of a protein in the tumor cell membrane called Protease-Activated Receptor-2 (PAR2). This leads to a cascade of intracellular reactions that activates the motility apparatus of the cell. Thus, the ECM-degrading proteases serve two functions by, (1) reducing the extracellular resistance to cell movement, and (2) activating the motility processes inside of cells through specific receptors.

The above defined information for NOV10 suggests that this protein may function as a member of a Trypsin-like protein family. Therefore, the NOV10 nucleic acids and proteins of the invention are useful in potential therapeutic and diagnostic applications. For example, a cDNA encoding the NOV10 protein may be useful in gene therapy, and the NOV10 protein may be useful when administered to a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from cancers. The NOV10 nucleic acid encoding Trypsin-like protein, and the Trypsin-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These proteins and nucleic acids are further useful in the generation of antibodies for use in therapeutic or diagnostic methods.

These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. The disclosed NOV10 protein has multiple hydrophilic regions, each of which can be used as an immunogen. In one embodiment, a contemplated NOV10 epitope is from about amino acids 25 to 65. In another embodiment, a NOV10 epitope is from about amino acids 85 to 135. In further specific embodiments, NOV10 epitopes are from about amino acids 155 to 180, from about amino acids 185 to 220 and from about amino acids 235 to 350.

NOVX Nucleic Acids and Polypeptides

One aspect of the invention pertains to isolated nucleic acid molecules that encode NOVX polypeptides or biologically active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify NOVX-encoding nucleic acids (*e.g.*, NOVX mRNAs) and fragments for use as PCR primers for the amplification and/or mutation of NOVX nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA), RNA molecules (*e.g.*, mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA.

An NOVX nucleic acid can encode a mature NOVX polypeptide. As used herein, a "mature" form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product, encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product "mature" form arises, again by way of nonlimiting example, as a result of one or more naturally occurring processing steps as they may take place within the cell, or host cell, in which the gene product arises. Examples of such processing steps leading to a "mature" form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF, or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal

sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to residue N remaining. Further as used herein, a "mature" form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristoylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.

The term "probes", as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), 100 nt, or as many as approximately, *e.g.*, 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and much slower to hybridize than shorter-length oligomer probes. Probes may be single- or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

The term "isolated" nucleic acid molecule, as utilized herein, is one, which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5'- and 3'-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOVX nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (*e.g.*, brain, heart, liver, spleen, etc.). Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the invention, *e.g.*, a nucleic acid molecule having the nucleotide sequence SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30, or a complement of this aforementioned nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30 as a hybridization probe, NOVX molecules can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook, *et al.*, (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2nd Ed., Cold Spring Harbor Laboratory

Press, Cold Spring Harbor, NY, 1989; and Ausubel, *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.)

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NOVX nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue.

Oligonucleotides comprise portions of a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30, or a complement thereof. Oligonucleotides may be chemically synthesized and may also be used as probes.

In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30, or a portion of this nucleotide sequence (*e.g.*, a fragment that can be used as a probe or primer or a fragment encoding a biologically-active portion of an NOVX polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence shown NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, or 30 is one that is sufficiently complementary to the nucleotide sequence shown NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, or 30 that it can hydrogen bond with little or no mismatches to the nucleotide sequence shown SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30 thereby forming a stable duplex.

As used herein, the term "complementary" refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term "binding" means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct

or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.

5 Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, respectively, and are at most some portion less than a full length sequence.

Fragments may be derived from any contiguous portion of a nucleic acid or amino acid
10 sequence of choice. Derivatives are nucleic acid sequences or amino acid sequences formed from the native compounds either directly or by modification or partial substitution. Analogs are nucleic acid sequences or amino acid sequences that have a structure similar to, but not identical to, the native compound but differs from it in respect to certain components or side chains. Analogs may be synthetic or from a different evolutionary origin and may have a
15 similar or opposite metabolic activity compared to wild type. Homologs are nucleic acid sequences or amino acid sequences of a particular gene that are derived from different species.

Derivatives and analogs may be full length or other than full length, if the derivative or analog contains a modified nucleic acid or amino acid, as described below. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to,
20 molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of
25 hybridizing to the complement of a sequence encoding the aforementioned proteins under stringent, moderately stringent, or low stringent conditions. *See e.g.* Ausubel, *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below.

A "homologous nucleic acid sequence" or "homologous amino acid sequence," or variations thereof, refer to sequences characterized by a homology at the nucleotide level or
30 amino acid level as discussed above. Homologous nucleotide sequences encode those sequences coding for isoforms of NOVX polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for an NOVX polypeptide of

species other than humans, including, but not limited to: vertebrates, and thus can include, e.g., frog, mouse, rat, rabbit, dog, cat, cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the exact nucleotide sequence encoding human NOVX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30, as well as a polypeptide possessing NOVX biological activity. Various biological activities of the NOVX proteins are described below.

An NOVX polypeptide is encoded by the open reading frame ("ORF") of an NOVX nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG "start" codon and terminates with one of the three "stop" codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a *bona fide* cellular protein, a minimum size requirement is often set, e.g., a stretch of DNA that would encode a protein of 50 amino acids or more.

The nucleotide sequences determined from the cloning of the human NOVX genes allows for the generation of probes and primers designed for use in identifying and/or cloning NOVX homologues in other cell types, e.g. from other tissues, as well as NOVX homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30; or an anti-sense strand nucleotide sequence of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30; or of a naturally occurring mutant of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30.

Probes based on the human NOVX nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe further comprises a label group attached thereto, e.g. the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which mis-express an NOVX protein, such as by measuring a level of an NOVX-encoding nucleic acid in

a sample of cells from a subject *e.g.*, detecting NOVX mRNA levels or determining whether a genomic NOVX gene has been mutated or deleted.

"A polypeptide having a biologically-active portion of an NOVX polypeptide" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a "biologically-active portion of NOVX" can be prepared by isolating a portion SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30, that encodes a polypeptide having an NOVX biological activity (the biological activities of the NOVX proteins are described below), expressing the encoded portion of NOVX protein (*e.g.*, by recombinant expression *in vitro*) and assessing the activity of the encoded portion of NOVX.

NOVX Nucleic Acid and Polypeptide Variants

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences shown in SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30 due to degeneracy of the genetic code and thus encode the same NOVX proteins as that encoded by the nucleotide sequences shown in SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31.

In addition to the human NOVX nucleotide sequences shown in SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the NOVX polypeptides may exist within a population (*e.g.*, the human population). Such genetic polymorphism in the NOVX genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame (ORF) encoding an NOVX protein, preferably a vertebrate NOVX protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOVX genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the NOVX polypeptides, which are the result of natural allelic variation and that do not alter the functional activity of the NOVX polypeptides, are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding NOVX proteins from other species, and thus that have a nucleotide sequence that differs from the human SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30 are intended to be within the scope of the

invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOVX cDNAs of the invention can be isolated based on their homology to the human NOVX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.

Homologs (*i.e.*, nucleic acids encoding NOVX proteins derived from species other than human) or other related sequences (*e.g.*, paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

As used herein, the phrase "stringent hybridization conditions" refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5 °C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at T_m , 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes, primers or oligonucleotides (*e.g.*, 10 nt to 50 nt) and at least about 60°C for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

Stringent conditions are known to those skilled in the art and can be found in Ausubel, *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C, followed by one or more washes in 0.2X SSC, 0.01% BSA at 50°C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequences SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (*e.g.*, encodes a natural protein).

In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55°C, followed by one or more washes in 1X SSC, 0.1% SDS at 37°C. Other conditions of moderate stringency that may be used are well-known within the art. *See, e.g.*, Ausubel, *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.

In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40°C, followed by one or more washes in 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50°C. Other conditions of low stringency that may be used are well known in the art (*e.g.*, as employed for cross-species hybridizations). *See, e.g.*, Ausubel, *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY

Conservative Mutations

5 In addition to naturally-occurring allelic variants of NOVX sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30, thereby leading to changes in the amino acid sequences of the encoded NOVX proteins, without altering the functional ability of said NOVX proteins. For example, 10 nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequences of the NOVX proteins without altering their biological activity, whereas an "essential" amino acid residue is required for such biological activity. For example, amino 15 acid residues that are conserved among the NOVX proteins of the invention are predicted to be particularly non-amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art.

Another aspect of the invention pertains to nucleic acid molecules encoding NOVX proteins that contain changes in amino acid residues that are not essential for activity. Such 20 NOVX proteins differ in amino acid sequence from SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30 yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 45% homologous to the amino acid sequences SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31. Preferably, 25 the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31; more preferably at least about 70% homologous SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31; still more preferably at least about 80% homologous to SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31; even more preferably at least about 90% homologous to SEQ ID 30 NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31; and most preferably at least about 95% homologous to SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31.

An isolated nucleic acid molecule encoding an NOVX protein homologous to the protein of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31 can be created

by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

5 Mutations can be introduced into SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted, non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue
10 having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine,
15 methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted non-essential amino acid residue in the NOVX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an NOVX coding sequence, such as by saturation
20 mutagenesis, and the resultant mutants can be screened for NOVX biological activity to identify mutants that retain activity. Following mutagenesis SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

The relatedness of amino acid families may also be determined based on side chain
25 interactions. Substituted amino acids may be fully conserved "strong" residues or fully conserved "weak" residues. The "strong" group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the "weak" group of conserved residues may be any one
30 of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, VLIM, HFY, wherein the letters within each group represent the single letter amino acid code.

In one embodiment, a mutant NOVX protein can be assayed for (i) the ability to form protein:protein interactions with other NOVX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant NOVX protein

and an NOVX ligand; or (iii) the ability of a mutant NOVX protein to bind to an intracellular target protein or biologically-active portion thereof; (e.g. avidin proteins).

In yet another embodiment, a mutant NOVX protein can be assayed for the ability to regulate a specific biological function (e.g., regulation of insulin release).

5 Antisense Nucleic Acids

Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a
10 nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein (e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire NOVX coding strand, or to only a portion thereof. Nucleic acid molecules
15 encoding fragments, homologs, derivatives and analogs of an NOVX protein of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31, or antisense nucleic acids complementary to an NOVX nucleic acid sequence of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30, are additionally provided.

In one embodiment, an antisense nucleic acid molecule is antisense to a "coding
20 region" of the coding strand of a nucleotide sequence encoding an NOVX protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding the NOVX protein. The term "noncoding region" refers to 5' and 3' sequences which
25 flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding the NOVX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary
30 to the entire coding region of NOVX mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOVX mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOVX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention

can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (*e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used).

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)_w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an NOVX protein to thereby inhibit expression of the protein (*e.g.*, by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (*e.g.*, by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell

surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

5 In yet another embodiment, the antisense nucleic acid molecule of the invention is an α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other. *See, e.g., Gaultier, et al., 1987. Nucl. Acids Res. 15: 6625-6641.* The antisense nucleic acid molecule can also comprise a
10 2'-o-methylribonucleotide (*See, e.g., Inoue, et al. 1987. Nucl. Acids Res. 15: 6131-6148*) or a chimeric RNA-DNA analogue (*See, e.g., Inoue, et al., 1987. FEBS Lett. 215: 327-330.*

Ribozymes and PNA Moieties

Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These
15 modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of
20 cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (*e.g., hammerhead ribozymes as described in Haselhoff and Gerlach 1988. Nature 334: 585-591*) can be used to catalytically cleave NOVX mRNA transcripts to thereby inhibit translation of NOVX mRNA. A ribozyme having specificity for an NOVX-encoding nucleic acid can be designed based upon the nucleotide
25 sequence of an NOVX cDNA disclosed herein (*i.e., SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30*). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an NOVX-encoding mRNA. *See, e.g., U.S. Patent 4,987,071 to Cech, et al. and U.S. Patent 5,116,742 to Cech, et al.* NOVX mRNA can also be
30 used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. *See, e.g., Bartel et al., (1993) Science 261:1411-1418.*

Alternatively, NOVX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOVX nucleic acid (*e.g., the NOVX promoter and/or enhancers*) to form triple helical structures that prevent transcription of the

NOVX gene in target cells. *See, e.g.,* Helene, 1991. *Anticancer Drug Des.* 6: 569-84; Helene, *et al.* 1992. *Ann. N.Y. Acad. Sci.* 660: 27-36; Maher, 1992. *Bioassays* 14: 807-15.

In various embodiments, the NOVX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g.,* the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. *See, e.g.,* Hyrup, *et al.*, 1996. *Bioorg Med Chem* 4: 5-23. As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics (*e.g.,* DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, *et al.*, 1996. *supra*; Perry-O'Keefe, *et al.*, 1996. *Proc. Natl. Acad. Sci. USA* 93: 14670-14675.

PNAs of NOVX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, *e.g.,* inducing transcription or translation arrest or inhibiting replication. PNAs of NOVX can also be used, for example, in the analysis of single base pair mutations in a gene (*e.g.,* PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, *e.g.,* S₁ nucleases (*See, Hyrup, et al.*, 1996. *supra*); or as probes or primers for DNA sequence and hybridization (*See, Hyrup, et al.*, 1996, *supra*; Perry-O'Keefe, *et al.*, 1996. *supra*).

In another embodiment, PNAs of NOVX can be modified, *e.g.,* to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NOVX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (*e.g.,* RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (*see, Hyrup, et al.*, 1996. *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, *et al.*, 1996. *supra* and Finn, *et al.*, 1996. *Nucl Acids Res* 24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, *e.g.,* 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine

phosphoramidite, can be used between the PNA and the 5' end of DNA. *See, e.g., Mag, et al., 1989. Nucl Acid Res 17: 5973-5988.* PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment. *See, e.g., Finn, et al., 1996. supra.* Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. *See, e.g., Petersen, et al., 1975. Bioorg. Med. Chem. Lett. 5: 1119-11124.*

In other embodiments, the oligonucleotide may include other appended groups such as peptides (*e.g., for targeting host cell receptors in vivo*), or agents facilitating transport across the cell membrane (*see, e.g., Letsinger, et al., 1989. Proc. Natl. Acad. Sci. U.S.A. 86: 6553-6556; Lemaitre, et al., 1987. Proc. Natl. Acad. Sci. 84: 648-652; PCT Publication No. WO88/09810*) or the blood-brain barrier (*see, e.g., PCT Publication No. WO 89/10134*). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (*see, e.g., Krol, et al., 1988. BioTechniques 6:958-976*) or intercalating agents (*see, e.g., Zon, 1988. Pharm. Res. 5: 539-549*). To this end, the oligonucleotide may be conjugated to another molecule, *e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.*

NOVX Polypeptides

A polypeptide according to the invention includes a polypeptide including the amino acid sequence of NOVX polypeptides whose sequences are provided in SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown in SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31 while still encoding a protein that maintains its NOVX activities and physiological functions, or a functional fragment thereof.

In general, an NOVX variant that preserves NOVX-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.

One aspect of the invention pertains to isolated NOVX proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOVX antibodies. In

one embodiment, native NOVX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOVX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, an NOVX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOVX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of NOVX proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language "substantially free of cellular material" includes preparations of NOVX proteins having less than about 30% (by dry weight) of non-NOVX proteins (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-NOVX proteins, still more preferably less than about 10% of non-NOVX proteins, and most preferably less than about 5% of non-NOVX proteins. When the NOVX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the NOVX protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins having less than about 30% (by dry weight) of chemical precursors or non-NOVX chemicals, more preferably less than about 20% chemical precursors or non-NOVX chemicals, still more preferably less than about 10% chemical precursors or non-NOVX chemicals, and most preferably less than about 5% chemical precursors or non-NOVX chemicals.

Biologically-active portions of NOVX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the NOVX proteins (*e.g.*, the amino acid sequence shown in SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31) that include fewer amino acids than the full-length NOVX proteins, and exhibit at least one activity of an NOVX protein. Typically, biologically-active

portions comprise a domain or motif with at least one activity of the NOVX protein. A

biologically-active portion of an NOVX protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acid residues in length.

Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOVX protein.

In an embodiment, the NOVX protein has an amino acid sequence shown SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31. In other embodiments, the NOVX protein is substantially homologous to SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31, and retains the functional activity of the protein of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the NOVX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31, and retains the functional activity of the NOVX proteins of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31.

Determining Homology Between Two or More Sequences

To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (*i.e.*, as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity").

The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. *See*, Needleman and Wunsch, 1970. *J Mol Biol* 48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence shown in SEQ ID NOS: 1, 3, 5, 7, 9,

11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30. The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (*i.e.*, the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.

Chimeric and Fusion Proteins

The invention also provides NOVX chimeric or fusion proteins. As used herein, an NOVX "chimeric protein" or "fusion protein" comprises an NOVX polypeptide operatively-linked to a non-NOVX polypeptide. An "NOVX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to an NOVX protein SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31, whereas a "non-NOVX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the NOVX protein, *e.g.*, a protein that is different from the NOVX protein and that is derived from the same or a different organism. Within an NOVX fusion protein the NOVX polypeptide can correspond to all or a portion of an NOVX protein. In one embodiment, an NOVX fusion protein comprises at least one biologically-active portion of an NOVX protein. In another embodiment, an NOVX fusion protein comprises at least two biologically-active portions of an NOVX protein. In yet another embodiment, an NOVX fusion protein comprises at least three biologically-active portions of an NOVX protein. Within the fusion protein, the term "operatively-linked" is intended to indicate that the NOVX polypeptide and the non-NOVX polypeptide are fused in-frame with one another. The non-NOVX polypeptide can be fused to the N-terminus or C-terminus of the NOVX polypeptide.

In one embodiment, the fusion protein is a GST-NOVX fusion protein in which the NOVX sequences are fused to the C-terminus of the GST (glutathione S-transferase)

sequences. Such fusion proteins can facilitate the purification of recombinant NOVX polypeptides.

In another embodiment, the fusion protein is an NOVX protein containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, mammalian host cells), expression and/or secretion of NOVX can be increased through use of a heterologous signal sequence.

In yet another embodiment, the fusion protein is an NOVX-immunoglobulin fusion protein in which the NOVX sequences are fused to sequences derived from a member of the immunoglobulin protein family. The NOVX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between an NOVX ligand and an NOVX protein on the surface of a cell, to thereby suppress NOVX-mediated signal transduction *in vivo*. The NOVX-immunoglobulin fusion proteins can be used to affect the bioavailability of an NOVX cognate ligand. Inhibition of the NOVX ligand/NOVX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (*e.g.* promoting or inhibiting) cell survival. Moreover, the NOVX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOVX antibodies in a subject, to purify NOVX ligands, and in screening assays to identify molecules that inhibit the interaction of NOVX with an NOVX ligand.

An NOVX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, *e.g.*, by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (*see, e.g.*, Ausubel, *et al.* (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide). An NOVX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOVX protein.

NOVX Agonists and Antagonists

The invention also pertains to variants of the NOVX proteins that function as either NOVX agonists (*i.e.*, mimetics) or as NOVX antagonists. Variants of the NOVX protein can be generated by mutagenesis (*e.g.*, discrete point mutation or truncation of the NOVX protein).

5 An agonist of the NOVX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOVX protein. An antagonist of the NOVX protein can inhibit one or more of the activities of the naturally occurring form of the NOVX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NOVX protein. Thus, specific
10 biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOVX proteins.

Variants of the NOVX proteins that function as either NOVX agonists (*i.e.*, mimetics)
15 or as NOVX antagonists can be identified by screening combinatorial libraries of mutants (*e.g.*, truncation mutants) of the NOVX proteins for NOVX protein agonist or antagonist activity. In one embodiment, a variegated library of NOVX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOVX variants can be produced by, for example,
20 enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NOVX sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for phage display) containing the set of NOVX sequences therein. There are a variety of methods which can be used to produce libraries of potential NOVX variants from a degenerate oligonucleotide sequence. Chemical
25 synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NOVX sequences. Methods for synthesizing degenerate
oligonucleotides are well-known within the art. *See, e.g.*, Narang, 1983. *Tetrahedron* 39: 3;
30 Itakura, *et al.*, 1984. *Annu. Rev. Biochem.* 53: 323; Itakura, *et al.*, 1984. *Science* 198: 1056; Ike, *et al.*, 1983. *Nucl. Acids Res.* 11: 477.

Polypeptide Libraries

In addition, libraries of fragments of the NOVX protein coding sequences can be used to generate a variegated population of NOVX fragments for screening and subsequent selection of variants of an NOVX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an NOVX coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S_1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the NOVX proteins.

Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOVX proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NOVX variants. See, e.g., Arkin and Yourvan, 1992. *Proc. Natl. Acad. Sci. USA* 89: 7811-7815; Delgrave, et al., 1993. *Protein Engineering* 6:327-331.

Anti-NOVX Antibodies

Also included in the invention are antibodies to NOVX proteins, or fragments of NOVX proteins. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F_{ab} , F_{ab}' and $F_{(ab)2}$ fragments, and an F_{ab} expression library. In general, an antibody molecule obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ

from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG₁, IgG₂, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

5 An isolated NOVX-related protein of the invention may be intended to serve as an antigen, or a portion or fragment thereof, and additionally can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as
10 immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20
15 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

 In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of NOVX-related protein that is located on the surface of the
20 protein, *e.g.*, a hydrophilic region. A hydrophobicity analysis of the human NOVX-related protein sequence will indicate which regions of a NOVX-related protein are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art,
25 including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, *e.g.*, Hopp and Woods, 1981, *Proc. Nat. Acad. Sci. USA* 78: 3824-3828; Kyte and Doolittle 1982, *J. Mol. Biol.* 157: 105-142, each of which is incorporated herein by reference in its entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided
30 herein.

 A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.

Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, *Antibodies: A Laboratory Manual*, Harlow and Lane, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference). Some of these antibodies are discussed below.

Polyclonal Antibodies

For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and *Corynebacterium parvum*, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (*The Scientist*, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).

Monoclonal Antibodies

The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.

Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, *Nature*, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, *MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE*, Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, *J. Immunol.*, 133:3001 (1984); Brodeur

et al., MONOCLONAL ANTIBODY PRODUCTION TECHNIQUES AND APPLICATIONS, Marcel Dekker, Inc., New York, (1987) pp. 51-63).

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, *Anal. Biochem.*, 107:220 (1980). Preferably, antibodies having a high degree of specificity and a high binding affinity for the target antigen are isolated.

After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.

The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, *Nature* 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant

domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

Humanized Antibodies

The antibodies directed against the protein antigens of the invention can further
5 comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human
10 immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeyen et al., *Science*, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539.) In some
15 instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those
20 of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, *Curr. Op. Struct. Biol.*, 2:593-596 (1992)).

Human Antibodies

Fully human antibodies relate to antibody molecules in which essentially the entire sequences of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell
30 hybridoma technique (see Kozbor, et al., 1983 *Immunol Today* 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by

using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).

In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, *J. Mol. Biol.*, 227:381 (1991); Marks et al., *J. Mol. Biol.*, 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (*Bio/Technology* 10, 779-783 (1992)); Lonberg et al. (*Nature* 368 856-859 (1994)); Morrison (*Nature* 368, 812-13 (1994)); Fishwild et al., (*Nature Biotechnology* 14, 845-51 (1996)); Neuberger (*Nature Biotechnology* 14, 826 (1996)); and Lonberg and Huszar (*Intern. Rev. Immunol.* 13 65-93 (1995)).

Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the XenomouseTM as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.

A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

F_{ab} Fragments and Single Chain Antibodies

According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of F_{ab} expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal F_{ab} fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotype to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F_{(ab)₂} fragment produced by pepsin digestion of an antibody molecule; (ii) an F_{ab} fragment generated by reducing the disulfide bridges of an F_{(ab)₂} fragment; (iii) an F_{ab} fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F_v fragments.

Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the

binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, *Nature*, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker *et al.*, 1991 *EMBO J.*, 10:3655-3659.

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh *et al.*, *Methods in Enzymology*, 121:210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab')₂ bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan *et al.*, *Science* 229:81 (1985) describe a

procedure wherein intact antibodies are proteolytically cleaved to generate $F(ab')_2$ fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab' -TNB derivatives is then reconverted to the Fab' -thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab' -TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Additionally, Fab' fragments can be directly recovered from *E. coli* and chemically coupled to form bispecific antibodies. Shalaby et al., *J. Exp. Med.* 175:217-225 (1992) describe the production of a fully humanized bispecific antibody $F(ab')_2$ molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., *J. Immunol.* 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., *Proc. Natl. Acad. Sci. USA* 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V_H) connected to a light-chain variable domain (V_L) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., *J. Immunol.* 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., *J. Immunol.* 147:60 (1991).

Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm

of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

10 Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

Effector Function Engineering

It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989).

Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include ^{212}Bi , ^{131}I , ^{131}In , ^{90}Y , and ^{186}Re .

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

In another embodiment, the antibody can be conjugated to a "receptor" (such as streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is in turn conjugated to a cytotoxic agent.

In one embodiment, methods for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme-linked immunosorbent assay (ELISA) and other immunologically-mediated techniques known within the art. In a specific embodiment, selection of antibodies that are specific to a particular domain of an NOVX protein is

facilitated by generation of hybridomas that bind to the fragment of an NOVX protein possessing such a domain. Thus, antibodies that are specific for a desired domain within an NOVX protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

5 Anti-NOVX antibodies may be used in methods known within the art relating to the localization and/or quantitation of an NOVX protein (*e.g.*, for use in measuring levels of the NOVX protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies for NOVX proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antibody
10 derived binding domain, are utilized as pharmacologically-active compounds (hereinafter "Therapeutics").

An anti-NOVX antibody (*e.g.*, monoclonal antibody) can be used to isolate an NOVX polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-NOVX antibody can facilitate the purification of natural NOVX polypeptide from
15 cells and of recombinantly-produced NOVX polypeptide expressed in host cells. Moreover, an anti-NOVX antibody can be used to detect NOVX protein (*e.g.*, in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the NOVX protein. Anti-NOVX antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given
20 treatment regimen. Detection can be facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of
25 suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I ,
30 ^{131}I , ^{35}S or ^3H .

NOVX Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an NOVX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable

of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably-linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell).

The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (*e.g.*, tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including

fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NOVX proteins, mutant forms of NOVX proteins, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of NOVX proteins in prokaryotic or eukaryotic cells. For example, NOVX proteins can be expressed in bacterial cells such as *Escherichia coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *Escherichia coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. *Gene* 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amrann *et al.*, (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.*, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (see, e.g.,

Wada, *et al.*, 1992. *Nucl. Acids Res.* 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the NOVX expression vector is a yeast expression vector. Examples of vectors for expression in yeast *Saccharomyces cerevisiae* include pYepSec1
5 (Baldari, *et al.*, 1987. *EMBO J.* 6: 229-234), pMFa (Kurjan and Herskowitz, 1982. *Cell* 30: 933-943), pJRY88 (Schultz *et al.*, 1987. *Gene* 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (Invitrogen Corp, San Diego, Calif.).

Alternatively, NOVX can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (*e.g.*,
10 SF9 cells) include the pAc series (Smith, *et al.*, 1983. *Mol. Cell. Biol.* 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. *Virology* 170: 31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. *Nature* 329: 840) and pMT2PC (Kaufman, *et al.*, 1987. *EMBO J.* 6: 187-195). When used in mammalian cells, the expression vector's control functions are
15 often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, *e.g.*, Chapters 16 and 17 of Sambrook, *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring
20 Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific
25 promoters include the albumin promoter (liver-specific; Pinkert, *et al.*, 1987. *Genes Dev.* 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. *Adv. Immunol.* 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. *EMBO J.* 8: 729-733) and immunoglobulins (Banerji, *et al.*, 1983. *Cell* 33: 729-740; Queen and Baltimore, 1983. *Cell* 33: 741-748), neuron-specific promoters (*e.g.*, the neurofilament
30 promoter; Byrne and Ruddle, 1989. *Proc. Natl. Acad. Sci. USA* 86: 5473-5477), pancreas-specific promoters (Edlund, *et al.*, 1985. *Science* 230: 912-916), and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also

encompassed, e.g., the murine hox promoters (Kessel and Gruss, 1990. *Science* 249: 374-379) and the α -fetoprotein promoter (Campes and Tilghman, 1989. *Genes Dev.* 3: 537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOVX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see, e.g., Weintraub, *et al.*, "Antisense RNA as a molecular tool for genetic analysis," *Reviews-Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, NOVX protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring

Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding NOVX or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) NOVX protein. Accordingly, the invention further provides methods for producing NOVX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOVX protein has been introduced) in a suitable medium such that NOVX protein is produced. In another embodiment, the method further comprises isolating NOVX protein from the medium or the host cell.

Transgenic NOVX Animals

The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOVX protein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NOVX sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOVX sequences have been altered. Such animals are useful for studying the function and/or activity of NOVX protein and for identifying and/or evaluating modulators of NOVX protein activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types

or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOVX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing NOVX-encoding nucleic acid into the male pronuclei of a fertilized oocyte (*e.g.*, by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The human NOVX cDNA sequences SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27,

28, and 30 can be introduced as a transgene into the genome of a non-human animal.

Alternatively, a non-human homologue of the human NOVX gene, such as a mouse NOVX gene, can be isolated based on hybridization to the human NOVX cDNA (described further *supra*) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A

tissue-specific regulatory sequence(s) can be operably-linked to the NOVX transgene to direct expression of NOVX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOVX transgene in its genome and/or expression of NOVX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding NOVX protein can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of an NOVX gene into which a deletion, addition or substitution has been introduced to thereby alter, *e.g.*, functionally disrupt, the NOVX gene. The NOVX gene can be a human gene (*e.g.*, the cDNA of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30), but more preferably, is a non-human homologue of a human NOVX gene. For example, a mouse homologue of human NOVX gene of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30 can be used to construct a homologous recombination vector suitable for altering an endogenous NOVX gene in the mouse genome. In one

embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOVX gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a "knock out" vector).

Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOVX gene is mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous NOVX protein). In the homologous recombination vector, the altered portion of the NOVX gene is flanked at its 5'- and 3'-termini by additional nucleic acid of the NOVX gene to allow for homologous recombination to occur between the exogenous NOVX gene carried by the vector and an endogenous NOVX gene in an embryonic stem cell. The additional flanking NOVX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5'- and 3'-termini) are included in the vector. *See, e.g.*, Thomas, *et al.*, 1987. *Cell* 51: 503 for a description of homologous recombination vectors. The vector is then introduced into an embryonic stem cell line (*e.g.*, by electroporation) and cells in which the introduced NOVX gene has homologously-recombined with the endogenous NOVX gene are selected. *See, e.g.*, Li, *et al.*, 1992. *Cell* 69: 915.

The selected cells are then injected into a blastocyst of an animal (*e.g.*, a mouse) to form aggregation chimeras. *See, e.g.*, Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. *Curr. Opin. Biotechnol.* 2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.

In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, *See, e.g.*, Lakso, *et al.*, 1992. *Proc. Natl. Acad. Sci. USA* 89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae*. *See, O'Gorman, et al.*, 1991. *Science* 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing

transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, *e.g.*, by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

5 Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, *et al.*, 1997. *Nature* 385: 810-813. In brief, a cell (*e.g.*, a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, *e.g.*, through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the
10 quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (*e.g.*, the somatic cell) is isolated.

Pharmaceutical Compositions

15 The NOVX nucleic acid molecules, NOVX proteins, and anti-NOVX antibodies (also referred to herein as "active compounds") of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically
20 acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents
25 include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active
30 compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (*i.e.*, topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral,

intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., an NOVX protein or anti-NOVX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable

solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *e.g.*, a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of

such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (*see, e.g.*, U.S. Patent No. 5,328,470) or by stereotactic injection (*see, e.g.*, Chen, *et al.*, 1994. *Proc. Natl. Acad. Sci. USA* 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, *e.g.*, retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

Screening and Detection Methods

The isolated nucleic acid molecules of the invention can be used to express NOVX protein (*e.g.*, via a recombinant expression vector in a host cell in gene therapy applications), to detect NOVX mRNA (*e.g.*, in a biological sample) or a genetic lesion in an NOVX gene, and to modulate NOVX activity, as described further, below. In addition, the NOVX proteins can be used to screen drugs or compounds that modulate the NOVX protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of NOVX protein or production of NOVX protein forms that have decreased or aberrant activity

compared to NOVX wild-type protein (*e.g.*; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease (possesses anti-microbial activity) and the various dyslipidemias. In addition, the anti-NOVX antibodies of the invention can be used to detect and isolate NOVX proteins and modulate NOVX activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.

The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, *supra*.

Screening Assays

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptides, peptidomimetics, small molecules or other drugs) that bind to NOVX proteins or have a stimulatory or inhibitory effect on, *e.g.*, NOVX protein expression or NOVX protein activity. The invention also includes compounds identified in the screening assays described herein.

In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of an NOVX protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. *See, e.g.*, Lam, 1997. *Anticancer Drug Design* 12: 145.

A "small molecule" as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, *e.g.*, nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, *et al.*, 1993. *Proc. Natl. Acad. Sci. U.S.A.* 90: 6909; Erb, *et al.*, 1994.

Proc. Natl. Acad. Sci. U.S.A. 91: 11422; Zuckermann, *et al.*, 1994. *J. Med. Chem.* 37: 2678; Cho, *et al.*, 1993. *Science* 261: 1303; Carrell, *et al.*, 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2059; Carrell, *et al.*, 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2061; and Gallop, *et al.*, 1994. *J. Med. Chem.* 37: 1233.

5 Libraries of compounds may be presented in solution (*e.g.*, Houghten, 1992. *Biotechniques* 13: 412-421), or on beads (Lam, 1991. *Nature* 354: 82-84), on chips (Fodor, 1993. *Nature* 364: 555-556), bacteria (Ladner, U.S. Patent No. 5,223,409), spores (Ladner, U.S. Patent 5,233,409), plasmids (Cull, *et al.*, 1992. *Proc. Natl. Acad. Sci. USA* 89: 1865-1869) or on phage (Scott and Smith, 1990. *Science* 249: 386-390; Devlin, 1990. *Science* 249: 404-406; Cwirla, *et al.*, 1990. *Proc. Natl. Acad. Sci. U.S.A.* 87: 6378-6382; Felici, 1991. *J. Mol. Biol.* 222: 301-310; Ladner, U.S. Patent No. 5,233,409.).

In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to an NOVX protein determined. The cell, for example, can be of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the NOVX protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the NOVX protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX protein or a biologically-active portion thereof as compared to the known compound.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to

modulate (*e.g.*, stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule. As used herein, a "target molecule" is a molecule with which an NOVX protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses an NOVX interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. An NOVX target molecule can be a non-NOVX molecule or an NOVX protein or polypeptide of the invention. In one embodiment, an NOVX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (*e.g.* a signal generated by binding of a compound to a membrane-bound NOVX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOVX.

Determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (*i.e.* intracellular Ca^{2+} , diacylglycerol, IP_3 , etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising an NOVX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, *e.g.*, luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting an NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOVX protein or biologically-active portion thereof. Binding of the test compound to the NOVX protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX

protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX or biologically-active portion thereof as compared to the known compound.

In still another embodiment, an assay is a cell-free assay comprising contacting NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g. stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX can be accomplished, for example, by determining the ability of the NOVX protein to bind to an NOVX target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of NOVX protein can be accomplished by determining the ability of the NOVX protein further modulate an NOVX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, *supra*.

In yet another embodiment, the cell-free assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the NOVX protein to preferentially bind to or modulate the activity of an NOVX target molecule.

The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOVX protein. In the case of cell-free assays comprising the membrane-bound form of NOVX protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOVX protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton[®] X-100, Triton[®] X-114, Thesit[®], Isotridecypoly(ethylene glycol ether)_n, N-dodecyl--N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).

In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOVX protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate

automation of the assay. Binding of a test compound to NOVX protein, or interaction of NOVX protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOVX fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or NOVX protein, and the mixture is incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, *supra*. Alternatively, the complexes can be dissociated from the matrix, and the level of NOVX protein binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOVX protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOVX protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOVX protein or target molecules, but which do not interfere with binding of the NOVX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOVX protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOVX protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOVX protein or target molecule.

In another embodiment, modulators of NOVX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOVX mRNA or protein in the cell is determined. The level of expression of NOVX mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOVX mRNA or protein in the absence of the candidate compound. The candidate

compound can then be identified as a modulator of NOVX mRNA or protein expression based upon this comparison. For example, when expression of NOVX mRNA or protein is greater (*i.e.*, statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NOVX mRNA or protein expression. Alternatively, when expression of NOVX mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NOVX mRNA or protein expression. The level of NOVX mRNA or protein expression in the cells can be determined by methods described herein for detecting NOVX mRNA or protein.

In yet another aspect of the invention, the NOVX proteins can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (*see, e.g.*, U.S. Patent No. 5,283,317; Zervos, *et al.*, 1993. *Cell* 72: 223-232; Madura, *et al.*, 1993. *J. Biol. Chem.* 268: 12046-12054; Bartel, *et al.*, 1993. *Biotechniques* 14: 920-924; Iwabuchi, *et al.*, 1993. *Oncogene* 8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOVX ("NOVX-binding proteins" or "NOVX-bp") and modulate NOVX activity. Such NOVX-binding proteins are also likely to be involved in the propagation of signals by the NOVX proteins as, for example, upstream or downstream elements of the NOVX pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOVX is fused to a gene encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming an NOVX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with NOVX.

The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.

Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.

Chromosome Mapping

Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the NOVX sequences, SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30, or fragments or derivatives thereof, can be used to map the location of the NOVX genes, respectively, on a chromosome. The mapping of the NOVX sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

Briefly, NOVX genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the NOVX sequences. Computer analysis of the NOVX sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the NOVX sequences will yield an amplified fragment.

Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e.g., D'Eustachio, *et al.*, 1983. *Science* 220: 919-924. Somatic cell hybrids containing only fragments of human

chromosomes can also be produced by using human chromosomes with translocations and deletions.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the NOVX sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes.

Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, see, Verma, *et al.*, HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, *e.g.*, in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, *e.g.*, Egeland, *et al.*, 1987. *Nature*, 325: 783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the NOVX gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then

the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

Tissue Typing

The NOVX sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP ("restriction fragment length polymorphisms," described in U.S. Patent No. 5,272,057).

Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the NOVX sequences described herein can be used to prepare two PCR primers from the 5'- and 3'-termini of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOVX sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).

Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in

SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

Predictive Medicine

The invention also pertains to the field of predictive medicine in which diagnostic
5 assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for
prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly,
one aspect of the invention relates to diagnostic assays for determining NOVX protein and/or
nucleic acid expression as well as NOVX activity, in the context of a biological sample (*e.g.*,
10 blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a
disease or disorder, or is at risk of developing a disorder, associated with aberrant NOVX
expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious
disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders,
Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders,
15 and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic
syndrome X and wasting disorders associated with chronic diseases and various cancers. The
invention also provides for prognostic (or predictive) assays for determining whether an
individual is at risk of developing a disorder associated with NOVX protein, nucleic acid
expression or activity. For example, mutations in an NOVX gene can be assayed in a
20 biological sample. Such assays can be used for prognostic or predictive purpose to thereby
prophylactically treat an individual prior to the onset of a disorder characterized by or
associated with NOVX protein, nucleic acid expression, or biological activity.

Another aspect of the invention provides methods for determining NOVX protein,
nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or
prophylactic agents for that individual (referred to herein as "pharmacogenomics").
25 Pharmacogenomics allows for the selection of agents (*e.g.*, drugs) for therapeutic or
prophylactic treatment of an individual based on the genotype of the individual (*e.g.*, the
genotype of the individual examined to determine the ability of the individual to respond to a
particular agent.)

Yet another aspect of the invention pertains to monitoring the influence of agents (*e.g.*,
30 drugs, compounds) on the expression or activity of NOVX in clinical trials.

These and other agents are described in further detail in the following sections.

Diagnostic Assays

An exemplary method for detecting the presence or absence of NOVX in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes NOVX protein such that the presence of NOVX is detected in the biological sample. An agent for detecting NOVX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOVX mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOVX nucleic acid, such as the nucleic acid of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and 30, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOVX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

An agent for detecting NOVX protein is an antibody capable of binding to NOVX protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NOVX mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of NOVX mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of NOVX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. *In vitro* techniques for detection of NOVX genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of NOVX protein include introducing into a subject a labeled anti-NOVX antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

5 In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOVX protein, mRNA, or genomic DNA, such that the presence of NOVX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOVX protein, mRNA or genomic DNA in the control sample with the
10 presence of NOVX protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of NOVX in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOVX protein or mRNA in a biological sample; means for determining the amount of NOVX in the sample; and means for comparing the amount of NOVX in the sample with a
15 standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NOVX protein or nucleic acid.

Prognostic Assays

The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOVX
20 expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a
25 disease or disorder associated with aberrant NOVX expression or activity in which a test sample is obtained from a subject and NOVX protein or nucleic acid (*e.g.*, mRNA, genomic DNA) is detected, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. As used herein, a "test sample" refers to a biological sample obtained
30 from a subject of interest. For example, a test sample can be a biological fluid (*e.g.*, serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (*e.g.*, an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder

associated with aberrant NOVX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NOVX expression or activity in which a test sample is obtained and NOVX protein or nucleic acid is detected (e.g., wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NOVX expression or activity).

The methods of the invention can also be used to detect genetic lesions in an NOVX gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding an NOVX-protein, or the misexpression of the NOVX gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from an NOVX gene; (ii) an addition of one or more nucleotides to an NOVX gene; (iii) a substitution of one or more nucleotides of an NOVX gene, (iv) a chromosomal rearrangement of an NOVX gene; (v) an alteration in the level of a messenger RNA transcript of an NOVX gene, (vi) aberrant modification of an NOVX gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of an NOVX gene, (viii) a non-wild-type level of an NOVX protein, (ix) allelic loss of an NOVX gene, and (x) inappropriate post-translational modification of an NOVX protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in an NOVX gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran, *et al.*, 1988. *Science* 241: 1077-1080; and Nakazawa, *et al.*, 1994. *Proc. Natl. Acad. Sci. USA* 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOVX-gene (see, Abravaya, *et al.*, 1995. *Nucl. Acids Res.* 23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating

nucleic acid (*e.g.*, genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to an NOVX gene under conditions such that hybridization and amplification of the NOVX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size
5 of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (*see*, Guatelli, *et al.*, 1990. *Proc. Natl. Acad. Sci. USA* 87: 1874-1878), transcriptional amplification
10 system (*see*, Kwoh, *et al.*, 1989. *Proc. Natl. Acad. Sci. USA* 86: 1173-1177); Q β Replicase (*see*, Lizardi, *et al.*, 1988. *BioTechnology* 6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

15 In an alternative embodiment, mutations in an NOVX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in
20 the sample DNA. Moreover, the use of sequence specific ribozymes (*see, e.g.*, U.S. Patent No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in NOVX can be identified by hybridizing a sample and control nucleic acids, *e.g.*, DNA or RNA, to high-density arrays containing
25 hundreds or thousands of oligonucleotides probes. *See, e.g.*, Cronin, *et al.*, 1996. *Human Mutation* 7: 244-255; Kozal, *et al.*, 1996. *Nat. Med.* 2: 753-759. For example, genetic mutations in NOVX can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, *et al.*, *supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base
30 changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation

array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOVX gene and detect mutations by comparing the sequence of the sample NOVX with the corresponding wild-type (control) sequence.

Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert, 1977. *Proc. Natl. Acad. Sci. USA* 74: 560 or Sanger, 1977. *Proc. Natl. Acad. Sci. USA* 74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (see, e.g., Naeve, *et al.*, 1995.

Biotechniques 19: 448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen, *et al.*, 1996. *Adv. Chromatography* 36: 127-162; and Griffin, *et al.*, 1993. *Appl. Biochem. Biotechnol.* 38: 147-159).

Other methods for detecting mutations in the NOVX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. See, e.g., Myers, *et al.*, 1985. *Science* 230: 1242. In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOVX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S₁ nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton, *et al.*, 1988. *Proc. Natl. Acad. Sci. USA* 85: 4397; Saleeba, *et al.*, 1992. *Methods Enzymol.* 217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in NOVX cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. See, e.g., Hsu, *et al.*, 1994. *Carcinogenesis* 15: 1657-1662. According to

an exemplary embodiment, a probe based on an NOVX sequence, e.g., a wild-type NOVX sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. *See, e.g., U.S. Patent No. 5,459,039.*

5 In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in NOVX genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. *See, e.g., Orita, et al., 1989. Proc. Natl. Acad. Sci. USA: 86: 2766; Cotton, 1993. Mutat. Res. 285: 125-144; Hayashi, 1992. Genet. Anal. Tech. Appl. 9: 73-79.*

10 Single-stranded DNA fragments of sample and control NOVX nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in
15 which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. *See, e.g., Keen, et al., 1991. Trends Genet. 7: 5.*

In yet another embodiment, the movement of mutant or wild-type fragments in
20 polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). *See, e.g., Myers, et al., 1985. Nature 313: 495.* When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a
25 denaturing gradient to identify differences in the mobility of control and sample DNA. *See, e.g., Rosenbaum and Reissner, 1987. Biophys. Chem. 265: 12753.*

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known
30 mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. *See, e.g., Saiki, et al., 1986. Nature 324: 163; Saiki, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 6230.* Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the

oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; *see, e.g.,* Gibbs, *et al.*, 1989. *Nucl. Acids Res.* 17: 2437-2448) or at the extreme 3'-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (*see, e.g.,* Prossner, 1993. *Tibtech.* 11: 238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. *See, e.g.,* Gasparini, *et al.*, 1992. *Mol. Cell Probes* 6: 1. It is anticipated that in certain embodiments amplification may also be performed using *Taq* ligase for amplification. *See, e.g.,* Barany, 1991. *Proc. Natl. Acad. Sci. USA* 88: 189. In such cases, ligation will occur only if there is a perfect match at the 3'-terminus of the 5' sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, *e.g.,* in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving an NOVX gene.

Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOVX is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

Pharmacogenomics

Agents, or modulators that have a stimulatory or inhibitory effect on NOVX activity (*e.g.,* NOVX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.) In conjunction with such treatment, the pharmacogenomics (*i.e.,* the study of the relationship between an individual's

genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (*e.g.*, drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See *e.g.*, Eichelbaum, 1996. *Clin. Exp. Pharmacol. Physiol.*, 23: 983-985; Linder, 1997. *Clin. Chem.*, 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (*e.g.*, N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by

its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Thus, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with an NOVX modulator, such as a modulator identified by one of the exemplary screening assays described herein.

Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of NOVX (*e.g.*, the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase NOVX gene expression, protein levels, or upregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting decreased NOVX gene expression, protein levels, or downregulated NOVX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOVX gene expression, protein levels, or downregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting increased NOVX gene expression, protein levels, or upregulated NOVX activity. In such clinical trials, the expression or activity of NOVX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a "read out" or markers of the immune responsiveness of a particular cell.

By way of example, and not of limitation, genes, including NOVX, that are modulated in cells by treatment with an agent (*e.g.*, compound, drug or small molecule) that modulates NOVX activity (*e.g.*, identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of NOVX and other genes implicated in the disorder. The levels of gene expression (*i.e.*, a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods

as described herein, or by measuring the levels of activity of NOVX or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

5 In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (*e.g.*, an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression
10 of an NOVX protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the pre-administration sample with the NOVX protein,
15 mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NOVX to higher levels than detected, *i.e.*, to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOVX to
20 lower levels than detected, *i.e.*, to decrease the effectiveness of the agent.

Methods of Treatment

The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOVX expression or activity. The disorders include cardiomyopathy, atherosclerosis,
25 hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation,
30 idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn's disease; multiple sclerosis, treatment of Albright Hereditary Osteodystrophy, and other diseases, disorders and conditions of the like.

These methods of treatment will be discussed more fully, below.

Disease and Disorders

Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (*i.e.*, reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are "dysfunctional" (*i.e.*, due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to "knockout" endogenous function of an aforementioned peptide by homologous recombination (*see, e.g.*, Capecchi, 1989. *Science* 244: 1288-1292); or (v) modulators (*i.e.*, inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.

Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (*i.e.*, are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.

Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (*e.g.*, from biopsy tissue) and assaying it *in vitro* for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (*e.g.*, by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (*e.g.*, Northern assays, dot blots, *in situ* hybridization, and the like).

Prophylactic Methods

In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant NOVX expression or activity, by administering to the subject an agent that modulates NOVX expression or at least one NOVX activity. Subjects at

risk for a disease that is caused or contributed to by aberrant NOVX expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NOVX aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of NOVX aberrancy, for example, an NOVX agonist or NOVX antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.

10 Therapeutic Methods

Another aspect of the invention pertains to methods of modulating NOVX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOVX protein activity associated with the cell. An agent that modulates NOVX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of an NOVX protein, a peptide, an NOVX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOVX protein activity. Examples of such stimulatory agents include active NOVX protein and a nucleic acid molecule encoding NOVX that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOVX protein activity. Examples of such inhibitory agents include antisense NOVX nucleic acid molecules and anti-NOVX antibodies. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of an NOVX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) NOVX expression or activity. In another embodiment, the method involves administering an NOVX protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOVX expression or activity.

Stimulation of NOVX activity is desirable *in situations* in which NOVX is abnormally downregulated and/or in which increased NOVX activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant

cell proliferation and/or differentiation (*e.g.*, cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (*e.g.*, preclampsia).

Determination of the Biological Effect of the Therapeutic

In various embodiments of the invention, suitable *in vitro* or *in vivo* assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.

In various specific embodiments, *in vitro* assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for *in vivo* testing, any of the animal model system known in the art may be used prior to administration to human subjects.

Prophylactic and Therapeutic Uses of the Compositions of the Invention

The NOVX nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders including, but not limited to: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.

As an example, a cDNA encoding the NOVX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have efficacy for treatment of patients suffering from: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias.

Both the novel nucleic acid encoding the NOVX protein, and the NOVX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as an anti-bacterial molecule (*i.e.*, some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies, which

immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods.

The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

5

Examples

Example 1. Quantitative expression analysis of clones in various cells and tissues

The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR). RTQ PCR was performed on a Perkin-Elmer Biosystems ABI PRISM® 7700 Sequence Detection System. Various collections of samples are assembled on the plates, and referred to as Panel 1 (containing normal tissues and cancer cell lines), Panel 2 (containing samples derived from tissues from normal and cancer sources), Panel 3 (containing cancer cell lines), Panel 4 (containing cells and cell lines from normal tissues and cells related to inflammatory conditions), Panel 5D/5I (containing human tissues and cell lines with an emphasis on metabolic diseases), AI_comprehensive_panel (containing normal tissue and samples from autoinflammatory diseases), Panel CNSD.01 (containing samples from normal and diseased brains) and CNS_neurodegeneration_panel (containing samples from normal and Alzheimer's diseased brains).

RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

First, the RNA samples were normalized to reference nucleic acids such as constitutively expressed genes (for example, β -actin and GAPDH). Normalized RNA (5 μ l) was converted to cDNA and analyzed by RTQ-PCR using One Step RT-PCR Master Mix Reagents (PE Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer's instructions. Probes and primers were designed for each assay according to Perkin Elmer Biosystem's *Primer Express* Software package (version I for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default

settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration = 250 nM, primer melting temperature (T_m) range = 58°-60° C, primer optimal T_m = 59° C, maximum primer difference = 2° C, probe does not have 5' G, probe T_m must be 10° C greater than primer T_m , amplicon size 75 bp to 100 bp.

The probes and primers selected (see below) were synthesized by Synthesgen (Houston, TX, USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5' and 3' ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900 nM each, and probe, 200nM.

PCR conditions: Normalized RNA from each tissue and each cell line was spotted in each well of a 96 well PCR plate (Perkin Elmer Biosystems). PCR cocktails including two probes (a probe specific for the target clone and another gene-specific probe multiplexed with the target probe) were set up using 1X TaqMan™ PCR Master Mix for the PE Biosystems 7700, with 5 mM MgCl₂, dNTPs (dA, G, C, U at 1:1:1:2 ratios), 0.25 U/ml AmpliTaq Gold™ (PE Biosystems), and 0.4 U/μl RNase inhibitor, and 0.25 U/μl reverse transcriptase. Reverse transcription was performed at 48° C for 30 minutes followed by amplification/PCR cycles as follows: 95° C 10 min, then 40 cycles of 95° C for 15 seconds, 60° C for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA difference and multiplying by 100.

Panels 1, 1.1, 1.2, and 1.3D

The plates for Panels 1, 1.1, 1.2 and 1.3D include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in these panels are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in these panels are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on these panels are

comprised of samples derived from all major organ systems from single adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose.

In the results for Panels 1, 1.1, 1.2 and 1.3D, the following abbreviations are used:

ca. = carcinoma,
* = established from metastasis,
met = metastasis,
s cell var = small cell variant,
non-s = non-sm = non-small,
squam = squamous,
pl. eff = pl effusion = pleural effusion,
glio = glioma,
astro = astrocytoma, and
neuro = neuroblastoma.

GENERAL_SCREENING_PANEL_V1.4

The plates for Panel 1.4 include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in Panel 1.4 are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in Panel 1.4 are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on Panel 1.4 are comprised of pools of samples derived from all major organ systems from 2 to 5 different adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose.

Panels 2D and 2.2

The plates for Panels 2D and 2.2 generally include 2 control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute's Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI). The tissues are derived from human malignancies and in cases where indicated many malignant tissues have "matched margins" obtained from noncancerous tissue just adjacent to the tumor. These are termed normal adjacent tissues and are denoted "NAT" in the results below. The tumor tissue and the "matched margins" are evaluated by two independent pathologists (the surgical pathologists and again by a pathologists at NDRI or CHTN). This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated "NAT", for normal adjacent tissue, in Table RR). In addition, RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, etc.). These tissues were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, CA), Research Genetics, and Invitrogen.

PANEL 3D

The plates of Panel 3D are comprised of 94 cDNA samples and two control samples. Specifically, 92 of these samples are derived from cultured human cancer cell lines, 2 samples of human primary cerebellar tissue and 2 controls. The human cell lines are generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: Squamous cell carcinoma of the tongue, breast cancer, prostate cancer, melanoma, epidermoid carcinoma, sarcomas, bladder carcinomas, pancreatic cancers, kidney cancers, leukemias/lymphomas, ovarian/uterine/cervical, gastric, colon, lung and CNS cancer cell lines. In addition, there are two independent samples of cerebellum. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. The cell lines in panel 3D and 1.3D are of the most common cell lines used in the scientific literature.

Panels 4D, 4R, and 4.1D

Panel 4 includes samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA (Panel 4R) or cDNA (Panels 4D/4.1D) isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, CA) and thymus and kidney (Clontech) were employed. Total RNA from liver tissue from cirrhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc., Hayward, CA). Intestinal tissue for RNA preparation from patients diagnosed as having Crohn's disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, PA).

Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, MD) and grown in the media supplied for these cell types by Clonetics. These primary cell types were activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-5 ng/ml, TNF alpha at approximately 5-10 ng/ml, IFN gamma at approximately 20-50 ng/ml, IL-4 at approximately 5-10 ng/ml, IL-9 at approximately 5-10 ng/ml, IL-13 at approximately 5-10 ng/ml. Endothelial cells were sometimes starved for various times by culture in the basal media from Clonetics with 0.1% serum.

Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco/Life Technologies, Rockville, MD), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20 ng/ml PMA and 1-2 μ g/ml ionomycin, IL-12 at 5-10 ng/ml, IFN gamma at 20-50 ng/ml and IL-18 at 5-10 ng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco) with PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately 5 μ g/ml. Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately 2×10^6 cells/ml in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1

mM sodium pyruvate (Gibco), mercaptoethanol (5.5×10^{-5} M) (Gibco), and 10 mM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1- 7 days for RNA preparation.

Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer's instructions.

Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, UT), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco), 50 ng/ml GMCSF and 5 ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10 mM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50 ng/ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at 100 ng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at 10 μ g/ml for 6 and 12-14 hours.

CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer's instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and positive selection. Then CD45RO beads were used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco) and plated at 10^6 cells/ml onto Falcon 6 well tissue culture plates that had been coated overnight with 0.5 μ g/ml anti-CD28 (Pharmingen) and 3 μ g/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. The isolated NK cells were

cultured in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.

To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and resuspended at 10^6 cells/ml in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco). To activate the cells, we used PWM at 5 μ g/ml or anti-CD40 (Pharmingen) at approximately 10 μ g/ml and IL-4 at 5-10 ng/ml. Cells were harvested for RNA preparation at 24, 48 and 72 hours.

To prepare the primary and secondary Th1/Th2 and Tr1 cells, six-well Falcon plates were coated overnight with 10 μ g/ml anti-CD28 (Pharmingen) and 2 μ g/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes

Poietic Systems, German Town, MD) were cultured at 10^5 - 10^6 cells/ml in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10 mM Hepes (Gibco) and IL-2 (4 ng/ml). IL-12 (5 ng/ml) and anti-IL4 (1 μ g/ml) were used to direct to Th1, while IL-4 (5 ng/ml) and anti-IFN gamma (1 μ g/ml) were used to direct to Th2 and IL-10 at 5 ng/ml was used to direct to Tr1. After 4-5 days, the activated Th1, Th2 and Tr1 lymphocytes were washed once in DMEM and expanded for 4-7 days in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10 mM Hepes (Gibco) and IL-2 (1 ng/ml). Following this, the activated Th1, Th2 and Tr1 lymphocytes were re-stimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1 μ g/ml) to prevent apoptosis. After 4-5 days, the Th1, Th2 and Tr1 lymphocytes were washed and then expanded again with IL-2 for 4-7 days. Activated Th1 and Th2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.

The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1 mM dbcAMP at 5×10^5 cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to 5×10^5 cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by

the ATCC), with the addition of 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10 mM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 10 ng/ml and ionomycin at 1 μ g/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco). CCD1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and 1 ng/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5 ng/ml IL-4, 5 ng/ml IL-9, 5 ng/ml IL-13 and 25 ng/ml IFN gamma.

For these cell lines and blood cells, RNA was prepared by lysing approximately 10^7 cells/ml using Trizol (Gibco BRL). Briefly, 1/10 volume of bromochloropropane (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was removed and placed in a 15 ml Falcon Tube. An equal volume of isopropanol was added and left at -20 degrees C overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300 μ l of RNase-free water and 35 μ l buffer (Promega) 5 μ l DTT, 7 μ l RNasin and 8 μ l DNase were added. The tube was incubated at 37 degrees C for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with 1/10 volume of 3 M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNase free water. RNA was stored at -80 degrees C.

AI_comprehensive panel_v1.0

The plates for AI_comprehensive panel_v1.0 include two control wells and 89 test samples comprised of cDNA isolated from surgical and postmortem human tissues obtained from the Backus Hospital and Clinomics (Frederick, MD). Total RNA was extracted from tissue samples from the Backus Hospital in the Facility at CuraGen. Total RNA from other tissues was obtained from Clinomics.

Joint tissues including synovial fluid, synovium, bone and cartilage were obtained from patients undergoing total knee or hip replacement surgery at the Backus Hospital. Tissue samples were immediately snap frozen in liquid nitrogen to ensure that isolated RNA was of optimal quality and not degraded. Additional samples of osteoarthritis and rheumatoid

arthritis joint tissues were obtained from Clinomics. Normal control tissues were supplied by Clinomics and were obtained during autopsy of trauma victims.

Surgical specimens of psoriatic tissues and adjacent matched tissues were provided as total RNA by Clinomics. Two male and two female patients were selected between the ages of 25 and 47. None of the patients were taking prescription drugs at the time samples were isolated.

Surgical specimens of diseased colon from patients with ulcerative colitis and Crohns disease and adjacent matched tissues were obtained from Clinomics. Bowel tissue from three female and three male Crohn's patients between the ages of 41-69 were used. Two patients were not on prescription medication while the others were taking dexamethasone, phenobarbital, or tylenol. Ulcerative colitis tissue was from three male and four female patients. Four of the patients were taking lebid and two were on phenobarbital.

Total RNA from post mortem lung tissue from trauma victims was purchased from Clinomics. Emphysema patients ranged in age from 40-70 and all were smokers, this age range was chosen to focus on patients with cigarette-linked emphysema and to avoid those patients with alpha-1 anti-trypsin deficiencies. Asthma patients ranged in age from 36-75, and excluded smokers to prevent those patients that could also have COPD. COPD patients ranged in age from 35-80 and included both smokers and non-smokers. Most patients were taking corticosteroids, and bronchodilators.

In the labels employed to identify tissues in the AI_comprehensive panel_v1.0 panel, the following abbreviations are used:

Syn = *Synovial*

Normal = No apparent disease

Rep22 /Rep20 = individual patients

RA = Rheumatoid arthritis

Backus = From Backus Hospital

OA = Osteoarthritis

(SS) (BA) (MF) = Individual patients

Adj = Adjacent tissue

Match control = adjacent tissues

-M = Male

-F = Female

COPD = Chronic obstructive pulmonary disease

Panels 5D and 5I

The plates for Panel 5D and 5I include two control wells and a variety of cDNAs isolated from human tissues and cell lines with an emphasis on metabolic diseases. Metabolic

tissues were obtained from patients enrolled in the Gestational Diabetes study. Cells were obtained during different stages in the differentiation of adipocytes from human mesenchymal stem cells. Human pancreatic islets were also obtained.

In the Gestational Diabetes study subjects are young (18 - 40 years), otherwise healthy women with and without gestational diabetes undergoing routine (elective) Caesarean section. After delivery of the infant, when the surgical incisions were being repaired/closed, the obstetrician removed a small sample (<1 cc) of the exposed metabolic tissues during the closure of each surgical level. The biopsy material was rinsed in sterile saline, blotted and fast frozen within 5 minutes from the time of removal. The tissue was then flash frozen in liquid nitrogen and stored, individually, in sterile screw-top tubes and kept on dry ice for shipment to or to be picked up by CuraGen. The metabolic tissues of interest include uterine wall (smooth muscle), visceral adipose, skeletal muscle (rectus) and subcutaneous adipose. Patient descriptions are as follows:

Patient 2	Diabetic Hispanic, overweight, not on insulin
Patient 7-9	Nondiabetic Caucasian and obese (BMI>30)
Patient 10	Diabetic Hispanic, overweight, on insulin
Patient 11	Nondiabetic African American and overweight
Patient 12	Diabetic Hispanic on insulin

Adiocyte differentiation was induced in donor progenitor cells obtained from Osirus (a division of Clonetics/BioWhittaker) in triplicate except for Donor 3U which had only two replicates. Scientists at Clonetics isolated, grew and differentiated human mesenchymal stem cells (HuMSCs) for CuraGen based on the published protocol found in Mark F. Pittenger, et al., Multilineage Potential of Adult Human Mesenchymal Stem Cells *Science* Apr 2 1999: 143-147. Clonetics provided Trizol lysates or frozen pellets suitable for mRNA isolation and ds cDNA production. A general description of each donor is as follows:

Donor 2 and 3 U	Mesenchymal Stem cells	Undifferentiated Adipose
Donor 2 and 3 AM	Adipose	AdiposeMidway Differentiated
Donor 2 and 3 AD	Adipose	Adipose Differentiated

Human cell lines were generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: kidney proximal convoluted tubule, uterine smooth muscle cells, small intestine, liver HepG2 cancer cells, heart primary stromal cells, and adrenal cortical adenoma cells. These cells are all

cultured under standard recommended conditions and RNA extracted using the standard procedures. All samples were processed at CuraGen to produce single stranded cDNA.

Panel 5I contains all samples previously described with the addition of pancreatic islets from a 58 year old female patient obtained from the Diabetes Research Institute at the University of Miami School of Medicine. Islet tissue was processed to total RNA at an outside source and delivered to CuraGen for addition to panel 5I.

In the labels employed to identify tissues in the 5D and 5I panels, the following abbreviations are used:

GO Adipose = Greater Omentum Adipose

SK = Skeletal Muscle

UT = Uterus

PL = Placenta

AD = Adipose Differentiated

AM = Adipose Midway Differentiated

U = Undifferentiated Stem Cells

Panel CNSD.01

The plates for Panel CNSD.01 include two control wells and 94 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center. Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at -80°C in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

Disease diagnoses are taken from patient records. The panel contains two brains from each of the following diagnoses: Alzheimer's disease, Parkinson's disease, Huntington's disease, Progressive Supranuclear Palsy, Depression, and "Normal controls". Within each of these brains, the following regions are represented: cingulate gyrus, temporal pole, globus pallidus, substantia nigra, Brodman Area 4 (primary motor strip), Brodman Area 7 (parietal cortex), Brodman Area 9 (prefrontal cortex), and Brodman area 17 (occipital cortex). Not all brain regions are represented in all cases; e.g., Huntington's disease is characterized in part by neurodegeneration in the globus pallidus, thus this region is impossible to obtain from confirmed Huntington's cases. Likewise Parkinson's disease is characterized by degeneration of the substantia nigra making this region more difficult to obtain. Normal control brains were examined for neuropathology and found to be free of any pathology consistent with neurodegeneration.

In the labels employed to identify tissues in the CNS panel, the following abbreviations are used:

PSP = Progressive supranuclear palsy

Sub Nigra = Substantia nigra

Glob Palladus= Globus palladus

Temp Pole = Temporal pole

Cing Gyr = Cingulate gyrus

BA 4 = Brodman Area 4

10 Panel CNS_Neurodegeneration_V1.0

The plates for Panel CNS_Neurodegeneration_V1.0 include two control wells and 47 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital) and the Human Brain and Spinal Fluid Resource Center (VA Greater Los Angeles Healthcare System). Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at -80°C in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

Disease diagnoses are taken from patient records. The panel contains six brains from Alzheimer's disease (AD) patients, and eight brains from "Normal controls" who showed no evidence of dementia prior to death. The eight normal control brains are divided into two categories: Controls with no dementia and no Alzheimer's like pathology (Controls) and controls with no dementia but evidence of severe Alzheimer's like pathology, (specifically senile plaque load rated as level 3 on a scale of 0-3; 0 = no evidence of plaques, 3 = severe AD senile plaque load). Within each of these brains, the following regions are represented: hippocampus, temporal cortex (Broddmann Area 21), parietal cortex (Broddmann area 7), and occipital cortex (Broddmann area 17). These regions were chosen to encompass all levels of neurodegeneration in AD. The hippocampus is a region of early and severe neuronal loss in AD; the temporal cortex is known to show neurodegeneration in AD after the hippocampus; the parietal cortex shows moderate neuronal death in the late stages of the disease; the occipital cortex is spared in AD and therefore acts as a "control" region within AD patients. Not all brain regions are represented in all cases.

In the labels employed to identify tissues in the CNS_Neurodegeneration_V1.0 panel, the following abbreviations are used:

AD = Alzheimer's disease brain; patient was demented and showed AD-like pathology upon autopsy

Control = Control brains; patient not demented, showing no neuropathology

Control (Path) = Control brains; patient not demented but showing severe AD-like pathology

Sup Temporal Ctx = Superior Temporal Cortex

Inf Temporal Ctx = Inferior Temporal Cortex

10 **NOV2a and NOV2c (JGIGC_ORDERED_CIT-HSPC_246B18_20000718_DA1/CG55265-01 and CG55265-03: fibronectin/LLR/Ig domain-containing protein)**

15 Expression of gene JGIGC_ORDERED_CIT-HSPC_246B18_20000718_DA1 and variant CG55265-03 was assessed using the primer-probe set Ag4317 described in Table AA. Results from RTQ-PCR runs are shown in Tables AB and AC.

Table AA. Probe Name Ag4317

Primers	Sequences	TM	Length	Start Position
Forward	5'-GATCCTTGGAAACAACCAGATC-3' (SEQ ID NO:148)	59.8	22	518
Probe	FAM-5'- CTTCCTGTCCACCGTGGAGGACCT-3'- TAMRA (SEQ ID NO:149)	70.7	24	569
Reverse	5'-CTCCAGGTTGTTGTAGGACAGA-3' (SEQ ID NO:150)	59.3	22	596

Table AB. Panel General_screening_panel_v1.4

Tissue Name	Relative Expression(%) tm7654f_ ag4317_a1	Tissue Name	Relative Expression(%) tm7654f_ ag4317_a1
D6005-01_Human adipose	0.8	Renal ca. TK-10	13.2
112193_Metastatic melanoma	0.0	Bladder	1.8
112192_Metastatic melanoma	0.1	Gastric ca.(liver met)_NCI-N87	3.0
95280_Epidermis (metastatic melanoma)	6.8	112197_Stomach	0.1
95279_Epidermis (metastatic melanoma)	0.9	94938_Colon Adenocarcinoma	0.0
Melanoma (met)_SK-MEL-5	10.5	Colon ca. SW480	8.1

112196_Tongue (oncology)	0.1	Colon ca.(SW480 met)_SW620	6.4
113461_Testis Pool	0.7	Colon ca._HT29	0.5
Prostate ca.(bone met)_PC-3	4.0	Colon ca._HCT-116	33.8
113455_Prostate Pool	0.7	Colon ca._CaCo-2	23.6
103396_Placenta	0.3	83219_CC Well to Mod Diff (ODO3866)	0.6
113463_Uterus Pool	0.2	94936_Colon Adenocarcinoma	0.0
Ovarian carcinoma_OVCAR-3	100.0	94930_Colon	0.0
Ovarian carcinoma(ascites)_SK-OV-3	13.0	94935_Colon Adenocarcinoma	0.0
95297_Adenocarcinoma (ovary)	4.1	113468_Colon Pool	2.1
Ovarian carcinoma_OVCAR-5	7.0	113457_Small Intestine Pool	0.4
Ovarian carcinoma_IGROV-1	16.9	113460_Stomach Pool	0.8
Ovarian carcinoma_OVCAR-8	5.4	113467_Bone Marrow Pool	0.3
103368_Ovary	0.8	103371_Fetal Heart	0.2
MCF7_breast carcinoma(pleural effusion)	3.0	113451_Heart Pool	0.2
Breast ca. (pleural effusion)_MDA-MB-231	0.3	113466_Lymph Node Pool	3.0
112189_ductal cell carcinoma(breast)	2.9	103372_Fetal Skeletal Muscle	0.4
Breast ca. (pleural effusion)_T47D	13.6	113456_Skeletal Muscle Pool	0.3
Breast carcinoma_MDA-N	6.3	113459_Spleen Pool	1.7
113452_Breast Pool	1.1	113462_Thymus Pool	5.6
103398_Trachea	0.8	CNS ca. (glio/astro)_U87-MG	0.5
112354_lung	0.3	CNS ca. (glio/astro)_U-118-MG	0.0
103374_Fetal Lung	2.2	CNS ca. (neuro;met)_SK-N-AS	24.3
94921_Small cell carcinoma of the lung	6.7	95264_Brain astrocytoma	2.6
Lung ca.(small cell)_LX-1	1.3	CNS ca. (astro)_SNB-75	11.3
94919_Small cell carcinoma of the lung	1.0	CNS ca. (glio)_SNB-19	13.3
Lung ca.(s.cell var.)_SHP-77	0.0	CNS ca. (glio)_SF-295	12.1
95268_Lung (Large cell carcinoma)	19.0	113447_Brain (Amygdala) Pool	8.4
94920_Small cell carcinoma of the lung	5.9	103382_Brain (cerebellum)	30.9

Lung ca.(non-s.cell)_NCI-H23	8.5	64019-1_brain(fetal)	28.6
Lung ca.(large cell)_NCI-H460	3.1	113448_Brain (Hippocampus) Pool	11.8
Lung ca.(non-s.cell)_HOP-62	2.0	113464_Cerebral Cortex Pool	9.5
Lung ca.(non-s.cl)_NCI-H522	7.0	113449_Brain (Substantia nigra) Pool	12.6
103392_Liver	0.3	113450_Brain (Thalamus) Pool	8.2
103393_Fetal Liver	1.2	103384_Brain (whole)	11.9
Liver ca.(hepatoblast)_HepG2	0.1	113458_Spinal Cord Pool	2.7
113465_Kidney Pool	1.2	103375_Adrenal Gland	0.8
103373_Fetal Kidney	1.1	113454_Pituitary gland Pool	0.3
Renal ca. 786-0	0.3	103397_Salivary Gland	0.7
112188_renal cell carcinoma	4.8	103369_Thyroid (female)	0.7
Renal ca._ACHN	0.9	Pancreatic ca._CAPAN2	1.5
112190_Renal cell carcinoma	4.6	113453_Pancreas Pool	1.9

Table AC. Panel 4.1D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	4.1dx4tm6582 f_ag4317_b2		4.1dx4tm6582 f_ag4317_b2
93768_Secondary Th1_anti-CD28/anti-CD3	6.4	93100_HUVEC (Endothelial)_IL-1b	0.6
93769_Secondary Th2_anti-CD28/anti-CD3	7.1	93779_HUVEC (Endothelial)_IFN gamma	1.4
93770_Secondary Tr1_anti-CD28/anti-CD3	3.5	93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	0.0
93573_Secondary Th1_resting day 4-6 in IL-2	8.3	93101_HUVEC (Endothelial)_TNF alpha + IL4	0.0
93572_Secondary Th2_resting day 4-6 in IL-2	8.5	93781_HUVEC (Endothelial)_IL-11	4.2
93571_Secondary Tr1_resting day 4-6 in IL-2	8.8	93583_Lung Microvascular Endothelial Cells_none	4.8
93568_primary Th1_anti-CD28/anti-CD3	13.8	93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	1.4
93569_primary Th2_anti-CD28/anti-CD3	12.9	92662_Microvascular Dermal endothelium_none	1.5

93570_primary Tr1_anti- CD28/anti-CD3	12.5	92663_Microsvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.6
93565_primary Th1_resting dy 4-6 in IL-2	7.9	93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	0.0
93566_primary Th2_resting dy 4-6 in IL-2	8.7	93347_Small Airway Epithelium_none	0.0
93567_primary Tr1_resting dy 4-6 in IL-2	10.5	93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93351_CD45RA CD4 lymphocyte_anti-CD28/anti- CD3	2.9	92668_Coronary Artery SMC_resting	0.0
93352_CD45RO CD4 lymphocyte_anti-CD28/anti- CD3	8.6	92669_Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.6
93251_CD8 Lymphocytes_anti- CD28/anti-CD3	8.3	93107_astrocytes_resting	0.7
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	10.1	93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	10.8	92666_KU-812 (Basophil)_resting	5.9
93354_CD4_none	5.0	92667_KU-812 (Basophil)_PMA/ionoycin	2.9
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	5.6	93579_CCD1106 (Keratinocytes)_none	0.5
93103_LAK cells_resting	8.4	93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	0.0
93788_LAK cells_IL-2	5.6	93791_Liver Cirrhosis	0.4
93787_LAK cells_IL-2+IL- 12	1.2	93577_NCI-H292	4.3
93789_LAK cells_IL-2+IFN gamma	3.5	93358_NCI-H292_IL-4	2.4
93790_LAK cells_IL-2+ IL- 18	5.1	93360_NCI-H292_IL-9	3.1
93104_LAK cells_PMA/ionomycin and IL-18	4.6	93359_NCI-H292_IL-13	4.6
93578_NK Cells IL- 2_resting	13.6	93357_NCI-H292_IFN gamma	14.7
93109_Mixed Lymphocyte Reaction_Two Way MLR	7.4	93777_HPAEC_-	0.0

93110_Mixed Lymphocyte Reaction Two Way MLR	3.1	93778_HPAEC_IL-1 beta/TNA alpha	0.0
93111_Mixed Lymphocyte Reaction Two Way MLR	5.4	93254_Normal Human Lung Fibroblast_none	0.0
93112_Mononuclear Cells (PBMCs)_resting	5.6	93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	1.6
93113_Mononuclear Cells (PBMCs)_PWM	3.4	93257_Normal Human Lung Fibroblast_IL-4	0.5
93114_Mononuclear Cells (PBMCs)_PHA-L	8.1	93256_Normal Human Lung Fibroblast_IL-9	0.6
93249_Ramos (B cell)_none	0.4	93255_Normal Human Lung Fibroblast_IL-13	1.0
93250_Ramos (B cell)_ionomycin	0.0	93258_Normal Human Lung Fibroblast_IFN gamma	0.0
93349_B lymphocytes_PWM	2.6	93106_Dermal Fibroblasts CCD1070_resting	0.0
93350_B lymphocytes_CD40L and IL-4	0.6	93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	7.6
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	5.2	93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	1.4
93248_EOL-1 (Eosinophil)_dbcAMP/PMA ionomycin	4.4	93772_dermal fibroblast_IFN gamma	1.2
93356_Dendritic Cells_none	1.7	93771_dermal fibroblast_IL-4	2.3
93355_Dendritic Cells_LPS 100 ng/ml	0.7	93892_Dermal fibroblasts_none	2.4
93775_Dendritic Cells_anti-CD40	2.7	99202_Neutrophils_TNFa+LPS	9.7
93774_Monocytes_resting	2.4	99203_Neutrophils_none	22.6
93776_Monocytes_LPS 50 ng/ml	3.4	735010_Colon_normal	5.0
93581_Macrophages_resting	0.7	735019_Lung_none	0.0
93582_Macrophages_LPS 100 ng/ml	0.5	64028-1_Thymus_none	31.9
93098_HUVEC (Endothelial)_none	0.6	64030-1_Kidney_none	100.0
93099_HUVEC (Endothelial)_starved	0.5		

Panel General_screening_panel_v1.4 Summary Expression of the

JGIGC_ORDERED_CIT-HSPC_246B18_20000718_DA1 gene is highest in an ovarian cancer cell line (CT = 27.2). Significant expression levels are also detected in a cluster of

ovarian derived cell when compared to normal ovarian tissue. Thus, expression of the JGIGC_ORDERED_CIT-HSPC_246B18_20000718_DA1 gene could be used to distinguish ovarian cancer tissue from normal tissue. There is also significant expression in cell lines derived from melanoma and colon, renal, lung, prostate, and breast cancers when compared to expression of the JGIGC_ORDERED_CIT-HSPC_246B18_20000718_DA1 gene in normal tissue. Thus expression of this gene could be used as a marker for melanoma and colon, renal, lung, prostate and breast cancers. Furthermore, therapeutic modulation of the expression or activity of the JGIGC_ORDERED_CIT-HSPC_246B18_20000718_DA1 protein product could be beneficial in the treatment of these cancers.

Among tissues with metabolic function, the JGIGC_ORDERED_CIT-HSPC_246B18_20000718_DA1 gene is expressed at low but significant levels in tissues derived from adipose, fetal liver, pancreas and the thyroid gland. The expression of this gene is higher in fetal liver (CT=33.6) relative to adult liver (CT=35.5), and may thus serve as a marker to differentiate the two

The JGIGC_ORDERED_CIT-HSPC_246B18_20000718_DA1 gene is also expressed in the fetal lung (CT = 32.7) and is detected at much lower levels in the adult lung. This suggests that the gene could be used to differentiate between fetal and adult lung tissue.

The protein encoded by the JGIGC_ORDERED_CIT-HSPC_246B18_20000718_DA1 gene is a homolog of a Leucine-rich-repeat protein and shows moderate expression during development and across all brain regions including the amygdala, cerebellum, hippocampus, cerebral cortex, substantia nigra, thalamus, and spinal cord. In *Drosophila*, the LRR region of axon guidance proteins has been shown to be critical for function (especially in axon repulsion). Therefore, the expression profile of the JGIGC_ORDERED_CIT-HSPC_246B18_20000718_DA1 gene makes its protein product an excellent candidate

neuronal guidance protein for axons, dendrites and/or growth cones in general. Therapeutic modulation of the levels of this protein, or possible signaling via this protein may be of utility in enhancing/directing compensatory synaptogenesis and fiber growth in the CNS in response to neuronal death (stroke, head trauma), axon lesion (spinal cord injury), or neurodegeneration (Alzheimer's, Parkinson's, Huntington's, vascular dementia or any neurodegenerative disease).

Furthermore, among non-cancerous tissues, this gene shows highest expression in the cerebellum (CT = 28.9) where loss of neurons is a hallmark of the various spinocerebellar ataxias. Thus, therapies targeted to the protein encoded by this gene may be particularly useful in these diseases.

Panel 4.1D Summary The JGIGC_ORDERED_CIT-HSPC_246B18_20000718_DA1 gene is expressed at moderate levels in many of the samples in this panel. Highest expression is seen in the kidney (CT = 30.8), thymus, and neutrophils, with low but significant expression in T lymphocytes, including all subsets studied and all conditions of stimulation. The protein encoded by the JGIGC_ORDERED_CIT-HSPC_246B18_20000718_DA1 gene is homologous to a LRR, FN, and Ig domain-containing membrane protein and may be useful as a target for the discovery of therapeutic antibodies that could reduce or eliminate inflammatory and autoimmune disease symptoms in patients with rheumatoid arthritis, asthma, allergies, lupus, and inflammatory bowel disease.

Slit is a repellent axon guidance cue produced by the midline glia in *Drosophila* that is required to regulate the formation of contralateral projections and the lateral position of longitudinal tracts. Four sequence motifs comprise the structure of Slit: a leucine-rich repeat (LRR), epidermal growth factor-like (EGF) repeats, a laminin-like globular (G)-domain, and a cysteine domain. Here it is demonstrated that the LRR is required for repellent signaling and in vitro binding to Robo. Repellent signaling by slit is reduced by point mutations that encode single amino acid changes in the LRR domain. By contrast to the EGF or G-domains, the LRR domain is required in transgenes to affect axon guidance. Finally, we show that the midline repellent receptor, Robo, binds Slit proteins with internal deletions that also retain repellent activity. However, Robo does not bind Slit protein missing the LRR. Taken together, our data demonstrate that Robinding and repellent signaling by Slit require the LRR region. *See generally* Battye R, et al., *J Neurosci* 21:4290-8 (2001); PMID: 11404414.

Drosophila Capricious (CAPS) is a transmembrane protein with leucine-rich repeat (LRR) motifs, expressed on small subsets of neurons and muscles, including muscle 12 and the motoneurons that innervate it (muscle 12 MNs). Panmuscle ectopic expression of CAPS alters the target specificity of muscle 12 MNs, indicating that CAPS can function in muscles as a target recognition molecule. This study first examined the effect of ectopic panneural expression of CAPS on the motoneuronal circuit. It was found that panneural expression of CAPS alters the pathfinding of muscle 12 MNs. The defect appeared to be caused by changes in the steering behavior of muscle 12 MNs at a specific choice point along their pathway to the target muscle. These results revealed a novel function of CAPS in axon pathfinding. Then deletion analyses of CAPS were performed. CAPS lacking the intracellular domain in all neurons or in all muscles was expressed and studied for their ability to induce the pathfinding and targeting phenotypes. The function of muscularly expressed CAPS in target recognition is intracellular domain dependent, whereas the function of neurally expressed CAPS in

pathfinding is not, suggesting that CAPS may function in neurons and muscles in a different manner. The requirement of the intracellular domain for the function of muscularly expressed CAPS suggests the presence of a signaling event within muscle cells that is essential for selective synapse formation. *See generally* Taniguchi et al, J Neurobiol. 42:104-116 (2000);

5 PMID: 10623905

NOV4a (14578444_0_47/ CG51018-01: Matrilin 2)

Expression of gene 14578444_0_47 was assessed using the primer-probe set Ag2764 described in Table BA Results from RTQ-PCR runs are shown in Tables BB, BC, BD, and BE.

10

Table BA. Probe Name Ag2764

Primers	Sequences	TM	Length	Start Position
Forward	5'-TTTGCAGTGCAACACAGATATC-3' (SEQ ID NO:151)	58.8	22	2695
Probe	TET-5'- TTACGGTCTACACAAAAGCTTTCCCA-3'- TAMRA (SEQ ID NO:152)	65.8	26	2737
Reverse	5'-GCTTCCTGAAGGTTTTGTTGA-3' (SEQ ID NO:153)	59.3	21	2764

Table BB. Panel 1.3D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	1.3dx4tm4868 t ag2764 a1		1.3dx4tm4868 t ag2764 a1
Liver adenocarcinoma	4.9	Kidney (fetal)	54.3
Pancreas	1.6	Renal ca. 786-0	1.6
Pancreatic ca. CAPAN 2	0.5	Renal ca. A498	6.3
Adrenal gland	6.7	Renal ca. RXF 393	14.0
Thyroid	100.0	Renal ca. ACHN	18.5
Salivary gland	6.4	Renal ca. UO-31	13.8
Pituitary gland	3.8	Renal ca. TK-10	5.4
Brain (fetal)	0.7	Liver	3.2
Brain (whole)	3.7	Liver (fetal)	4.6
Brain (amygdala)	8.2	Liver ca. (hepatoblast) HepG2	0.6
Brain (cerebellum)	5.4	Lung	4.9
Brain (hippocampus)	7.4	Lung (fetal)	8.2

Brain (substantia nigra)	2.5	Lung ca. (small cell) LX-1	0.0
Brain (thalamus)	5.4	Lung ca. (small cell) NCI-H69	7.7
Cerebral Cortex	8.1	Lung ca. (s.cell var.) SHP-77	4.8
Spinal cord	37.2	Lung ca. (large cell) NCI-H460	0.0
CNS ca. (glio/astro) U87-MG	5.4	Lung ca. (non-sm. cell) A549	1.4
CNS ca. (glio/astro) U-118-MG	24.5	Lung ca. (non-s.cell) NCI-H23	3.4
CNS ca. (astro) SW1783	33.7	Lung ca (non-s.cell) HOP-62	0.9
CNS ca.* (neuro; met) SK-N-AS	0.1	Lung ca. (non-s.cl) NCI-H522	0.5
CNS ca. (astro) SF-539	13.1	Lung ca. (squam.) SW 900	0.4
CNS ca. (astro) SNB-75	7.0	Lung ca. (squam.) NCI-H596	3.3
CNS ca. (glio) SNB-19	0.7	Mammary gland	29.7
CNS ca. (glio) U251	5.6	Breast ca.* (pl. effusion) MCF-7	6.0
CNS ca. (glio) SF-295	1.0	Breast ca.* (pl.ef) MDA-MB-231	6.3
Heart (fetal)	8.9	Breast ca.* (pl. effusion) T47D	1.8
Heart	20.0	Breast ca. BT-549	7.4
Fetal Skeletal	54.0	Breast ca. MDA-N	0.0
Skeletal muscle	6.9	Ovary	65.4
Bone marrow	0.9	Ovarian ca. OVCAR-3	0.9
Thymus	7.3	Ovarian ca. OVCAR-4	0.1
Spleen	2.3	Ovarian ca. OVCAR-5	2.0
Lymph node	5.1	Ovarian ca. OVCAR-8	16.3
Colorectal	6.7	Ovarian ca. IGROV-1	0.6
Stomach	7.4	Ovarian ca.* (ascites) SK-OV-3	1.1
Small intestine	34.8	Uterus	55.1
Colon ca. SW480	0.7	Placenta	14.8
Colon ca.* (SW480 met)SW620	0.1	Prostate	20.4
Colon ca. HT29	0.7	Prostate ca.* (bone met)PC-3	5.5
Colon ca. HCT-116	0.4	Testis	13.3
Colon ca. CaCo-2	1.5	Melanoma Hs688(A).T	0.9
83219 CC Well to Mod Diff (ODO3866)	0.9	Melanoma* (met) Hs688(B).T	0.8
Colon ca. HCC-2998	1.0	Melanoma UACC-62	0.1
Gastric ca.* (liver met) NCI-N87	10.0	Melanoma M14	0.6

Bladder	10.0	Melanoma LOX IMVI	0.1
Trachea	26.1	Melanoma* (met) SK-MEL-5	0.8
Kidney	12.3	Adipose	13.2

Table BC. Panel 2D

Tissue Name	Relative Expression(%) 2dx4tm4648t ag2764 a2	Tissue Name	Relative Expression(%) 2dx4tm4648t ag2764 a2
Normal Colon GENPAK 061003	21.3	Kidney NAT Clontech 8120608	1.3
83219 CC Well to Mod Diff (ODO3866)	0.3	Kidney Cancer Clontech 8120613	0.3
83220 CC NAT (ODO3866)	4.1	Kidney NAT Clontech 8120614	1.0
83221 CC Gr.2 rectosigmoid (ODO3868)	0.5	Kidney Cancer Clontech 9010320	0.9
83222 CC NAT (ODO3868)	2.2	Kidney NAT Clontech 9010321	1.2
83235 CC Mod Diff (ODO3920)	1.0	Normal Uterus GENPAK 061018	12.3
83236 CC NAT (ODO3920)	5.7	Uterus Cancer GENPAK 064011	17.5
83237 CC Gr.2 ascend colon (ODO3921)	4.3	Normal Thyroid Clontech A+ 6570-1	100.0
83238 CC NAT (ODO3921)	4.4	Thyroid Cancer GENPAK 064010	6.8
83241 CC from Partial Hepatectomy (ODO4309)	1.0	Thyroid Cancer INVITROGEN A302152	3.6
83242 Liver NAT (ODO4309)	3.8	Thyroid NAT INVITROGEN A302153	39.9
87472 Colon mets to lung (OD04451-01)	0.4	Normal Breast GENPAK 061019	9.1
87473 Lung NAT (OD04451-02)	0.4	84877 Breast Cancer (OD04566)	2.1
Normal Prostate Clontech A+ 6546-1	77.5	85975 Breast Cancer (OD04590-01)	2.0
84140 Prostate Cancer (OD04410)	15.1	85976 Breast Cancer Mets (OD04590-03)	4.4
84141 Prostate NAT (OD04410)	21.4	87070 Breast Cancer Metastasis (OD04655-05)	2.0
87073 Prostate Cancer (OD04720-01)	18.4	GENPAK Breast Cancer 064006	1.5
87074 Prostate NAT (OD04720-02)	23.8	Breast Cancer Res. Gen. 1024	3.6
Normal Lung GENPAK 061010	5.1	Breast Cancer Clontech 9100266	2.1

<u>83239 Lung Met to Muscle</u> <u>(ODO4286)</u>	0.4	Breast NAT Clontech 9100265	4.9
<u>83240 Muscle NAT</u> <u>(ODO4286)</u>	0.6	Breast Cancer INVITROGEN A209073	6.3
<u>84136 Lung Malignant</u> <u>Cancer (OD03126)</u>	1.1	Breast NAT INVITROGEN A2090734	8.5
<u>84137 Lung NAT</u> <u>(OD03126)</u>	1.6	Normal Liver GENPAK 061009	3.5
<u>84871 Lung Cancer</u> <u>(OD04404)</u>	2.2	Liver Cancer GENPAK 064003	0.8
<u>84872 Lung NAT</u> <u>(OD04404)</u>	2.1	Liver Cancer Research Genetics RNA 1025	1.4
<u>84875 Lung Cancer</u> <u>(OD04565)</u>	3.1	Liver Cancer Research Genetics RNA 1026	0.4
<u>84876 Lung NAT</u> <u>(OD04565)</u>	0.8	Paired Liver Cancer Tissue Research Genetics RNA 6004-T	1.2
<u>85950 Lung Cancer</u> <u>(OD04237-01)</u>	1.0	Paired Liver Tissue Research Genetics RNA 6004-N	0.2
<u>85970 Lung NAT</u> <u>(OD04237-02)</u>	2.4	Paired Liver Cancer Tissue Research Genetics RNA 6005-T	0.6
<u>83255 Ocular Mel Met to</u> <u>Liver (ODO4310)</u>	9.7	Paired Liver Tissue Research Genetics RNA 6005-N	0.3
<u>83256 Liver NAT</u> <u>(ODO4310)</u>	3.6	Normal Bladder GENPAK 061001	4.3
<u>84139 Melanoma Mets to</u> <u>Lung (OD04321)</u>	2.2	Bladder Cancer Research Genetics RNA 1023	0.5
<u>84138 Lung NAT</u> <u>(OD04321)</u>	1.5	Bladder Cancer INVITROGEN A302173	1.9
Normal Kidney GENPAK 061008	16.8	<u>87071 Bladder Cancer</u> <u>(OD04718-01)</u>	6.8
<u>83786 Kidney Ca, Nuclear</u> <u>grade 2 (OD04338)</u>	2.7	<u>87072 Bladder Normal</u> <u>Adjacent (OD04718-03)</u>	8.3
<u>83787 Kidney NAT</u> <u>(OD04338)</u>	9.3	Normal Ovary Res. Gen.	6.4
<u>83788 Kidney Ca Nuclear</u> <u>grade 1/2 (OD04339)</u>	0.6	Ovarian Cancer GENPAK 064008	7.2
<u>83789 Kidney NAT</u> <u>(OD04339)</u>	7.5	<u>87492 Ovary Cancer</u> <u>(OD04768-07)</u>	4.4
<u>83790 Kidney Ca, Clear cell</u> <u>type (OD04340)</u>	9.4	<u>87493 Ovary NAT</u> <u>(OD04768-08)</u>	3.9
<u>83791 Kidney NAT</u> <u>(OD04340)</u>	8.6	Normal Stomach GENPAK 061017	6.7
<u>83792 Kidney Ca, Nuclear</u> <u>grade 3 (OD04348)</u>	0.8	Gastric Cancer Clontech 9060358	1.7
<u>83793 Kidney NAT</u>	5.8	NAT Stomach Clontech	2.2

(OD04348)		9060359	
87474 Kidney Cancer (OD04622-01)	0.6	Gastric Cancer Clontech 9060395	7.2
87475 Kidney NAT (OD04622-03)	1.0	NAT Stomach Clontech 9060394	3.3
85973 Kidney Cancer (OD04450-01)	6.9	Gastric Cancer Clontech 9060397	1.6
85974 Kidney NAT (OD04450-03)	8.2	NAT Stomach Clontech 9060396	0.4
Kidney Cancer Clontech 8120607	1.9	Gastric Cancer GENPAK 064005	6.6

Table BD. Panel 4D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	4dx4tm4524t ag2764 a1		4dx4tm4524t ag2764 a1
93768_Secondary Th1_anti- CD28/anti-CD3	0.1	93100_HUVEC (Endothelial)_IL-1b	0.1
93769_Secondary Th2_anti- CD28/anti-CD3	0.2	93779_HUVEC (Endothelial)_IFN gamma	0.9
93770_Secondary Tr1_anti- CD28/anti-CD3	0.2	93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	0.1
93573_Secondary Th1_resting day 4-6 in IL-2	0.0	93101_HUVEC (Endothelial)_TNF alpha + IL4	0.1
93572_Secondary Th2_resting day 4-6 in IL-2	0.1	93781_HUVEC (Endothelial)_IL-11	0.6
93571_Secondary Tr1_resting day 4-6 in IL-2	0.0	93583_Lung Microvascular Endothelial Cells_none	0.2
93568_primary Th1_anti- CD28/anti-CD3	0.2	93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.2
93569_primary Th2_anti- CD28/anti-CD3	0.1	92662_Microvascular Dermal endothelium none	0.1
93570_primary Tr1_anti- CD28/anti-CD3	0.1	92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.2
93565_primary Th1_resting dy 4-6 in IL-2	0.5	93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	0.3
93566_primary Th2_resting dy 4-6 in IL-2	0.1	93347_Small Airway Epithelium_none	0.2
93567_primary Tr1_resting	0.1	93348_Small Airway	1.5

dy 4-6 in IL-2		Epithelium_TNF α (4 ng/ml) and IL1b (1 ng/ml)	
93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	100.0	92668_Coronary Artery SMC_resting	0.5
93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	0.3	92669_Coronary Artery SMC_TNF α (4 ng/ml) and IL1b (1 ng/ml)	0.4
93251_CD8 Lymphocytes_anti-CD28/anti-CD3	0.1	93107_astrocytes_resting	3.6
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	0.1	93108_astrocytes_TNF α (4 ng/ml) and IL1b (1 ng/ml)	2.3
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	0.1	92666_KU-812 (Basophil)_resting	0.1
93354_CD4_none	0.1	92667_KU-812 (Basophil)_PMA/ionoycin	0.4
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	0.1	93579_CCD1106 (Keratinocytes)_none	0.5
93103_LAK cells_resting	0.1	93580_CCD1106 (Keratinocytes)_TNF α and IFN γ **	0.4
93788_LAK cells_IL-2	0.2	93791_Liver Cirrhosis	1.4
93787_LAK cells_IL-2+IL-12	0.2	93792_Lupus Kidney	1.6
93789_LAK cells_IL-2+IFN gamma	0.4	93577_NCI-H292	7.6
93790_LAK cells_IL-2+ IL-18	0.2	93358_NCI-H292_IL-4	7.2
93104_LAK cells_PMA/ionomycin and IL-18	0.1	93360_NCI-H292_IL-9	10.8
93578_NK Cells IL-2_resting	0.2	93359_NCI-H292_IL-13	4.1
93109_Mixed Lymphocyte Reaction_Two Way MLR	0.3	93357_NCI-H292_IFN gamma	3.9
93110_Mixed Lymphocyte Reaction_Two Way MLR	0.1	93777_HPAEC_-	0.2
93111_Mixed Lymphocyte Reaction_Two Way MLR	0.0	93778_HPAEC_IL-1 beta/TNA alpha	0.1
93112_Mononuclear Cells (PBMCs)_resting	0.1	93254_Normal Human Lung Fibroblast_none	4.8
93113_Mononuclear Cells (PBMCs)_PWM	0.4	93253_Normal Human Lung Fibroblast_TNF α (4 ng/ml) and IL-1b (1 ng/ml)	1.7
93114_Mononuclear Cells	0.1	93257_Normal Human	7.8

(PBMcs) PHA-L		Lung Fibroblast_IL-4	
93249_Ramos (B cell) none	0.1	93256_Normal Human Lung Fibroblast_IL-9	6.7
93250_Ramos (B cell) ionomycin	0.5	93255_Normal Human Lung Fibroblast_IL-13	6.0
93349_B lymphocytes PWM	0.7	93258_Normal Human Lung Fibroblast_IFN gamma	11.2
93350_B lymphocytes_CD40L and IL-4	0.5	93106_Dermal Fibroblasts CCD1070_resting	10.3
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	0.1	93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	7.0
93248_EOL-1 (Eosinophil)_dbcAMP/PMAionomycin	0.1	93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	3.7
93356_Dendritic Cells none	0.1	93772_dermal_fibroblast_IFN gamma	0.8
93355_Dendritic Cells_LPS 100 ng/ml	0.1	93771_dermal_fibroblast_IL-4	3.2
93775_Dendritic Cells_anti-CD40	0.1	93260_IBD Colitis 2	0.8
93774_Monocytes_resting	0.0	93261_IBD Crohns	4.3
93776_Monocytes_LPS 50 ng/ml	0.1	735010_Colon_normal	15.9
93581_Macrophages_resting	0.1	735019_Lung_none	1.5
93582_Macrophages_LPS 100 ng/ml	0.0	64028-1_Thymus_none	7.7
93098_HUVEC (Endothelial) none	0.0	64030-1_Kidney_none	1.3
93099_HUVEC (Endothelial)_starved	0.3		

Table BE. Panel CNS_neurodegeneration_v1.0

Tissue Name	Relative Expression(%) tm7029t_ag2764_b1_s2	Tissue Name	Relative Expression(%) tm7029t_ag2764_b1_s2
AD 1 Hippo	13.5	Control (Path) 3 Temporal Ctx	3.8
AD 2 Hippo	39.9	Control (Path) 4 Temporal Ctx	18.4
AD 3 Hippo	9.6	AD 1 Occipital Ctx	10.4
AD 4 Hippo	18.2	AD 2 Occipital Ctx (Missing)	0.0
AD 5 hippo	30.0	AD 3 Occipital Ctx	6.9
AD 6 Hippo	100.0	AD 4 Occipital Ctx	14.6
Control 2 Hippo	24.2	AD 5 Occipital Ctx	18.3

Control 4 Hippo	39.5	AD 6 Occipital Ctx	17.1
Control (Path) 3 Hippo	8.3	Control 1 Occipital Ctx	2.1
AD 1 Temporal Ctx	21.3	Control 2 Occipital Ctx	17.6
AD 2 Temporal Ctx	19.0	Control 3 Occipital Ctx	6.3
AD 3 Temporal Ctx	7.5	Control 4 Occipital Ctx	15.3
AD 4 Temporal Ctx	22.0	Control (Path) 1 Occipital Ctx	47.9
AD 5 Inf Temporal Ctx	43.1	Control (Path) 2 Occipital Ctx	9.1
AD 5 Sup Temporal Ctx	51.7	Control (Path) 3 Occipital Ctx	1.0
AD 6 Inf Temporal Ctx	51.7	Control (Path) 4 Occipital Ctx	9.2
AD 6 Sup Temporal Ctx	61.3	Control 1 Parietal Ctx	5.2
Control 1 Temporal Ctx	4.2	Control 2 Parietal Ctx	32.5
Control 2 Temporal Ctx	11.2	Control 3 Parietal Ctx	6.8
Control 3 Temporal Ctx	6.9	Control (Path) 1 Parietal Ctx	18.8
Control 4 Temporal Ctx	11.2	Control (Path) 2 Parietal Ctx	25.6
Control (Path) 1 Temporal Ctx	33.7	Control (Path) 3 Parietal Ctx	1.9
Control (Path) 2 Temporal Ctx	18.4	Control (Path) 4 Parietal Ctx	17.0

Panel 1.3D Summary The 14578444_0_47 gene is most highly expressed in the thyroid gland (CT = 26.2), fetal kidney and fetal skeletal muscle (CTs = 27.1) and appears to show an association with normal tissue when compared to samples derived from cancer cell lines. The 14578444_0_47 gene is also expressed at moderate levels in the pancreas, adrenal and pituitary glands, adipose, fetal and adult heart, fetal and adult liver, and adult skeletal muscle (CT = 30). The relative overexpression of the 14578444_0_47 gene in fetal skeletal muscle as compared to expression in adult skeletal muscle suggests that the protein product may enhance muscular growth or development in the fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the 14578444_0_47 gene could be useful in treatment of muscle related diseases. More specifically, treatment of weak or dystrophic muscle with the protein encoded by this gene could restore muscle mass or function.

The 14578444_0_47 gene is expressed in many tissues originating in the central nervous system, including the amygdala, cerebellum, hippocampus, substantia nigra, thalamus, cerebral cortex, spinal cord, and the developing brain. Please see Panel

CNS_neurodegeneration_v1.0 for discussion of potential utility of this gene in the central nervous system.

Panel 2D Summary Highest expression of the 14578444_0_47 gene is detected in normal thyroid tissue (CT = 24.7) which is consistent with the results in panel 1.3D. In addition, there is a strong association of the expression of the 14578444_0_47 gene in normal prostate tissue (CT = 25). The 14578444_0_47 gene appears to be overexpressed in normal thyroid tissue when compared to expression of the 14578444_0_47 gene in samples derived from matched thyroid cancer tissue. Thus, the expression of this gene could be used to distinguish normal thyroid tissue from the other samples in the panel, and more specifically, from thyroid cancer tissue. Furthermore, therapeutic modulation of the activity or expression of the 14578444_0_47 gene product, through the use of small molecule drugs, antibodies or protein therapeutics, could be effective in the treatment of thyroid and prostate cancers.

Panel 4D Summary The 14578444_0_47 gene is most highly expressed in CD4 lymphocytes activated by anti-CD28 and anti-CD3 cells (CT = 23.4). The gene is also highly expressed in resting and cytokine-activated dermal fibroblasts, lung fibroblasts, resting and cytokine-activated mucoepidermoid cell line NCI-H292, and normal colon. The protein encoded by the 14578444_0_47 gene is homologous to a secreted extracellular matrix protein that may be useful as a protein therapeutic to reduce or eliminate the inflammation and autoimmune disease symptoms in patients with psoriasis, chronic obstructive pulmonary disease, asthma, allergies, lupus erythematosus, Crohn's disease, and ulcerative colitis.

Panel CNS_neurodegeneration_v1.0 Summary The 14578444_0_47 gene, a homolog of matrilin-2, appears to be an intercellular matrix protein. While this gene does not appear to be differentially expressed in the Alzheimer's disease brain, the results shown in this panel confirm expression in the brain in independent samples. Glial scarring is a major inhibitor of CNS repair/regeneration involving intra and extra-cellular proteins. Reduction of levels of the protein encoded by the 14578444_0_47 gene may decrease levels of glial scarring in response to CNS injury, and promote healing in spinal cord and/or brain trauma.

A mouse cDNA encoding a novel member of the von Willebrand factor type A-like module superfamily was cloned. The protein precursor of 956 amino acids consists of a putative signal peptide, two von Willebrand factor type A-like domains connected by 10

epidermal growth factor-like modules, a potential oligomerization domain, and a unique segment, and it contains potential N-glycosylation sites. A sequence similarity search indicated the closest relation to the trimeric cartilage matrix protein (CMP). Since they constitute a novel protein family, the term matrilin-2 for the new protein has been introduced, reserving matrilin-1 as an alternative name for CMP. A 3.9-kilobase matrilin-2 mRNA was detected in a variety of mouse organs, including calvaria, uterus, heart, and brain, as well as fibroblast and osteoblast cell lines. Expressed human and rat cDNA sequence tags indicate a high degree of interspecies conservation. A group of 120-150-kDa bands was, after reduction, recognized specifically with an antiserum against the matrilin-2-glutathione S-transferase fusion protein in media of the matrilin-2-expressing cell lines. Assuming glycosylation, this agrees well with the predicted minimum Mr of the mature protein (104,300).

Immunolocalization of matrilin-2 in developing skeletal elements showed reactivity in the perichondrium and the osteoblast layer of trabecular bone. CMP binds both collagen fibrils and aggrecan, and because of the similar structure and complementary expression pattern, matrilin-2 is likely to perform similar functions the extracellular matrix assembly of other tissues. *See generally* Deak F et al., J Bio Chem 272:9268-74 (1997); PMID: 9083061.

NOV5 (SC85803748_A/ CG54683-04: GABA receptor)

Expression of gene SC85803748_A was assessed using the primer-probe sets Ag1307 and Ag1651 described in Tables CA.

Table CA. Probe Name Ag1307/Ag1651 (identical sequences)

Primers	Sequences	TM	Length	Start Position
Forward	5'-GGTTTGTGCTGCTTCTAACATC-3' (SEQ ID NO:154)	58.9	22	121
Probe	TET-5'- ACACCAGCGGTGCTCCTCTTCAAT-3'- TAMRA (SEQ ID NO:155)	69.3	24	151
Reverse	5'-CATTGAGCATCTTACGGTTTGT-3' (SEQ ID NO:156)	59.2	22	178

Expression of the gene SC85803748_A is low/undetectable (Ct values >35) in all samples in Panel 1.3D, Panel 2.2, Panel 2D and Panel 4D (data not shown).

NOV6a and NOV6b (sggc_draft_ba465b22_20000727/ CG55891-01 and CG55891-02: Giant larvae-like protein)

- 5 Expression of gene sggc_draft_ba465b22_20000727 and variant CG55891-02 was assessed using the primer-probe set Ag2023 described in Table DA. Results from RTQ-PCR runs are shown in Tables DB and DC.

Table DA. Probe Name Ag2023

Primers	Sequences	TM	Length	Start Position
Forward	5'-CTGGGCATCCAGAAGATCTT-3' (SEQ ID NO:157)	59.2	20	1310
Probe	FAM-5'-CTCTGCAAGTACAGCGGCTACCTGG-3'-TAMRA (SEQ ID NO:158)	69.1	25	1331
Reverse	5'-CCTCGTCATTTCAGTTCCAGTAC-3' (SEQ ID NO:159)	58.7	22	1385

10

Table DB. Panel 1.3D

Tissue Name	Relative Expression(%) 1.3dtm3202f_ag2023	Tissue Name	Relative Expression(%) 1.3dtm3202f_ag2023
Liver adenocarcinoma	42.3	Kidney (fetal)	27.4
Pancreas	24.3	Renal ca. 786-0	3.9
Pancreatic ca. CAPAN 2	28.9	Renal ca. A498	6.2
Adrenal gland	3.8	Renal ca. RXF 393	1.0
Thyroid	14.2	Renal ca. ACHN	3.7
Salivary gland	14.5	Renal ca. UO-31	0.3
Pituitary gland	9.7	Renal ca. TK-10	12.6
Brain (fetal)	0.3	Liver	3.6
Brain (whole)	3.0	Liver (fetal)	11.2
Brain (amygdala)	3.6	Liver ca. (hepatoblast) HepG2	27.2
Brain (cerebellum)	1.2	Lung	36.6
Brain (hippocampus)	15.0	Lung (fetal)	36.6
Brain (substantia nigra)	4.2	Lung ca. (small cell) LX-1	37.6
Brain (thalamus)	7.9	Lung ca. (small cell) NCI-H69	20.6
Cerebral Cortex	1.3	Lung ca. (s.cell var.) SHP-77	4.4

Spinal cord	2.4	Lung ca. (large cell) NCI-H460	1.6
CNS ca. (glio/astro) U87-MG	0.0	Lung ca. (non-sm. cell) A549	13.9
CNS ca. (glio/astro) U-118-MG	0.0	Lung ca. (non-s.cell) NCI-H23	0.9
CNS ca. (astro) SW1783	0.2	Lung ca (non-s.cell) HOP-62	0.5
CNS ca.* (neuro; met) SK-N-AS	2.5	Lung ca. (non-s.cl) NCI-H522	9.9
CNS ca. (astro) SF-539	0.1	Lung ca. (squam.) SW 900	9.5
CNS ca. (astro) SNB-75	7.6	Lung ca. (squam.) NCI-H596	12.1
CNS ca. (glio) SNB-19	0.1	Mammary gland	20.7
CNS ca. (glio) U251	2.1	Breast ca.* (pl. effusion) MCF-7	76.8
CNS ca. (glio) SF-295	1.4	Breast ca.* (pl.ef) MDA-MB-231	1.8
Heart (fetal)	9.3	Breast ca.* (pl. effusion) T47D	9.2
Heart	0.3	Breast ca. BT-549	0.0
Fetal Skeletal	19.5	Breast ca. MDA-N	0.0
Skeletal muscle	0.5	Ovary	1.7
Bone marrow	0.8	Ovarian ca. OVCAR-3	6.8
Thymus	2.1	Ovarian ca. OVCAR-4	3.3
Spleen	44.4	Ovarian ca. OVCAR-5	78.5
Lymph node	5.0	Ovarian ca. OVCAR-8	3.8
Colorectal	45.1	Ovarian ca. IGROV-1	9.5
Stomach	66.0	Ovarian ca.* (ascites) SK-OV-3	5.5
Small intestine	33.7	Uterus	3.0
Colon ca. SW480	32.1	Placenta	5.9
Colon ca.* (SW480 met)SW620	5.9	Prostate	21.0
Colon ca. HT29	13.3	Prostate ca.* (bone met)PC-3	10.4
Colon ca. HCT-116	19.1	Testis	10.2
Colon ca. CaCo-2	17.2	Melanoma Hs688(A).T	0.0
83219 CC Well to Mod Diff (ODO3866)	23.2	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	100.0	Melanoma UACC-62	0.0
Gastric ca.* (liver met) NCI-N87	45.7	Melanoma M14	1.6
Bladder	21.2	Melanoma LOX IMVI	0.0
Trachea	35.6	Melanoma* (met) SK-MEL-5	1.1
Kidney	22.8	Adipose	1.4

Table DC. Panel 4B

Tissue Name	Relative Expression(%) 4dx4tm4241f ag2023 a1	Tissue Name	Relative Expression(%) 4dx4tm4241f ag2023 a1
93768_Secondary Th1_anti-CD28/anti-CD3	0.0	93100_HUVEC (Endothelial)_IL-1b	0.6
93769_Secondary Th2_anti-CD28/anti-CD3	5.6	93779_HUVEC (Endothelial)_IFN gamma	1.3
93770_Secondary Tr1_anti-CD28/anti-CD3	6.7	93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	0.3
93573_Secondary Th1_resting day 4-6 in IL-2	5.6	93101_HUVEC (Endothelial)_TNF alpha + IL4	1.7
93572_Secondary Th2_resting day 4-6 in IL-2	12.6	93781_HUVEC (Endothelial)_IL-11	1.5
93571_Secondary Tr1_resting day 4-6 in IL-2	4.1	93583_Lung Microvascular Endothelial Cells_none	3.0
93568_primary Th1_anti-CD28/anti-CD3	1.4	93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.4
93569_primary Th2_anti-CD28/anti-CD3	1.8	92662_Microvascular Dermal endothelium_none	1.6
93570_primary Tr1_anti-CD28/anti-CD3	1.6	92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	3.2
93565_primary Th1_resting dy 4-6 in IL-2	4.9	93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	13.8
93566_primary Th2_resting dy 4-6 in IL-2	10.0	93347_Small Airway Epithelium_none	12.2
93567_primary Tr1_resting dy 4-6 in IL-2	4.4	93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	34.9
93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	5.9	92668_Coronary Artery SMC_resting	0.0
93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	6.3	92669_Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93251_CD8 Lymphocytes_anti-CD28/anti-CD3	7.4	93107_astrocytes_resting	0.8
93353_chronic CD8 Lymphocytes 2ry_resting dy	3.8	93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0

4-6 in IL-2			
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	1.7	92666_KU-812 (Basophil)_resting	8.9
93354_CD4_none	8.5	92667_KU-812 (Basophil)_PMA/ionoycin	9.8
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	4.6	93579_CCD1106 (Keratinocytes)_none	1.8
93103_LAK cells_resting	4.1	93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	2.8
93788_LAK cells_IL-2	5.4	93791_Liver Cirrhosis	14.1
93787_LAK cells_IL-2+IL- 12	7.9	93792_Lupus Kidney	68.7
93789_LAK cells_IL-2+IFN gamma	6.4	93577_NCI-H292	61.5
93790_LAK cells_IL-2+ IL- 18	11.1	93358_NCI-H292_IL-4	100.0
93104_LAK cells_PMA/ionomycin and IL-18	5.3	93360_NCI-H292_IL-9	58.9
93578_NK Cells IL- 2_resting	17.5	93359_NCI-H292_IL-13	93.6
93109_Mixed Lymphocyte Reaction_Two Way MLR	9.1	93357_NCI-H292_IFN gamma	52.9
93110_Mixed Lymphocyte Reaction_Two Way MLR	3.9	93777_HPAEC_-	0.3
93111_Mixed Lymphocyte Reaction_Two Way MLR	4.0	93778_HPAEC_IL-1 beta/TNA alpha	0.3
93112_Mononuclear Cells (PBMcs)_resting	7.0	93254_Normal Human Lung Fibroblast_none	0.0
93113_Mononuclear Cells (PBMcs)_PWM	7.0	93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	0.0
93114_Mononuclear Cells (PBMcs)_PHA-L	1.7	93257_Normal Human Lung Fibroblast_IL-4	0.0
93249_Ramos (B cell)_none	0.8	93256_Normal Human Lung Fibroblast_IL-9	0.0
93250_Ramos (B cell)_ionomycin	2.6	93255_Normal Human Lung Fibroblast_IL-13	0.0
93349_B lymphocytes_PWM	1.0	93258_Normal Human Lung Fibroblast_IFN gamma	0.0
93350_B lymphocytes_CD40L and IL-4	3.3	93106_Dermal Fibroblasts CCD1070_resting	0.0
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	12.9	93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	4.7

93248_EOL-1 (Eosinophil)_dbcAMP/PMA/ onomycin	14.2	93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	0.0
93356_Dendritic Cells_none	1.4	93772_dermal fibroblast_IFN gamma	0.0
93355_Dendritic Cells_LPS 100 ng/ml	2.9	93771_dermal fibroblast_IL-4	0.0
93775_Dendritic Cells_anti- CD40	1.5	93260_IBD Colitis 2	5.0
93774_Monocytes_resting	1.7	93261_IBD Crohns	29.0
93776_Monocytes_LPS 50 ng/ml	0.0	735010_Colon_normal	53.5
93581_Macrophages_resting	3.2	735019_Lung_none	13.3
93582_Macrophages_LPS 100 ng/ml	2.9	64028-1_Thymus_none	97.5
93098_HUVEC (Endothelial)_none	3.6	64030-1_Kidney_none	4.9
93099_HUVEC (Endothelial)_starved	0.8		

Panel 1.3D Summary Expression of the *sggc_draft_ba465b22_20000727* gene is highest in a sample from a colon cancer cell line (CT=27.9). In addition, there appears to be substantial expression in samples derived from a series of colon cancer cell lines, ovarian cancer cell lines and a breast cancer cell line. Thus, the expression of this gene could be used to distinguish the HCC-2889 cell line from the other samples in the panel. In addition, therapeutic modulation of the protein encoded by the *sggc_draft_ba465b22_20000727* gene, through the use of small molecule drugs, antibodies or protein therapeutics, may be useful in the treatment of colon, ovarian or breast cancer.

Among tissues with metabolic function, the *sggc_draft_ba465b22_20000727* gene is expressed at moderate levels in adipose, fetal and adult liver, pancreas, and the adrenal, thyroid, and pituitary glands. In addition, the *sggc_draft_ba465b22_20000727* gene is expressed in fetal heart and skeletal muscle (CTs = 31), but expressed at much lower levels in adult heart and skeletal muscle. This expression profile suggests that expression of the *sggc_draft_ba465b22_20000727* gene could be used to differentiate between adult and fetal heart and skeletal muscle tissues. Furthermore, the presence of expression of the *sggc_draft_ba465b22_20000727* gene in fetal skeletal muscle when compared to adult skeletal muscle suggests that the protein product may enhance muscular growth or development in the fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the *sggc_draft_ba465b22_20000727* gene could be useful in treatment of

muscle related diseases. More specifically, treatment of weak or dystrophic muscle with the protein encoded by this gene could restore muscle mass or function.

The sggc_draft_ba465b22_20000727 gene is also widely expressed among tissues originating in the central nervous system, including the amygdala, cerebellum, hippocampus, thalamus, cerebral cortex, substantia nigra and the spinal cord. The protein encoded by the sggc_draft_ba465b22_20000727 gene is a homolog of the giant larvae-like protein, which is involved in the development of neurons from stem cells. Therefore, therapeutic modulation of the protein product of sggc_draft_ba465b22_20000727 could be used in stem cell therapy in the treatment of diseases characterized by neuronal loss (Alzheimer's, Parkinson's, Huntington's, stroke, head and/or spinal cord trauma).

Panel 4D Summary The sggc_draft_ba465b22_20000727 gene is widely expressed across the samples in this panel. Highest expression of the sggc_draft_ba465b22_20000727 gene is observed in the IL-4 stimulated mucoepidermoid cell line NCI-H292 (CT=28.2), with moderate expression detected in the mucoepidermoid cell line NCI-H292 under resting conditions and following stimulation with IL-9, IL-13, or IFN-gamma. The protein encoded by the sggc_draft_ba465b22_20000727 gene may be involved in regulation of cytoskeletal functions in these cells, as is known for the drosophila gene product. Therefore, the sggc_draft_ba465b22_20000727 gene product could potentially be used as a target for the discovery of small molecule drugs that reduce or eliminate the symptoms in patients with chronic obstructive lung disease.

Loss of cell polarity and tissue architecture are characteristics of malignant cancers derived from epithelial tissues. Evidence from Drosophila has been provided that a group of membrane-associated proteins act in concert to regulate both epithelial structure and cell proliferation. Scribble (Scrib) is a cell junction-localized protein required for polarization of embryonic and imaginal disc and follicular epithelia. The tumor suppressors lethal giant larvae (lgl) and discs-large (dlg) have identical effects on all three epithelia, and that scrib also acts as a tumor suppressor. Scrib and Dlg colocalize and overlap with Lgl in epithelia; activity of all three genes is required for cortical localization of Lgl and junctional localization of Scrib and Dlg. scrib, dlg, and lgl show strong genetic interactions. Data indicate that the three tumor suppressors act together in a common pathway to regulate cell polarity and growth control. See generally, Bilder et al., Science 2000 Jul 7;289(5476):113-6 (2000); PMID: 10884224.

NOV8a and NOV8b (138531995 and CG111627-01: Nucleotide sugar transporter)

Expression of gene 138531995 and variant CG11627-01 was assessed using the primer-probe set Ag1867 described in Table EA. Results from RTQ-PCR runs are shown in Tables EB, EC, ED, EE, and EF.

5

Table EA. Probe Name Ag1867

Primers	Sequences	TM	Length	Start Position
Forward	5'-GGTGCCAATACGAAGCTCTTA-3' (SEQ ID NO:160)	59.4	21	593
Probe	FAM-5'-AGTTCGTCAGCTTCCCCACCCAG-3'-TAMRA (SEQ ID NO:161)	69.8	23	614
Reverse	5'-CATGACAGGGATCACCTTAGAG-3' (SEQ ID NO:162)	58.7	22	651

Table EB. Panel General_screening_panel_v1.4

Tissue Name	Relative Expression(%) tm7173f_ ag1867_b1	Tissue Name	Relative Expression(%) tm7173f_ ag1867_b1
D6005-01 Human adipose	3.5	Renal ca. TK-10	22.3
112193_Metastatic melanoma	21.0	Bladder	10.4
112192_Metastatic melanoma	25.3	Gastric ca.(liver met)_NCI-N87	35.9
95280_Epidermis (metastatic melanoma)	66.5	112197_Stomach	56.1
95279_Epidermis (metastatic melanoma)	42.8	94938_Colon Adenocarcinoma	14.1
Melanoma (met)_SK-MEL-5	65.1	Colon ca. SW480	32.3
112196_Tongue (oncology)	14.8	Colon ca.(SW480 met)_SW620	22.9
113461_Testis Pool	3.8	Colon ca. HT29	32.5
Prostate ca.(bone met)_PC-3	44.4	Colon ca. HCT-116	29.6
113455_Prostate Pool	2.9	Colon ca. CaCo-2	17.4
103396_Placenta	6.0	83219_CC Well to Mod Diff (ODO3866)	14.4
113463_Uterus Pool	2.1	94936_Colon Adenocarcinoma	6.8
Ovarian carcinoma_OVCAR-3	24.2	94930_Colon	8.4
Ovarian	35.6	94935_Colon	9.8

carcinoma(ascites)_SK-OV-3		Adenocarcinoma	
95297_Adenocarcinoma (ovary)	19.3	113468_Colon Pool	9.0
Ovarian carcinoma_OVCAR-5	49.8	113457_Small Intestine Pool	4.6
Ovarian carcinoma_IGROV-1	19.3	113460_Stomach Pool	4.3
Ovarian carcinoma_OVCAR-8	16.0	113467_Bone Marrow Pool	3.7
103368_Ovary	7.9	103371_Fetal Heart	7.7
MCF7_breast carcinoma(pleural effusion)	48.1	113451_Heart Pool	4.3
Breast ca. (pleural effusion)_MDA-MB-231	65.0	113466_Lymph Node Pool	8.0
112189_ductal cell carcinoma(breast)	65.2	103372_Fetal Skeletal Muscle	4.9
Breast ca. (pleural effusion)_T47D	100.0	113456_Skeletal Muscle Pool	4.7
Breast carcinoma_MDA-N	45.1	113459_Spleen Pool	2.6
113452_Breast Pool	8.0	113462_Thymus Pool	6.3
103398_Trachea	8.6	CNS ca. (glio/astro)_U87-MG	37.7
112354_lung	1.9	CNS ca. (glio/astro)_U-118-MG	44.4
103374_Fetal Lung	11.5	CNS ca. (neuro;met)_SK-N-AS	35.7
94921_Small cell carcinoma of the lung	5.9	95264_Brain astrocytoma	42.0
Lung ca.(small cell)_LX-1	18.6	CNS ca. (astro)_SNB-75	40.3
94919_Small cell carcinoma of the lung	18.5	CNS ca. (glio)_SNB-19	17.6
Lung ca.(s.cell var.)_SHP-77	22.5	CNS ca. (glio)_SF-295	39.7
95268_Lung (Large cell carcinoma)	19.1	113447_Brain (Amygdala) Pool	4.5
94920_Small cell carcinoma of the lung	8.4	103382_Brain (cerebellum)	18.1
Lung ca.(non-s.cell)_NCI-H23	24.4	64019-1_brain(fetal)	11.2
Lung ca.(large cell)_NCI-H460	16.8	113448_Brain (Hippocampus) Pool	3.9
Lung ca.(non-s.cell)_HOP-62	33.1	113464_Cerebral Cortex Pool	5.3
Lung ca.(non-s.cl)_NCI-H522	28.4	113449_Brain (Substantia nigra) Pool	5.6
103392_Liver	3.8	113450_Brain (Thalamus) Pool	6.2
103393_Fetal Liver	8.8	103384_Brain (whole)	7.9
Liver	28.1	113458_Spinal Cord Pool	6.7

ca.(hepatoblast) HepG2			
113465 Kidney Pool	7.4	103375 Adrenal Gland	13.4
103373 Fetal Kidney	9.2	113454 Pituitary gland Pool	1.1
Renal ca. 786-0	28.0	103397 Salivary Gland	9.6
112188 renal cell carcinoma	10.9	103369 Thyroid (female)	6.1
Renal ca. ACHN	17.1	Pancreatic ca. CAPAN2	23.4
112190 Renal cell carcinoma	24.9	113453 Pancreas Pool	9.7

Table EC. Panel 2.2

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	2.2x4tm6390f ag1867_a2		2.2x4tm6390f ag1867_a2
Normal Colon GENPAK 061003	11.7	83793 Kidney NAT (OD04348)	49.8
97759 Colon cancer (OD06064)	88.6	98938 Kidney malignant cancer (OD06204B)	13.1
97760 Colon cancer NAT (OD06064)	36.8	98939 Kidney normal adjacent tissue (OD06204E)	18.9
97778 Colon cancer (OD06159)	6.4	85973 Kidney Cancer (OD04450-01)	43.9
97779 Colon cancer NAT (OD06159)	16.2	85974 Kidney NAT (OD04450-03)	14.3
98861 Colon cancer (OD06297-04)	6.7	Kidney Cancer Clontech 8120613	6.1
98862 Colon cancer NAT (OD06297-015)	13.1	Kidney NAT Clontech 8120614	30.1
83237 CC Gr.2 ascend colon (ODO3921)	11.0	Kidney Cancer Clontech 9010320	6.9
83238 CC NAT (ODO3921)	5.8	Kidney NAT Clontech 9010321	15.8
97766 Colon cancer metastasis (OD06104)	14.2	Kidney Cancer Clontech 8120607	51.5
97767 Lung NAT (OD06104)	10.5	Kidney NAT Clontech 8120608	23.8
87472 Colon mets to lung (OD04451-01)	14.6	Normal Uterus GENPAK 061018	17.4
87473 Lung NAT (OD04451-02)	10.6	Uterus Cancer GENPAK 064011	100.0
Normal Prostate Clontech A+ 6546-1 (8090438)	12.7	Normal Thyroid Clontech A+ 6570-1 (7080817)	4.9
84140 Prostate Cancer (OD04410)	7.1	Thyroid Cancer GENPAK 064010	13.5
84141 Prostate NAT (OD04410)	4.9	Thyroid Cancer INVITROGEN A302152	20.7

Normal Ovary Res. Gen.	24.5	Thyroid NAT INVITROGEN A302153	3.0
98863 Ovarian cancer (OD06283-03)	15.0	Normal Breast GENPAK 061019	18.4
98865 Ovarian cancer NAT/fallopian tube (OD06283-07)	7.4	84877 Breast Cancer (OD04566)	5.9
Ovarian Cancer GENPAK 064008	7.1	Breast Cancer Res. Gen. 1024	25.3
97773 Ovarian cancer (OD06145)	6.3	85975 Breast Cancer (OD04590-01)	17.7
97775 Ovarian cancer NAT (OD06145)	7.8	85976 Breast Cancer Mets (OD04590-03)	17.0
98853 Ovarian cancer (OD06455-03)	9.4	87070 Breast Cancer Metastasis (OD04655-05)	18.1
98854 Ovarian NAT (OD06455-07) Fallopian tube	7.0	GENPAK Breast Cancer 064006	16.8
Normal Lung GENPAK 061010	8.3	Breast Cancer Clontech 9100266	23.8
92337 Invasive poor diff. lung adeno (ODO4945-01)	6.8	Breast NAT Clontech 9100265	12.2
92338 Lung NAT (ODO4945-03)	6.5	Breast Cancer INVITROGEN A209073	21.8
84136 Lung Malignant Cancer (OD03126)	13.8	Breast NAT INVITROGEN A2090734	21.9
84137 Lung NAT (OD03126)	4.3	97763 Breast cancer (OD06083)	40.3
90372 Lung Cancer (OD05014A)	10.7	97764 Breast cancer node metastasis (OD06083)	18.9
90373 Lung NAT (OD05014B)	15.7	Normal Liver GENPAK 061009	16.9
97761 Lung cancer (OD06081)	7.2	Liver Cancer Research Genetics RNA 1026	16.2
97762 Lung cancer NAT (OD06081)	3.5	Liver Cancer Research Genetics RNA 1025	27.3
85950 Lung Cancer (OD04237-01)	12.0	Paired Liver Cancer Tissue Research Genetics RNA 6004-T	17.1
85970 Lung NAT (OD04237-02)	10.8	Paired Liver Tissue Research Genetics RNA 6004-N	13.6
83255 Ocular Mel Met to Liver (ODO4310)	56.4	Paired Liver Cancer Tissue Research Genetics RNA 6005-T	74.8
83256 Liver NAT (ODO4310)	9.3	Paired Liver Tissue Research Genetics RNA 6005-N	58.3
84139 Melanoma Mets to	39.3	Liver Cancer GENPAK	11.0

Lung (OD04321)		064003	
84138 Lung NAT (OD04321)	7.6	Normal Bladder GENPAK 061001	8.7
Normal Kidney GENPAK 061008	8.3	Bladder Cancer Research Genetics RNA 1023	11.7
83786 Kidney Ca, Nuclear grade 2 (OD04338)	25.3	Bladder Cancer INVITROGEN A302173	14.1
83787 Kidney NAT (OD04338)	13.3	Normal Stomach GENPAK 061017	26.5
83788 Kidney Ca Nuclear grade 1/2 (OD04339)	23.6	Gastric Cancer Clontech 9060397	14.2
83789 Kidney NAT (OD04339)	13.8	NAT Stomach Clontech 9060396	17.2
83790 Kidney Ca, Clear cell type (OD04340)	10.9	Gastric Cancer Clontech 9060395	8.5
83791 Kidney NAT (OD04340)	11.2	NAT Stomach Clontech 9060394	26.6
83792 Kidney Ca, Nuclear grade 3 (OD04348)	14.7	Gastric Cancer GENPAK 064005	6.6

Table ED. Panel 3.1

Tissue Name	Relative Expression(%) tm7536f_ ag1867	Tissue Name	Relative Expression(%) tm7536f_ ag1867
94905_Daoy_Medulloblastoma/Cerebellum_sscDNA	4.9	94954_Ca Ski_Cervical epidermoid carcinoma (metastasis)_sscDNA	53.6
94906_TE671_Medulloblastom/Cerebellum_sscDNA	3.4	94955_ES-2_Ovarian clear cell carcinoma_sscDNA	21.6
94907_D283 Med_Medulloblastoma/Cerebellum_sscDNA	26.8	94957_Ramos/6h stim_ Stimulated with PMA/ionomycin 6h_sscDNA	6.2
94908_PFSK-1_Primitive Neuroectodermal/Cerebellum_sscDNA	27.2	94958_Ramos/14h stim_ Stimulated with PMA/ionomycin 14h_sscDNA	6.0
94909_XF- 498_CNS_sscDNA	70.2	94962_MEG-01_Chronic myelogenous leukemia (megokaryoblast)_sscDNA	28.5
94910_SNB- 78_CNS/glioma_sscDNA	23.8	94963_Raji_Burkitt's lymphoma_sscDNA	4.7
94911_SF- 268_CNS/glioblastoma_sscDNA	20.2	94964_Daudi_Burkitt's lymphoma_sscDNA	6.9
94912_T98G_Glioblastoma_sscDNA	25.9	94965_U266_B-cell plasmacytoma/myeloma ss	22.8

		cDNA	
96776_SK-N-SH_Neuroblastoma (metastasis) sscDNA	36.6	94968_CA46_Burkitt's lymphoma sscDNA	4.0
94913_SF-295_CNS/glioblastoma sscDNA	16.8	94970_RL_non-Hodgkin's B-cell lymphoma sscDNA	4.2
94914_Cerebellum sscDNA	12.4	94972_JM1_pre-B-cell lymphoma/leukemia sscDNA	4.6
96777_Cerebellum sscDNA	8.3	94973_Jurkat_T cell leukemia sscDNA	8.8
94916_NCI-H292_Mucoepidermoid lung carcinoma sscDNA	57.0	94974_TF-1_Erythroleukemia sscDNA	22.8
94917_DMS-114_Small cell lung cancer sscDNA	18.7	94975_HUT 78_T-cell lymphoma sscDNA	29.3
94918_DMS-79_Small cell lung cancer/neuroendocrine sscDNA	27.4	94977_U937_Histiocytic lymphoma sscDNA	54.3
94919_NCI-H146_Small cell lung cancer/neuroendocrine sscDNA	41.5	94980_KU-812_Myelogenous leukemia sscDNA	18.6
94920_NCI-H526_Small cell lung cancer/neuroendocrine sscDNA	29.1	94981_769-P_Clear cell renal carcinoma sscDNA	21.5
94921_NCI-N417_Small cell lung cancer/neuroendocrine sscDNA	13.3	94983_Caki-2_Clear cell renal carcinoma sscDNA	27.9
94923_NCI-H82_Small cell lung cancer/neuroendocrine sscDNA	13.4	94984_SW 839_Clear cell renal carcinoma sscDNA	18.2
94924_NCI-H157_Squamous cell lung cancer (metastasis) sscDNA	23.8	94986_G401_Wilms' tumor sscDNA	7.9
94925_NCI-H1155_Large cell lung cancer/neuroendocrine sscDNA	28.7	94987_Hs766T_Pancreatic carcinoma (LN metastasis) sscDNA	28.7
94926_NCI-H1299_Large cell lung cancer/neuroendocrine sscDNA	17.1	94988_CAPAN-1_Pancreatic adenocarcinoma (liver metastasis) sscDNA	12.2
94927_NCI-H727_Lung carcinoid sscDNA	26.2	94989_SU86.86_Pancreatic carcinoma (liver	12.5

		metastasis)_sscDNA	
94928_NCI-UMC-11_Lung carcinoid_sscDNA	100.0	94990_BxPC-3_Pancreatic adenocarcinoma_sscDNA	8.8
94929_LX-1_Small cell lung cancer_sscDNA	19.1	94991_HPAC_Pancreatic adenocarcinoma_sscDNA	24.0
94930_Colo-205_Colon cancer_sscDNA	13.8	94992_MIA PaCa- 2_Pancreatic carcinoma_sscDNA	7.4
94931_KM12_Colon cancer_sscDNA	21.0	94993_CFPAC- 1_Pancreatic ductal adenocarcinoma_sscDNA	47.0
94932_KM20L2_Colon cancer_sscDNA	25.0	94994_PANC- 1_Pancreatic epithelioid ductal carcinoma_sscDNA	43.5
94933_NCI-H716_Colon cancer_sscDNA	49.7	94996_T24_Bladder carcinoma (transitional cell)_sscDNA	19.5
94935_SW-48_Colon adenocarcinoma_sscDNA	20.0	94997_5637_Bladder carcinoma_sscDNA	11.9
94936_SW1116_Colon adenocarcinoma_sscDNA	9.7	94998_HT-1197_Bladder carcinoma_sscDNA	23.5
94937_LS 174T_Colon adenocarcinoma_sscDNA	23.8	94999_UM-UC-3_Bladder carcinoma (transitional cell)_sscDNA	9.7
94938_SW-948_Colon adenocarcinoma_sscDNA	15.3	95000_A204_Rhabdomyos arcoma_sscDNA	26.2
94939_SW-480_Colon adenocarcinoma_sscDNA	20.9	95001_HT- 1080_Fibrosarcoma_sscD NA	32.5
94940_NCI-SNU-5_Gastric carcinoma_sscDNA	21.5	95002_MG- 63_Osteosarcoma (bone)_sscDNA	92.0
112197_KATO III_Stomach_sscDNA	24.7	95003_SK-LMS- 1_Leiomyosarcoma (vulva)_sscDNA	38.2
94943_NCI-SNU-16_Gastric carcinoma_sscDNA	25.0	95004_SJRH30_Rhabdom yosarcoma (met to bone marrow)_sscDNA	10.6
94944_NCI-SNU-1_Gastric carcinoma_sscDNA	18.7	95005_A431_Epidermoid carcinoma_sscDNA	27.7
94946_RF-1_Gastric adenocarcinoma_sscDNA	8.2	95007_WM266- 4_Melanoma_sscDNA	42.0
94947_RF-48_Gastric adenocarcinoma_sscDNA	8.2	112195_DU 145_Prostate_sscDNA	51.4
96778_MKN-45_Gastric carcinoma_sscDNA	28.1	95012_MDA-MB- 468_Breast adenocarcinoma_sscDNA	14.0
94949_NCI-N87_Gastric carcinoma_sscDNA	25.7	112196_SSC- 4_Tongue_sscDNA	16.5

94951_OVCAR-5_Ovarian carcinoma_sscDNA	11.8	112194_SSC-9_Tongue_sscDNA	41.8
94952_RL95-2_Uterine carcinoma_sscDNA	10.4	112191_SSC-15_Tongue_sscDNA	18.3
94953_HelaS3_Cervical adenocarcinoma_sscDNA	21.2	95017_CAL 27_Squamous cell carcinoma of tongue_sscDNA	26.4

Table EE. Panel 4D

Tissue Name	Relative Expression(%) 4dx4tm5555f ag1867_a2	Tissue Name	Relative Expression(%) 4dx4tm5555f ag1867_a2
93768_Secondary Th1_anti-CD28/anti-CD3	30.7	93100_HUVEC (Endothelial)_IL-1b	24.0
93769_Secondary Th2_anti-CD28/anti-CD3	26.5	93779_HUVEC (Endothelial)_IFN gamma	30.2
93770_Secondary Tr1_anti-CD28/anti-CD3	33.7	93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	17.9
93573_Secondary Th1_resting day 4-6 in IL-2	24.6	93101_HUVEC (Endothelial)_TNF alpha + IL4	23.1
93572_Secondary Th2_resting day 4-6 in IL-2	19.0	93781_HUVEC (Endothelial)_IL-11	21.0
93571_Secondary Tr1_resting day 4-6 in IL-2	18.5	93583_Lung Microvascular Endothelial Cells_none	29.0
93568_primary Th1_anti-CD28/anti-CD3	16.3	93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	20.9
93569_primary Th2_anti-CD28/anti-CD3	26.5	92662_Microvascular Dermal endothelium_none	32.2
93570_primary Tr1_anti-CD28/anti-CD3	34.3	92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	19.4
93565_primary Th1_resting dy 4-6 in IL-2	47.9	93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	34.1
93566_primary Th2_resting dy 4-6 in IL-2	20.2	93347_Small Airway Epithelium_none	22.7
93567_primary Tr1_resting dy 4-6 in IL-2	23.2	93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	78.6
93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	33.8	92668_Coronary Artery SMC_resting	45.5

93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	34.9	92669_Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	42.8
93251_CD8 Lymphocytes_anti-CD28/anti-CD3	29.9	93107_astrocytes_resting	57.9
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	26.3	93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	74.9
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	22.9	92666_KU-812 (Basophil)_resting	33.3
93354_CD4_none	8.1	92667_KU-812 (Basophil)_PMA/ionoycin	75.5
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	20.2	93579_CCD1106 (Keratinocytes)_none	55.8
93103_LAK cells_resting	9.2	93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	100.0
93788_LAK cells_IL-2	37.3	93791_Liver Cirrhosis	19.3
93787_LAK cells_IL-2+IL-12	32.5	93792_Lupus Kidney	24.3
93789_LAK cells_IL-2+IFN gamma	39.7	93577_NCI-H292	75.5
93790_LAK cells_IL-2+ IL-18	28.9	93358_NCI-H292_IL-4	89.5
93104_LAK cells_PMA/ionomycin and IL-18	11.2	93360_NCI-H292_IL-9	93.5
93578_NK Cells IL-2_resting	21.2	93359_NCI-H292_IL-13	66.4
93109_Mixed Lymphocyte Reaction_Two Way MLR	22.7	93357_NCI-H292_IFN gamma	48.5
93110_Mixed Lymphocyte Reaction_Two Way MLR	22.3	93777_HPAEC_-	24.8
93111_Mixed Lymphocyte Reaction_Two Way MLR	18.3	93778_HPAEC_IL-1 beta/TNA alpha	29.0
93112_Mononuclear Cells (PBMcs)_resting	8.1	93254_Normal Human Lung Fibroblast_none	79.4
93113_Mononuclear Cells (PBMcs)_PWM	23.0	93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	97.2
93114_Mononuclear Cells (PBMcs)_PHA-L	9.9	93257_Normal Human Lung Fibroblast_IL-4	67.0
93249_Ramos (B cell)_none	25.9	93256_Normal Human Lung Fibroblast_IL-9	51.7
93250_Ramos (B cell)_ionomycin	14.2	93255_Normal Human Lung Fibroblast_IL-13	44.9

93349_B lymphocytes_PWM	25.3	93258_Normal Human Lung Fibroblast_IFN gamma	66.6
93350_B lymphocytes_CD40L and IL-4	28.3	93106_Dermal Fibroblasts CCD1070_resting	66.7
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	36.8	93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	71.1
93248_EOL-1 (Eosinophil)_dbcAMP/PMA/onomycin	21.5	93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	49.5
93356_Dendritic Cells_none	15.1	93772_dermal fibroblast_IFN gamma	37.8
93355_Dendritic Cells_LPS 100 ng/ml	12.4	93771_dermal fibroblast_IL-4	49.6
93775_Dendritic Cells_anti-CD40	16.3	93260_IBD Colitis 2	4.8
93774_Monocytes_resting	13.6	93261_IBD Crohns	6.1
93776_Monocytes_LPS 50 ng/ml	25.3	735010_Colon_normal	75.0
93581_Macrophages_resting	19.4	735019_Lung_none	20.4
93582_Macrophages_LPS 100 ng/ml	12.0	64028-1_Thymus_none	24.7
93098_HUVEC (Endothelial)_none	41.1	64030-1_Kidney_none	23.9
93099_HUVEC (Endothelial)_starved	57.2		

Table EF. Panel 5

Tissue Name	Relative Expression(%) 5dtm7486f_ag1867_s1	Tissue Name	Relative Expression(%) 5dtm7486f_ag1867_s1
97457_Patient-02go_adipose	13.6	94709_Donor 2 AM - A_adipose	66.9
97476_Patient-07sk_skeletal muscle	8.5	94710_Donor 2 AM - B_adipose	39.5
97477_Patient-07ut_uterus	14.1	94711_Donor 2 AM - C_adipose	28.1
97478_Patient-07pl_placenta	14.4	94712_Donor 2 AD - A_adipose	45.7
97481_Patient-08sk_skeletal muscle	12.9	94713_Donor 2 AD - B_adipose	56.6
97482_Patient-08ut_uterus	8.1	94714_Donor 2 AD - C_adipose	49.3
97483_Patient-08pl_placenta	9.9	94742_Donor 3 U - A_Mesenchymal Stem Cells	34.2

97486_Patient-09sk_skeletal muscle	3.9	94743_Donor 3 U - B_Mesenchymal Stem Cells	40.9
97487_Patient-09ut_uterus	11.2	94730_Donor 3 AM - A_adipose	59.9
97488_Patient-09pl_placenta	5.3	94731_Donor 3 AM - B_adipose	42.3
97492_Patient-10ut_uterus	19.8	94732_Donor 3 AM - C_adipose	42.6
97493_Patient-10pl_placenta	16.4	94733_Donor 3 AD - A_adipose	77.4
97495_Patient-11go_adipose	9.0	94734_Donor 3 AD - B_adipose	38.4
97496_Patient-11sk_skeletal muscle	8.4	94735_Donor 3 AD - C_adipose	54.3
97497_Patient-11ut_uterus	16.0	77138_Liver_HepG2untreated	100.0
97498_Patient-11pl_placenta	7.6	73556_Heart_Cardiac stromal cells (primary)	31.9
97500_Patient-12go_adipose	14.5	81735_Small Intestine	19.8
97501_Patient-12sk_skeletal muscle	21.3	72409_Kidney_Proximal Convoluted Tubule	17.0
97502_Patient-12ut_uterus	22.5	82685_Small intestine Duodenum	7.7
97503_Patient-12pl_placenta	7.1	90650_Adrenal_Adrenocortical adenoma	7.4
94721_Donor 2 U - A_Mesenchymal Stem Cells	39.8	72410_Kidney_HRCE	54.7
94722_Donor 2 U - B_Mesenchymal Stem Cells	33.7	72411_Kidney_HRE	52.5
94723_Donor 2 U - C_Mesenchymal Stem Cells	34.2	73139_Uterus_Uterine smooth muscle cells	30.1

Panel General_screening_panel_v1.4 Summary The 138531995 gene is ubiquitously

expressed in all the samples in this panel, with highest expression in a breast cancer cell line -

- 5 T47D (CT = 23.5). In addition there is substantial expression of this gene in samples derived from other breast cancer cell lines as well as cell lines derived from ovarian cancer, lung cancer, melanoma, renal cancer, colon cancer, gastric cancer and brain cancer. Thus, the expression of this gene could be used to distinguish samples derived from T47D cells from other samples in this panel. In addition, therapeutic modulation of this gene, through the use
- 10 of small molecule drugs, antibodies or protein therapeutics might useful in the treatment of colon cancer, lung cancer, ovarian cancer, renal cancer, breast cancer, gastric cancer, brain cancer or melanoma.

The 138531995 gene is widely expressed among tissues with metabolic function including adipose, fetal and adult skeletal muscle, fetal and adult liver, fetal and adult heart, the pancreas, and the adrenal, thyroid and pituitary glands. Please see Panel 5 for discussion of potential utility in metabolic function.

5 The 138531995 gene is homologous to the nucleotide sugar transporters, and is expressed at high levels in the brain (CT = 26.0). The nucleotide sugar transporters are indispensable for cellular glycoconjugate synthesis and may have regulatory roles in producing the structural variety of cellular glycoconjugates. Therefore, the protein encoded by the 138531995 gene may be involved in the process of synaptogenesis, and therapeutic up-
10 regulation of the gene or its protein product may be beneficial in the repair process following spinal cord trauma, head trauma, or stroke

Panel 2.2 Summary Highest expression of the 138531995 gene is seen in a sample from a uterine cancer (CT = 27.3). In addition, there is substantial expression in samples derived from
15 melanoma and a colon cancer. Of note is the differential expression between some samples of kidney cancer and thyroid cancer, when compared to their respective normal adjacent tissue. Thus, the expression of this gene could be used to distinguish uterine cancer from other samples in the panel. In addition, therapeutic modulation of this gene, through the use of small molecule drugs, antibodies or protein therapeutics might be of benefit in the treatment of
20 kidney cancer, uterine cancer, colon cancer, and melanoma.

Panel 3.1 Summary The 138531995 gene appears to be widely expressed in all of the samples of panel 3.1. This gene is most highly expressed in a sample derived from a lung characinoid cell line (NCI-UMC-11). Thus, the expression of this gene could be used to
25 distinguish NIC-UMC-11 from other samples present in this panel.

Panel 4D Summary The 138531995 gene is expressed in every sample in this panel, with highest expression in keratinocytes stimulated with TNF-alpha and IL-1beta (CT = 26.1). Significant expression is also detected in the KU-812 basophil cell line treated with phorbol
30 ester and ionomycin, and in small airway epithelium treated with TNF-alpha and IL-1-beta. The 138531995 gene product is homologous to nucleotide sugar transporters and extracellular epitopes on the membrane protein encoded by the 138531995 gene could potentially be useful as targets for the preparation of therapeutic antibodies that reduce or eliminate the symptoms in patients with psoriasis, allergies, and asthma.

Panel 5 Summary The expression of the 138531995 gene, a putative nucleotide sugar transporter, is highest in panel 5D in the hepatoma cell line HepG2 (CT=26.3). It also shows high expression in mesenchymal stem cells, midway differentiated adipocytes and fully differentiated adipocytes from two human donors. A skeletal muscle sample from a diabetic patient (CT=28.5) shows slightly higher levels of expression of the gene than muscle from patients without diabetes (CTs=30). This may indicate higher levels of glycosylation of proteins in the diabetic patient, since the product of this gene may transport sugars from the cytosol to the Golgi for protein glycosylation. This gene may therefore be involved in carbohydrate metabolism, lipid metabolism and deposition, and lipid disorders such as diabetes.

NOV9 (AC018755_da1/CG53521-01: OB binding protein 2)

Expression of gene AC018755_da1 was assessed using the primer-probe set Ag1913 described in Table FA. Results from RTQ-PCR runs are shown in Tables FB, FC, and FD.

Table FA. Probe Name Ag1913

Primers	Sequences	TM	Length	Start Position
Forward	5'-GAGAACTGTCCAGCTCAATGTC-3' (SEQ ID NO:163)	59	22	675
Probe	FAM-5'- CTCCACAGACCATCACCATCTTCAGG-3'- TAMRA (SEQ ID NO:164)	69.1	26	704
Reverse	5'-TATGAGGTGTTTTCAGGATCT-3' (SEQ ID NO:165)	58.7	22	746

Table FB. Panel 1.3D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	1.3Dtm2787f ag1913		1.3Dtm2787f ag1913
Liver adenocarcinoma	0.0	Kidney (fetal)	2.3
Pancreas	0.7	Renal ca. 786-0	0.0
Pancreatic ca. CAPAN 2	0.0	Renal ca. A498	0.0
Adrenal gland	0.5	Renal ca. RXF 393	0.0
Thyroid	0.8	Renal ca. ACHN	0.4

Salivary gland	0.5	Renal ca. UO-31	0.0
Pituitary gland	0.8	Renal ca. TK-10	0.0
Brain (fetal)	0.4	Liver	0.4
Brain (whole)	0.0	Liver (fetal)	12.2
Brain (amygdala)	1.3	Liver ca. (hepatoblast) HepG2	0.0
Brain (cerebellum)	0.0	Lung	16.5
Brain (hippocampus)	2.0	Lung (fetal)	17.6
Brain (substantia nigra)	1.3	Lung ca. (small cell) LX-1	0.0
Brain (thalamus)	2.5	Lung ca. (small cell) NCI-H69	0.0
Cerebral Cortex	6.0	Lung ca. (s.cell var.) SHP-77	0.0
Spinal cord	2.9	Lung ca. (large cell) NCI-H460	0.0
CNS ca. (glio/astro) U87-MG	0.0	Lung ca. (non-sm. cell) A549	0.0
CNS ca. (glio/astro) U-118-MG	0.0	Lung ca. (non-s.cell) NCI-H23	0.0
CNS ca. (astro) SW1783	0.0	Lung ca (non-s.cell) HOP-62	0.0
CNS ca.* (neuro; met) SK-N-AS	0.0	Lung ca. (non-s.cl) NCI-H522	0.0
CNS ca. (astro) SF-539	0.0	Lung ca. (squam.) SW 900	0.0
CNS ca. (astro) SNB-75	47.0	Lung ca. (squam.) NCI-H596	0.0
CNS ca. (glio) SNB-19	0.0	Mammary gland	2.2
CNS ca. (glio) U251	0.0	Breast ca.* (pl. effusion) MCF-7	0.0
CNS ca. (glio) SF-295	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0
Heart (fetal)	9.7	Breast ca.* (pl. effusion) T47D	0.0
Heart	0.4	Breast ca. BT-549	0.0
Fetal Skeletal	9.7	Breast ca. MDA-N	0.0
Skeletal muscle	0.0	Ovary	3.7
Bone marrow	100.0	Ovarian ca. OVCAR-3	0.0
Thymus	1.3	Ovarian ca. OVCAR-4	0.0
Spleen	24.3	Ovarian ca. OVCAR-5	0.0
Lymph node	9.7	Ovarian ca. OVCAR-8	0.0
Colorectal	4.2	Ovarian ca. IGROV-1	0.0
Stomach	6.2	Ovarian ca.* (ascites) SK-OV-3	0.0
Small intestine	0.5	Uterus	0.6
Colon ca. SW480	0.0	Placenta	9.4
Colon ca.* (SW480 met)SW620	0.0	Prostate	1.3

Colon ca. HT29	0.0	Prostate ca.* (bone met)PC-3	0.0
Colon ca. HCT-116	0.0	Testis	0.8
Colon ca. CaCo-2	0.6	Melanoma Hs688(A).T	0.0
83219 CC Well to Mod Diff (ODO3866)	5.1	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	0.0	Melanoma UACC-62	0.0
Gastric ca.* (liver met) NCI-N87	0.0	Melanoma M14	0.0
Bladder	1.6	Melanoma LOX IMVI	0.0
Trachea	1.9	Melanoma* (met) SK-MEL-5	0.0
Kidney	0.0	Adipose	3.8

Table FC. Panel 2.2

Tissue Name	Relative Expression(%) 2.2x4tm6417f ag1913_a1	Tissue Name	Relative Expression(%) 2.2x4tm6417f ag1913_a1
Normal Colon GENPAK 061003	4.7	83793 Kidney NAT (OD04348)	34.7
97759 Colon cancer (OD06064)	52.3	98938 Kidney malignant cancer (OD06204B)	0.0
97760 Colon cancer NAT (OD06064)	24.9	98939 Kidney normal adjacent tissue (OD06204E)	4.8
97778 Colon cancer (OD06159)	0.0	85973 Kidney Cancer (OD04450-01)	4.8
97779 Colon cancer NAT (OD06159)	19.6	85974 Kidney NAT (OD04450-03)	0.0
98861 Colon cancer (OD06297-04)	2.7	Kidney Cancer Clontech 8120613	1.1
98862 Colon cancer NAT (OD06297-015)	0.0	Kidney NAT Clontech 8120614	0.0
83237 CC Gr.2 ascend colon (ODO3921)	2.6	Kidney Cancer Clontech 9010320	2.2
83238 CC NAT (ODO3921)	3.5	Kidney NAT Clontech 9010321	8.8
97766 Colon cancer metastasis (OD06104)	3.4	Kidney Cancer Clontech 8120607	24.8
97767 Lung NAT (OD06104)	22.9	Kidney NAT Clontech 8120608	0.0
87472 Colon mets to lung (OD04451-01)	4.5	Normal Uterus GENPAK 061018	27.5
87473 Lung NAT (OD04451-02)	27.8	Uterus Cancer GENPAK 064011	4.8
Normal Prostate Clontech A+ 6546-1 (8090438)	0.0	Normal Thyroid Clontech A+ 6570-1 (7080817)	4.4

<u>84140 Prostate Cancer</u> (OD04410)	0.0	Thyroid Cancer GENPAK 064010	0.0
<u>84141 Prostate NAT</u> (OD04410)	15.8	Thyroid Cancer INVITROGEN A302152	0.0
Normal Ovary Res. Gen.	10.1	Thyroid NAT INVITROGEN A302153	4.4
98863 Ovarian cancer (OD06283-03)	14.8	Normal Breast GENPAK 061019	21.5
98865 Ovarian cancer NAT/fallopian tube (OD06283-07)	16.1	<u>84877 Breast Cancer</u> (OD04566)	8.4
Ovarian Cancer GENPAK 064008	3.0	Breast Cancer Res. Gen. 1024	22.3
97773 Ovarian cancer (OD06145)	12.7	<u>85975 Breast Cancer</u> (OD04590-01)	23.4
97775 Ovarian cancer NAT (OD06145)	21.3	<u>85976 Breast Cancer Mets</u> (OD04590-03)	15.4
98853 Ovarian cancer (OD06455-03)	0.0	<u>87070 Breast Cancer</u> <u>Metastasis (OD04655-05)</u>	9.3
98854 Ovarian NAT (OD06455-07) Fallopian tube	3.6	GENPAK Breast Cancer 064006	10.7
Normal Lung GENPAK 061010	23.2	Breast Cancer Clontech 9100266	33.8
92337 Invasive poor diff. lung adeno (ODO4945-01)	4.1	Breast NAT Clontech 9100265	22.9
92338 Lung NAT (ODO4945-03)	26.8	Breast Cancer INVITROGEN A209073	9.3
<u>84136 Lung Malignant</u> <u>Cancer (OD03126)</u>	21.3	Breast NAT INVITROGEN A2090734	0.0
<u>84137 Lung NAT</u> (OD03126)	14.5	97763 Breast cancer (OD06083)	3.9
90372 Lung Cancer (OD05014A)	1.6	97764 Breast cancer node metastasis (OD06083)	19.4
90373 Lung NAT (OD05014B)	35.7	Normal Liver GENPAK 061009	21.1
97761 Lung cancer (OD06081)	0.0	Liver Cancer Research Genetics RNA 1026	18.8
97762 Lung cancer NAT (OD06081)	0.0	Liver Cancer Research Genetics RNA 1025	25.5
<u>85950 Lung Cancer</u> (OD04237-01)	13.5	Paired Liver Cancer Tissue Research Genetics RNA 6004-T	52.0
<u>85970 Lung NAT</u> (OD04237-02)	50.3	Paired Liver Tissue Research Genetics RNA 6004-N	23.7
<u>83255 Ocular Mel Met to</u> <u>Liver (ODO4310)</u>	0.0	Paired Liver Cancer Tissue Research Genetics RNA 6005-T	20.2

83256 Liver NAT (ODO4310)	28.6	Paired Liver Tissue Research Genetics RNA 6005-N	100.0
84139 Melanoma Mets to Lung (OD04321)	0.0	Liver Cancer GENPAK 064003	8.8
84138 Lung NAT (OD04321)	74.0	Normal Bladder GENPAK 061001	23.6
Normal Kidney GENPAK 061008	0.0	Bladder Cancer Research Genetics RNA 1023	15.3
83786 Kidney Ca, Nuclear grade 2 (OD04338)	19.8	Bladder Cancer INVITROGEN A302173	9.8
83787 Kidney NAT (OD04338)	1.2	Normal Stomach GENPAK 061017	4.9
83788 Kidney Ca Nuclear grade 1/2 (OD04339)	22.1	Gastric Cancer Clontech 9060397	7.2
83789 Kidney NAT (OD04339)	9.4	NAT Stomach Clontech 9060396	14.4
83790 Kidney Ca, Clear cell type (OD04340)	0.0	Gastric Cancer Clontech 9060395	26.5
83791 Kidney NAT (OD04340)	3.4	NAT Stomach Clontech 9060394	38.2
83792 Kidney Ca, Nuclear grade 3 (OD04348)	9.7	Gastric Cancer GENPAK 064005	0.0

Table FD. Panel 4D

Tissue Name	Relative Expression(%) 4dx4tm4409f ag1913 a1	Tissue Name	Relative Expression(%) 4dx4tm4409f ag1913 a1
93768_Secondary Th1_anti- CD28/anti-CD3	0.0	93100_HUVEC (Endothelial)_IL-1b	0.0
93769_Secondary Th2_anti- CD28/anti-CD3	0.0	93779_HUVEC (Endothelial)_IFN gamma	0.0
93770_Secondary Tr1_anti- CD28/anti-CD3	0.0	93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	0.0
93573_Secondary Th1_resting day 4-6 in IL-2	0.0	93101_HUVEC (Endothelial)_TNF alpha + IL4	0.0
93572_Secondary Th2_resting day 4-6 in IL-2	0.0	93781_HUVEC (Endothelial)_IL-11	0.0
93571_Secondary Tr1_resting day 4-6 in IL-2	0.0	93583_Lung Microvascular Endothelial Cells none	0.0
93568_primary Th1_anti- CD28/anti-CD3	0.0	93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0

93569_primary Th2_anti-CD28/anti-CD3	0.0	92662_Microvascular Dermal endothelium_none	0.2
93570_primary Tr1_anti-CD28/anti-CD3	0.0	92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93565_primary Th1_resting dy 4-6 in IL-2	0.0	93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	0.0
93566_primary Th2_resting dy 4-6 in IL-2	0.0	93347_Small Airway Epithelium_none	0.0
93567_primary Tr1_resting dy 4-6 in IL-2	0.0	93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	0.0	92668_Coronary Artery SMC_resting	0.0
93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	0.6	92669_Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93251_CD8 Lymphocytes_anti-CD28/anti-CD3	0.0	93107_astrocytes_resting	0.0
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	0.6	93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	0.0	92666_KU-812 (Basophil)_resting	0.1
93354_CD4_none	0.5	92667_KU-812 (Basophil)_PMA/ionoycin	3.4
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	0.0	93579_CCD1106 (Keratinocytes)_none	0.0
93103_LAK cells_resting	26.1	93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	0.0
93788_LAK cells_IL-2	0.3	93791_Liver Cirrhosis	1.0
93787_LAK cells_IL-2+IL-12	0.3	93792_Lupus Kidney	0.5
93789_LAK cells_IL-2+IFN gamma	2.6	93577_NCI-H292	0.0
93790_LAK cells_IL-2+ IL-18	0.9	93358_NCI-H292_IL-4	0.1
93104_LAK cells_PMA/ionomycin and IL-18	5.9	93360_NCI-H292_IL-9	0.3
93578_NK Cells IL-2_resting	1.5	93359_NCI-H292_IL-13	0.0

93109_Mixed Lymphocyte Reaction_Two Way MLR	12.1	93357_NCI-H292_IFN gamma	0.3
93110_Mixed Lymphocyte Reaction_Two Way MLR	6.4	93777_HPAEC -	0.0
93111_Mixed Lymphocyte Reaction_Two Way MLR	0.3	93778_HPAEC_IL-1 beta/TNA alpha	0.0
93112_Mononuclear Cells (PBMCs)_resting	6.7	93254_Normal Human Lung Fibroblast_none	0.0
93113_Mononuclear Cells (PBMCs)_PWM	13.0	93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	0.0
93114_Mononuclear Cells (PBMCs)_PHA-L	9.0	93257_Normal Human Lung Fibroblast_IL-4	0.0
93249_Ramos (B cell)_none	0.0	93256_Normal Human Lung Fibroblast_IL-9	0.0
93250_Ramos (B cell)_ionomycin	0.0	93255_Normal Human Lung Fibroblast_IL-13	0.0
93349_B lymphocytes_PWM	5.7	93258_Normal Human Lung Fibroblast_IFN gamma	0.0
93350_B lymphocytes_CD40L and IL-4	6.4	93106_Dermal Fibroblasts CCD1070_resting	0.0
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	5.1	93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	0.0
93248_EOL-1 (Eosinophil)_dbcAMP/PMA/ ionomycin	14.2	93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	0.0
93356_Dendritic Cells_none	26.5	93772_dermal fibroblast_IFN gamma	0.0
93355_Dendritic Cells_LPS 100 ng/ml	39.9	93771_dermal fibroblast_IL-4	0.0
93775_Dendritic Cells_anti-CD40	36.2	93260_IBD Colitis 2	0.2
93774_Monocytes_resting	100.0	93261_IBD Crohns	0.6
93776_Monocytes_LPS 50 ng/ml	80.6	735010_Colon_normal	3.7
93581_Macrophages_resting	19.4	735019_Lung_none	3.3
93582_Macrophages_LPS 100 ng/ml	11.7	64028-1_Thymus_none	0.3
93098_HUVEC (Endothelial)_none	0.0	64030-1_Kidney_none	2.2
93099_HUVEC (Endothelial)_starved	0.0		

Panel 1.3D Summary The AC018755_dal gene is most highly expressed in bone marrow (CT=29). Thus, the expression of this gene could be used to distinguish bone marrow from other samples in this panel.

Expression of this gene appears to be restricted to a subset of normal tissue samples.

Among tissues with metabolic function, the AC018755_da1 gene is expressed in adipose and is also expressed in fetal skeletal muscle, heart, and liver, but is expressed at much lower levels in the corresponding mature tissues. This expression profile suggests that expression of the AC018755_da1 gene could be used to differentiate between the two sources of tissue in heart, liver and skeletal muscle. The difference in expression in fetal and adult tissue may also indicate an involvement of the gene product in the differentiation processes leading to the formation of the adult organs. In addition, the higher expression in fetal skeletal muscle when compared to adult skeletal muscle suggests that the AC018755_da1 gene product could be involved in muscular growth or development in the fetus and could potentially act in a regenerative capacity in the adult. Thus, therapeutic modulation of the AC018755_da1 gene could be useful in the treatment of muscle related diseases and treatment with the protein product could restore muscle mass or function to weak or dystrophic muscle. Furthermore, expression of the AC018755_da1 gene in the placenta may suggest that the AC018755_da1 protein is involved in the regulation of metabolic processes.

Expression of the AC018755_da1 gene in tissues associated with the central nervous system is limited to low but significant expression in the hippocampus, thalamus, cerebral cortex and spinal cord. This expression pattern suggests that the protein encoded by the AC018755_da1 gene could play a role in CNS processes. The sialic acid-binding immunoglobulin-like lectins, to which the AC018755_da1 gene product is homologous, are a subgroup of the immunoglobulin (Ig) superfamily that mediate protein-carbohydrate interactions. They specifically interact with sialic acids in glycoproteins and glycolipids, with each SIGLEC having a particular preference for both the nature of the sialic acid and its glycosidic linkage to adjacent sugars. Specific sialic acids are known to mediate cell-cell adhesion between neurons at synaptic contacts. These sialic acid mediated synaptic interactions are modified during the synaptic restructuring that takes place during the process of learning and memory formation. Therefore, drugs that inhibit the protein encoded by the AC018755_da1 gene could serve to treat disorders of memory that occur with CNS diseases such as Alzheimer's disease or with normal aging.

Panel 2.2 Summary Highest expression of the AC018755_da1 gene is detected in normal liver tissue adjacent to a liver tumor (CT=33.1). In addition, there is substantial expression in samples derived from normal adjacent lung tissue (2 samples) and a colon cancer. Thus, AC018755_da1 gene could be used to distinguish normal adjacent liver from other samples in

the panel. In addition, the expression of this gene could also be used to distinguish normal lung margin when compared to their partner samples in the panel.

Panel 4D Summary The AC018755_da1 gene is highly expressed in both resting (CT=27.7) and LPS-activated monocytes, resting and LPS-activated macrophages, and resting and anti-CD40- or LPS-activated dendritic cells. The AC018755_da1 gene is also expressed at lower levels in a (dibutyryl-cAMP + phorbol ester + ionomycin)-differentiated eosinophil cell line EOL-1, and in resting lymphokine-activated killer cells. The protein encoded by the AC018755_da1 gene is homologous to an integral membrane protein and could be used as a target for antagonist therapeutic antibodies that block the signaling functions of the AC018755_da1 gene product in these inflammatory mediator cells. In addition, the soluble extracellular domain of the putative single-pass membrane protein may be useful as a therapeutic protein that binds the AC018755_da1 gene product ligand(s) and inhibits the pro-inflammatory signaling function of the protein encoded by the AC018755_da1 gene. Such therapeutic antibodies and soluble extracellular domain therapeutic proteins may reduce or eliminate the inflammatory and autoimmune disease symptoms in patients with rheumatoid arthritis, lupus erythematosus, inflammatory bowel disease, Crohn's disease, allergies, and asthma.

The addition of poly-alpha2,8-N-acetylneuraminic acid (polysialic acid; PSA) to the neural cell adhesion molecule NCAM plays a crucial role in neural development [1-3], neural regeneration [4], and plastic processes in the vertebrate brain associated with neurite outgrowth [5], axonal pathfinding [6], and learning and memory [7,-9]. PSA levels are decreased in people affected by schizophrenia [10], and PSA has been identified as a specific marker for some neuroendocrine and lymphoblastoid tumours [11-13]; expression of PSA on the surface of these tumour cells modulates their metastatic potential [11-13]. Studies aimed at understanding PSA biosynthesis and the dynamics of its production have largely been promoted by the cloning of polysialyltransferases (PST-1 in hamster; PST in human and mouse) [14-16]. However, the number of enzymes involved in the biosynthesis of PSA has not been identified. Using incompletely glycosylated NCAM variants and soluble recombinant glycosyltransferases, the site at which PST-1 acts to polysialylate NCAM in vitro was reconstructed. The data presented clearly demonstrate that polysialylation of NCAM is catalyzed by a single enzyme, PST-1, and that terminal sialylation of the N-glycan core is sufficient to generate the PSA acceptor site. Results also show that PST-1 can act on core

structures with the terminal sialic acid connected to galactose via an alpha2,3 or alpha2,6 linkage. See generally, Muhlenhoff et al., Curr Biol. 6:1188-91 (1996); PMID: 8805371

NOV10 (30675745.0.499_da1/ CG52083-01: Trypsin-like)

Expression of gene 30675745.0.499_da1 was assessed using the primer-probe set Ag1876 described in Table GA. Results from RTQ-PCR runs are shown in Tables GB and GC.

Table GA. Probe Name Ag1876

Primers	Sequences	TM	Length	Start Position
Forward	5'-AGCAAGATTGCTCACACAGAGT-3' (SEQ ID NO:166)	59.2	22	668
Probe	TET-5'-CCAGTCAATACCATCATCATCCATGAGG-3'-TAMRA (SEQ ID NO:167)	69.1	28	692
Reverse	5'-TATGTTGTTGCTCATGGAGTTG-3' (SEQ ID NO:168)	58.7	22	730

Table GB. Panel 1.3D

Tissue Name	Relative Expression(%) 1.3dx4tm5422 t ag1876_a1	Tissue Name	Relative Expression(%) 1.3dx4tm5422 t ag1876_a1
Liver adenocarcinoma	0.0	Kidney (fetal)	0.0
Pancreas	0.0	Renal ca. 786-0	0.0
Pancreatic ca. CAPAN 2	0.4	Renal ca. A498	0.5
Adrenal gland	0.7	Renal ca. RXF 393	0.0
Thyroid	0.0	Renal ca. ACHN	0.6
Salivary gland	0.4	Renal ca. UO-31	0.0
Pituitary gland	0.0	Renal ca. TK-10	0.4
Brain (fetal)	0.3	Liver	0.0
Brain (whole)	4.2	Liver (fetal)	0.0
Brain (amygdala)	2.5	Liver ca. (hepatoblast) HepG2	0.0
Brain (cerebellum)	0.8	Lung	0.0
Brain (hippocampus)	2.7	Lung (fetal)	0.0
Brain (substantia nigra)	1.4	Lung ca. (small cell) LX-1	1.3
Brain (thalamus)	1.6	Lung ca. (small cell) NCI-H69	0.0

Cerebral Cortex	0.6	Lung ca. (s.cell var.) SHP-77	0.0
Spinal cord	0.4	Lung ca. (large cell) NCI-H460	0.4
CNS ca. (glio/astro) U87-MG	0.0	Lung ca. (non-sm. cell) A549	0.5
CNS ca. (glio/astro) U-118-MG	0.2	Lung ca. (non-s.cell) NCI-H23	0.0
CNS ca. (astro) SW1783	0.0	Lung ca (non-s.cell) HOP-62	0.0
CNS ca.* (neuro; met) SK-N-AS	0.7	Lung ca. (non-s.cl) NCI-H522	0.3
CNS ca. (astro) SF-539	0.0	Lung ca. (squam.) SW 900	0.8
CNS ca. (astro) SNB-75	0.0	Lung ca. (squam.) NCI-H596	0.0
CNS ca. (glio) SNB-19	2.2	Mammary gland	0.0
CNS ca. (glio) U251	1.3	Breast ca.* (pl. effusion) MCF-7	2.9
CNS ca. (glio) SF-295	0.4	Breast ca.* (pl.ef) MDA-MB-231	0.0
Heart (fetal)	0.0	Breast ca.* (pl. effusion) T47D	0.0
Heart	0.0	Breast ca. BT-549	0.6
Fetal Skeletal	0.0	Breast ca. MDA-N	0.0
Skeletal muscle	0.0	Ovary	0.0
Bone marrow	0.0	Ovarian ca. OVCAR-3	0.0
Thymus	1.0	Ovarian ca. OVCAR-4	0.0
Spleen	0.0	Ovarian ca. OVCAR-5	0.3
Lymph node	0.5	Ovarian ca. OVCAR-8	0.8
Colorectal	0.0	Ovarian ca. IGROV-1	0.0
Stomach	0.4	Ovarian ca.* (ascites) SK-OV-3	0.6
Small intestine	0.7	Uterus	0.0
Colon ca. SW480	0.0	Placenta	5.5
Colon ca.* (SW480 met)SW620	0.6	Prostate	0.0
Colon ca. HT29	0.0	Prostate ca.* (bone met)PC-3	0.0
Colon ca. HCT-116	0.3	Testis	100.0
Colon ca. CaCo-2	0.0	Melanoma Hs688(A).T	0.0
83219 CC Well to Mod Diff (ODO3866)	0.0	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	0.2	Melanoma UACC-62	1.4
Gastric ca.* (liver met) NCI-N87	0.0	Melanoma M14	0.0
Bladder	0.0	Melanoma LOX IMVI	0.0
Trachea	32.3	Melanoma* (met) SK-MEL-5	0.0

Kidney	0.0	Adipose	8.2
--------	-----	---------	-----

Table GC. Panel CNS_neurodegeneration_v1.0

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	tm6994t_ag1876_b1_s1		tm6994t_ag1876_b1_s1
AD 1 Hippo	5.1	Control (Path) 3 Temporal Ctx	5.1
AD 2 Hippo	37.1	Control (Path) 4 Temporal Ctx	13.5
AD 3 Hippo	3.3	AD 1 Occipital Ctx	1.0
AD 4 Hippo	9.4	AD 2 Occipital Ctx (Missing)	0.0
AD 5 Hippo	100.0	AD 3 Occipital Ctx	2.8
AD 6 Hippo	45.4	AD 4 Occipital Ctx	25.6
Control 2 Hippo	8.0	AD 5 Occipital Ctx	21.4
Control 4 Hippo	2.0	AD 6 Occipital Ctx	6.2
Control (Path) 3 Hippo	5.7	Control 1 Occipital Ctx	0.0
AD 1 Temporal Ctx	5.0	Control 2 Occipital Ctx	35.5
AD 2 Temporal Ctx	6.9	Control 3 Occipital Ctx	4.7
AD 3 Temporal Ctx	2.0	Control 4 Occipital Ctx	6.4
AD 4 Temporal Ctx	17.2	Control (Path) 1 Occipital Ctx	40.1
AD 5 Inf Temporal Ctx	77.8	Control (Path) 2 Occipital Ctx	5.8
AD 5 Sup Temporal Ctx	19.1	Control (Path) 3 Occipital Ctx	0.0
AD 6 Inf Temporal Ctx	15.0	Control (Path) 4 Occipital Ctx	22.4
AD 6 Sup Temporal Ctx	21.8	Control 1 Parietal Ctx	0.0
Control 1 Temporal Ctx	1.4	Control 2 Parietal Ctx	10.0
Control 2 Temporal Ctx	17.1	Control 3 Parietal Ctx	5.9
Control 3 Temporal Ctx	10.8	Control (Path) 1 Parietal Ctx	25.4
Control 3 Temporal Ctx	4.2	Control (Path) 2 Parietal Ctx	26.1
Control (Path) 1 Temporal Ctx	27.6	Control (Path) 3 Parietal Ctx	1.4
Control (Path) 2 Temporal Ctx	41.9	Control (Path) 4 Parietal Ctx	22.3

- 5 **Panel 1.3D Summary** The 30675745.0.499_dal gene is most highly expressed in the testis (CT = 30). In addition, there appears to be substantial expression in samples derived from

adipose, placenta and trachea. Thus the expression of this gene could be used to distinguish these samples from other samples in the panel.

Panel CNS_neurodegeneration_v1.0 Summary The 30675745.0.499_da1 gene appears to be more highly expressed in the hippocampus of some patients with Alzheimer's disease than in the hippocampus of normal control brains. The hippocampus is a critical focus of the neurodegeneration that occurs as a central pathology of Alzheimer's disease. Proteolytic activity plays an important role in numerous aspects of Alzheimer's disease, both favorably and unfavorably. For example, increased expression of serine proteases is thought to have detrimental effects on hippocampal function in Alzheimer's disease, whereas impairment of proteolytic degradation of amyloid beta peptide (Abeta) may be a key factor in the progression of the disease. The protease homology of the protein encoded by the 30675745.0.499_da1 gene suggests that it may contribute to Alzheimer's disease pathology and that agents that inhibit the 30675745.0.499_da1 protein's activity may potentially have therapeutic value in the treatment of Alzheimer's disease and other neurodegenerative diseases.

Expression of the 30675745.0.499_da1 gene is low/undetectable (Ct values >35) in all samples in Panel 4D (data not shown).

The human kallikrein gene family consists of 15 serine proteases. The expression of the kallikrein genes in human cerebral cortex and hippocampus was examined by RT-PCR and compared their expression between Alzheimer's disease (AD) and control tissue. KLK1, 4, 5, 6, 7, 8, 10, 11, 13 and 14 are expressed in both cerebral cortex and hippocampus. KLK9 is expressed in cortex but not hippocampus, whereas KLK2, 3, 12 and 15 are not expressed in either tissue. An 11.5-fold increase in KLK8 mRNA levels in AD hippocampus compared to controls. The KLK8 gene product, neuropsin, processes extracellular matrix and is important for neuronal plasticity. Therefore, the increase in KLK8 could have detrimental effects on hippocampal function in AD. See generally Shimizu-Okabe et al., Neuroreport. 12:2747-51 (2001); PMID: 11522960.

The formation, aggregation and deposition of amyloid beta peptide (Abeta) is implicated in the aetiology of Alzheimer's disease. Impairment of proteolytic degradation of Abeta may be a key factor in the progression of the disease. RP-HPLC and thioflavin T fluorescence has been used to demonstrate that Abeta42 is rapidly cleaved by the protease plasmin and that cleavage prevented the aggregation of Abeta42, and its cleavage products,

into beta-pleated sheet structures. Plasmin may fulfil a similar role in vivo. *See generally*, Exley et al., Neuroreport 2001 Sep 17;12(13):2967-70; PMID: 11588612.

Example 2. Identification of NOVX clones

The novel NOVX target sequences identified in the present invention were subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. Table HA shows the sequences of the PCR primers used for obtaining different clones. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on *in silico* predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences from other species. These primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain - whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus.

Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The PCR product derived from exon linking was cloned into the pCR2.1 vector from Invitrogen. The resulting bacterial clone has an insert covering the entire open reading frame cloned into the pCR2.1 vector. Table HB shows a list of these bacterial clones. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp. In addition, sequence traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported herein.

Table HA. PCR Primers for Exon Linking

NOVX Clone	Primer 1 (5' - 3')	SEQ ID NO	Primer 2 (5' - 3')	SEQ ID NO
NOV1a	TGGCTTATTCAGAAGAGCATAAAGG	169	AGTGACTAGAGATCCTCCAGGTCAGTT	170

NOV1b	TGGCTTATTCAGAAAGCATAAAGG	171	AGTGACTAGAGATCCTCCAGGTCAGTT	172
NOV4a	CGCGTGACCTTGCCCTCTTG	173	CGTCATCCTGAGCCCGTCCGTC	174
NOV6a	GTTTCGGGCCCTGTGCGG	175	GTGGTGCCCATTTGTTTCTCAGAGT	176
NOV6b	GGTCATGGAAGAACGGGAAGAGGT	177	CTGGGGAGGGTCAAAGAAGGAGCT	178
NOV7	CTCCCACTCCTGCTGCTTCTGACT	179	AAGGCTGGGCCTAACCCAGTCTCAT	180
NOV9	GTCCCTGCAGGAGAAGCCAAGTGAC	181	CTGGGCAAATCCTCACTTGCTTGCT	182
NOV10	CCTCTTTACCACACAGAACCAAGCAC	183	AGCCCCAGTGTGCAACTATCAAAAAC	184
	T			

Example 3. SNP analysis of NOVX clones

SeqCalling™ Technology: cDNA was derived from various human samples

5 representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, cell lines, primary cells or tissue cultured primary cells and cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression for example, growth factors, chemokines, steroids. The cDNA thus derived was then sequenced using CuraGen's

10 proprietary SeqCalling technology. Sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled with themselves and with public ESTs using bioinformatics programs to generate CuraGen's human SeqCalling database of SeqCalling assemblies. Each assembly contains one or more overlapping cDNA sequences derived from one or more human samples. Fragments and ESTs were included as

15 components for an assembly when the extent of identity with another component of the assembly was at least 95% over 50 bp. Each assembly can represent a gene and/or its variants such as splice forms and/or single nucleotide polymorphisms (SNPs) and their combinations. Variant sequences are included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to

20 denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap

25 with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, however, in the case that a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any

30 amino acid sequence of a protein but may result in altered regulation of the expression pattern

for example, alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, stability of transcribed message.

Method of novel SNP Identification: SNPs are identified by analyzing sequence assemblies using CuraGen's proprietary SNPTool algorithm. SNPTool identifies variation in assemblies with the following criteria: SNPs are not analyzed within 10 base pairs on both ends of an alignment; Window size (number of bases in a view) is 10; The allowed number of mismatches in a window is 2; Minimum SNP base quality (PHRED score) is 23; Minimum number of changes to score an SNP is 2/assembly position. SNPTool analyzes the assembly and displays SNP positions, associated individual variant sequences in the assembly, the depth of the assembly at that given position, the putative assembly allele frequency, and the SNP sequence variation. Sequence traces are then selected and brought into view for manual validation. The consensus assembly sequence is imported into CuraTools along with variant sequence changes to identify potential amino acid changes resulting from the SNP sequence variation. Comprehensive SNP data analysis is then exported into the SNPCalling database.

Method of novel SNP Confirmation: SNPs are confirmed employing a validated method known as Pyrosequencing (Pyrosequencing, Westborough, MA). Detailed protocols for Pyrosequencing can be found in: Alderborn et al. Determination of Single Nucleotide Polymorphisms by Real-time Pyrophosphate DNA Sequencing. (2000). *Genome Research*. 10, Issue 8, August. 1249-1265. In brief, Pyrosequencing is a real time primer extension process of genotyping. This protocol takes double-stranded, biotinylated PCR products from genomic DNA samples and binds them to streptavidin beads. These beads are then denatured producing single stranded bound DNA. SNPs are characterized utilizing a technique based on an indirect bioluminometric assay of pyrophosphate (PPi) that is released from each dNTP upon DNA chain elongation. Following Klenow polymerase-mediated base incorporation, PPi is released and used as a substrate, together with adenosine 5'-phosphosulfate (APS), for ATP sulfurylase, which results in the formation of ATP. Subsequently, the ATP accomplishes the conversion of luciferin to its oxi-derivative by the action of luciferase. The ensuing light output becomes proportional to the number of added bases, up to about four bases. To allow processivity of the method dNTP excess is degraded by apyrase, which is also present in the starting reaction mixture, so that only dNTPs are added to the template during the sequencing. The process has been fully automated and adapted to a 96-well format, which allows rapid screening of large SNP panels. The DNA and protein sequences for the novel single nucleotide polymorphic

variants are reported. Variants are reported individually but any combination of all or a select subset of variants are also included. In addition, the positions of the variant bases and the variant amino acid residues are underlined.

Results

5 Variants are reported individually but any combination of all or a select subset of variants are also included as contemplated NOVX embodiments of the invention.

NOV1a SNP data:

10 The DNA and protein sequences for the novel single nucleotide polymorphic variants of the TNF Receptor Associated Factor 5-like gene of CuraGen Acc. No. wugc_draft_h_nh0318116_20000809_da1_ (NOV1a) are reported in Table IA. Variants are reported individually but any combination of all or a select subset of variants are also included. In summary, NOV1a has 1 SNP variant (variant 13375596), whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:1 and 2,
15 respectively. The nucleotide and amino acid sequence of the NOV1a variant differs as shown in Table IA.

Table IA. cSNP and Coding Variants for NOV1a				
NT Position of cSNP	Wild Type NT	Variant NT	Amino Acid position	Amino Acid Change
1099	A	G	349	Arg→Gly

20 NOV4a SNP data:

The DNA and protein sequences for the novel single nucleotide polymorphic variants of the Matrilin 2-like gene of CuraGen Acc. No. 14578444_0_47_ (NOV4a) are reported in Table IB. Variants are reported individually but any combination of all or a select subset of variants are also included. NOV4a has 3 SNP variants (variant 13374217; variant c110.4365;
25 and variant 110.4364), whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:13 and 14, respectively. The nucleotide sequence of the NOV4a variant differs as shown in Table IB.

Table IB. cSNP and Coding Variants for NOV4a					
Variant	NT Position of cSNP	Wild Type NT	Variant NT	Amino Acid position	Amino Acid Change
13374217	462	T	C	--	silent
c110.4365	3043	A	G	--	no change (outside of coding region)
c110.4364	3323	C	T	--	no change (outside of coding region)

NOV7 SNP data:

The DNA and protein sequences for the novel single nucleotide polymorphic variants of the Macrophage Stimulating Protein Precursor-like gene of CuraGen Acc. No.

dj1182a14_da1_ (NOV7) are reported in Table IC. Variants are reported individually but any combination of all or a select subset of variants are also included. NOV7 has one SNP variant (variant cg34a.348), whose variant position for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:23 and 24, respectively. The nucleotide sequence of the NOV7 variant differs as shown in Table IC.

Table IC. cSNP and Coding Variants for NOV7				
NT Position of cSNP	Wild Type NT	Variant NT	Amino Acid position	Amino Acid Change
C	T	997	333	Arg→Trp

NOV8a SNP data:

The DNA and protein sequences for the novel single nucleotide polymorphic variants of the Nucleotide sugar transporter-like gene of CuraGen Acc. No. 138531995_ (NOV8a) are reported in Table 1D. Variants are reported individually but any combination of all or a select subset of variants are also included. NOV8a has one variant (variant 13375602), whose variant position for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:25 and 26, respectively. The nucleotide sequence of the NOV8a variant differs as shown in Table ID.

Table ID. cSNP and Coding Variants for NOV8a

NT Position of cSNP	Wild Type NT	Variant NT	Amino Acid position	Amino Acid Change
G	T	1296	378	Ala→Ser

NOV9 SNP data:

The DNA and protein sequences for the novel single nucleotide polymorphic variants of the OB binding protein 2-like gene of CuraGen Acc. No. AC018755_da1_ (NOV9) are reported in Table IE. Variants are reported individually but any combination of all or a select subset of variants are also included. NOV9 has 3 SNP variants (variant 13375603; variant 13375604; and variant 13375605), whose variant position for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:28 and 29, respectively. The nucleotide sequence of the NOVX variant differs as shown in Table IE.

Table IE. cSNP and Coding Variants for NOV9

Variant	NT Position of cSNP	Wild Type NT	Variant NT	Amino Acid position	Amino Acid Change
13375603	215	T	C	72	Val→Ala
13375604	1008	C	T	--	silent
13375605	1207	C	G	403	Pro→Ala

NOV10 SNP data:

The DNA and protein sequences for the novel single nucleotide polymorphic variants of the Trypsin-like gene of CuraGen Acc. No. 30675745.0.499_da1_ (NOV10) are reported in Table IF. Variants are reported individually but any combination of all or a select subset of variants are also included. NOV10 has 5 variants (variant 13373902; variant 13373903; variant 13373904; variant 13373905; variant 13373906), whose variant position for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:30 and 31, respectively. The nucleotide sequences of the NOV10 variants differ as shown in Table IF.

Table IF. cSNP and Coding Variants for NOV10

Variant	NT Position of cSNP	Wild Type NT	Variant NT	Amino Acid position	Amino Acid Change
13373902	246	A	G	--	no change

					(outside of the coding region)
13373903	271	C	T	--	no change (outside of the coding region)
13373904	374	T	C	3	Ser→Pro
13373905	442	T	C	--	silent
13373906	739	C	T	--	silent

Example 4: SAGE analysis for NOVX

Serial Analysis of Gene Expression, or SAGE, is an experimental technique designed to gain a quantitative measure of gene expression. The SAGE technique itself includes several steps utilizing molecular biological, DNA sequencing and bioinformatics techniques. These steps (reviewed in Adams MD, "Serial analysis of gene expression: ESTs get smaller." Bioessays. 18(4):261-2 (1996)) have been used to produce 9 or 10 base "tags", which are then, in some manner, assigned gene descriptions. For experimental reasons, these tags are immediately adjacent to the 3' end of the 3'-most NlaIII restriction site in cDNA sequences. The Cancer Genome Anatomy Project, or CGAP, is an NCI-initiated and sponsored project, which hopes to delineate the molecular fingerprint of the cancer cell. It has created a database of those cancer-related projects that used SAGE analysis in order to gain insight into the initiation and development of cancer in the human body. The SAGE expression profiles reported in this invention are generated by first identifying the Unigene accession ID associated with the given MTC gene by querying the Unigene database at <http://www.ncbi.nlm.nih.gov/UniGene/>. This page has then a link to the SAGE : Gene to Tag mapping ([http://www.ncbi.nlm.nih.gov/SAGE/SAGEcid.cgi?cid="unigeneID"](http://www.ncbi.nlm.nih.gov/SAGE/SAGEcid.cgi?cid=)).

This generated the reports that are included in this application, which list the number of tags found for the given gene in a given sample along with the relative expression. This information is then used to understand whether the gene has a more general role in tumorigenesis and/or tumor progression. A list of the SAGE libraries generated by CGAP and used in the analysis can be found at <http://www.ncbi.nlm.nih.gov/SAGE/sagelb.cgi>.

SAGE library data and reliable tag summary for NOV8b

Reliable tags found in SAGE libraries:

AGCCTGTTGC

Library Name

Tags per

Tag counts

Total tags

	<i>million</i>		
	51	2	38836
<u>SAGE Duke 1273</u>			
<u>SAGE duke thalamus</u>	41	1	24371
<u>SAGE293-CTRL</u>	23	1	43442
<u>SAGE HCT116</u>	33	2	60322
<u>SAGE Cace2</u>	64	4	61601
<u>SAGE Chen LNCaP</u>	16	1	62267
<u>SAGE Chen LNCaP no-DHT</u>	15	1	64631
<u>SAGE Chen Normal Pr</u>	15	1	66193
<u>SAGE Chen Turner PR</u>	29	2	68384
<u>SAGE CAPAN2</u>	43	1	23222
<u>SAGE Panel</u>	80	2	24879
<u>SAGE HX</u>	31	1	32157
<u>SAGE H126</u>	61	2	32420
<u>SAGE Duke H54lacZ</u>	119	8	67101
<u>SAGE Duke H54 EGFR III</u>	227	13	57164
<u>SAGE Duke H392</u>	69	4	57529
<u>SAGE Duke GEM H100</u>	85	6	70061
<u>SAGE SW837</u>	32	2	60986
<u>SAGE RKO</u>	38	2	52064
<u>SAGE CPDR LNCaP-T</u>	22	1	44122
<u>SAGE 293-IND</u>	40	1	24481
<u>SAGE PR317 normal prostate</u>	16	1	59419
<u>SAGE PR317 prostate tumor</u>	30	2	65109
<u>SAGE pooled GMB</u>	48	3	61841
	10	1	94806
<u>SAGE BB542 white matter</u>			
<u>SAGE Normal pool (oth)</u>	15	1	63064
<u>SAGE Pane 91-16113</u>	29	1	33941
<u>SAGE QVCA432-2</u>	349	1	2861
<u>SAGE OV1063-3</u>	102	4	38938
<u>SAGE Tul02</u>	121	7	57636
<u>SAGE Tu98</u>	20	1	49005
<u>SAGE Duke Mhh-1</u>	41	2	48488
<u>SAGE Science Park MCF7 control 3h</u>	169	1	5903
<u>SAGE SciencePark MCF7 control oh</u>	130	8	61079
<u>SAGE SciencePark MCF7 estradiol 3h</u>	50	3	59978
<u>SAGE SciencePark MCF7 esttraadiol 18h</u>	132	8	60435
<u>SAGE lacZ</u>	53	1	18528
<u>SAGE 95-347</u>	74	5	67240

WO 02/46408

PCT/US01/46057

<u>SAGE 95-259</u>	152	6	39473
<u>SAGE 95-260</u>	66	3	45179
<u>SAGE 95-348</u>	99	6	60484
<u>SAGE Ped GBM1062</u>	33	2	59935
<u>SAGE Hose 4</u>	103	5	48413
<u>SAGE Es2-1</u>	63	2	31502
<u>SAGE Perito-13</u>	18	1	53728
<u>SAGE Meso-12</u>	28	1	35032
<u>SAGE Duke H1126</u>	35	1	27820
<u>SAGE LNCaP</u>	44	1	22637
<u>SAGE OVT-6</u>	23	1	42336
<u>SAGE MDA453</u>	105	2	18924
<u>SAGE Duke HMVEC</u>	38	2	52532
<u>SAGE HMVEC-VEGF</u>	17	1	57928
<u>SAGE DCIS</u>	194	8	41230
<u>SAGE Normal cerebeilum</u>	19	1	51135
<u>SAGE OVCT-8</u>	89	3	33575
<u>SAGE Duke 96-349</u>	179	1	5560
<u>SAGE A2780-9</u>	44	1	22256
<u>SAGE ML10-10</u>	87	5	56943
<u>SAGE Duke H247 normal</u>	115	7	60543
<u>SAGE Duke H247 Hypoxia</u>	27	2	71937
<u>SAGE Duke post crisis fibroblasts</u>	180	4	22207
<u>SAGE Duke precrisis fibroblasts</u>	113	1	8797
<u>SAGE DCIS 2</u>	34	1	28888
<u>SAGE Br N</u>	53	2	37558
<u>SAGE A+</u>	98	3	30551
<u>SAGE Jose29-11</u>	82	4	48498
<u>SAGE Duke H1043</u>	26	2	76673

OTHER EMBODIMENTS

Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein. Other aspects, advantages, and modifications considered to be within the scope of the following claims.

WHAT IS CLAIMED IS:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - (a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and/or 31;
 - (b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and/or 31, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
 - (c) an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and/or 31; and
 - (d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and/or 31 wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence.
2. The polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of a naturally-occurring allelic variant of an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and/or 31.
3. The polypeptide of claim 2, wherein said allelic variant comprises an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and/or 30.
4. The polypeptide of claim 1, wherein the amino acid sequence of said variant comprises a conservative amino acid substitution.

5. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:
 - (a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and/or 31;
 - (b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and/or 31, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
 - (c) an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and/or 31;
 - (d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and/or 31, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence;
 - (e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and/or 31, or a variant of said polypeptide, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; and
 - (f) a nucleic acid molecule comprising the complement of (a), (b), (c), (d) or (e).
6. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises the nucleotide sequence of a naturally-occurring allelic nucleic acid variant.

7. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of a naturally-occurring polypeptide variant.
8. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and/or 30.
9. The nucleic acid molecule of claim 5, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of
 - (a) a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and/or 30;
 - (b) a nucleotide sequence differing by one or more nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and/or 30, provided that no more than 20% of the nucleotides differ from said nucleotide sequence;
 - (c) a nucleic acid fragment of (a); and
 - (d) a nucleic acid fragment of (b).
10. The nucleic acid molecule of claim 5, wherein said nucleic acid molecule hybridizes under stringent conditions to a nucleotide sequence chosen from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, and/or 30, or a complement of said nucleotide sequence.
11. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of
 - (a) a first nucleotide sequence comprising a coding sequence differing by one or more nucleotide sequences from a coding sequence encoding said amino acid sequence, provided that no more than 20% of the nucleotides in the coding sequence in said first nucleotide sequence differ from said coding sequence;
 - (b) an isolated second polynucleotide that is a complement of the first polynucleotide; and

- (c) a nucleic acid fragment of (a) or (b).
12. A vector comprising the nucleic acid molecule of claim 11.
 13. The vector of claim 12, further comprising a promoter operably-linked to said nucleic acid molecule.
 14. A cell comprising the vector of claim 12.
 15. An antibody that immunospecifically-binds to the polypeptide of claim 1.
 16. The antibody of claim 15, wherein said antibody is a monoclonal antibody.
 17. The antibody of claim 15, wherein the antibody is a humanized antibody.
 18. A method for determining the presence or amount of the polypeptide of claim 1 in a sample, the method comprising:
 - (a) providing the sample;
 - (b) contacting the sample with an antibody that binds immunospecifically to the polypeptide; and
 - (c) determining the presence or amount of antibody bound to said polypeptide,thereby determining the presence or amount of polypeptide in said sample.
 19. A method for determining the presence or amount of the nucleic acid molecule of claim 5 in a sample, the method comprising:
 - (a) providing the sample;
 - (b) contacting the sample with a probe that binds to said nucleic acid molecule; and
 - (c) determining the presence or amount of the probe bound to said nucleic acid molecule,thereby determining the presence or amount of the nucleic acid molecule in said sample.
 20. A method of identifying an agent that binds to a polypeptide of claim 1, the method comprising:

- (a) contacting said polypeptide with said agent; and
 - (b) determining whether said agent binds to said polypeptide.
- 21. A method for identifying an agent that modulates the expression or activity of the polypeptide of claim 1, the method comprising:
 - (a) providing a cell expressing said polypeptide;
 - (b) contacting the cell with said agent; and
 - (c) determining whether the agent modulates expression or activity of said polypeptide,whereby an alteration in expression or activity of said peptide indicates said agent modulates expression or activity of said polypeptide.
- 22. A method for modulating the activity of the polypeptide of claim 1, the method comprising contacting a cell sample expressing the polypeptide of said claim with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.
- 23. A method of treating or preventing a NOVX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the polypeptide of claim 1 in an amount sufficient to treat or prevent said NOVX-associated disorder in said subject.
- 24. The method of claim 23, wherein said subject is a human.
- 25. A method of treating or preventing a NOVX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the nucleic acid of claim 5 in an amount sufficient to treat or prevent said NOVX-associated disorder in said subject.
- 26. The method of claim 25, wherein said subject is a human.
- 27. A method of treating or preventing a NOVX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the antibody

of claim 15 in an amount sufficient to treat or prevent said NOVX-associated disorder in said subject.

28. The method of claim 27, wherein the subject is a human.
29. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically-acceptable carrier.
30. A pharmaceutical composition comprising the nucleic acid molecule of claim 5 and a pharmaceutically-acceptable carrier.
31. A pharmaceutical composition comprising the antibody of claim 15 and a pharmaceutically-acceptable carrier.
32. A kit comprising in one or more containers, the pharmaceutical composition of claim 29.
33. A kit comprising in one or more containers, the pharmaceutical composition of claim 30.
34. A kit comprising in one or more containers, the pharmaceutical composition of claim 31.
35. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a NOVX-associated disorder, wherein said therapeutic is selected from the group consisting of a NOVX polypeptide, a NOVX nucleic acid, and a NOVX antibody.
36. A method for screening for a modulator of activity or of latency or predisposition to a NOVX-associated disorder, said method comprising:
 - (a) administering a test compound to a test animal at increased risk for a NOVX-associated disorder, wherein said test animal recombinantly expresses the polypeptide of claim 1;
 - (b) measuring the activity of said polypeptide in said test animal after administering the compound of step (a);
 - (c) comparing the activity of said protein in said test animal with the activity of said polypeptide in a control animal not administered said polypeptide, wherein a change in the activity of said polypeptide in said test animal

relative to said control animal indicates the test compound is a modulator of latency of or predisposition to a NOVX-associated disorder.

37. The method of claim 36, wherein said test animal is a recombinant test animal that expresses a test protein transgene or expresses said transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein said promoter is not the native gene promoter of said transgene.
38. A method for determining the presence of or predisposition to a disease associated with altered levels of the polypeptide of claim 1 in a first mammalian subject, the method comprising:
- (a) measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and
 - (b) comparing the amount of said polypeptide in the sample of step (a) to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, said disease,
- wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to said disease.
39. A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid molecule of claim 5 in a first mammalian subject, the method comprising:
- (a) measuring the amount of the nucleic acid in a sample from the first mammalian subject; and
 - (b) comparing the amount of said nucleic acid in the sample of step (a) to the amount of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease;
- wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.
40. A method of treating a pathological state in a mammal, the method comprising

administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide is a polypeptide having an amino acid sequence at least 95% identical to a polypeptide comprising an amino acid sequence of at least one of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and/or 31, or a biologically active fragment thereof.

41. A method of treating a pathological state in a mammal, the method comprising administering to the mammal the antibody of claim 15 in an amount sufficient to alleviate the pathological state.

THIS PAGE BLANK (USPTO)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
13 June 2002 (13.06.2002)

PCT

(10) International Publication Number
WO 02/046408 A3(51) International Patent Classification⁷: **C12N 15/12**,
5/10, C07K 14/47, 16/18, C12Q 1/68, G01N 33/577,
33/68, A61K 38/12, 39/395, C07K 14/715, 14/475, C12N
9/76

(21) International Application Number: PCT/US01/46057

(22) International Filing Date: 24 October 2001 (24.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/242,882	24 October 2000 (24.10.2000)	US
60/242,765	24 October 2000 (24.10.2000)	US
60/242,768	24 October 2000 (24.10.2000)	US
60/242,789	24 October 2000 (24.10.2000)	US
60/242,767	24 October 2000 (24.10.2000)	US
60/243,502	26 October 2000 (26.10.2000)	US
60/243,622	26 October 2000 (26.10.2000)	US
60/243,593	26 October 2000 (26.10.2000)	US
60/243,591	26 October 2000 (26.10.2000)	US
60/243,950	27 October 2000 (27.10.2000)	US
60/273,047	2 March 2001 (02.03.2001)	US
60/300,206	22 June 2001 (22.06.2001)	US
60/316,509	31 August 2001 (31.08.2001)	US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US	60/242,882 (CIP)
Filed on	24 October 2000 (24.10.2000)
US	60/242,765 (CIP)
Filed on	24 October 2000 (24.10.2000)
US	60/300,206 (CIP)
Filed on	22 June 2001 (22.06.2001)
US	60/242,789 (CIP)
Filed on	24 October 2000 (24.10.2000)
US	60/242,768 (CIP)
Filed on	24 October 2000 (24.10.2000)
US	60/242,767 (CIP)
Filed on	24 October 2000 (24.10.2000)
US	60/243,622 (CIP)
Filed on	26 October 2000 (26.10.2000)
US	60/273,047 (CIP)
Filed on	2 March 2001 (02.03.2001)
US	60/243,591 (CIP)
Filed on	26 October 2000 (26.10.2000)

US	60/243,950 (CIP)
Filed on	27 October 2000 (27.10.2000)
US	60/316,509 (CIP)
Filed on	31 August 2001 (31.08.2001)
US	60/243,593 (CIP)
Filed on	26 October 2000 (26.10.2000)
US	60/243,502 (CIP)
Filed on	26 October 2000 (26.10.2000)

(71) Applicant (for all designated States except US): **CURA-GEN CORPORATION** [US/US]; 555 Long Wharf Drive, 11th floor, New Haven, CT 06511 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LI, Li** [CN/US]; 56 Jerimoth Drive, Branford, CT 06405 (US). **FUR-TAK, Katarzyna** [PL/US]; 31 Park Place, Ansonia, CT 06401 (US). **MEZICK, Amanda** [US/US]; 555 Long Wharf Drive, 11th Floor, New Haven, CT 06511 (US). **PATTURAJAN, Meera** [IN/US]; 45 Harrison Avenue, Apartment 1C, Branford, CT 06405 (US). **SHIMKETS, Richard, A.** [US/US]; 191 Leete Street, West Haven, CT 06516 (US). **GUO, Xiaojia** [CN/US]; 713 Robert Frost Drive, Branford, CT 06405 (US). **CASMAN, Stacie, J.** [US/US]; 17 Peck Street, North Haven, CT 06473 (US). **BURGESS, Catherine, E.** [US/US]; 90 Carriage Hill Drive, Wethersfield, CT 06109 (US). **MALYANKAR, Uriel, M.** [IN/US]; 35 Averill Place, Branford, CT 06405 (US). **TCHERNEV, Velizar, T.** [BG/US]; 45 Jefferson Road, #3-12, Branford, CT 06405 (US). **VERNET, Corine, A., M.** [FR/US]; 1739 Foxon Road, North Branford, CT 06471 (US). **SPYTEK, Kimberly, A.** [US/US]; 28 Court Street, #1, New Haven, CT 06511 (US). **AGEE, Michele** [US/US]; 107 Knollwood Road, Wallingford, CT 06492 (US). **RASTELLI, Luca** [IT/US]; 52 Pepperbush Lane, Guilford, CT 06437 (US). **SHENOY, Suresh, G.** [IN/US]; 15 Millwood Drive, Branford, CT 06405 (US). **GROSSE, William, M.** [US/US]; 15 Rice Terrace Road, Apartment C, Branford, CT 06405 (US). **ALSOBROOK, John, P., II** [US/US]; 60 Lake Drive, Madison, CT 06443 (US). **LEPLEY, Denise, M.** [US/US]; 51 Church Street, Branford, CT 06405 (US). **GERLACH, Valerie** [US/US]; 18 Rock Pasture Road, Branford, CT 06405 (US). **EDINGER, Shlomit** [US/US]; 555 Long Wharf Drive, 11th Floor, New Haven, CT 06511 (US). **MACDOUGALL, John, R.** [CA/US]; 117 Russell Street, Hamden, CT 06517 (US). **PEYMAN, John, A.** [US/US]; 336 West Rock Avenue, New Haven, CT 06515 (US). **GUNTHER, Erik** [US/US]; 555 Long Wharf Drive, 11th Floor, New Haven, CT 06511 (US). **STONE, David, J.**

[Continued on next page]

(54) Title: HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS OF USING THE SAME

(57) Abstract: Disclosed are novel polypeptides and nucleic acids encoding same. Also disclosed are vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same.

WO 02/046408 A3



[US/US]; 223 Whitehorn Drive, Guilford, CT 06437 (US).
ELLERMAN, Karen [US/US]; 87 Montoya Drive, Branford, CT 06405 (US). **GANGOLLI, Esha, A.** [IN/US]; 383 Walden Green, Branford, CT 06405 (US).

patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(74) **Agent:** **ELRIFI, Ivor, R.**; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) **Date of publication of the international search report:**
3 July 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

 Internat: Application No
 PCT/US 01/46057

A. CLASSIFICATION OF SUBJECT MATTER

 IPC 7 C12N15/12 C12N5/10 C07K14/47 C07K16/18 C12Q1/68
 G01N33/577 G01N33/68 A61K38/12 A61K39/395 C07K14/715
 C07K14/475 C12N9/76

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EP0-Internal, SEQUENCE SEARCH, MEDLINE, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 882 790 A (SUMITOMO ELECTRIC INDUSTRIES) 9 December 1998 (1998-12-09) abstract; claims 1-10; figures 1,SEQ.3,4 ---	1-22, 29-39
X	EP 0 915 155 A (MOCHIDA PHARM CO LTD) 12 May 1999 (1999-05-12) claims 1-40; figures 1,SEQ.1,2,6 ---	1-22, 29-39
X	WO 00 20435 A (COWSERT LEX M ;MONIA BRETT P (US); XU XIAOXING S (US); BAKER BREND) 13 April 2000 (2000-04-13) page 93 -page 99; claims 1-19; figure SEQ.5 --- -/--	1-22, 29-39

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

29 January 2003

Date of mailing of the international search report

09. 05. 2003

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Gurdjian, D

INTERNATIONAL SEARCH REPORT

Internat'l Application No
PCT/US 01/46057

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NAKANO H ET AL: "HUMAN TNF RECEPTOR-ASSOCIATED FACTOR 5 (TRAF5): CDNA CLONING, EXPRESSION AND ASSIGNMENT OF THE TRAF5 GENE TO CHROMOSOME 1Q32" GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 42, 1997, pages 26-32, XP002948963 ISSN: 0888-7543 abstract; figure 1 ---	1-22, 29-39
X	MIZUSHIMA S-I ET AL: "Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5)" GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 207, no. 2, 30 January 1998 (1998-01-30), pages 135-140, XP004108911 ISSN: 0378-1119 abstract; figure 1 ---	1-22, 29-39
A	GOMI FUMI ET AL: "Molecular cloning of a novel membrane glycoprotein, Pal, specifically expressed in photoreceptor cells of the retina and containing leucine-rich repeat." JOURNAL OF NEUROSCIENCE, vol. 20, no. 9, 1 May 2000 (2000-05-01), pages 3206-3213, XP002229022 ISSN: 0270-6474 abstract; figure 1 -----	1-22, 29-39

INTERNATIONAL SEARCH REPORT

Int tional application No.
PCT/US 01/46057

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 23-28,40,41 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-41 (partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-41 partially

putative TRAF5 like proteins with amino acid sequence with seq.id.2 and nucleotide sequences with seq.id.1 ,
corresponding vector, host cell , antibody , method of
determining the presence of the protein, method of
identifying binding or modulating agents , pharmaceutical
composition , kit , method of manufacture of a medicament ,
method of determining the the presence of predisposition to
a disease .

2. Claims: 1-41 partially

putative TRAF5 like proteins with amino acid sequence with
seq.id.4 and nucleotide sequences with seq.id.3 ,
corresponding vector, host cell , antibody , method of
determining the presence of the protein, method of
identifying binding or modulating agents , pharmaceutical
composition , kit , method of manufacture of a medicament ,
method of determining the the presence of predisposition to
a disease .

3. Claims: 1-41 partially

putative fibronectin like protein with amino acid sequence
with seq.id.6 and nucleotide sequences with seq.id.5 ,
corresponding vector, host cell , antibody , method of
determining the presence of the protein, method of
identifying binding or modulating agents , pharmaceutical
composition , kit , method of manufacture of a medicament ,
method of determining the the presence of predisposition to
a disease .

4. Claims: 1-41 partially

putative fibronectin like proteins with amino acid sequence
with seq.id.8 and nucleotide sequences with seq.id.7 ,
corresponding vector, host cell , antibody , method of
determining the presence of the protein, method of
identifying binding or modulating agents , pharmaceutical
composition , kit , method of manufacture of a medicament ,
method of determining the the presence of predisposition to
a disease .

5. Claims: 1-41 partially

putative fibronectin like proteins with amino acid sequence
with seq.id.10 and nucleotide sequences with seq.id.9 ,

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

corresponding vector, host cell , antibody , method of determining the presence of the protein, method of identifying binding or modulating agents , pharmaceutical composition , kit , method of manufacture of a medicament , method of determining the the presence of predisposition to a disease .

6. Claims: 1-41 partially

putative dematin like proteins with amino acid sequence with seq.id.12 and nucleotide sequences with seq.id.11, corresponding vector, host cell , antibody , method of determining the presence of the protein, method of identifying binding or modulating agents , pharmaceutical composition , kit , method of manufacture of a medicament , method of determining the the presence of predisposition to a disease .

7. Claims: 1-41 partially

putative matrilin-2 like proteins with amino acid sequence with seq.id.14 and nucleotide sequences with seq.id.13 , corresponding vector, host cell , antibody , method of determining the presence of the protein, method of identifying binding or modulating agents , pharmaceutical composition , kit , method of manufacture of a medicament , method of determining the the presence of predisposition to a disease .

8. Claims: 1-41 partially

putative matrilin-2 like proteins with amino acid sequence with seq.id.16 and nucleotide sequences with seq.id.15 , corresponding vector, host cell , antibody , method of determining the presence of the protein, method of identifying binding or modulating agents , pharmaceutical composition , kit , method of manufacture of a medicament , method of determining the the presence of predisposition to a disease .

9. Claims: 1-41 partially

putative GABA receptor like proteins with amino acid sequence with seq.id.18 and nucleotide sequences with seq.id.17, corresponding vector, host cell , antibody , method of determining the presence of the protein, method of identifying binding or modulating agents , pharmaceutical composition , kit , method of manufacture of a medicament , method of determining the the presence of predisposition to a disease .

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

10. Claims: 1-41 partially

putative giant larvae homolog like proteins with amino acid sequence with seq.id.20 and nucleotide sequences with seq.id.19 , corresponding vector, host cell , antibody , method of determining the presence of the protein, method of identifying binding or modulating agents , pharmaceutical composition , kit , method of manufacture of a medicament , method of determining the the presence of predisposition to a disease .

11. Claims: 1-41 partially

putative giant larvae homolog like proteins with amino acid sequence with seq.id.22 and nucleotide sequences with seq.id.21 , corresponding vector, host cell , antibody , method of determining the presence of the protein, method of identifying binding or modulating agents , pharmaceutical composition , kit , method of manufacture of a medicament , method of determining the the presence of predisposition to a disease .

12. Claims: 1-41 partially

putative Macrophage Stimulating Protein Precursor like proteins with amino acid sequence with seq.id.24 and nucleotide sequences with seq.id.23 , corresponding vector, host cell , antibody , method of determining the presence of the protein, method of identifying binding or modulating agents , pharmaceutical composition , kit , method of manufacture of a medicament , method of determining the the presence of predisposition to a disease .

13. Claims: 1-41 partially

putative nucleotide sugar transport like proteins with amino acid sequence with seq.id.26 and nucleotide sequences with seq.id.25,27 , corresponding vector, host cell , antibody , method of determining the presence of the protein, method of identifying binding or modulating agents , pharmaceutical composition , kit , method of manufacture of a medicament , method of determining the the presence of predisposition to a disease .

14. Claims: 1-41 partially

putative OB binding protein-2 with amino acid sequence with seq.id.29 and nucleotide sequences with seq.id.28, corresponding vector, host cell , antibody , method of determining the presence of the protein, method of

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

identifying binding or modulating agents , pharmaceutical composition , kit , method of manufacture of a medicament , method of determining the the presence of predisposition to a disease .

15. Claims: 1-41 partially

putative trypsin like proteins with amino acid sequence with seq.id.31 and nucleotide sequences with seq.id.30 , corresponding vector, host cell , antibody , method of determining the presence of the protein, method of identifying binding or modulating agents , pharmaceutical composition , kit , method of manufacture of a medicament , method of determining the the presence of predisposition to a disease .

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/46057

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0882790	A	09-12-1998	EP 0882790 A1 US 6426403 B1 WO 9731110 A1	09-12-1998 30-07-2002 28-08-1997
EP 0915155	A	12-05-1999	AU 2307697 A EP 0915155 A1 CA 2251578 A1 WO 9738099 A1	29-10-1997 12-05-1999 16-10-1997 16-10-1997
WO 0020435	A	13-04-2000	US 6399297 B1 AU 1102300 A EP 1119580 A1 JP 2002526095 T US 2003055015 A1 WO 0020435 A1	04-06-2002 26-04-2000 01-08-2001 20-08-2002 20-03-2003 13-04-2000